<SEC-DOCUMENT>0001628280-21-016912.txt : 20210813
<SEC-HEADER>0001628280-21-016912.hdr.sgml : 20210813
<ACCEPTANCE-DATETIME>20210813080319
ACCESSION NUMBER:		0001628280-21-016912
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210813
DATE AS OF CHANGE:		20210813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		211169791

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ardx-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91,d:ba274a23d3f04ea8a3bf82e7a8ef31ca--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ardx="http://www.ardelyx.com/20210630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18wLTEtMS0xLTA_7d35fc13-65ba-440a-8b6b-270bbc0a4877">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18xLTEtMS0xLTA_da76370e-e275-4f8f-b649-493cadc2f76e">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18yLTEtMS0xLTA_82a67bf6-450a-42ac-b7a7-a4b4d094671e">2021</ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18zLTEtMS0xLTA_4c5270d4-2ba4-4e4d-9f46-510a96d0b603">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM180LTEtMS0xLTA_df3685f3-f59f-4152-904e-6c964ad6e6de">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ff198d368245179917bda45ce11447_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:OtherAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic2a86335175446c3b31159227a07237e_I20210810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7ce11e50673c4ce593372c02d75ba21d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f4c36f4b554b9b8908a7e166a96117_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5169c85622a346fb9062ffb6b012fd12_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic844400b43a7400da61df183e26a583f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b324fd57d14e27bcd90f57c095fb22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44aa89a05a754d1b891d684b45030896_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70adb02e2ed84dbfbb84ecc59e237f22_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46815f43fb5147de827a675a8e9bff26_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f93c6e57284dcdb9ba529c830b9ddc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d70bc74d694a89afe4beef05f285a0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifefc52610f304fc29c70ee02bfdad54f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6dc4b98bc94f80aee011fe441527d8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cbe2d3588447c6a15715bc02d7d4c5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305ca64104904718823ba7cb678ddb2d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91cafc3f3d549f29a542a11fe2aef57_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe4795385734cbb8a81bf1b0bcd78a5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a85d71d0204688a7b741f604983349_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e91b1a5dd24c928910e0eb927abf63_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996b9b49c28f44a59ede689736e3c19b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b5a2b6ba734b409098fe1a0d30c5e2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd017782e8d453ca3fbb2a862a9ba90_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5b6508dc384cedb263a3547a372fce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ff1f828c934f0f88513250a9fcec8e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0080ccb444c45f6820630de940835f5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18cceea8b49b4f9996c4425728df8ddb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e3cd82573141db8cb46c3d4aff5c1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40995d012e245ab8f368eab46de01fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9599acbfae04ff2926fa311f5b1fa11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa2601d5c60400197dae7d0b451836e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4740541ee7924fea863cb9f577326fd3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia909a04442314115a14cb637f127f9a0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab525b262fba48b39730d896423dd7fe_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2175ce28f9d54b8083c2d9170d124b24_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521561e365cb4f9aa0c62af71fc32133_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if512d3ccb798492096508a8d2449275e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i055e0b998d064537b3d88828cb52ae44_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1fb8a7c88e498f92aa1aae68c2fea8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c73b1263494577a798b153956f45fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5481c5ac22b441f1a636dc6115281e1d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37628ae924f0472da65e1caaf4ca8ce8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74c05e19ce74538b7ea429c28d19a88_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic53ee417fef84d79a20f0137c9009129_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb8a5ab08814d09a475fc45cb62c355_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0bc9463f684e9b8d4d88cb346673ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe50953188ac47108208481d704ce612_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd41c948817d46d799997c58b6d1030b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52df4b25bae450697308ad35e1759ba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i783b4aad17a142a08d4f48f537af01a4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ardx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5b98058de4da42c294fa91c66eeb6e89_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ad3f3857994eafbf8092a727a20054_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibccabbde714945ec89a64f78f0954426_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad7361da3114524894d528d36761938_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7acd89d799254005a61260d4785cc411_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd17446ca75477084ef05a6506f3a4d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07744061b93432eb1154ad3a3a36816_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2251a0841514418a8a29bca5526a858_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b26e91f4014480084d27170ccd8c8fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b9eea8333f47a1b077cabf000e2716_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a0e0f970d3480faac49ec39d277a5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80c54e2862a942258157af583a390e08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ardx:investment</xbrli:measure></xbrli:unit><xbrli:context id="ied42e28071324f2ebd2db962a44477e1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6f276be494047f297ca9e5088e20b96_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e74d17c420a47afaac9eca94b5c23eb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3063806f84794b4ca0e47322baed68bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf01a41f9d048ed926937a9e81f57f5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acef194906f40c4b0bc625b1fe030d8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89a5f8f089048d695069dfd0f3ddb1e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16d7277926b4ae1a8bf1f8ccc7f5fdd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6b406bbf6f45849047db8c4c1bd725_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7317f8962714c4b83d096692d77f4c5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9635984f4f30476f8f150e932200d84f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de92fed80134bcdb3a7fc397526ea81_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1f62f1e1524a1bb1796ea45572aa13_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a8a52b89c442b0802c08887c2a4136_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37c22c74c3a41568c43be19dee6db9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d0ce291981454e84664b7d247bbd2e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331cc003c0d04f078a6a32154ebd1c19_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5fb96fe51e419887a5821e069bbb56_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c3ad7f462746299218071393ac1e76_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec0006dbb884a2688382b808984430a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f9b87841b6410e833b3c2aec531508_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e6a25c0cce4489942fd3fe7e7c649b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e9e314500242078338cfabc68e7044_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2604c61a3d4a84a43dc5a5223d046b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf133615c36b4ab3a3e102804e0b1395_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f163fd764f4b419a6b868c74be4819_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67057377152479a8f17df5a513c8a7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343e1acc71bd421f93de6475da3bff62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3066659e3a14837b312644f5691a4bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1a8fad572045d6bef48f3a3f6b19e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83afd2bc4c346a6981483552dc69b41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a252b2bdcfa4716b77eb9c9da774c15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i359ed40755d742d598b2a7d817c16d1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fa54e72d4843718c001d9ccb44924b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777ba44fc4ef4475b9a38bc841b0576d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718d02cc72e24371be1e76266dcf5064_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84bae8c4960433d93fdb8f2d7158729_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a26be08aec4aeea36c9609cfd1b404_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8614004f13e5407d91653ae48dae6571_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d8f87376786455daba169deb2cd6918_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id472a845edd54c8788fc87a0d47191f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c27facfc44a42718fa0b68303467103_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie506d6ee79ea43278c382f43160888b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c71f6dc2c144e6bde1f09a7d4d318c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaafed114ecbb40428246f042c26c16d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0667655fab5c49cc8a9064756e708041_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75ed11eb6d6e4fd99e38e05050686318_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd4156d88704e5dbe480f29b020b4b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed64ecd7425451a846dd9c27093960b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2769548737144611a050277733a53d55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0206150a344137a26fa4bb438d55b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i428867f600214f18bfdfb49712d4abf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="item"><xbrli:measure>ardx:item</xbrli:measure></xbrli:unit><xbrli:context id="id9f52e3ac5894f0d82d3246f26b4426f_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if971ec15d09646659e6f792d4e0c33c1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9980b470ca44ceb2a1da9962e99de8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6882c8ec77184cfc83073e6f4ae139de_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891ee02e0c064d5fac9eef456b775d16_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8816a7551b42f7b0f4ee113d914fe6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if032ba3b809943c691949710d1c0d6e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ac419220864a3e96c1c6f85f0e3d6c_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7ffc17c4ea41b8942ca8c90aef5985_D20171101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i1534860e131847dd8b0713fab040d16d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca092a95ab44a3fbec59b1d0b8dead2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i283b29715ca94bd7bff20ea912e2dc44_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ed442c04974d718d23c4fab2737e51_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc13520e38174911bb24b8da85289f37_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2816086d585e4b8ab2a5d4fcf91cc35b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78360eebb07744fe9d6aa96a4bb1ccec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e4b72e7e4047f7963dc1ef571b8610_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9445347caff444659496b5c488ed0fa2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:OtherProductOrServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98776866f5974807b9f5978a8f14c768_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:OtherProductOrServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5d2add0495488f81876f95890d813f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if14136718f7645a09e5144e34b83338e_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i988b12581c6e42f6b02b04fe7c54a484_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c99d81bd754260871242f4e771916c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc25084bb364545944e03f1663c5e5e_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a52e2793ccc45d7acd1aa68fc3d6d54_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf132b0a9774bdc872ca3d86d11edd7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc36ba0cdfe49288d9249c20ff9f953_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c458d292e4c40c6a13a0002a7985e5c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e8922e9c354c27894a0e726cd808d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie588300a61314fd1a511fc90bc57b89c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f983056a234617bb02529bdab92604_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3eac47e3784f54a4d7c86adfabdc2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822c7141162e4b328f9131de3d247ea5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc7bd2e9a8044539a1c899e40063725_I20180516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcaf515abe2840c282d0b24ba36d7735_D20201009-20201009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-09</xbrli:startDate><xbrli:endDate>2020-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090b2bbf6d4a488396b2cfe21eb06705_I20201009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7210d52700b243169235360a519811d9_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23709eda801d451e8c51e46f71e084aa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabae158ea16a4d0db01673f4d02bd862_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7f10228e774928bcb37829f399cf64_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic930520ff3b24850b76418b4769ee010_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd06b4585e1420e94a3a1bc12e8bde5_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0977925bb314a0d989a37372b6e92e9_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b9f41836824ed3b567440b012e50ee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a442e4da84048eda09938d7030e2b4c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63131bdabbd8434aaf8c26325f068bd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae411fbdd0534f02bc4fdf3a5d2ca8a5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013c596cde5f4e4195fb7311188973d7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c87d785bda4e47beed917e20627d9a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f3cfb47f314559af19e068ea3c36e7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ib702c69d1490476d80c3cd108100c164_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9190bfc1045649fbbed0e5bf15c56905_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2e99912d72427fa13d8d0bf46271f8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityWalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2170430801c4c239779ff73419a0839_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityWalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>ardx:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="if3dc7ec6f5ed4386a5ff6d842b738934_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4fc789a9b84f18b38090c85e7db5bc_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785930e859ee4be7bb7b7fb96ea4cb11_D20201113-20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-13</xbrli:startDate><xbrli:endDate>2021-02-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc1fab5cf114d6a87de78c84c48449b_D20210511-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-11</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-13</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4e511a9eaa4a259b6f2af0a9346f02_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d3b6aaec8145c3b159056fc132c464_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3795671d1695460f9521163c5473a1b8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edc45d4a609489c93f139ccdfc04755_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94913409dc945679a54fb334278a1a4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id449269d05cb4a7bb376cb25ae99695c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee13a843486b4b1dba0ef49f9b47772a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd939d4bd73a4f909c2aade26597c328_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd803553a9b495da7e99b9a2beac824_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11f4aa0f44f40bd8da00137040b43e3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8bc56233124f56814734f35647572c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7650d015d8f4d54b605259abc29e66e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6de6db9967249b18554b23602a09e1a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6421afe2e3a4ee69726ba784046ad51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57135135174447be98ce98bf5cae8472_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7334dc0c28ed479ea8dd4c7d8a181fcd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4477929b6b09482994b251a77283960d_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f1bc8e4fe941348afc91140237ac09_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2465ac8d53a4afba2b987515d381da9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ardx:position</xbrli:measure></xbrli:unit><xbrli:context id="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2021-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131c578fa03b4050ae8b161b42ffff16_D20210802-20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis">us-gaap:ReducedEmployeeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2021-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c10d6ea1834cf0a59df57076605afc_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>ardx:defendant</xbrli:measure></xbrli:unit><xbrli:context id="icfc6f67e8c63440689c94f063c69ad9f_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:PutativeSecuritiesClassActionLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg1_398bc0a4-7173-484f-a113-c2a5f5003da9">10-Q</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6OWZkYjQ1NjA4NjQyNGQ0ZWJlOGE5NzJjM2Y4MmYxMGYvdGFibGVyYW5nZTo5ZmRiNDU2MDg2NDI0ZDRlYmU4YTk3MmMzZjgyZjEwZl8wLTAtMS0xLTA_de4d30b3-1489-4cb4-9103-dcd96c606537">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8xMzg_b5efa580-5613-4c4f-89cb-20975e5ccdb7">June 30, 2021</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NDc1ZDJiNzM4YTUxNDBkN2E2MTAxM2Y5NWM3OGI4ZGQvdGFibGVyYW5nZTo0NzVkMmI3MzhhNTE0MGQ3YTYxMDEzZjk1Yzc4YjhkZF8wLTAtMS0xLTA_05600940-1ab1-4b85-989e-d23bc859c252">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY4_7179742b-9114-46e7-a7e7-50df64f6114b">001-36485</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ardx-20210630_g1.jpg" alt="ardx-20210630_g1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYy_73ff9288-2ed8-4c07-b16a-90ebc90c0a1f">ARDELYX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MmE0NGJkZmZmYmVlNGZkNjljYmVmNTA5MDYxZDBkZjMvdGFibGVyYW5nZToyYTQ0YmRmZmZiZWU0ZmQ2OWNiZWY1MDkwNjFkMGRmM18wLTAtMS0xLTA_8927e623-0d89-492a-adc8-7eb40e767868">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MmE0NGJkZmZmYmVlNGZkNjljYmVmNTA5MDYxZDBkZjMvdGFibGVyYW5nZToyYTQ0YmRmZmZiZWU0ZmQ2OWNiZWY1MDkwNjFkMGRmM18wLTEtMS0xLTA_a631d98d-ea5b-44bc-9102-ab860d702533">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc2_96a696f2-227a-488d-be85-edcb912e756b">34175 Ardenwood Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY5_9f304a78-d91c-4a40-914f-7dc6492eb3bb">Fremont</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc0_04943293-6fe1-42f4-a2cc-fa8dbe3bc5f6">California</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYz_39868989-8731-4547-ac3a-26ee68c2007e">94555</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg2_10e4d35e-c52d-4bf0-8770-9e7b1ace80c1">400 Fifth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc4_97aa1d6e-e314-4de6-82b0-4df2e49d09e8">Suite 210</ix:nonNumeric>, <ix:nonNumeric contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY1_03f09e46-4760-47c8-b408-d356df72ff93">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc5_3a5ca8c9-a762-4820-af9a-730f387d2063">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTgz_d666f259-f000-4f9c-a8f9-1c3871f553b5">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY2_31e16897-0c96-4fcd-8f4c-839a79ec55a6">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg0_c2ba2d7f-f149-43fc-a0df-5d1b0d18946c">745-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTAtMS0xLTA_be8f25a3-c2d2-48ca-b9b7-f65ebbf09419">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTItMS0xLTA_f89aa78c-86c1-47d9-99ed-6e273fb0d7d2">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTQtMS0xLTA_98afac7f-e0e6-4aa8-99d2-531a3325152b">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY3_964bd75b-3b63-48ed-a101-7ead07354627">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTgw_2aa30d2e-9f9b-4db8-9410-b84de551f263">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF8yLTEtMS0xLTA_a6a696a2-a9da-45f0-837f-741dd8fa5f02">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF8yLTUtMS0xLTA_b338a941-ec9b-4825-84d4-043075a2a358">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF80LTUtMS0xLTA_05617856-13e7-4582-af02-3591a0a7ac69">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYw_18c4f7f3-12e8-4e57-a235-f6008ba7067a">&#9746;</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of issued and outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value per share, as of August&#160;10, 2021, was <ix:nonFraction unitRef="shares" contextRef="ic2a86335175446c3b31159227a07237e_I20210810" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTU0_8e25e63d-2013-434b-b7c8-d12fb033fa5f">103,119,010</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_13">Item 1. Financial Statements:</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_16">Condensed Balance Sheets (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_19">Condensed Statements of Operations and Comprehensive Loss (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_22">Condensed Statements of Changes in Stockholders' Equity (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_25">Condensed Statements of Cash Flows (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_28">Notes to Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_106">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_109">Item 4. Controls and Procedures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_112">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_115">Item 1. Legal Proceedings</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_118">Item 1A. Risk Factors</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_121">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_124">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_127">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_130">Item 5. Other Information</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_133">Item 6. Exhibits</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_136">Signatures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMy0xLTEtMS0w_de70d7e0-a598-4e36-a39e-e529400b7c0c">86,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMy0zLTEtMS0w_06292eaa-95d7-4802-9f69-73ca19304d34">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNC0xLTEtMS0w_5d14d30d-cfb7-4b79-b5b1-5756cfb68824">85,064</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNC0zLTEtMS0w_b3329f02-e5d8-4a25-8100-4a64a4ee8b70">95,452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNi0xLTEtMS0w_c23c05fc-ce4a-4e99-b884-216901031929">14,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNi0zLTEtMS0w_087b2038-0c42-4f3d-a5ec-ee22c8bd5729">8,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNy0xLTEtMS0w_e1f45e4c-9158-4d50-ab11-a40fe73ecfab">186,492</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNy0zLTEtMS0w_48aaf61c-f8df-4337-aa19-175b0be383c9">194,686</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOC0xLTEtMS0w_29d363a3-6c16-4f7b-bdb3-f98f026faa44">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOC0zLTEtMS0w_085a3337-cf67-4377-9eab-cbe9637676eb">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOS0xLTEtMS0w_9dbbb4c0-cf02-4ffd-acad-5757442c6e90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOS0zLTEtMS0w_e94670c8-7c5f-4f46-ad56-1dc3bfd06cfe">2,114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTAtMS0xLTEtMA_38d64189-0a38-4461-9453-ef70b147a15c">14,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTAtMy0xLTEtMA_93732216-2263-411c-8296-86e9eacdf612">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTEtMS0xLTEtMA_e40c4648-98d4-4c31-864e-491936b9972e">1,305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTEtMy0xLTEtMA_f7d4cbd3-6047-4fbd-859d-20939ca2e801">552</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTItMS0xLTEtMA_509fd983-8044-4b11-aeec-e828fedb9a7e">204,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTItMy0xLTEtMA_fc5fca9b-50aa-446a-ac4a-caf2fc6fe9f9">201,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTUtMS0xLTEtMA_34efdf2c-3424-4bfd-bd8f-9fe26e6bec1f">2,587</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTUtMy0xLTEtMA_e5e45c04-5ce6-412a-a070-c2cc846f4f02">5,626</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTYtMS0xLTEtMA_f8ef0c18-0d77-4104-88a1-694fe850c3ba">5,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTYtMy0xLTEtMA_4a85110d-7dc8-4025-b2d8-2c4d6be0a0f2">5,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTctMS0xLTEtMA_807d19d4-b405-4ab9-af68-8dc317b8f820">3,184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTctMy0xLTEtMA_0bad859b-0375-4e8e-b1ee-42a566fd53b9">2,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTgtMS0xLTEtMA_4a7b7805-ca46-440a-9f60-3d1bef7e591b">36,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTgtMy0xLTEtMA_ae189a5b-7dd9-42d9-aecf-b51c76bf7a37">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTktMS0xLTEtMA_cecd03ca-5271-4264-9ecf-b9f06ce3b371">1,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTktMy0xLTEtMA_a1dc81fa-836f-4fdb-b1f3-cf6b4a656d6e">4,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjAtMS0xLTEtMA_78aa114c-4020-4d78-9af3-00edf29daeae">8,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjAtMy0xLTEtMA_8d508ac1-7f8d-4682-9656-dd5e3cae373d">6,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjEtMS0xLTEtMA_78e0a6d2-17e1-4331-9418-f78aeb065198">57,785</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjEtMy0xLTEtMA_b65486a8-61ef-4fe9-9d02-2c6e28278c5c">28,416</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjItMS0xLTEtMA_0f4e655a-04f0-4223-a936-d2dad1c54074">11,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjItMy0xLTEtMA_7663f15f-f5c5-4ada-bd08-22529f89604d">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjMtMS0xLTEtMA_91e36da4-0887-4863-bda4-212ceace6503">15,133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjMtMy0xLTEtMA_e8240558-a103-49dc-ba96-3b8011256486">46,621</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjQtMS0xLTEtMA_de45f1ef-fe8d-4579-9a4e-d31b47cca415">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjQtMy0xLTEtMA_faafe729-9674-4b36-9be2-a75706d18d85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjUtMS0xLTEtMA_028c3138-d4d7-43e5-add2-5bc42cd63141">87,413</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjUtMy0xLTEtMA_888950a1-1355-4baa-a4cd-6799ba17b81e">75,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjYtMS0xLTEtMA_14334b63-0bca-4423-9522-e085dfc55cb1"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjYtMy0xLTEtMA_bbe8d74f-2cc8-4fad-a614-989078739ae2"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzIx_2bda0c15-c022-4859-acdf-8be51c225e4a"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzIx_cde8418f-febe-4dd3-b58e-7ea459e3b09e">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzM1_3d843ac7-9488-41d6-a8a7-eb40909b51dc"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzM1_699cb8cc-8706-4e25-a509-36053be31cbe">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_19ba2a5e-3e5c-4386-96f7-f2017ad1faae"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_2ba06891-eed7-4736-9cab-85d8a05710e3"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_585ffe2a-4c57-419a-bc79-ffda4939acae"><ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_e8122fc6-4e3e-4223-b80f-045c26cbd13a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMS0xLTEtMA_b514ee2f-9441-49db-9112-b56119f202b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMy0xLTEtMA_11b0ab8e-8a5c-44ff-a58c-f5abf034e5a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzE4_29760cbc-ef6f-4802-b350-61b4af6ab853"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzE4_a143fd69-aa1b-4750-8d18-76977182a0b7">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzMy_39c23a65-0380-4a1a-abb8-875bc7f9dbbf"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzMy_3e7394ad-502a-4344-ae01-4d361ea6bcea">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzU0_90ae7b79-60c5-4ade-b18e-edcd1c7b8c26"><ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzU0_db8c89f0-3c32-4c8e-bbae-df42af31636d">102,967,017</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzYx_91fbc735-dd1b-4ab3-ad9e-ec8c3b882c48"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzYx_eea31663-41c2-4bc4-b345-208a5a6f01ce">93,599,975</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMS0xLTEtMA_bb7d0c57-617e-4afd-8972-2893ff0458a2">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMy0xLTEtMA_59320495-d0d2-4ea9-a7ad-0e7b4201a3e4">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzAtMS0xLTEtMA_d0e6d3bc-fe28-4f3b-aae4-b2ef9f73e91d">750,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzAtMy0xLTEtMA_491de9ce-4a84-4023-ab6f-1f28a3e80b69">680,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzEtMS0xLTEtMA_a039fc75-1ec1-43e3-9935-25896faf50bd">633,109</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzEtMy0xLTEtMA_b29f888a-d20b-4ac0-b08e-a5f82fb7e685">554,765</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzItMS0xLTEtMA_2b0ce254-134f-4391-bcfc-f90ec18637dc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzItMy0xLTEtMA_3374ff7e-48d1-4232-846c-22e3c663fe71">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzMtMS0xLTEtMA_fd420e3a-de02-4776-8ea6-5a8ef99c81b2">117,569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzMtMy0xLTEtMA_fc83ec89-984a-45d8-9e8f-a1fef6493272">126,112</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzQtMS0xLTEtMA_c4652467-999f-4154-bea1-c760a00623c5">204,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzQtMy0xLTEtMA_2951c3ce-01d0-4581-b2d2-e871d7c3df7d">201,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5169c85622a346fb9062ffb6b012fd12_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy0xLTEtMS0w_0e675c44-a596-4213-9ab4-f529be20a307">1,310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic844400b43a7400da61df183e26a583f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy0zLTEtMS0w_be67838b-3bda-4d48-8a4e-ea923d6cc76b">1,125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b324fd57d14e27bcd90f57c095fb22_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy01LTEtMS0w_755e5607-58d2-41d7-a4e7-b899503742ea">2,764</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44aa89a05a754d1b891d684b45030896_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy03LTEtMS0w_9c2c69db-737f-44fd-844a-9417622c7a95">2,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70adb02e2ed84dbfbb84ecc59e237f22_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC0xLTEtMS0w_c0e6dfdc-11d3-411b-88a6-c869c83ca216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46815f43fb5147de827a675a8e9bff26_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC0zLTEtMS0w_38a66b4d-f612-4c0f-83a7-7519c49d2a43">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f93c6e57284dcdb9ba529c830b9ddc_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC01LTEtMS0w_41e56a80-0648-4181-afb2-e6b08e0abba7">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d70bc74d694a89afe4beef05f285a0_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC03LTEtMS0w_e631ced3-d881-4deb-804f-80136435bc98">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefc52610f304fc29c70ee02bfdad54f_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS0xLTEtMS0w_c9af0644-4ea8-41bd-b01b-2f163c12ee19">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6dc4b98bc94f80aee011fe441527d8_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS0zLTEtMS0w_04965215-fe18-4629-bb09-e47137e31179">706</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63cbe2d3588447c6a15715bc02d7d4c5_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS01LTEtMS0w_2034d4cd-0c00-48be-9d34-1f687e2f31e0">5,005</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305ca64104904718823ba7cb678ddb2d_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS03LTEtMS0w_c01c08bf-8b8f-47a1-8543-55425087eb24">706</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi0xLTEtMS0w_043ffa85-1125-4a71-a3bd-677c92c14ad7">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi0zLTEtMS0w_fae0c03a-afdb-4286-a0b1-6eadc0c74ab4">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi01LTEtMS0w_1f289167-a77b-4b08-8d84-d5e3ccc7109c">7,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi03LTEtMS0w_f33ebe0f-8f51-4f04-adaa-fae4b0719dbf">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC0xLTEtMS0w_987d149f-86ea-42d9-a7c6-dcf905cfdf09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC0zLTEtMS0w_44e22628-6e3b-4862-9f35-87b43b634be6">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC01LTEtMS0w_ac7f83a7-9974-464f-9a33-8b8fc1ddf951">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC03LTEtMS0w_8a4192bc-8044-4734-97df-e6c42b34e2aa">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS0xLTEtMS0w_d86b7c29-6fd4-4617-94b4-60ebc1ecdac5">26,021</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS0zLTEtMS0w_87c2b0a7-8d5c-480c-b6ed-f9ee8d14ed54">18,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS01LTEtMS0w_3b110c36-1500-43a3-89f1-e74d581042fa">46,477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS03LTEtMS0w_5e7fa451-e7d4-42f8-9086-edadd3d040cf">34,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtMS0xLTEtMA_2f26f59f-6711-4d94-9335-e05deaf89346">20,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtMy0xLTEtMA_5614b2b9-427b-446a-baf2-24dc0c84c4ec">7,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtNS0xLTEtMA_2465003f-41c4-40a6-abcc-32e055b76ef7">37,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtNy0xLTEtMA_1675071a-87e4-4fc3-bc26-ceed7bb071b1">14,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtMS0xLTEtMA_b5e772cc-9390-4143-9a34-c4901fbf0969">46,145</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtMy0xLTEtMA_8f92de22-a0b5-4b4d-8063-30a3e7c1e8ee">26,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtNS0xLTEtMA_6a460265-e4ef-4055-b908-9f66062ec1d0">84,732</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtNy0xLTEtMA_255aeb46-a71d-4aec-b6d8-cf9270ad56a0">49,025</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItMS0xLTEtMA_d6654d33-e899-4fa1-bb3d-24e668219396">44,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItMy0xLTEtMA_d86ce272-1eaa-4ce7-a02b-ace3fe495f2e">24,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItNS0xLTEtMA_46cc345f-06dc-48f8-8126-bb4f16fb1111">76,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItNy0xLTEtMA_f10d5e0c-2e3f-437a-b389-5cbd0056551a">45,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtMS0xLTEtMA_e5483768-6deb-4955-930e-fbb8e5fda75a">1,202</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtMy0xLTEtMA_84362921-dc32-4b38-99d9-7195812b82fc">1,226</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtNS0xLTEtMA_7f0c2e0c-1419-4cfe-aaaf-cdb8080c05b7">2,302</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtNy0xLTEtMA_f1aaf233-a36f-41a4-8af8-e7787fa5afcf">2,583</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtMS0xLTEtMA_52435d31-d31f-44f7-bd58-246acdef732c">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtMy0xLTEtMA_24931e9e-b650-4efd-87a6-e2f519651cb3">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtNS0xLTEtMA_a95cfbb0-2a9c-4164-a86d-16cdc5db5f88">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtNy0xLTEtMA_88230f70-9b29-4e12-bce6-a5ba30a91ac6">1,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtMS0xLTEtMA_78b1c04a-7671-4864-9a9b-2652614e100e">45,187</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtMy0xLTEtMA_965f6a75-83ee-4276-8b8e-f4c93e09ff7f">24,956</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtNS0xLTEtMA_15a04e0d-556a-435d-ae03-a53ab94e4e27">78,341</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtNy0xLTEtMA_2d1fd419-4266-405f-bd37-1bff4c35dfbf">47,329</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtMS0xLTEtMA_bffdd046-7b66-406f-a056-e41ce490cef0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtMy0xLTEtMA_b883faa6-f4b4-47dc-b200-feb5e8774bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtNS0xLTEtMA_a881bf87-adef-4c41-81e3-82b4bbb91f5b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtNy0xLTEtMA_37f35cee-99e2-437b-9a78-65dc8b1bc094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctMS0xLTEtMA_36b1a710-f49a-4252-bb30-be22204d3ebc">45,189</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctMy0xLTEtMA_c0031e41-f89b-4230-86a9-8347f3e680e2">24,956</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctNS0xLTEtMA_6670e331-2aa3-4a4c-b0fa-285f531ae058">78,344</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctNy0xLTEtMA_fe2daaae-b1f4-4653-a48b-5cb9626a6084">47,329</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMS0xLTEtMA_3231ae0b-5441-4177-bace-c718a4904339"><ix:nonFraction unitRef="usdPerShare" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMS0xLTEtMA_4f1d2145-46a1-4e54-a23c-f9b91939bf80">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMy0xLTEtMA_66675b4a-0cf1-46bf-ad2c-71de9f816993"><ix:nonFraction unitRef="usdPerShare" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMy0xLTEtMA_ed339dfc-d849-4ac0-9ce4-970f9375bc17">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNS0xLTEtMA_69bbd04b-1e46-47a4-8ac5-078b4c590e1e"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNS0xLTEtMA_e7ddc54e-7d66-4532-981c-f6f47089aced">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNy0xLTEtMA_30fc0c2d-8e1b-4ee6-adf3-e95ce3969b1b"><ix:nonFraction unitRef="usdPerShare" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNy0xLTEtMA_4da18ea2-bc6b-4ed9-9b3d-bbbdfa1449be">0.53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per share - basic and diluted</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMS0xLTEtMA_309d9cec-93a9-48bd-ac93-de27612209cb"><ix:nonFraction unitRef="shares" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMS0xLTEtMA_87805e5a-9d0f-4d6d-b26f-a3c78249d983">100,040,083</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMy0xLTEtMA_bdea2ffa-a104-4572-bcef-3bf4ee31db46"><ix:nonFraction unitRef="shares" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMy0xLTEtMA_ee7940d2-cb9a-40f6-ba2f-739c5d2bc2e9">89,080,046</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNS0xLTEtMA_db96cfd9-54a7-4b15-b75e-01f7115ee3ac"><ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNS0xLTEtMA_f642723b-6388-4104-aa02-40917d4416fc">98,617,564</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNy0xLTEtMA_ec9fb02d-e882-4fcd-8a1a-44e82cee4ec4"><ix:nonFraction unitRef="shares" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNy0xLTEtMA_f2a77d11-8532-417d-8a35-ee2d18d692dd">88,890,353</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtMS0xLTEtMA_9adfd863-b8bf-4b65-b923-12c4994f1957">45,189</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtMy0xLTEtMA_618c0c18-2db9-4e4a-aae7-09b6419a1d88">24,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtNS0xLTEtMA_9809d3b9-cecb-425f-92c4-934a9a424935">78,344</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtNy0xLTEtMA_43580f25-4af8-42e9-9484-0b1afbeb9aaa">47,329</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItMS0xLTEtMA_9da9d98c-383a-4e26-bd23-ac2bca5fbfd9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItMy0xLTEtMA_626baee1-16b1-4733-ac7e-21922505607e">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItNS0xLTEtMA_c7279384-0b3b-4905-970a-f2748909f8b4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItNy0xLTEtMA_000e65b6-a063-44d1-915c-f0df91551230">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtMS0xLTEtMA_5c1a8bbc-1223-4f75-ba97-f7b20bc27df9">45,178</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtMy0xLTEtMA_4cd72bfe-df2b-4a7e-94b3-1c7aca5a69f1">24,595</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtNS0xLTEtMA_cb4fc910-2b6c-4cba-8183-e235e47c2985">78,336</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtNy0xLTEtMA_f8077811-0942-4d99-978d-7e387d0e749c">47,032</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three and Six Months ended June&#160;30, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia91cafc3f3d549f29a542a11fe2aef57_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0xLTEtMS0w_3ade4308-c436-4ec1-9a80-6ad9fa8b8a99">98,688,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91cafc3f3d549f29a542a11fe2aef57_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0zLTEtMS0w_6eb70f2f-0a47-445c-88b7-8fcd7c328375">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe4795385734cbb8a81bf1b0bcd78a5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy01LTEtMS0w_db749189-2a68-4285-85f1-5ac7fbcf1df1">718,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65a85d71d0204688a7b741f604983349_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy03LTEtMS0w_126f0859-b951-4785-b23b-9e0bdf935c25">587,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7e91b1a5dd24c928910e0eb927abf63_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy05LTEtMS0w_3d789782-fac7-4c63-8a0f-627e4e72c100">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996b9b49c28f44a59ede689736e3c19b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0xMS0xLTEtMA_7841acdd-31de-4199-8653-4164ba3273f0">130,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi0xLTEtMS0w_3926987e-0fc1-40db-9335-cf15b284c417">194,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi01LTEtMS0w_460eb337-fa77-48d4-89c7-6382315dc8ff">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi0xMS0xLTEtMA_2cd2beaf-c5ef-4dd5-85f1-33a1011a023c">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNy0xLTEtMS0w_af4d65b5-c264-484b-a66f-a5c510571321">44,684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at-the-market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC0xLTEtMS0w_d00c5d8c-6d18-49be-ad71-aa1b77c19c50">4,038,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC01LTEtMS0w_db0f200a-f670-468f-82e2-7a79811bc75c">28,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC0xMS0xLTEtMA_2ed488b6-99e3-4969-b232-4bcc76e01633">28,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOS01LTEtMS0w_fd5f7821-e20c-4b2d-8f41-51d741952d78">3,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOS0xMS0xLTEtMA_f62b7572-1d9c-4f88-98f1-47e30d851917">3,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b5a2b6ba734b409098fe1a0d30c5e2_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTAtOS0xLTEtMA_9dcf393c-84c4-4fa4-861c-10ddfafc36df">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTAtMTEtMS0xLTA_e28e3acc-f485-45ab-945f-b958bc374bc8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bd017782e8d453ca3fbb2a862a9ba90_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTEtNy0xLTEtMA_96c42f62-1159-40db-bd2b-9c202c088baf">45,189</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTEtMTEtMS0xLTA_f0c432e8-39f0-4808-9fe1-aa41e07640ca">45,189</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMS0xLTEtMA_9a3513f0-b0e9-4e66-84a8-42001b2d1ed8">102,967,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMy0xLTEtMA_2553b5af-77bc-4009-ad95-729268d8e6d8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ff1f828c934f0f88513250a9fcec8e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItNS0xLTEtMA_2096f7fa-71a6-422e-8dc7-93ca55e1e6ef">750,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItNy0xLTEtMA_8e47effe-7cf4-47ea-99b4-6d4dc69a2151">633,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0080ccb444c45f6820630de940835f5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItOS0xLTEtMA_caf248a3-afd4-4bc0-9441-0796789a1635">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMTEtMS0xLTA_8704aa2a-7298-42d4-8e62-04ba713896f2">117,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18cceea8b49b4f9996c4425728df8ddb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0xLTEtMS0zOA_3fd02609-484b-49f6-be4c-de309ca3cb02">93,599,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18cceea8b49b4f9996c4425728df8ddb_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0zLTEtMS0zOA_07d4ec43-454a-42a3-ab84-4e0231c09e15">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e3cd82573141db8cb46c3d4aff5c1b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy01LTEtMS0zOA_bd11b23e-f929-41f0-87df-4071dca7f399">680,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia40995d012e245ab8f368eab46de01fe_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy03LTEtMS0zOA_61967fca-4075-4b45-b8b7-d003e58aaa10">554,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9599acbfae04ff2926fa311f5b1fa11_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy05LTEtMS0zOA_d0e95b0e-c6fc-4e27-8595-c17b99bb4fb7">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0xMS0xLTEtMzg_6f55765a-99ac-4b3f-94d1-3413909595b3">126,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC0xLTEtMS0zOA_9b1c6cd8-4680-484b-ba80-2a04b15b51ce">102,208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC01LTEtMS0zOA_f8ffa616-ee7a-42ba-bb9e-9a6f2c01f74f">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC0xMS0xLTEtMzg_773e4eb2-3395-4cc1-baa5-df51d3658442">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi0xLTEtMS0zOA_e136aa98-28b0-47fe-a638-14aec0a2d1da">205,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi01LTEtMS0zOA_b642e51b-8043-4bd2-b231-d39445453b00">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi0xMS0xLTEtMzg_cff54803-4056-46a8-ab58-210a1cfa0fe0">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNy0xLTEtMS0zOA_b734bf82-91a7-498a-b570-eab6f60e978b">79,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at-the-market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0xLTEtMS0zOA_a6ecd68b-2e97-4116-a1fe-cc122a845ac0">8,979,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0zLTEtMS0zOA_2614dee2-ebc4-45c0-a901-195d0d4c2831">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC01LTEtMS0zOA_30d0b047-90dd-493a-acef-ba6080d412ac">62,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0xMS0xLTEtMzg_4dbc6e68-d276-462f-b21d-522764d11342">62,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOS01LTEtMS0zOA_88acb922-5b6e-4e29-8973-07fd00cb6189">6,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOS0xMS0xLTEtMzg_f31492c1-5f97-4fed-8341-434ceaaf1b81">6,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa2601d5c60400197dae7d0b451836e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTAtOS0xLTEtMzg_736ceb70-2afd-4777-b6e8-c444183156db">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTAtMTEtMS0xLTM4_e3e19890-ae8d-448d-86ed-b5768eef6417">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4740541ee7924fea863cb9f577326fd3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTEtNy0xLTEtMzg_bc15edec-9889-4388-97f2-4ad7eb2eeaea">78,344</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTEtMTEtMS0xLTM4_c262b52a-c56d-4544-bbe3-5599caf6e6f2">78,344</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMS0xLTEtMzg_6c3034c1-2bac-401f-b032-71d96771278a">102,967,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMy0xLTEtMzg_97f6a539-800e-4cb2-9321-4a8e425d470b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ff1f828c934f0f88513250a9fcec8e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItNS0xLTEtMzg_d9611c55-c0ff-44f7-8efb-dead6f26dbc3">750,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItNy0xLTEtMzg_b680cfbf-abea-4891-b0b5-1967ae85729f">633,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0080ccb444c45f6820630de940835f5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItOS0xLTEtMzg_e80c649b-5d0f-4bc9-af5c-a3894a5df45f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMTEtMS0xLTM4_6f74a787-7f48-4b40-857a-9eb6ad9589ef">117,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three and Six Months ended June&#160;30, 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0xLTEtMS0w_5d0aa610-7f99-4760-a508-62c75bd1bfcf">89,035,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0zLTEtMS0w_f7c4680d-b825-42c8-8d46-2a9e0362eebb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia909a04442314115a14cb637f127f9a0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy01LTEtMS0w_da00833a-bef6-4b75-b096-f97d531b51f4">650,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab525b262fba48b39730d896423dd7fe_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy03LTEtMS0w_6bb0bf41-4091-414f-a2f4-2ef5d3e70804">482,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2175ce28f9d54b8083c2d9170d124b24_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy05LTEtMS0w_fdefc506-fc0a-4509-9c10-8d958f3c4b98">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521561e365cb4f9aa0c62af71fc32133_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0xMS0xLTEtMA_b52aebdd-bc67-4697-82d7-9114d5d78aad">167,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if512d3ccb798492096508a8d2449275e_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS0xLTEtMS0w_d26eb4a3-b510-4bb4-ba60-be7974f31e3d">42,403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS01LTEtMS0w_7b90328d-4608-4863-bebb-30fa25ba125d">310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS0xMS0xLTEtMA_aee3a60d-e7b9-485c-943c-9129c5badba3">310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if512d3ccb798492096508a8d2449275e_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi0xLTEtMS0w_23fb46f6-761c-4c59-91b3-aef7a6a83c2a">63,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi01LTEtMS0w_641fa403-7786-4e3c-9e15-afd8d43d00ba">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi0xMS0xLTEtMA_704b5255-ac13-4ee9-909f-67f7eacc7589">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOC01LTEtMS0w_c069e09e-697b-4bc6-9640-ff3ca45ddd90">2,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOC0xMS0xLTEtMA_40d3fb05-01e4-48cd-a570-95fbd4a97812">2,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055e0b998d064537b3d88828cb52ae44_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOS05LTEtMS0w_f7230cd9-dc36-436d-adf2-f13cc96fc47d">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOS0xMS0xLTEtMA_32155cf0-038c-470b-9d48-4c7e33f46be1">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f1fb8a7c88e498f92aa1aae68c2fea8_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTAtNy0xLTEtMA_8145fbe8-06cf-467e-ab70-4f9d7d4c9288">24,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTAtMTEtMS0xLTA_83b7497f-0438-45a8-8ba3-4208de0fb441">24,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMS0xLTEtMA_9a85ad53-a22d-453a-9792-a9479d73f099">89,140,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMy0xLTEtMA_a528c7cf-feb4-43c3-864e-3d4a4ad62872">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c73b1263494577a798b153956f45fc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtNS0xLTEtMA_68207679-7158-47f8-8c26-dd01a6a71f0a">653,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5481c5ac22b441f1a636dc6115281e1d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtNy0xLTEtMA_bac5860d-c7a1-46c4-8629-24234e2f0735">507,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37628ae924f0472da65e1caaf4ca8ce8_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtOS0xLTEtMA_37c58149-9f39-46b7-8666-7aff6f22f475">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMTEtMS0xLTA_9de8bb7a-1f17-4c31-95ae-73addde050d8">146,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53ee417fef84d79a20f0137c9009129_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0xLTEtMS01NA_a667c1cc-a7d7-4588-bcd5-943af553ac25">88,817,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53ee417fef84d79a20f0137c9009129_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0zLTEtMS01NA_b24ae5cd-99e2-48f4-9256-9c553c3c3028">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb8a5ab08814d09a475fc45cb62c355_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy01LTEtMS01NA_e8c7cbe2-b762-4fb4-b641-1ddf5a7fd19e">647,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf0bc9463f684e9b8d4d88cb346673ec_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy03LTEtMS01NA_a9ef80a7-d2ea-4d43-9719-2e0c3e030fff">460,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe50953188ac47108208481d704ce612_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy05LTEtMS01NA_34c13332-8bc0-4333-92c2-dc83d90a4a8a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd41c948817d46d799997c58b6d1030b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0xMS0xLTEtNTQ_3e03af83-b7b4-479e-a02a-8ebabbc9396f">186,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC0xLTEtMS01NA_8ffc9252-0aa8-452f-b122-2becf3f3f7a0">75,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC01LTEtMS01NA_31bc9d8d-456a-47a6-932d-03c4c3ae6389">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC0xMS0xLTEtNTQ_5a8cf86c-7e38-48ce-aeea-b83d49b49b53">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS0xLTEtMS01NA_0ffb8daf-cc23-4242-a452-32756b9ac017">42,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS01LTEtMS01NA_ac778148-281f-4b7a-89ee-8e6a75df1302">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS0xMS0xLTEtNTQ_750f73a5-0074-4108-b5ee-4f7633e71f41">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi0xLTEtMS01NA_39fd2c6e-fd92-4499-9e4a-43777118991a">204,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi01LTEtMS01NA_03eb4f03-8b1b-40c3-a247-c0503afda12d">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi0xMS0xLTEtNTQ_66506489-bf45-44b5-b975-53574bf0834a">420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOC01LTEtMS01NA_63059854-f104-4ad7-be9e-8f26c16ad574">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOC0xMS0xLTEtNTQ_8acde3ad-4c28-4169-8191-f7ec938e7c0e">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52df4b25bae450697308ad35e1759ba_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOS05LTEtMS01NA_74dc79a9-9330-4963-9090-0836101ce1b5">297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOS0xMS0xLTEtNTQ_8a95803c-232c-4311-a76d-635e8605d6e6">297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i783b4aad17a142a08d4f48f537af01a4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTAtNy0xLTEtNTQ_0942bd3f-8dca-4173-a32d-79bec39777aa">47,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTAtMTEtMS0xLTU0_94ae78e4-fba7-47f6-9de9-856d35752777">47,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMS0xLTEtNTQ_d89dca5b-28a4-4baa-ac2e-ccc6a778dd63">89,140,563</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMy0xLTEtNTQ_78b25a28-bdb9-49f8-a223-ebdcc5aa7d9e">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c73b1263494577a798b153956f45fc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtNS0xLTEtNTQ_d56d0bd8-f725-4b4e-905a-bc260ca72ab1">653,805</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5481c5ac22b441f1a636dc6115281e1d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtNy0xLTEtNTQ_f6da4004-a20c-4f13-bd78-43850cdc05ac">507,781</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37628ae924f0472da65e1caaf4ca8ce8_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtOS0xLTEtNTQ_8d569947-02c5-4039-a710-65ec0ca9c43b">317</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMTEtMS0xLTU0_a5caabdd-ef46-4b8b-89d2-74a0e051975a">146,350</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMy0xLTEtMS0w_69e15acc-5dca-41d1-ac1c-f02a25430863">78,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMy0zLTEtMS0w_b7cdebd4-8ab8-469e-bda2-31752cfc586f">47,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNS0xLTEtMS0w_67fcb4df-f622-4b5d-b1aa-da627476ae87">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNS0zLTEtMS0w_0228565a-0169-4eec-8ffa-916c1abdee1f">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNi0xLTEtMS0w_f684add3-45ae-4c2b-8d45-abc6ecb1ec14">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNi0zLTEtMS0w_022189f8-dd08-43ec-bf5d-9b7999c37c5f">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred compensation for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNy0xLTEtMS0w_c917fa18-c2a5-4b48-9cf3-9ecd3d1d1d15">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNy0zLTEtMS0w_479edd39-ad86-4d80-b8fd-f0396c442726">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (discount) premium on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOC0xLTEtMS0w_0867fad5-d3ae-4825-8323-a9da96a6f3f5">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOC0zLTEtMS0w_a5d6ecd4-178b-4511-82df-1641b28fefd2">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOS0xLTEtMS0w_9e753b2a-f65d-4447-84d3-ddc5166a1110">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOS0zLTEtMS0w_3259ef6b-b083-4f91-b0f1-4f027cb7bf24">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTAtMS0xLTEtMA_ba8e266a-1050-4170-ab3e-583204f8fc92">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTAtMy0xLTEtMA_47ce6392-48d4-4ef7-8536-b136aa1981b4">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTEtMS0xLTEtMA_55874ec5-2958-4c69-b5a6-48bbc2b111c6">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTEtMy0xLTEtMA_18a67405-d298-4109-a271-2efa99988825">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest associated with debt discount accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTItMS0xLTEtMA_0baa630a-bc39-4a7f-aa58-f6c0136340ed">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTItMy0xLTEtMA_7af055aa-65c3-43da-a0fa-307ce60eb273">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTUtMS0xLTEtMA_1d3e29a4-dc5c-452a-b89f-fb406c13008f">7,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTUtMy0xLTEtMA_ec7e7246-34a9-4d82-9033-07c95bb6ab62">2,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTYtMS0xLTEtMA_bff629b1-8a45-4b46-bba9-f08f1ce8e281">3,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTYtMy0xLTEtMA_1488f539-82d3-4f8d-a25a-80840831ea1d">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTctMS0xLTEtMA_eb2c0c74-8f1c-435d-bdcd-acf5410f6f0c">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTctMy0xLTEtMA_3f8ff4fd-9e89-4706-9a17-11516e51c907">1,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTgtMS0xLTEtMA_25e2f592-dde4-4830-b233-7edc6a0ed1b1">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTgtMy0xLTEtMA_bbf0c2f3-64e5-4a68-a04c-72d8a080c12a">1,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTktMS0xLTEtMA_fbe73f6f-fb81-4af7-abac-eaa7eaf0b142">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTktMy0xLTEtMA_9348747c-7d3a-468b-9734-e37b965f0841">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjAtMS0xLTEtMA_3734a759-03c2-4275-b8d7-dec12062bcc6">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjAtMy0xLTEtMA_607bc570-ec96-406e-8fca-b5a64a501709">2,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjEtMS0xLTEtMA_4fe02038-f6ec-4c3b-95fb-9cec40cbf758">78,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjEtMy0xLTEtMA_db776a38-649d-4570-8860-1a878262b21e">43,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and redemptions of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjMtMS0xLTEtMA_96fd7ccb-455c-4799-b43b-aa2ca0d88117">60,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjMtMy0xLTEtMA_ea23a441-f358-48c0-81b6-1c2214c97640">25,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjQtMS0xLTEtMA_d9123c6c-d447-4134-8026-e7ae0d618dd2">48,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjQtMy0xLTEtMA_fc8f2c51-6454-4128-ac7d-1e2fb4d4422c">62,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjUtMS0xLTEtMA_ce4065d3-8bc5-41b5-a442-8560af394d3c">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjUtMy0xLTEtMA_e6e6117e-c0bb-4d2c-b74d-9bfc5d84e916">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjYtMS0xLTEtMA_5a814ff3-c832-4d63-b514-c1e30ac02090">10,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjYtMy0xLTEtMA_63f2971f-8068-4c8e-8c3c-9ba940c1ba29">37,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in at-the-market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzAtMS0xLTEtMA_110bc062-1688-4821-a771-6fd5710d5d20">62,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzAtMy0xLTEtMA_9ccc520a-ef6e-4e7a-9a49-367566e324a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzEtMS0xLTEtMA_9002e238-4fe9-4420-9a29-aa8a8446cc60">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzEtMy0xLTEtMA_304975d2-eaee-427a-a9c7-541f6c81525d">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzMtMS0xLTEtMA_dadbf070-6906-4714-aa73-eca5f9446db8">63,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzMtMy0xLTEtMA_18079268-0b81-4b0e-8a16-c9296f87ef31">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzQtMS0xLTEtMA_91896fc0-d1d9-4388-a400-5e821519be97">4,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzQtMy0xLTEtMA_420578b9-60a3-4725-a4b6-141a6a121fc9">80,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzUtMS0xLTEtMA_ae59333b-fcf3-4e54-8373-576b922fa340">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd41c948817d46d799997c58b6d1030b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzUtMy0xLTEtMA_84236673-f80b-4aae-af8e-dbc4cb146335">181,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzYtMS0xLTEtMA_73b85d62-ac9e-4c56-8933-8e7103f84341">86,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzYtMy0xLTEtMA_a13ab9e4-c0b8-4dc8-aa87-425d3285b3f9">100,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzgtMS0xLTEtMA_17c5846d-ea2b-4529-80c9-5dba787ecae8">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzgtMy0xLTEtMA_07fc3d2e-1904-400f-a2eb-e78e57281abd">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzktMS0xLTEtMA_f7a490f0-97eb-46bc-a824-8dd099b88e82">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzktMy0xLTEtMA_d33fc9e7-fd61-49d0-ab62-5c007440f0b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDEtMS0xLTEtMA_19a240bf-a985-40c5-b87b-29b9259be28b">14,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDEtMy0xLTEtMA_11f9042c-4680-40ab-8caf-23dc85aff44a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDItMS0xLTEtMA_1059c51e-6bf4-426a-99d6-0e7fb74e3b7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDItMy0xLTEtMA_fee1cd0e-2601-4632-8dc6-0a0e245d6142">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amounts in thousands, except per share amounts and where otherwise noted)</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_31"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1NQ_b1378a5b-4ec9-48eb-9209-caacd14603aa" continuedAt="i159242b1f0de448a9d77182df355b94b" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i159242b1f0de448a9d77182df355b94b" continuedAt="i7ae74660cd9743758b2a7884a74afc1e"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfMzIy_c57f9308-7e18-4d69-8a31-3893bdfbad5e">one</ix:nonFraction> business segment, which is the research, development and commercialization of biopharmaceutical products.</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1Ng_6181fcaa-a6cf-4654-96bd-e6d1713b8764" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position at&#160;June&#160;30, 2021&#160;and results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods ended&#160;June&#160;30, 2021&#160;and&#160;2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2020. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2021, or for any other interim period or future year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1Nw_5c0a5ced-c6e5-4b65-ab79-a923b01c6a57" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfMjUzNA_f12101bb-693d-4df7-9bad-45733c3b37cf">171.8</ix:nonFraction> million. We believe our current available cash, cash equivalents marketable securities will be sufficient to fund our planned expenditures and meet our obligations for at least 12 months following the filing of this Report on Form 10-Q. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding our New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis in which the FDA noted additional requirements would need to be met in order to obtain approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. On July 29, 2021 we entered into a Fourth Amendment to our Term Loan Agreement which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021, provided, however, if the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on or before October 25, 2021, then the interest-only period will expire and principal repayments will be required to begin on November 1, 2021. Further, on July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. For additional information see Note 12, Subsequent Events.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to raise sufficient capital when needed or generate product revenue will further impact our ability to pursue our business strategies and could require us to further delay, scale back or discontinue one or more of our product development programs, commercialization efforts, or other aspects of our business plans. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i7ae74660cd9743758b2a7884a74afc1e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in our most recent Annual Report on Form 10-K.</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1NA_e9d8f8ce-27bf-41c9-8318-306c857933dd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. On June 30, 2021, our public float exceeded $700 million and therefore, on December 31, 2021, we will no longer qualify as a &#8220;smaller reporting company&#8221; and will instead be considered a large accelerated filer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to adopt Topic 326 in the fourth quarter of 2021. We do not expect the adoption of ASU 2016-13 to have a material impact on our financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTg2Mg_24870e53-d8c3-4136-ba52-db80fe3b2bfe" continuedAt="i653b0eb4f4a1438d96fa5c825a135e5f" escape="true">CASH, CASH EQUIVALENTS AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i653b0eb4f4a1438d96fa5c825a135e5f" continuedAt="i2e06667752d742f092669b437b1bac16"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTg2Mw_27466f41-0f4a-4363-80ea-98902e1cf439" continuedAt="i93af5206cb3847f6a55b5ebf378ca615" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b98058de4da42c294fa91c66eeb6e89_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNC0xLTEtMS0w_e06b3ec2-9b16-4728-a46f-854bae3f2f93">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b98058de4da42c294fa91c66eeb6e89_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNC03LTEtMS0w_a19a028a-8ccd-475c-9a31-894d13ef0bc2">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ad3f3857994eafbf8092a727a20054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNS0xLTEtMS0w_b1a52901-b57c-4c6f-9581-396f9b9fb2ea">84,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ad3f3857994eafbf8092a727a20054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNS03LTEtMS0w_3cfb826a-bfc2-4ead-9336-7a2e439279f3">84,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccabbde714945ec89a64f78f0954426_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNi0xLTEtMS0w_a2450eef-fcb0-48cc-9dae-4f2b84ddf076">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccabbde714945ec89a64f78f0954426_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNi03LTEtMS0w_89373bff-e329-4f8e-b489-9bb5e86d1d2e">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfOC0xLTEtMS0w_9c622cbf-432b-4fd0-a902-31a2b6fd2be6">86,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfOC03LTEtMS0w_8a904b49-7b15-48cf-8e96-0d31bab3ecf5">86,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7361da3114524894d528d36761938_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtMS0xLTEtMA_bd6db30b-8a9b-429c-8e80-992cc18e4a17">62,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7361da3114524894d528d36761938_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtMy0xLTEtMA_ed6069bc-099c-4134-bed5-63de7b0c6819">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7361da3114524894d528d36761938_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtNS0xLTEtMA_1a7ad0fb-9a03-49a7-b7b6-63bc7a575041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad7361da3114524894d528d36761938_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtNy0xLTEtMA_9521ea6f-b2e8-492d-a730-fb5a0e52b6c5">62,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acd89d799254005a61260d4785cc411_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtMS0xLTEtMA_aae22df4-226c-438a-9c2e-24fd14d4dbb4">16,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acd89d799254005a61260d4785cc411_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtMy0xLTEtMA_c3d968b4-95b8-44ed-8fd2-7103cfa985ea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7acd89d799254005a61260d4785cc411_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtNS0xLTEtMA_73a20545-b816-4882-9577-7b8631fea109">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acd89d799254005a61260d4785cc411_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtNy0xLTEtMA_f4fef0df-a32a-4dc6-b4c7-c2fa58ce1d58">16,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtMS0xLTEtMA_76474513-1e28-472a-9d33-b1a4c740b4c3">5,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtMy0xLTEtMA_af2f6de5-d5b7-4d80-8bb0-414a13eb3af2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtNS0xLTEtMA_235788fb-5cbf-406b-bc6c-edfeb6a06d77">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtNy0xLTEtMA_1176f6d8-a348-439a-9a9d-811ef580c50f">5,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtMS0xLTEtMA_e7646119-b61d-4253-8daa-c327e889316d">85,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtMy0xLTEtMA_11793310-5a42-4680-8353-ff0046443998">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtNS0xLTEtMA_591d99c8-744f-45af-9f60-d78e9179fb10">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtNy0xLTEtMA_c63c3974-7c1f-4e94-a248-a2ace870493f">85,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtMS0xLTEtMA_f7f52f9e-83cc-499e-a8c5-c445a8c709da">171,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtMy0xLTEtMA_6bb3a7a1-5103-499d-9312-f3af8b0dd325">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtNS0xLTEtMA_438f8516-bf19-44bb-9c53-262176f2e11a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ardx:InvestmentsAndCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtNy0xLTEtMA_ed5d506b-0dd4-44e7-a81d-661c5ac79e86">171,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="i2e06667752d742f092669b437b1bac16"><div><ix:continuation id="i93af5206cb3847f6a55b5ebf378ca615"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNC0xLTEtMS0w_08cc1e00-b370-43bb-b74f-0a2d360b7dbb">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNC03LTEtMS0w_8c16ba4a-1bcc-45e7-836c-55a17ec5836b">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07744061b93432eb1154ad3a3a36816_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNS0xLTEtMS0w_a8ff797c-1ec7-43ff-b828-b88ef840c605">88,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07744061b93432eb1154ad3a3a36816_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNS03LTEtMS0w_4eae09e2-1dd0-47b9-bd83-d479882da460">88,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2251a0841514418a8a29bca5526a858_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNi0xLTEtMS0w_01bd2b9e-5d93-41c3-bb9f-a5ab149867f8">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2251a0841514418a8a29bca5526a858_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNi03LTEtMS0w_153bd4e0-4c81-438a-8d85-ce3c882b4f62">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfOC0xLTEtMS0w_b8560561-8227-4dfc-9c3d-74072e4e7210">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfOC03LTEtMS0w_6384e6b8-421e-4ec0-a57b-d03b646daa88">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtMS0xLTEtMA_02b8ea16-ab6c-455c-a824-3be5c698c5c6">60,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtMy0xLTEtMA_5c2c54d0-656a-4a1e-a069-c0d7ca334f94">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtNS0xLTEtMA_c8176768-7d2c-474f-94f8-ff69f8f9f503">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtNy0xLTEtMA_a66a5eb1-d046-482b-8bf5-17eaeb65704e">60,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtMS0xLTEtMA_74cc1227-fc6a-4226-9285-cd2f73812db7">24,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtMy0xLTEtMA_52deab03-ad92-4e49-bc26-ffdcd532529b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtNS0xLTEtMA_ed1b15ae-c08d-4043-8966-a092793669c7">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtNy0xLTEtMA_329d597c-940a-4424-8712-aa84719df357">24,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItMS0xLTEtMA_980c8de6-7b88-4472-b70b-843ad9ece312">9,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItMy0xLTEtMA_b1f0ed6b-cffa-4275-b03d-17800d2b9f79">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItNS0xLTEtMA_86fe8b1a-2a74-42d7-8975-8cb1e14bfc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItNy0xLTEtMA_3a6c19e7-5514-446c-b99b-2037842644ab">9,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c54e2862a942258157af583a390e08_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtMS0xLTEtMA_8134d00c-e36f-4b5d-bebc-3fe87b7e7db5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c54e2862a942258157af583a390e08_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtMy0xLTEtMA_ee534029-7cb4-4885-aea8-e15e488ff21c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c54e2862a942258157af583a390e08_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtNS0xLTEtMA_3956043b-5e31-44a8-b668-5594a1f51499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c54e2862a942258157af583a390e08_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtNy0xLTEtMA_e76fa941-caf9-4155-8de3-5790b4141b95">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtMS0xLTEtMA_9785b19b-dc3f-45e7-ae16-26f7b8584ac8">95,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtMy0xLTEtMA_57686541-5a13-465d-98d7-1259c9f3c723">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtNS0xLTEtMA_83ecafe7-6a3f-4dba-bb41-890ba0602029">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtNy0xLTEtMA_bf7824ce-260c-415b-8b43-663d05ebf7c2">95,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ardx:LongTermInvestmentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtMS0xLTEtMA_407791e3-d9f3-4e31-9b8f-273c1adefcf1">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" xsi:nil="true" name="ardx:LongTermInvestmentsAccumulatedGrossUnrealizedGain" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtMy0xLTEtMA_7f63260c-9a94-4382-87da-6f4e85510eba"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" name="ardx:LongTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtNS0xLTEtMA_10c7d8dc-ca2a-4d91-8471-48ccd6000756">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ardx:LongTermInvestmentsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtNy0xLTEtMA_f33bbe9d-fe7d-4996-be62-0fac9d1f6f81">2,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsAndCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctMS0xLTEtMA_8bd84e46-2304-4d69-9932-403b57e955f6">188,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctMy0xLTEtMA_9c15477e-f0d6-4543-bad4-4dcdc88c1599">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" name="ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctNS0xLTEtMA_1cae3403-62ba-496a-b701-ef31681a9497">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ardx:InvestmentsAndCashFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctNy0xLTEtMA_0203fbff-5ac8-43d6-8dec-29d8fbb4ab65">188,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest excess cash in marketable securities with high credit ratings. These securities consist primarily of money market funds, commercial paper, corporate bonds, asset-backed securities, and U.S. treasury and agency securities and are classified as &#8220;available-for-sale.&#8221;  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale securities held as of June&#160;30, 2021 had contractual maturities of less than one&#160;year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when the fair value of that security is less than its carrying cost, in which case we would further evaluate the investment to determine whether the security is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition or creditworthiness of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write the investment down through the statement of operations to its fair value and establishes that value as the new cost basis for the investment. Management has determined that <ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_760fd7e8-0911-41c6-bbf8-feb9b7292e26"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_844b7221-92e3-4c42-9b4a-8e55d4c901a4"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_894f5ec5-29e1-4eec-a5b9-fb028fea8573"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_d2f6bcc2-b50a-44b2-a904-1dd58d0df351">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> of our available-for-sale securities were other-than-temporarily impaired in any of the periods presented, and as of June&#160;30, 2021, <ix:nonFraction unitRef="investment" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTY0MA_f84d0018-d99d-4c38-9a02-05ce4b20a2b3">no</ix:nonFraction> investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that investments in a loss position will be held until maturity or a forecasted recovery of fair value.</span></div></ix:continuation><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5MQ_6248fdd5-34cf-417b-9181-ab019172ce3f" continuedAt="i05d469169f544bb49d3db1685370a4e7" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i05d469169f544bb49d3db1685370a4e7" continuedAt="i4048e0160173446eafd122d96d908414"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5Mg_a74af059-6cec-422e-a13f-596daa982f63" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="i4048e0160173446eafd122d96d908414"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5Mw_839906e5-a3af-434c-a826-5c08a88ab55f" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied42e28071324f2ebd2db962a44477e1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy0xLTEtMS0w_c0d1d318-8462-4dd4-abb0-15dd01db45ae">84,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f276be494047f297ca9e5088e20b96_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy0zLTEtMS0w_d276be21-3176-4c0c-87ca-20164c95e042">84,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e74d17c420a47afaac9eca94b5c23eb_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy01LTEtMS0w_c4b13013-5b8a-4018-bf1e-5a6461a27e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3063806f84794b4ca0e47322baed68bc_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy03LTEtMS0w_f001eebc-8ff6-46ce-82da-827aa3563694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf01a41f9d048ed926937a9e81f57f5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC0xLTEtMS0w_8626ac59-cb34-494d-8473-fb6a994685aa">63,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acef194906f40c4b0bc625b1fe030d8_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC0zLTEtMS0w_87315b95-71e3-4a3f-8710-b20e256beb20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89a5f8f089048d695069dfd0f3ddb1e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC01LTEtMS0w_2425f9ba-da4d-46fd-b72d-bf6e3bb787ed">63,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16d7277926b4ae1a8bf1f8ccc7f5fdd_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC03LTEtMS0w_c02aad11-ce23-4a4f-8ce0-c7feef3962ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6b406bbf6f45849047db8c4c1bd725_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS0xLTEtMS0w_d127c00a-31e6-4676-8d02-1b4e19e458a8">16,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7317f8962714c4b83d096692d77f4c5_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS0zLTEtMS0w_64e17a19-a68d-4405-956c-ce42b3b6833e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9635984f4f30476f8f150e932200d84f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS01LTEtMS0w_23f0b2e7-a6b0-4069-add5-f147ca128191">16,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de92fed80134bcdb3a7fc397526ea81_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS03LTEtMS0w_f788d024-2361-44ad-9449-fefa41ffed35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1f62f1e1524a1bb1796ea45572aa13_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy0xLTEtMS0w_ea39f226-e60e-41d5-b479-56c91db9b6e1">5,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a8a52b89c442b0802c08887c2a4136_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy0zLTEtMS0w_33650c3b-dba1-4024-92e0-1889c66912a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c22c74c3a41568c43be19dee6db9b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy01LTEtMS0w_22ca5838-42b4-47eb-9890-f320ed1e3cbd">5,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d0ce291981454e84664b7d247bbd2e_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy03LTEtMS0w_61db5840-383e-42db-90f0-df8c14c4e570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331cc003c0d04f078a6a32154ebd1c19_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS0xLTEtMS0w_c2eea0d9-fb28-4647-905a-6f4eb1af3316">170,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5fb96fe51e419887a5821e069bbb56_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS0zLTEtMS0w_62a7b499-8005-4474-8e1f-cca6adb23627">84,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c3ad7f462746299218071393ac1e76_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS01LTEtMS0w_f01d83f8-6763-479f-af5b-87c96e6649ed">86,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec0006dbb884a2688382b808984430a_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS03LTEtMS0w_0a6c50c4-07e3-4492-984e-b3760fda0900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f9b87841b6410e833b3c2aec531508_I20210630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItMS0xLTEtMA_5611d9eb-08b4-4edc-8a82-b7c2414015ae">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e6a25c0cce4489942fd3fe7e7c649b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItMy0xLTEtMA_6477c9aa-8d16-4e52-83ca-47f927fa63ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e9e314500242078338cfabc68e7044_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItNS0xLTEtMA_935b55ca-d72a-41a2-91c7-b0ae1b597015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad2604c61a3d4a84a43dc5a5223d046b_I20210630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItNy0xLTEtMA_7d76a8e6-1a57-4ef3-9cad-0c7938c0f96f">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331cc003c0d04f078a6a32154ebd1c19_I20210630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtMS0xLTEtMA_42c4e38a-334b-4705-b0fe-f71bab546615">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5fb96fe51e419887a5821e069bbb56_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtMy0xLTEtMA_24fb7439-d78d-48a2-a737-b44af469bd6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c3ad7f462746299218071393ac1e76_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtNS0xLTEtMA_9e20a044-5164-49f5-a6a4-05281cabe952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec0006dbb884a2688382b808984430a_I20210630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtNy0xLTEtMA_d9df1cc4-5c14-438d-9a9b-f66de7c0fe6e">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf133615c36b4ab3a3e102804e0b1395_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy0xLTEtMS0w_be7c12b9-074b-4fc4-9035-2bf3083f6d57">88,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f163fd764f4b419a6b868c74be4819_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy0zLTEtMS0w_1042230c-4b34-4cff-9c80-956ef21f4b84">88,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67057377152479a8f17df5a513c8a7c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy01LTEtMS0w_f4b66a61-94ea-476c-b787-93d9b6d7be05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343e1acc71bd421f93de6475da3bff62_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy03LTEtMS0w_5702fd5b-3e43-479c-ab7e-b08b3d364d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3066659e3a14837b312644f5691a4bf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC0xLTEtMS0w_48afa3fa-32b3-4add-9f49-7610ea6459c5">62,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1a8fad572045d6bef48f3a3f6b19e5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC0zLTEtMS0w_fdfb4eb6-211a-4af8-a781-ca82c25cbfee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83afd2bc4c346a6981483552dc69b41_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC01LTEtMS0w_9fa17897-96bc-45c4-84ab-a69dd64b8a7b">62,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a252b2bdcfa4716b77eb9c9da774c15_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC03LTEtMS0w_fd5efb70-ee14-4b36-bc5b-226a4891d8c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359ed40755d742d598b2a7d817c16d1b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS0xLTEtMS0w_4faa9216-c4c8-4ddb-a002-02f561963783">26,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fa54e72d4843718c001d9ccb44924b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS0zLTEtMS0w_6456a38c-4c3d-489b-90b0-fe5af18fbe30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ba44fc4ef4475b9a38bc841b0576d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS01LTEtMS0w_ef865ec5-33a2-4425-b275-0ead39b8fe70">26,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718d02cc72e24371be1e76266dcf5064_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS03LTEtMS0w_ff8c29cd-1850-4742-bc90-11d85909e5b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84bae8c4960433d93fdb8f2d7158729_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi0xLTEtMS0w_68944bdf-2602-4ac0-b01c-65b872da3f4b">9,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a26be08aec4aeea36c9609cfd1b404_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi0zLTEtMS0w_4f0515dd-6d7e-45e5-8e83-c8927ad6d0e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8614004f13e5407d91653ae48dae6571_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi01LTEtMS0w_29b9a978-b3a3-430a-9706-8102de4f8c77">9,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8f87376786455daba169deb2cd6918_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi03LTEtMS0w_700bf53e-f9d9-432b-9b12-d53473cdb81a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id472a845edd54c8788fc87a0d47191f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy0xLTEtMS0w_07aad0bc-ca34-483e-91ec-f68c5b99f530">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c27facfc44a42718fa0b68303467103_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy0zLTEtMS0w_5369677b-69e6-4b78-9502-e388fc52c288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie506d6ee79ea43278c382f43160888b0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy01LTEtMS0w_ce411956-bc03-43cf-9b17-9142354555da">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c71f6dc2c144e6bde1f09a7d4d318c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy03LTEtMS0w_7d45db1e-5546-49ed-87c4-c3dddf985819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafed114ecbb40428246f042c26c16d2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC0xLTEtMS0w_00c2dd8b-6b31-4c42-a716-0c4afe9bd9e8">187,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0667655fab5c49cc8a9064756e708041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC0zLTEtMS0w_82ae12d3-7b7a-47db-9a6f-d445838671b2">88,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ed11eb6d6e4fd99e38e05050686318_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC01LTEtMS0w_013d475e-5607-4fd7-bd7d-80143cbc8fd4">99,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd4156d88704e5dbe480f29b020b4b9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC03LTEtMS0w_d4229fcf-4530-4ce8-a225-1dc9fc0d8de5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed64ecd7425451a846dd9c27093960b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtMS0xLTEtMA_d14bcc46-e4d2-4361-bfa3-aef6d8cd5a96">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2769548737144611a050277733a53d55_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtMy0xLTEtMA_f85239d9-671f-46cd-9847-dd6bb92a851f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0206150a344137a26fa4bb438d55b5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtNS0xLTEtMA_e39c486c-7456-4ddf-8141-44ea87fb6663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428867f600214f18bfdfb49712d4abf5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtNy0xLTEtMA_7690fa52-c1ac-48d7-988a-6648107475fc">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafed114ecbb40428246f042c26c16d2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItMS0xLTEtMA_bf1aee31-f776-45d3-b520-443f6bba0edf">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0667655fab5c49cc8a9064756e708041_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItMy0xLTEtMA_89656c89-2948-4780-8960-094cab657012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ed11eb6d6e4fd99e38e05050686318_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItNS0xLTEtMA_a7d30f69-a512-4978-87f9-6b99adc2255b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd4156d88704e5dbe480f29b020b4b9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItNy0xLTEtMA_69bdc66d-57ca-40cc-81c6-49ff58c8795e">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, asset-backed securities and foreign currency derivative contracts as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities such as the Exit Fee, as defined and discussed in Note 6, are classified as Level 3.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2021 and December&#160;31, 2020, due to their short-term nature. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at June&#160;30, 2021 and December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTI3Mw_5c08c736-583e-4e29-bac0-4119f229025b" continuedAt="i7a3fd8e413d64f26b040e0f5f1fb8d1f" escape="true">COLLABORATION AND LICENSING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i7a3fd8e413d64f26b040e0f5f1fb8d1f" continuedAt="i1f5263cb7d9c475698f1dc156c644cb3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute <ix:nonFraction unitRef="item" contextRef="id9f52e3ac5894f0d82d3246f26b4426f_D20191101-20191130" decimals="INF" format="ixt-sec:numwordsen" name="ardx:NumberOfSeparateCollaborativeAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjU4_6b546ba7-c117-4cc1-a499-11df4107d95b">one</ix:nonFraction> or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTE5_a49a399c-f37c-4215-849b-cbd1f72e7cf0">10.0</ix:nonFraction>&#160;million in two installments as follows: the first installment of $<ix:nonFraction unitRef="usd" contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTY4_b336618f-ad2c-44c0-b97a-40a561dde70e">5.0</ix:nonFraction> million within <ix:nonNumeric contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130" format="ixt-sec:durday" name="ardx:TermOfPaymentOfLicenseFeeFirstInstallment" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTc4_3bcef376-a81f-4d2a-bf98-31ac5f06c390">30</ix:nonNumeric> days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $<ix:nonFraction unitRef="usd" contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA1Ng_c18f0484-74cd-4c9a-bcad-e88a4e1ad4ff">5.0</ix:nonFraction>&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) <ix:nonNumeric contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130" format="ixt-sec:duryear" name="ardx:TermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTI5Ng_3e4ef167-203a-4bc7-be37-dd7f5af25480">2</ix:nonNumeric> years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="if971ec15d09646659e6f792d4e0c33c1_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTYxNQ_a7896006-e5d4-4752-bce4-6ba4fa63022e">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc9980b470ca44ceb2a1da9962e99de8_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzM2MA_52f7979c-9923-4844-bca6-4297a93e4274">2.8</ix:nonFraction> million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. During the three and six months ended June&#160;30, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i6882c8ec77184cfc83073e6f4ae139de_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzY4NA_eed63e22-1307-4ad1-8617-13dd9de4286b">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i891ee02e0c064d5fac9eef456b775d16_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzY5OQ_91a0242a-e3d4-43bd-b0bf-283ea0b4c806">2.3</ix:nonFraction> million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. The aggregate amount of the transaction price allocated to our partially unsatisfied performance obligations as of June&#160;30, 2021 and December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8f8816a7551b42f7b0f4ee113d914fe6_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzODA5OA_cdcbabdf-335e-4539-a037-9c903d99561a">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if032ba3b809943c691949710d1c0d6e8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzODEwMg_780a8dde-330d-4c13-8cd3-76f56745bdc5">4.2</ix:nonFraction> million, respectively, which is presented in the accompanying condensed balance sheet as deferred revenue. As of June&#160;30, 2021, we expect to recognize the remaining transaction price allocated to our partially unsatisfied performance obligations over the remaining research terms, which is currently expected to extend through the end of 2021. There were no significant changes in estimates associated with the 2019 KKC Agreement during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130" decimals="-3" format="ixt:numdotdecimal" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMzY1Ng_05ba0c04-e2bd-479f-a838-4d99c4141048">30.0</ix:nonFraction> million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the up-front license fee received of $<ix:nonFraction unitRef="usd" contextRef="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130" decimals="-3" format="ixt:numdotdecimal" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDA1Mg_05ba0c04-e2bd-479f-a838-4d99c4141048">30.0</ix:nonFraction> million, we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i69ac419220864a3e96c1c6f85f0e3d6c_I20171130" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDA5Mg_5f4f72d6-0b0a-4b25-8890-37f63916b396">55.0</ix:nonFraction>&#160;million in total development milestones, of which $<ix:nonFraction unitRef="usd" contextRef="ifd7ffc17c4ea41b8942ca8c90aef5985_D20171101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDEzNw_155d1188-6775-4093-bf0e-9b4ca7db36b3">10.0</ix:nonFraction> million has been received and recognized as revenue as of June&#160;30, 2021, and approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="i1534860e131847dd8b0713fab040d16d_I20210630" decimals="-8" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDIyNA_f0e151b2-8918-4a2a-9bf9-2c55bc2ad5bb">8.5</ix:nonFraction> billion for commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="i1534860e131847dd8b0713fab040d16d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDI3OA_75f3f8ea-7a31-455d-921d-ab3e8aa7dcee">76.5</ix:nonFraction>&#160;million at the currency exchange rate on June&#160;30, 2021, as well as reimbursement of costs plus a reasonable overhead for the supply of product and high-teen royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 we recognized <ix:nonFraction unitRef="usd" contextRef="i6ca092a95ab44a3fbec59b1d0b8dead2_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzE1Mg_b4c11dec-9a89-4540-af65-b7587583ca36">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i283b29715ca94bd7bff20ea912e2dc44_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzM3MA_77fdb7bc-0f13-429a-97e7-bcd6f0ed0f3d">5.0</ix:nonFraction>&#160;million, respectively, as licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2020, we </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="i1f5263cb7d9c475698f1dc156c644cb3" continuedAt="i5a6e2bb74bb64e07a0bed523738313cb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized <ix:nonFraction unitRef="usd" contextRef="id2ed442c04974d718d23c4fab2737e51_D20200101-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDcwOA_7ba9e921-9eaf-4f5c-b6c9-ddc7c1826ab5"><ix:nonFraction unitRef="usd" contextRef="ifc13520e38174911bb24b8da85289f37_D20200401-20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDcwOA_b677d1e4-1cb4-4e67-9d67-67c9d5a5de70">no</ix:nonFraction></ix:nonFraction> licensing revenue upon the achievement of development milestones. The $<ix:nonFraction unitRef="usd" contextRef="i2816086d585e4b8ab2a5d4fcf91cc35b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMzI5ODUzNDg5Mjg4Ng_71e4f3ab-48b1-411c-81de-d1d7e6716491">5.0</ix:nonFraction>&#160;million development milestone recognized during the three months ended March 31, 2021 related to the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2021, we recognized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i78360eebb07744fe9d6aa96a4bb1ccec_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTAyOA_74de27fc-82e2-4468-93bd-c59ad24ccec4">zero</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i33e4b72e7e4047f7963dc1ef571b8610_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzcxMA_9ca83ab2-6bd5-4829-92d9-9491cea7ac30">0.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized $<ix:nonFraction unitRef="usd" contextRef="i9445347caff444659496b5c488ed0fa2_D20200401-20200630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc1Nw_c5c7fe5e-7bff-4774-a756-6b6c0df9a458">5.0</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i98776866f5974807b9f5978a8f14c768_D20200101-20200630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc2OQ_3e4771f5-fc9c-4a4b-bd8c-d977cb74e75c">43.0</ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as product supply revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 we received a $<ix:nonFraction unitRef="usd" contextRef="i7f5d2add0495488f81876f95890d813f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTI5Nw_a02128db-7e59-4287-902c-13818b34290f"><ix:nonFraction unitRef="usd" contextRef="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTI5Nw_f5f4923f-1fcf-46bd-89bd-026168161d82">2.9</ix:nonFraction></ix:nonFraction> million prepayment from KKC for the manufacturing of tenapanor drug substance. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="if14136718f7645a09e5144e34b83338e_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjAyMA_f850f617-e456-4857-b955-857d4065d2a9">12.0</ix:nonFraction> million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fees which was recognized as revenue when the agreement was executed. Based on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we determined</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the license and the manufacturing supply services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material performance obligations at the inception of the agreement, and as such,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distinct. &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjQ1MA_7a3b324c-5c39-44a2-8c6e-58b0c562b994">110.0</ix:nonFraction> million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630" decimals="INF" name="ardx:ThresholdPercentageOfSalesForTieredRoyalties" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjYwNA_2e1b9604-cc34-4a36-8e80-8c5fd8880468">20</ix:nonFraction>%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i988b12581c6e42f6b02b04fe7c54a484_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjc5NA_c32a21fd-fd60-4b3d-a2e2-15b4cdf75a1f"><ix:nonFraction unitRef="usd" contextRef="ie5c99d81bd754260871242f4e771916c_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjc5NA_da3d9c0a-4513-4c5a-85d0-013bcab7694c">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three and six months ended June&#160;30, 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#8217;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNzU0MA_46db6a67-957a-4bf7-a878-b26883e625e4">2.3</ix:nonFraction> million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $<ix:nonFraction unitRef="usd" contextRef="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNzcwMQ_1a6fb242-c515-421f-844a-55ddd2869133">17.9</ix:nonFraction> million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of <ix:nonFraction unitRef="number" contextRef="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODI0MA_c005b14c-4744-4e4f-9f77-b209629336ed">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODMyNQ_4d6416de-1fdd-4056-8911-f839eea37854">20</ix:nonFraction>% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="idcc25084bb364545944e03f1663c5e5e_I20150630" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODUzNA_1e8df4fa-09d4-4e0f-bdbd-052bc97dcd05">75.0</ix:nonFraction> million in aggregate for (i) and (ii). As of June&#160;30, 2021, to date in aggregate, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODYxOQ_dcddabd9-16ff-422a-b55f-33511177eb28">11.6</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="idcc25084bb364545944e03f1663c5e5e_I20150630" decimals="-5" format="ixt:numdotdecimal" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODYyOQ_1e8df4fa-09d4-4e0f-bdbd-052bc97dcd05">75.0</ix:nonFraction> million, which has been recorded as cost of revenue, and have paid AstraZeneca $<ix:nonFraction unitRef="usd" contextRef="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:PaymentsOfUnchargedLicenseFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODcwMw_81dcf31c-82bc-4324-84e7-681e1d6f4cfa">10.6</ix:nonFraction> million. For the three and six months ended June&#160;30, 2021 we recognized and recorded as cost of revenue <ix:nonFraction unitRef="usd" contextRef="i0a52e2793ccc45d7acd1aa68fc3d6d54_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODc4MA_cf5dd3cb-2e31-4fb7-9dbf-81c1932ebe58">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0bf132b0a9774bdc872ca3d86d11edd7_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc5NA_f1da356b-1c53-4be0-a3bb-f46ed04ac83c">1.0</ix:nonFraction> million related to the AstraZeneca Termination Agreement. For the three and six months ended June&#160;30, 2020 we recognized $<ix:nonFraction unitRef="usd" contextRef="i2fc36ba0cdfe49288d9249c20ff9f953_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODg3NA_11b71e67-a4b6-4f97-adc1-0bd849495ebb"><ix:nonFraction unitRef="usd" contextRef="i9c458d292e4c40c6a13a0002a7985e5c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODg3NA_63828beb-9ddd-4176-b1f4-7c197d2bc176">0.1</ix:nonFraction></ix:nonFraction> million cost of revenue related to the AstraZeneca Termination Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="i5a6e2bb74bb64e07a0bed523738313cb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTI3Mg_a1c77ab2-f243-447f-8533-bf0f2a66ab76" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balance is attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e8922e9c354c27894a0e726cd808d4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfMS0xLTEtMS0w_3f44e983-9300-40e3-ae67-2c59a7e14160">4,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie588300a61314fd1a511fc90bc57b89c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfMy0xLTEtMS0w_9d3fe2c7-4c7d-4177-bef0-60536b5aa915">2,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f983056a234617bb02529bdab92604_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfNS0xLTEtMS0w_08af3b71-84d8-4a74-b6e9-ae1614a3a84d">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:81.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3eac47e3784f54a4d7c86adfabdc2d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfMS0xLTEtMS0w_363f5cc5-b75e-45ab-b959-5a7428639539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfMy0xLTEtMS0w_05bb5bd1-8aa5-49b8-8e7f-a4f619a18cef">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822c7141162e4b328f9131de3d247ea5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfNi0xLTEtMS0w_e2410c60-87b5-459a-9973-724c344a64b2">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDM2MA_728087af-a400-427f-b426-6da89ad560ba" continuedAt="i75b3522c230d48d59c09e73c567fce5c" escape="true">BORROWING </ix:nonNumeric></span></div><ix:continuation id="i75b3522c230d48d59c09e73c567fce5c" continuedAt="ie72230d39eb34cd9a94d3b6d2f72314c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;16, 2018, we entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;), with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;Lenders&#8221;). The Loan Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjgx_4f081b21-af24-456d-b17c-1bf184e770fe">50.0</ix:nonFraction> million term loan facility with a maturity date of November&#160;1, 2022 (the &#8220;Term Loan&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2020, we and the Lenders entered into an amendment to the Loan Agreement (&#8220;the 2020 Amendment&#8221;) to extend the date through which we are permitted to make interest-only payments on the Term Loan by <ix:nonNumeric contextRef="ibcaf515abe2840c282d0b24ba36d7735_D20201009-20201009" format="ixt-sec:durwordsen" name="ardx:DebtInstrumentInterestPaymentExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNTc2_537c73e6-648c-46bc-9910-a726d2b86628">twelve months</ix:nonNumeric> to December 1, 2021. The 2020 amendment also required that if either the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issues a CRL with respect to our NDA Number 213931, then we are to begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issues us a CRL. On April 29, 2021, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis by three months to July 29, 2021, making it unlikely that the FDA would approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May and July 2021, we and the Lenders entered into additional amendments to the Loan Agreement (&#8220;the 2021 Amendments&#8221;) which together extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. As of June 30, 2021, we have classified our loan payable, current to include all principal payments that would have been due beginning on June 1, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We paid a closing fee of <ix:nonFraction unitRef="number" contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516" decimals="INF" name="ardx:DebtInstrumentClosingFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjQ5OQ_6b0db210-efd4-402b-a4f6-8006aef47f11">1</ix:nonFraction>% of the Term Loan, or $<ix:nonFraction unitRef="usd" contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516" decimals="-5" format="ixt:numdotdecimal" name="ardx:DebtInstrumentClosingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjUyMw_4606dd79-41ce-4c0f-ac25-342e610e037e">0.5</ix:nonFraction> million, upon the closing of the Term Loan, $<ix:nonFraction unitRef="usd" contextRef="i090b2bbf6d4a488396b2cfe21eb06705_I20201009" decimals="-5" format="ixt:numdotdecimal" name="ardx:DebtInstrumentClosingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjU2Ng_9858cca4-4221-4981-8273-bf011dcdbed4">0.1</ix:nonFraction> million upon closing of the 2020 Amendment and $<ix:nonFraction unitRef="usd" contextRef="i7210d52700b243169235360a519811d9_I20210731" decimals="-5" format="ixt:numdotdecimal" name="ardx:DebtInstrumentClosingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMTA5OTUxMTY0MDI3MQ_617446eb-4c26-4a9b-9ca7-050d4face06c">0.1</ix:nonFraction> million upon closing of the 2021 Amendments. Under the Term Loan, we are also obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="i23709eda801d451e8c51e46f71e084aa_I20210630" decimals="INF" name="ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjY3Ng_f3f68a51-a2c0-497c-adf2-4f3e8467f68e">4.95</ix:nonFraction>% of the Term Loan upon the earliest to occur of the maturity date, the acceleration of the Term Loan, the prepayment or repayment of the Term Loan or the termination of the Loan Agreement. We may voluntarily prepay the outstanding Term Loan, subject to a prepayment premium of (i)&#160;<ix:nonFraction unitRef="number" contextRef="iabae158ea16a4d0db01673f4d02bd862_I20210630" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjk1OQ_66b0e372-5f20-4715-ab07-7ba7575bc047">3</ix:nonFraction>% of the principal amount of the Term Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii)&#160;<ix:nonFraction unitRef="number" contextRef="iac7f10228e774928bcb37829f399cf64_I20210630" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMzA3Nw_fc740e18-151c-4a17-9dc3-37064022dceb">2</ix:nonFraction>% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii)&#160;<ix:nonFraction unitRef="number" contextRef="ic930520ff3b24850b76418b4769ee010_I20210630" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMzI1NQ_0a042985-e119-4868-930c-b85925a07441">1</ix:nonFraction>% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The Term Loan is secured by substantially all our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the Term Loan, we entered into the Exit Fee Agreement, as discussed in Note 6.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement also contains customary events of default that entitle the Lender to cause us indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="ie72230d39eb34cd9a94d3b6d2f72314c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan, including our cash.&#160;Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to <ix:nonFraction unitRef="number" contextRef="iabd06b4585e1420e94a3a1bc12e8bde5_D20210630-20210630" decimals="INF" name="ardx:DebtInstrumentInterestRateOnDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDAyMQ_c4f6dc1b-8d00-4408-b995-f6263cf7b8a9">4</ix:nonFraction>% per annum will apply to all amounts owed under the Loan Agreement. As of June&#160;30, 2021, to our knowledge, there were no facts or circumstances in existence that would give rise to an event of default.</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDM2MQ_f74d962e-13b8-48d8-8ac0-0681321cfbe9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMC0xLTEtMS0w_2b164d23-cbdd-4f68-a5f0-efa04b41018a">52,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMS0xLTEtMS0w_e92dbaef-1061-4691-9c09-52d6a5419529">378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMi0xLTEtMS0w_c637cd39-afa6-417a-8078-5bc6e65b7d32">853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMy0xLTEtMS0w_7eb18bdf-8b8c-4be4-b4c0-8c647ed92c2c">51,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Loan payable, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfNC0xLTEtMS0w_17445426-a460-4c08-afa3-c956332ec8b5">36,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfNS0xLTEtMS0w_b62b873b-0a51-4755-ab04-096ec43eb8ba">15,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjQ4OA_a647e5be-6e37-4755-bc3c-8d68e8797421" continuedAt="idde1366768144d9289dd9109d3bfa444" escape="true">DERIVATIVE LIABILITY</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="idde1366768144d9289dd9109d3bfa444"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the Loan Agreement, as defined and discussed in Note 5, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="ib0977925bb314a0d989a37372b6e92e9_I20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjEx_5b6d8c65-392c-494d-8ec3-23dcfe5d92f4">1.5</ix:nonFraction> million in cash (the &#8220;Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;), which was obtained on September 12, 2019 when the FDA approved IBSRELA&#174; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;Exit Fee Agreement&#8221;). Notwithstanding the prepayment or termination of the Term Loan, as defined and discussed in Note 5, our obligation to pay the Exit Fee will expire on May 16, 2028. We concluded that the Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative liability include: (i) our estimates of both the probability and timing of a potential $<ix:nonFraction unitRef="usd" contextRef="ia4b9f41836824ed3b567440b012e50ee_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMTY0OA_d35ef541-2db6-421a-a335-7521b2ba7007">1.5</ix:nonFraction>&#160;million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i7a442e4da84048eda09938d7030e2b4c_I20210630" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjEwMw_aad13f77-88af-422d-92a5-0064ea3becb5">10</ix:nonFraction>% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $<ix:nonFraction unitRef="usd" contextRef="i7a442e4da84048eda09938d7030e2b4c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjIzNw_9395203b-b702-422d-8873-b972826d0fc3">0.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjQ4OQ_1159a123-e82f-43f1-8ee7-fadd8801ed11" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the six months ended June&#160;30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMi0xLTEtMS0w_c25f717b-00a7-4108-a0f9-57c5eba59415">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63131bdabbd8434aaf8c26325f068bd3_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMi0zLTEtMS0w_e6d7d465-2d8c-4d8e-a5be-d3d801d159c7">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae411fbdd0534f02bc4fdf3a5d2ca8a5_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMy0xLTEtMS0w_3087fa3b-0b6c-4b58-8d82-4007d9904998">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013c596cde5f4e4195fb7311188973d7_D20200101-20200630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMy0zLTEtMS0w_db44bfff-bf7d-47b4-9e92-2204c217fdce">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at June 30</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c87d785bda4e47beed917e20627d9a_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfNC0xLTEtMS0w_c35c0ae1-4a5d-4e8b-b6da-2180708a8bea">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f3cfb47f314559af19e068ea3c36e7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfNC0zLTEtMS0w_f6844cbb-9535-4338-a814-415f90b26b57">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended June 30, 2021 we reduced the value of the derivative liability due the receipt of the CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYx_3805fdfd-cf91-4c74-b65a-cd0b012db0e0" continuedAt="i62e636845bc941aebe4b69bb4bc742e7" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i62e636845bc941aebe4b69bb4bc742e7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, we entered into an amendment to the lease for our Fremont, California facility that extended the term of the lease to March 2025. The office space consists of <ix:nonFraction unitRef="sqft" contextRef="ib702c69d1490476d80c3cd108100c164_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTgwNw_d00c18c7-3636-465d-9ed6-786e9a169a2c">72,500</ix:nonFraction> square feet with the lease terminating in September 2025. We increased the right-of-use asset and lease liability by $<ix:nonFraction unitRef="usd" contextRef="i9190bfc1045649fbbed0e5bf15c56905_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTQzMg_81eeb9fc-8b9a-4dbe-a28f-780298a92dfa">11.9</ix:nonFraction>&#160;million for the Fremont lease upon commencement of the amendment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, we recorded a right-of-use operating lease asset for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of <ix:nonFraction unitRef="sqft" contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTYzOQ_3fec378c-55ce-4bf2-a2f7-2a810939c736">12,864</ix:nonFraction> square feet with the lease terminating in June 2026. We have an option to <ix:nonNumeric contextRef="ie2170430801c4c239779ff73419a0839_D20210101-20210630" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzI1NA_352b325d-eeba-4db6-a1ad-8729d0cd41a9">extend</ix:nonNumeric> the lease term for <ix:nonFraction unitRef="renewal_option" contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="ardx:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzI0Ng_54cadd6b-5d17-450e-9fe5-630f678b8cc0">one</ix:nonFraction> additional <ix:nonNumeric contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzM2Nw_8ce7dc6e-75e1-462a-a1b3-93e2349730b6">five year</ix:nonNumeric> period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $<ix:nonFraction unitRef="usd" contextRef="ie2170430801c4c239779ff73419a0839_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTY2Nw_c25b7ded-ca94-4169-83da-489bc477b915">1.6</ix:nonFraction>&#160;million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYy_21d56ca5-d01d-4edb-86c5-e342e652caa4" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in the condensed balance sheet as of June&#160;30, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfMS0xLTEtMS0w_fc09795f-b732-4432-9a3a-bfc72b99e7ce">14,519</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfMy0xLTEtMS0w_98a1f99b-106f-46e0-86e7-e318ac3be840">3,184</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNC0xLTEtMS0w_e640687a-4d91-4481-aaa1-c5ab76b65dff">11,548</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNS0xLTEtMS0w_55599071-605e-4ed4-bee4-5ed2a354e359">14,732</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNy0xLTEtMS0w_4f88955f-5ea7-44b8-bd56-626462e237cb">3.90</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfOC0xLTEtMS0w_6d27b8c7-78aa-4ba1-a723-e679589d6fb3">6.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYz_1805e486-516a-4e3d-ac77-ab4d70c4c961" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi0xLTEtMS0w_d45ea9dc-5cfd-4214-b3d8-9a53ac93a54b">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi0zLTEtMS0w_3aa34f8c-28f5-47ff-a809-863c09a6b4c9">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi01LTEtMS0w_6466592c-f7d6-455b-ada7-616ba16ef92f">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi03LTEtMS0w_17ac8d8e-bfed-4de2-a134-ea8eb6354fed">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy0xLTEtMS0w_edbbc89e-2efc-4234-8e7d-f3f78c9ec182">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy0zLTEtMS0w_fb7bd8f2-f42f-4fc5-8030-a5dc3c316839">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy01LTEtMS0w_445e9274-e9e9-4666-898e-d7a034f69330">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy03LTEtMS0w_c874fd01-0ec2-4f05-bdec-95209311cacb">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzY0_6c2d52a2-ba68-4201-9ab3-4684adb248ab" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMC0xLTEtMS0w_ac89da76-c2e7-4f39-9a02-9790c63d8c55">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMS0xLTEtMS0xOTk3_f515e64f-ee00-4f20-91a1-66c6a1761618">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMi0xLTEtMS0xOTk3_86028669-4297-4acd-8e71-54dcc2f86c18">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMy0xLTEtMS0xOTk3_1e87fca7-1466-4a2c-86c4-9d0707a9ccb0">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNC0xLTEtMS0xOTk3_d9ca83f9-d656-4f36-a264-283e5d2e5b84">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" name="ardx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMS0xLTEtMS0w_efa0ceef-a7ea-40d2-8002-aca55f7547f8">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMi0xLTEtMS0w_abf33c2e-7b64-4276-b6c8-cf830f941d0c">16,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMy0xLTEtMS0w_d3c14124-afe7-4e81-9efb-588ebacc9007">2,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNC0xLTEtMS0w_6123e94d-53f6-4367-84a6-1a6bc9f6d3c0">14,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNS0xLTEtMS0w_f1a75b19-8fdd-4cdc-8253-909e8c6c89fd">3,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNi0xLTEtMS0w_7fccc18d-2d40-41da-aae3-2c455ca3f670">11,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTI5Mg_4e198037-3013-4b9b-ac5e-3b1d301ef42b" continuedAt="i63fbcf7e5d1644c0a7a0bba3599971a8" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i63fbcf7e5d1644c0a7a0bba3599971a8" continuedAt="i33bd01df843242ef939481ed55399611">At the Market Offerings Agreement</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i33bd01df843242ef939481ed55399611">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020, containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="if3dc7ec6f5ed4386a5ff6d842b738934_I20200731" decimals="INF" format="ixt:numdotdecimal" name="ardx:MaximumAggregateOfferingPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMjg3_228ac5c7-ab89-4ff6-9a9e-c204e27acb21">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i5a4fc789a9b84f18b38090c85e7db5bc_I20200731" decimals="-3" format="ixt:numdotdecimal" name="ardx:MaximumAggregateOfferingPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNTM0_28402d25-0503-4ddd-9f53-8672dbf9289d">100.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC, deemed to be &#8220;at the market offerings.&#8221; During the six months ended June&#160;30, 2021 we sold <ix:nonFraction unitRef="shares" contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNzMx_930279c3-25c9-4ede-abc2-67cbe73dd1c1">9.0</ix:nonFraction> million shares of our common stock for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNzkz_ac008554-cab1-417b-9728-ed5c9fb671da">63.8</ix:nonFraction> million at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfODI3_aceeb3f0-80af-4f84-a22c-07712abde3eb">7.10</ix:nonFraction> per share under the Open Market Sales Agreement. We sold <ix:nonFraction unitRef="shares" contextRef="i785930e859ee4be7bb7b7fb96ea4cb11_D20201113-20210219" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA5OTUxMTYyOTYxOA_0f61b430-d56e-4662-9cd5-3aff929d5b53">8.2</ix:nonFraction>&#160;million shares of our common stock between the dates of November 13, 2020 through February 19, 2021 and <ix:nonFraction unitRef="shares" contextRef="ifdc1fab5cf114d6a87de78c84c48449b_D20210511-20210618" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA5OTUxMTYyOTYzMg_2c52c716-f6db-4697-bb67-02fe18a00bf3">4.0</ix:nonFraction>&#160;million shares between the dates of May 11, 2021 through June 18, 2021 for a cumulative total of <ix:nonFraction unitRef="shares" contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfOTcx_5b150f80-0558-453e-a70f-de89d019c39d">12.2</ix:nonFraction>&#160;million shares and gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTAyMw_1f1a2192-0462-4069-a3c3-03936560e0af">85.4</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA3Nw_2d7179bc-de4f-4d25-a303-9c6e93373b32">6.98</ix:nonFraction> per share during the life of the Open Market Sales Agreement. Pursuant to the Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to <ix:nonFraction unitRef="number" contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTE5NA_04dcaf56-e695-4784-8ac7-531e9a2c8fa8">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the Open Market Sales Agreement.</ix:continuation> </span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMjAxOA_b09c7fbe-596f-48c3-bdee-035e9f316c1b" continuedAt="i2c84135291e448f9bb23de5f1d61bc22" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><ix:continuation id="i2c84135291e448f9bb23de5f1d61bc22" continuedAt="i026fc4631f8c4290b313930678656aaf"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMQ_760073ec-3fb9-4ddf-af6e-109dc7e0e0ba" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:44.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4e511a9eaa4a259b6f2af0a9346f02_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi0xLTEtMS0yMDE2_d1b3876f-01cb-416c-9f1c-42d876a2a03b">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d3b6aaec8145c3b159056fc132c464_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi0zLTEtMS0yMDE2_515ae6e0-f099-4e78-9bb8-c36f8179aed8">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3795671d1695460f9521163c5473a1b8_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi01LTEtMS0yMDE2_8cc4d1de-2791-45e4-bb42-24705475c50f">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edc45d4a609489c93f139ccdfc04755_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi03LTEtMS0yMDE2_61361f07-aed8-4288-8587-7b0c314bb351">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94913409dc945679a54fb334278a1a4_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy0xLTEtMS0yMDE2_1320f2dd-29f6-45f1-881e-2860f559d367">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id449269d05cb4a7bb376cb25ae99695c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy0zLTEtMS0yMDE2_2c9a061d-999e-4158-9adc-cf862d09e653">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee13a843486b4b1dba0ef49f9b47772a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy01LTEtMS0yMDE2_eaf5930d-9707-4be5-9ac5-749a6bab174d">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd939d4bd73a4f909c2aade26597c328_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy03LTEtMS0yMDE2_baaf64e1-acc5-43e4-98a5-6d53deea8de5">3,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC0xLTEtMS0yMDE2_3c3b389a-1591-4af9-b17f-79d427b31076">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC0zLTEtMS0yMDE2_b10fde2e-f8f5-4814-bc08-f2972ba415ae">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC01LTEtMS0yMDE2_1d3c6dc2-e7d1-4326-8e85-254276a1bcd6">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC03LTEtMS0yMDE2_6a97f215-e534-4e38-98d0-fc2955930609">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMA_0529aff1-f976-4efb-95be-3f3a01f08f94" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation<br/>&#160;Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining<br/>&#160;Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMS0xLTEtMS0yMDE2_8182f4d1-71f1-4f3d-af5f-e5a0f1b46259">25,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedd803553a9b495da7e99b9a2beac824_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMS0zLTEtMS0yMDE2_51841598-99bc-4f98-82a3-1c0d4033f011">2.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMi0xLTEtMS0yMDE2_f9fe85f2-d8ae-431c-b7ff-30af9e25dd41">6,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMi0zLTEtMS0yMDE2_1dc4eb3b-efe4-459d-8ae0-79bc832074da">3.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7650d015d8f4d54b605259abc29e66e_I20210630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMy0xLTEtMS0yMDE2_77eb8890-2a58-4f51-80b2-456deb301250">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6de6db9967249b18554b23602a09e1a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMy0zLTEtMS0yMDE2_f1f79bce-1410-43f8-96b5-2e35db09046e">0.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMg_9d6f98ad-d7ed-4303-b2ca-8b902f598ae1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMS0xLTEtMS0xNzIy_5a8a4ed2-e2db-4ac0-bcef-0d3149552bff">9,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMS0yLTEtMS0xNzIy_337efab1-e5c6-4955-94fe-952debe86c5d">6.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMi0xLTEtMS0xNzIy_e60ca25d-d15a-40f5-ad83-b5b33f0854e1">3,328</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMi0yLTEtMS0xNzIy_dad6560b-c28b-4e02-b0e5-07ae35bbc536">6.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMy0xLTEtMS0xNzIy_48258814-0b8f-4512-ad56-e20f2c407593">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMy0yLTEtMS0xNzIy_c0646bc5-877d-4b2e-ba66-bb38480f3bbc">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNC0xLTEtMS0xNzIy_6a562e3a-f2ce-4af7-8f3c-52e600f5df87">401</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNC0yLTEtMS0xNzIy_64e91a0b-9b78-4ad8-b3a7-2d9e4b2f87cc">7.56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNS0xLTEtMS0xNzIy_bcdfe088-da69-4ff7-af97-f6f51d033e23">12,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNS0yLTEtMS0xNzIy_04630478-5569-4c59-96ea-4fc69526a06d">6.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNi0xLTEtMS0xNzIy_a604576b-0491-4160-9d5e-01078fedd910">6,043</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNi0yLTEtMS0xNzIy_e5138da8-3a32-4d1a-a894-74c5b195c138">7.38</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><ix:continuation id="i026fc4631f8c4290b313930678656aaf" continuedAt="i60aac10e33924bcbbc60bd5c9abf4e71"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMw_73126498-bb88-4e5c-8ce6-7ffaad6fff15" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Value at Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6421afe2e3a4ee69726ba784046ad51_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMS0xLTEtMS0xNzk4_61730083-322e-4fca-b14c-066d6f70ecb3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6421afe2e3a4ee69726ba784046ad51_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMS0zLTEtMS0xNzk4_b1635f00-aeb1-41c6-864f-b5e67b9945d9">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMi0xLTEtMS0xNzk4_04951e44-b6c0-44ef-8a82-84989a1448dc">1,088</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMi0zLTEtMS0xNzk4_28b992d9-aba1-43c5-bc33-91603dfeb3c3">6.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMy0xLTEtMS0xNzk4_0d4603ca-8834-4d4a-a181-16ca1f0405c8">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMy0zLTEtMS0xNzk4_fc6d6aa7-341f-4627-af98-ae1e90ab0c10">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNC0xLTEtMS0xNzk4_ffb05304-5ba5-4a3b-9d83-5afe8b94183d">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNC0zLTEtMS0xNzk4_0ba6e623-2cd7-4d61-b495-6487a4930583">6.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNS0xLTEtMS0xNzk4_565e1a3b-7561-4203-af11-f3596bf44f5c">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNS0zLTEtMS0xNzk4_f7246cef-1078-4f92-9a71-16a4e0a5ce1b">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued <ix:nonFraction unitRef="shares" contextRef="i57135135174447be98ce98bf5cae8472_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNzE1NA_8fc8bb0e-0bf4-4507-8f7b-396f0e572f1d">no</ix:nonFraction> PRSUs during the six months ended June&#160;30, 2021 and we have <ix:nonFraction unitRef="shares" contextRef="i7334dc0c28ed479ea8dd4c7d8a181fcd_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNzE1OQ_5372cd08-6bc2-4aad-9cd5-6972cc17301f">no</ix:nonFraction> PRSUs outstanding as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we sold approximately <ix:nonFraction unitRef="shares" contextRef="i4477929b6b09482994b251a77283960d_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA1OA_21642820-1ea0-4d39-a9a5-6cebea20aebb">0.2</ix:nonFraction> million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie5f1bc8e4fe941348afc91140237ac09_I20210228" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTIwNg_f2eab088-f31c-4f2a-8bce-dd320d1721f6">5.84</ix:nonFraction> per share resulting in proceeds to us of approximately $<ix:nonFraction unitRef="usd" contextRef="i4477929b6b09482994b251a77283960d_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTI2NA_217cf695-c510-47f2-a8b8-6acae590d732">1.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60aac10e33924bcbbc60bd5c9abf4e71">Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2021, we issued <ix:nonFraction unitRef="shares" contextRef="ie2465ac8d53a4afba2b987515d381da9_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNjk0OQ_b6952b5f-7016-4a6f-8392-52cc05f77218">no</ix:nonFraction> shares of our common stock to members of the board of directors in accordance with the program.</ix:continuation> </span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMzI5ODUzNDg4NDY2Nw_6b9ad0f4-c4de-4aa9-970f-df2ff99f693d" continuedAt="ic1f93e49c883455f96da77a22e05b99c" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="ic1f93e49c883455f96da77a22e05b99c"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three and six months ended June&#160;30, 2021 and 2020, all potential common shares were determined to be anti-dilutive. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTIwOQ_dfafec6c-90e1-4ab9-884b-7288808cac2c" continuedAt="i76b4f42275804663bb07054511bddb91" escape="true">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts):</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i76b4f42275804663bb07054511bddb91"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy0xLTEtMS0w_b6f38ecf-e6fe-478f-baf1-e2aee0fc4187">45,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy0zLTEtMS0w_8150c461-88c2-493a-b7c1-3a1427a8d43a">24,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy01LTEtMS0w_b459609f-28d1-4f65-90ce-e4599c91bbc7">78,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy03LTEtMS0w_6b5f1e4d-a6d1-4934-9d37-5f46911f9f3d">47,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0xLTEtMS0w_6330ff13-4ad6-47ab-9b70-a6af7d98bcf9"><ix:nonFraction unitRef="shares" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0xLTEtMS0w_deb887ef-8516-4125-a545-ab1f9bb12d73">100,040</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0zLTEtMS0w_39418405-4a38-4a43-9ed4-b874ffc302f0"><ix:nonFraction unitRef="shares" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0zLTEtMS0w_665a46a1-2caf-49a8-9b5c-0760fb8a6afc">89,080</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS01LTEtMS0w_06cfcbfc-fb58-4f99-b440-69bd135d3668"><ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS01LTEtMS0w_f6435e9d-429a-48ce-8e1b-f72273836752">98,618</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS03LTEtMS0w_3622bfc2-6400-4cd9-8b3a-39e614e88784"><ix:nonFraction unitRef="shares" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS03LTEtMS0w_e36229bc-223b-4086-953d-0288f106bc14">88,890</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0xLTEtMS0w_32c6255d-fdf6-435d-863d-56e7f1ca01dd"><ix:nonFraction unitRef="usdPerShare" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0xLTEtMS0w_66c3ce86-a45c-438d-b90e-4fd778d4a074">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0zLTEtMS0w_578efa1b-c945-4bb8-92e1-6c1b2c5723c6"><ix:nonFraction unitRef="usdPerShare" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0zLTEtMS0w_98a544fc-6e73-4e39-9c4b-9574c952ddd4">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi01LTEtMS0w_d5272259-749f-44dd-83f3-c4c9aa937675"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi01LTEtMS0w_f9013a83-a98e-4b31-bdf6-a9f0ce5f3222">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi03LTEtMS0w_6af24a4b-fab2-4283-a008-425ba7b505cb"><ix:nonFraction unitRef="usdPerShare" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi03LTEtMS0w_8f5990db-7a4e-48ab-a6e7-2498339df7fe">0.53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was <ix:nonFraction unitRef="shares" contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfOTUw_bc204ad2-35a3-4fc8-8819-8b7a0cc2c06f">13.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTA5OTUxMTYyOTA2Nw_adb5c09c-a716-49db-8125-20600ee84cfb">13.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2020, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was <ix:nonFraction unitRef="shares" contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTIwNg_dcbd63b3-d919-40ea-be43-536773d48d99">11.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTA5OTUxMTYyOTAzMA_d208ab6c-4f7f-49cb-9bc4-f79f35fb4ed5">11.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfNDA2_cf11a402-f498-41f0-8ecd-63bd85f5eafa" continuedAt="i85f1e95d57024ca4882445b62e5e1468" escape="true">CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i85f1e95d57024ca4882445b62e5e1468">From time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us would not be material to our financial condition or cash flows, and <ix:nonFraction unitRef="usd" contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfMzUz_8784310a-fe9b-4728-93fc-ba9cf3710f1e"><ix:nonFraction unitRef="usd" contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfMzUz_c9bf59d6-0455-4982-acaf-656dd75d23fe">no</ix:nonFraction></ix:nonFraction> contingent liabilities were accrued as of June&#160;30, 2021 or 2020.</ix:continuation></span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;<ix:nonNumeric contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfNTc0_545f862f-cba9-41e1-a562-d9f869247880" continuedAt="i2706114a99c24a51a54e05736f772830" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i2706114a99c24a51a54e05736f772830"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 28, 2021, we received a CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#8220;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis,&#8221; the FDA characterizes the magnitude of the treatment effect as &#8220;small and of unclear clinical significance.&#8221; Additionally, the FDA noted that for the application to be approved, we will need &#8220;to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis.&#8221; There were no safety, clinical pharmacology/biopharmaceutics, chemistry, manufacturing, and controls or non-clinical issues identified in the CRL. We intend to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 29, 2021, we entered into a Fourth Amendment to the Loan Agreement (the &#8220;Amendment&#8221;) which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. The restructuring plan is expected to be completed in August 2021. Under the restructuring plan, we are reducing our workforce by approximately <ix:nonFraction unitRef="position" contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTA4MQ_4f44c270-077e-4b5f-8c76-1de8c3ee09e0">83</ix:nonFraction> employees (approximately <ix:nonFraction unitRef="number" contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802" decimals="2" name="ardx:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTExMA_d39d429f-ac81-4550-89f7-926555e24635">33</ix:nonFraction>%). Impacted employees will receive cash payments equal to their base pay for a notice period of sixty (<ix:nonNumeric contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802" format="ixt-sec:durday" name="ardx:RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTIxNg_17418573-ff42-4df4-971d-685babfdd319">60</ix:nonNumeric>) days and Company funded COBRA premiums through such notice period. In addition, impacted employees are eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#8217;s execution (and non-revocation) of a separation agreement, which includes a general release of claims against the Company. We expect that the workforce reduction will decrease our annual cash compensation costs by approximately $<ix:nonFraction unitRef="usd" contextRef="i131c578fa03b4050ae8b161b42ffff16_D20210802-20210802" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EffectOnFutureEarningsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTY3NQ_4ff8253c-ced0-40d5-9e72-8110ef882eea">17</ix:nonFraction>&#160;million. In connection with the restructuring, we estimate that we will incur restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i12c10d6ea1834cf0a59df57076605afc_I20210802" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTc4OA_90967a24-ab6b-49c0-9517-d7041e08b142">3.4</ix:nonFraction>&#160;million, which will be recorded primarily in the third quarter of 2021, related to one-time termination notice and severance payments and other employee-related costs. The cash payments related to the reduction in workforce will be paid primarily during the third quarter of 2021. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 30, 2021, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and <ix:nonFraction unitRef="defendant" contextRef="icfc6f67e8c63440689c94f063c69ad9f_D20210730-20210730" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMzI5ODUzNDkxNzQyMQ_4d904c95-0bbc-475f-b3cf-c88a3dd3d721">two</ix:nonFraction> current officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiff seeks to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiff seeks damages and interest, and an award of costs, including attorneys&#8217; fees. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div></ix:continuation><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_70"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed financial statements and notes thereto included elsewhere in this report and with the audited financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2020. This discussion and analysis and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements for any reason. Unless the context requires otherwise, the terms &#8220;Ardelyx&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221; refer to Ardelyx,&#160;Inc.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> OVERVIEW</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases. This includes patients with chronic kidney disease ("CKD") on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and CKD patients and/or heart failure patients with elevated serum potassium, or hyperkalemia. Tenapanor has a unique mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 ("NHE3"). This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCT PIPELINE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenapanor: A New Approach for The Control of Serum Phosphorus in Adult Patients with CKD on Dialysis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our portfolio is led by the development of tenapanor, a first-in-class medicine for the control of serum phosphorus in adult patients with CKD on dialysis. Tenapanor for the control of serum phosphorus has a unique mechanism of action and acts locally in the gut to inhibit the NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. On July 28, 2021, we received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding our New Drug Application ("NDA") for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#8220;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis,&#8221; the FDA characterizes the magnitude of the treatment effect as &#8220;small and of unclear clinical significance.&#8221; Additionally, the FDA noted that for the application to be approved, we will need &#8220;to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis.&#8221; There were no safety, clinical pharmacology/biopharmaceutics, chemistry, manufacturing, and controls or non-clinical issues identified in the CRL. We intend to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to tenapanor in the U.S. and we have established agreements with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) in Japan, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;) in China and Knight Therapeutics, Inc. (&#8220;Knight&#8220;) in Canada for the development and commercialization of tenapanor for certain indications in their respective territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we reported statistically significant topline efficacy results from our second monotherapy Phase 3 clinical trial, the PHREEDOM trial, which evaluated tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. The PHREEDOM trial followed a successful monotherapy Phase 3 clinical trial completed in 2017, the BLOCK trial, which achieved statistical significance for the primary endpoint. The only adverse event reported in these Phase 3 trials in greater than 5% of patients was diarrhea, with an incidence rate of 52% in the PHREEDOM trial and 39% in the BLOCK trial, with most incidences in each trial being mild to moderate in nature. PHREEDOM is a one-year study with a 26-week open-label treatment period and a 12-week double-blind, placebo-controlled randomized withdrawal period followed by a 14-week open-label safety extension period. An active safety control group, for safety analysis only, received sevelamer, open-label, for the entire 52-week study period. Patients completing the PHREEDOM trial from both the tenapanor arm and the sevelamer active safety control arm had the option to participate in NORMALIZE, an ongoing open-label 18-month extension study.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we announced positive results from a planned interim data analysis from our ongoing NORMALIZE extension study evaluating tenapanor, as monotherapy or in combination with sevelamer, to achieve serum phosphorus levels in the normal range (2.5 &#8211; 4.5 mg/dL) in patients with CKD on dialysis. The NORMALIZE extension study allowed patients from our PHREEDOM study to continue therapy with tenapanor and enabled those patients in the PHREEDOM safety control arm receiving sevelamer carbonate to transition to tenapanor. The data from the planned interim analysis demonstrated that the use of tenapanor as monotherapy or in combination with sevelamer carbonate produces a significant phosphorus-lowering effect with a mean serum phosphorous reduction of 2.33 mg/dL, from a mean baseline phosphorus of 7.27 mg/dL at the beginning of the PHREEDOM trial to a mean of 4.94 mg/dL at the time of this analysis. Of the 171 patients in this interim analysis who completed up to 9 months of treatment in this extension study, up to 47.4% achieved a normal serum phosphorus level, and of those, the majority were on tenapanor alone or tenapanor with low dose sevelamer of three or fewer sevelamer tablets per day. These data represent a 58% improvement in the rate of patients who achieve a normal serum phosphorus level, as compared to current treatment practice data as reported in the April 2020 Dialysis Outcomes Practice Patterns Study (&#8220;DOPPS&#8221;) Practice Monitor. The DOPPS data demonstrate that, with currently available treatments, only 30% of patients have serum phosphorous </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">levels less than 4.6 mg/dL. The only adverse event reported in greater than 5% of patients in NORMALIZE was diarrhea, with an incidence rate of 23.3%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we reported positive results from the AMPLIFY trial, a Phase 3 study evaluating tenapanor in adult patients with CKD on dialysis who had uncontrolled hyperphosphatemia despite phosphate binder treatment. In this trial, approximately twice the number of patients achieved the serum phosphorus treatment goal of less than 5.5 mg/dL with tenapanor and phosphate binders versus phosphate binders alone. The only adverse event with a placebo-adjusted rate greater than 3% was diarrhea, with an incidence rate of 43%, with most being mild to moderate in nature. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, our partner KKC, a Japan-based global specialty pharmaceutical company exclusively developing tenapanor in Japan, presented results from a Phase 2 trial of tenapanor at the European Renal Association-European Dialysis and Transplant Association annual meeting (&#8220;ERA-EDTA 2020&#8221;). The trial was designed to evaluate if, with tenapanor, patients with hyperphosphatemia undergoing hemodialysis could achieve at least a 30% decrease in mean pill burden while maintaining their serum phosphorus level. The study results were statistically significant, with 71.6% (p&lt;0.001) of patients achieving at least a 30% reduction in mean pill burden. The overall mean reduction in phosphate binder usage was 80% (reduction from 14.7 to 3.0 pills per day), while maintaining serum phosphorus control. The mean phosphorus level of patients entering the study on treatment with binders was 5.2 mg/dL at baseline and 4.7 mg/dL at the end of the 26-week study.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenapanor is the first therapy for phosphate management that blocks phosphorus absorption at the primary pathway of uptake. It is not a phosphate binder. Tenapanor is a novel, potent, small molecule, that has been shown in  phase 3 studies to treat hyperphosphatemia as monotherapy and as a dual mechanism approach.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IBSRELA&#174;&#160;(tenapanor) for Irritable Bowel Syndrome with Constipation (IBS-C)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the development of tenapanor for hyperphosphatemia, we have developed tenapanor for the treatment of patients with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). In September 2019, we received FDA approval of IBSRELA&#174; (tenapanor) for the treatment of IBS-C in adults. IBS-C is a burdensome gastrointestinal (&#8220;GI&#8221;) disorder. It is characterized by significant abdominal pain, constipation, straining during bowel movements, bloating and/or gas.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX013 Program: Small Molecule for Treating Hyperkalemia</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing a small molecule potassium secretagogue program, RDX013, for the potential treatment of hyperkalemia. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking common blood pressure medications known as renin-angiotensin-aldosterone system (&#8220;RAAS&#8221;) inhibitors. Similar to what we have done with tenapanor in developing a non-binder approach for the treatment of elevated serum phosphate levels, RDX013 is designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. While currently available therapies are all ion exchange agents, RDX013 is a first in class approach that exerts its effects by amplifying the underlying pathways of potassium secretion in the colon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX020 Program:  Small molecule for Treating Metabolic Acidosis </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate secretion. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We have not generated any revenues from product sales. As of June&#160;30, 2021, we had an accumulated deficit of $633.1&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur substantial operating losses for the foreseeable future as a result of costs associated with the following activities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">efforts to determine and execute upon the best way to address the deficiencies noted in the CRL regarding our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, and the execution of such; preparing for the potential commercialization of tenapanor, including significantly increased personnel costs associated with our commercial team; the performance of certain activities required as a result of our NDA approval of tenapanor for IBS-C; the continued development of RDX013 and the advancement of our research programs into the preclinical stage. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">collaboration partnerships, which includes license fees, milestones and product supply revenue, as well as funds from our Loan Agreement with Solar Capital Ltd. and Western Alliance Bank.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has impacted the operational decisions of companies worldwide. It also has created and may continue to create significant uncertainty in the global economy. We have undertaken measures to protect our employees, partners, collaborators, and vendors, some of which impact our normal operations. To date, we have been able to continue our operations with our workforce, most of whom are working remotely, and our pre-existing infrastructure that supports secure access to our internal systems. If, however, the COVID-19 pandemic has a substantial impact on the productivity of our employees, our ability to successfully prepare for the commercial launch of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, including our ability to hire and successfully integrate into the company the new personnel required to prepare for such launch, or our ability to progress our research and development efforts, the results of our operations and overall financial performance may be adversely impacted. The extent of the impact from the COVID-19 pandemic on our business will depend largely on future developments that are highly uncertain and cannot be predicted. For a discussion of risks of COVID-19 relating to our business, see &#8220;Part II: Other Information-Item 1A.- Risk Factors- Risks Related to Our Business-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic, or any other outbreak of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As of the date of issuance of this financial report, we are not aware of any specific event or circumstance that would require updates to our estimates and judgments or revisions to the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those that require significant judgment and/or estimates by management at the time that financial statements are prepared such that materially different results might have been reported if other assumptions had been made. These estimates form the basis for making judgments about the carrying values of assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our financial statements presented in this report are described in Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our Annual Report on Form 10-K filed with the SEC on March&#160;8, 2021. There have been no significant changes to our critical accounting policies as disclosed in our most recently filed Annual Report on Form 10-K during the&#160;three and six months ended June&#160;30, 2021.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of recent accounting pronouncements that we have adopted or may expect to adopt is included in Note 1 &#8211; Organization and Basis of Presentation to our condensed financial statements (see Part I, Item 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q).</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue to date has been generated primarily through license, research and development collaborative agreements with various collaboration partners. We have not generated any revenue from commercial product sales. In the future, we may generate revenue from a combination of our own product sales, if regulatory approval is received, and payments in connection with our current or future collaborative partnerships, including license fees, other upfront payments, milestone payments, royalties and payments for drug product and/or drug substance. We expect that any revenue we generate will fluctuate in future periods as a result of, among other factors: the extent to which we are successful in our efforts to commercialize tenapanor for such indication&#894; the timing and progress of goods and services provided pursuant to our current or future collaborative partnerships; our or our collaborators&#8217; achievement of preclinical, clinical, regulatory or commercialization milestones, to the extent achieved; the timing and amount of any payments to us relating to the aforementioned milestones; and the extent to which any of our product candidates are approved and successfully commercialized by a collaboration partner. If our current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">collaboration partners or any future collaboration partners fail to obtain regulatory approval for tenapanor, our ability to generate future revenue from our product sales or from our collaborative arrangements, and our results of operations and financial position, would be materially and adversely affected. Our past revenue performance is not necessarily indicative of results to be expected in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue currently represents payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners should we elect to which we provide rights to develop and commercialize tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0&#160;million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.6&#160;million as cost of revenue under the AZ Termination Agreement since 2017.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all research and development expenses as they are incurred to support the discovery, research, development and manufacturing of our product candidates. Research and development expenses include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with consultants, third-party contract research organizations ("CROs") and investigative sites where a substantial portion of our clinical studies are conducted, and with contract manufacturing organizations where our clinical supplies are produced;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with supplies and materials consumed in connection with our research operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;expenses associated with producing tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis prior to FDA approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;other costs associated with research, clinical development and regulatory activities; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, bonuses, benefits, travel and stock-based compensation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology expense and other supplies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to make substantial investments in research and development activities as we further progress the development of tenapanor, particularly if the FDA should require additional clinical trials in connection with our NDA for the control of serum phosphorus in adult patients with CKD on dialysis, RDX013 and our other product candidates, as we advance our research programs into the preclinical stage and as we continue our early stage research. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. On July 28, 2021, we received a CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis. We intend to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. We may not succeed in achieving marketing approval for our product candidates, including tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. The probability of success of each of the product candidates may be affected by numerous factors, including preclinical data, clinical data, the regulatory process, market acceptance, sufficient third-party coverage or reimbursement, our ability to access capital on acceptable terms, competition, manufacturing capability and commercial viability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each product candidate, ongoing assessment as to each product candidate&#8217;s commercial potential, and our ability to access capital on acceptable terms. We will need to raise additional capital to complete the development and commercialization of tenapanor. If we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the development or commercialization of tenapanor, the development of RDX013 or certain of our product candidates through the use of alternative structures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, for certain of our executives, our board members, and our finance, legal, business development, market development, commercial and support staff. Other general and administrative expenses include facility related costs and professional fees for legal, accounting and audit, investor relations, other consulting services and allocated facility-related costs not otherwise included in research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future primarily because of increased commercial activities, personnel costs and professional fees for services to support the launch and commercialization of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense represents the interest paid on our loan payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income earned on our cash and cash equivalents and available-for-sale investments, the periodic revaluation of the exit fee related to our loan and currency exchange gains and losses. </span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, for any other interim period, or for any other future year.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three and six months ended June&#160;30, 2021 and 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our total revenue (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease to total revenues during the three months ended June&#160;30, 2021 as compared to the same period in 2020 is primarily attributable to a $0.7 million development milestone which was achieved and recognized as revenue in the prior year pursuant to the Knight Agreement. There was no comparable revenue during the three months ended June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase to total revenues during the six months ended June&#160;30, 2021 as compared to the same period in 2020 is primarily attributable to a $5.0 million development milestone which we earned during three months ended March 31, 2021 upon the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our operating expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,732&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not incur any cost of revenue under the AZ termination Agreement during the three months ended June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cost of revenue for the six months ended June&#160;30, 2021 was for payment due to AstraZeneca under the AZ Termination Agreement related to the development milestone we earned upon the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses (dollars in thousands): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, equipment and depreciation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1197.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our external R&amp;D expenses for the three and six months ended June&#160;30, 2021 is primarily the result of clinical study costs from the advancement of our OPTIMIZE study which were partially offset by lower costs for the PHREEDOM clinical study. The increase in our employee-related expenses for the three months ended June&#160;30, 2021 is related to recruiting, compensation and benefits expenses for our research and development workforce.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses for the three and six months ended June&#160;30, 2021 was primarily due to an increase in costs associated with building and staffing our commercial infrastructure and teams as we prepared for the U.S. launch of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. The increase consisted of headcount and related personnel costs and an increase in external spending for disease awareness initiatives, commercial infrastructure and strategy, partially offset by a decrease in stock-based compensation costs related to performance-based restricted stock units.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our other income, net (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(749)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense for the three and six months ended June&#160;30, 2021 was primarily due to lower interest rates on our variable-rate term loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other&#160;Income, net</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in other income, net for the three and six months ended June&#160;30, 2021 were primarily due to revaluation of our derivative liability related to our term loan agreement following receipt of the FDA CRL on July 28, 2021 in the amount of  $0.7 million and decreases in investment income.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our cash, cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liquid funds</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,809&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,598&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities totaling $171.8 million compared to $188.6 million as of December&#160;31, 2020. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020, containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC, deemed to be &#8220;at the market offerings.&#8221; During the three months ended June&#160;30, 2021, we sold 9.0 million shares of our common stock for aggregate gross proceeds of $63.8 million at a weighted average price of $7.10 per share under the Open Market Sales Agreement. In aggregate during the life of the Open Market Sales Agreement, we sold 8.2 million shares of our common stock between the dates of November 13, 2020 through February 19, 2021 and 4.0 million shares between the dates of May 11, 2021 through June 18, 2021 for a cumulative total of 12.2 million shares of our common stock for gross proceeds of $85.4 million at a weighted average sales price of approximately $6.98 per share. Pursuant to the Open Market Sales Agreement, Jefferies, as sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of cash have been from the sale and issuance of common stock (in both public offerings and private placements) and private placements of convertible preferred stock, funds from our collaboration partnerships and funds from our loan agreement. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures and pre-commercial expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources as of June&#160;30, 2021 will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months following our financial statement issuance date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. In particular, our operating plan can change, and we may require significant additional capital to fund our operations, including to support the development, commercialization and manufacturing efforts for tenapanor. We may seek to obtain such additional capital through debt financings, credit facilities, additional equity offerings and/or strategic collaborations. We currently have no unutilized credit facility or committed sources of capital, and there can be no assurances that such sources of capital will be available to us when needed or on acceptable terms. There are numerous risks and uncertainties associated with research, development and commercialization initiatives, and actual results could vary materially as a result of a number of factors, many of which are outside of our control. Failure to raise sufficient capital when needed or generate product revenue will further impact our ability to pursue our business strategies and could require us to further delay, scale back or discontinue one or more of our product development programs, commercialization efforts, or other aspects of our business plans. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis in which the FDA noted additional requirements would need to be met in order to obtain approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. In addition, on July 29, 2021 we entered into a Fourth Amendment to our Term Loan Agreement which extended the period of time that we are permitted to make interest-only payments on the Term Loan to November 1, 2021 and our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. For additional information see Note 12, Subsequent Events, in the notes to our unaudited condensed financial statements in Part I, Item 1, Notes to Condensed Financial Statements, of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify a path to address the deficiencies noted in the CRL regarding our NDA that is achievable in terms of clinical endpoints, time and cost;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize tenapanor for any approved indication, either alone or with one or more collaboration partners;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sales price and the availability of adequate third-party reimbursement for tenapanor, if commercialized;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing costs of our product candidates, and the availability of one or more suppliers for our product candidates at reasonable costs, both for clinical and commercial supply;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the selling and marketing costs associated with tenapanor, including the cost and timing of maintaining our sales and marketing capabilities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of preclinical and discovery programs that we decide to pursue or initiate, and any clinical trials we decide to pursue for other product candidates, including RDX013;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with Solar Capital and Western Alliance Bank in May 2018, as amended in October 2020, March 2021, May 2021 and July 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the risk factors set forth in Part II, Item 1A, Risk Factors, in this Quarterly Report on Form 10-Q for additional risks associated with our capital requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOW ACTIVITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,287)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,639)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the three months ended June&#160;30, 2021 increased by $34.5 million as a result of our increased net loss for the period. The increased net loss was primarily driven by costs associated with building and staffing our commercial infrastructure and teams as we prepare for the U.S. launch of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. An increase of $5.2 million of cash used in prepaid expenses and other assets which was primarily for prepayments for raw materials and production of tenapanor also contributed to the increase in net cash used during the three months ended June&#160;30, 2021.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities increased by $48.2&#160;million as our investment maturities increased to fully offset the cost to purchase investments. During the three months ended June&#160;30, 2021, investment purchases exceeded maturities by approximately $37.4&#160;million.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities increased by $62.7&#160;million due to net proceeds from issuance of our common stock pursuant to the Open Market Sales Agreement, or at-the-market offering. </span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and 2020, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to market risks, including interest rate fluctuation exposure through our investments, in the ordinary course of our business. However, the goals of our investment policy are the preservation of capital, fulfillment of liquidity needs and fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and short-term debt securities. Because of the short-term maturities of our cash equivalents, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities of $171.8&#160;million, which consist of bank deposits and money market funds, as well as high quality fixed income instruments including corporate bonds, commercial paper, and asset-backed securities collateralized by non-mortgage consumer receivables. The credit rating of our short-term investments must be rated A-1/P-1, or better by Standard and Poor&#8217;s and Moody&#8217;s Investors Service. Asset-backed securities must be rated AAA/Aaa. Money Market funds must be rated AAAm/Aaa. Such interest-earning instruments carry a degree of interest rate risk. However, because our investments are high quality and short-term in duration, we believe that our exposure to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest rate risk is not significant and that a 10% movement in market interest rates would not have a significant impact on the total value of our portfolio, as noted above. We do not enter into investments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate fluctuation exposure through our borrowings under the Loan Agreement and our investment in money market accounts which bear a variable interest rate. Borrowings under the Loan Agreement bear interest at a rate equal to one-month London Interbank Offered Rate (&#8220;LIBOR&#8221;), plus 7.45% per annum. A hypothetical increase in one-month LIBOR of 100 basis points above the current one-month LIBOR rates would have increased our interest expense by approximately $0.3&#160;million for the six months ended June&#160;30, 2021. As of June&#160;30, 2021, we had an aggregate principal amount of $50.0&#160;million outstanding pursuant to our Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The majority of our transactions are denominated in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily Swiss francs and the euro, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities associated with a limited number of manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the earnings effects of changes in foreign currency exchange rates. The counterparties to our forward foreign currency exchange contracts are creditworthy commercial banks, which minimizes the risk of counterparty nonperformance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had no open forward foreign currency exchange contracts.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our management, under the supervision and with the participation of our principal executive officer and principal accounting and financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of June&#160;30, 2021. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal accounting and financial officer have concluded that, as of June&#160;30, 2021, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation to minimize the impact on the design and operating effectiveness of our internal controls over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of June&#160;30, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of June&#160;30, 2021.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other information in this Quarterly Report on Form 10-Q, including our condensed financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock and our growth prospects. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Principal Risks Related to Our Business</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of our lead product candidate, tenapanor, which may not receive regulatory approval for the control of serum phosphorus in adult patients with CKD on dialysis or for any other related indication (the &#8220;Hyperphosphatemia Indication&#8221;), and if approved, may not be successfully commercialized for such indication. On July 28, 2021, we received a complete response letter (&#8220;CRL&#8221;) from the FDA regarding our New Drug Application (&#8220;NDA&#8221;) for tenapanor for the Hyperphosphatemia Indication. According to the CRL, the FDA has determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and unclear of clinical significance. Additionally, in the CRL, the FDA noted that in order for the NDA to be approved, we will need to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in adult patients with CKD on dialysis. While we intend to request a Type A meeting as soon as possible, there can be no assurances that the Type A meeting will result in a clear path to approval of our NDA that is achievable in terms of clinical endpoints, time or cost. If following the Type A meeting we determine to pursue an additional clinical trial, there can be no assurances that results of the trial will demonstrate a clinically relevant treatment effect, noted by the FDA as being required for approval of the NDA. If we decide to appeal the issuance of the CRL, there can be no assurances that our request for appeal will be granted, or that, if granted, we will be successful in our appeal. As a result, the regulatory approval process for our NDA is highly uncertain. We may not obtain approval at all, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize tenapanor for the Hyperphosphatemia Indication, our business and our results of operations. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are successful in obtaining regulatory approval for tenapanor for the Hyperphosphatemia Indication, and tenapanor is ultimately commercialized for such indication or for irritable bowel syndrome (&#8220;IBS-C&#8221;), tenapanor may never achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success, which will depend, in part, upon the degree of acceptance among physicians, patients, patient advocacy groups, health care payors and the medical community. Additionally, if the number of patients in the market for the indication for which tenapanor is commercialized or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate coverage and reimbursement for tenapanor, we may not generate sufficient revenue from sales of tenapanor.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never generated any revenue from product sales and may never be profitable. Our ability to generate future revenue from product sales or pursuant to milestone payments is dependent upon many factors, including, but not limited to, obtaining regulatory approvals for tenapanor for the control of serum phosphorus or for any other related indication, and establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate supply of product to support the market demand for tenapanor; and obtaining market acceptance of tenapanor as a viable treatment option for the indications for which it is approved and commercialized. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional financing to achieve our goals, and the inability to access this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our efforts to obtain approval for tenapanor and our other product development and platform development activities.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payor coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for tenapanor for any indication for which it is commercialized could limit our ability to market tenapanor for the approved indication and decrease our ability to generate revenue. For example, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain policies of the Biden administration with respect to drug pricing or reimbursement may impact our business and industry. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the United States, there is additional uncertainty related to insurance coverage and reimbursement for drugs that are marketed to the CKD on dialysis population, as would be tenapanor, if approved, for the Hyperphosphatemia Indication. If we are successful in obtaining regulatory approval to market tenapanor for the Hyperphosphatemia Indication, our ability to generate and sustain future revenues from sales of tenapanor for such indication, may be dependent upon whether and when tenapanor, along with other oral end-stage renal disease (&#8220;ESRD&#8221;) related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have hired sales and marketing leadership and employees with technical expertise, and we are required to train, retain and incentivize those sales and marketing personnel. With the issuance of the CRL by the FDA, the regulatory approval process for our NDA is highly uncertain. We plan to request a Type A meeting with the FDA to obtain more clarity on the path forward for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. There can be no assurances that we will be successful in retaining our sales and marketing leadership or other key employees through the Type A meeting or thereafter, or that we will be able to replace any such leadership or other sales personnel that may leave the Company.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely completely on third parties to manufacture tenapanor and our other product candidates. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization efforts for any approved product, and our development efforts for tenapanor, RDX013 and our other product candidates may be materially harmed.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to develop RDX013 or expand our pipeline of product candidates, as a result of numerous factors, which may include the inability to access capital necessary to fund such efforts on acceptable terms.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic may impact our business, manufacturing, preclinical development activities, preclinical studies, planned and ongoing clinical trials, as well as the regulatory process will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as, the duration of the pandemic, travel restrictions and actions to contain the pandemic or treat its impact, such as social distancing, quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Specifically, in order to address the deficiencies noted by the FDA in the CRL, we be required to conduct additional clinical trials, that may be delayed as a result of the restrictions placed on access to dialysis centers during the COVID-19 pandemic. Other potential impacts of the COVID-19 pandemic on our various clinical trials, including our ongoing Phase 2 clinical trial for RDX013, include delays or difficulties in any planned clinical site initiation, including difficulties in obtaining Institutional Review Board approvals, recruiting clinical site investigators and clinical site staff, delays or difficulties in enrolling patients, interruption of planned key clinical trial activities, such as clinical trial site data monitoring due to diversion of resources at clinical sites or limitation on travel imposed by federal or state governments.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, including tenapanor for the control of serum phosphorus, or any related indication, our business will be substantially harmed. Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, any product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant losses since our inception and we will incur losses in the future, which makes it difficult to assess our future viability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused substantially all of our efforts on our research and development activities, including developing tenapanor and developing our proprietary drug discovery and design platform. To date, we have not commercialized any products or generated any revenue from the sale of products. In July 2021, we received a CRL from the FDA regarding our NDA for tenapanor for the Hyperphosphatemia Indication. While we intend to request a Type A meeting as soon as possible, there can be no assurances that the Type A meeting with result in a clear path to approval of our NDA that is achievable in terms of clinical endpoints, time and cost.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know whether or when we will become profitable. We continue to incur significant research, development and other expenses related to our ongoing operations. As of June&#160;30, 2021, we had an accumulated deficit of $633.1 million. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we seek to determine the best way to address the deficiencies noted in the CRL regarding our NDA for tenapanor for the Hyperphosphatemia Indication; prepare for the potential commercialization of, and incur manufacturing and development costs for, tenapanor; commence commercialization of tenapanor for any approved indication; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incur development costs for RDX013; and continue our discovery and research activities. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial net operating loss and tax credit carryforwards for Federal and California income tax purposes. Such net operating losses and tax credits carryforwards may be reduced as a result of certain intercompany restructuring transactions. In addition, the future utilization of such net operating loss and tax credit carryforwards and credits will be subject to limitations, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that have occurred previously and additional limitations may be applicable as a result of ownership changes that could occur in the future. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and may never be profitable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for our NDA for tenapanor for the treatment of IBS-C in adults in September 2019. However, we have not commercialized tenapanor for IBS-C ourselves in the United States and have not entered into a collaboration partnership for such commercialization. We have no other products approved for sale and have received a CRL from the FDA for tenapanor relating to our NDA for the Hyperphosphatemia Indication. There can be no assurances that our NDA for tenapanor for the Hyperphosphatemia Indication will be approved for such indication or any other related indication. We have never generated any revenue from product sales. Our ability to generate revenue from product sales and achieve profitability depends on our ability to obtain such approval by the FDA; our ability to successfully commercialize tenapanor for an approved indication; and the ability of our collaboration partners to obtain regulatory approval to market tenapanor in their respective territories. There can be no assurances that we will generate product revenue from sales of tenapanor, either on our own, or with a collaboration partner. Our ability to generate future revenue from product sales or pursuant to milestone payments depends heavily on many factors, including but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to address the deficiencies noted in the CRL regarding our NDA for the Hyperphosphatemia Indication and obtain regulatory approvals for tenapanor for such indication, either on our own or with one or more collaboration partners;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize tenapanor, which has been approved by the FDA for the treatment of IBS-C in adults, and/or tenapanor for the Hyperphosphatemia Indication, if approved, either on our own or with one or more collaboration partners;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate (in amount and quality) supply of product to support the market demand for tenapanor for the treatment of IBS-C, and/or, if approved, tenapanor for the Hyperphosphatemia Indication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of tenapanor as a viable treatment option for the indications for which it is approved and commercialized;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where we are successful in obtaining regulatory approvals to market tenapanor for one or more indications, our revenue will be dependent, in part, upon the size of the markets in the territories for which regulatory approval is granted, the breadth of the indication and the label for which approval is granted, accepted price for the product, the ability to get reimbursement at any price and whether we are commercializing the product or the product is being commercialized by a collaboration partner, and in such case, whether we have royalty and/or co-promotion rights for that territory, and whether any royalty we have a right to receive from a collaboration partner is in excess of the royalty we owe AstraZeneca as a result of the termination of our License Agreement with AstraZeneca in 2015. See Note 4, Collaboration and Licensing Agreements, in the notes to our financial statements, included in Part II, Item 8, for details on our obligations to AstraZeneca. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the United States, there is additional uncertainty related to insurance coverage and reimbursement for drugs, like tenapanor for the Hyperphosphatemia Indication, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. If we are successful in obtaining regulatory approval to market tenapanor for such indication, our ability to generate and sustain future revenues from sales of tenapanor for such indication, may be dependent upon whether and when tenapanor, along with other oral ESRD related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur. See &#8220;Third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate revenue&#8221; below. Additionally, if the number of patients for the approved indication suitable for tenapanor is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, coverage and reimbursement for tenapanor are not available in the manner and to the extent which we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of tenapanor, even if approved. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to generate revenue from product sales would likely depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our common stock could cause our stockholders to lose all or part of their investment.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals, including our goal of responding to the CRL received from the FDA relating to our NDA for tenapanor for the Hyperphosphatemia Indication and the inability to access this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our efforts to seek and obtain approval for tenapanor for the Hyperphosphatemia Indication, our efforts to commercial tenapanor any approved indications, and our other product development and platform development activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, most of our resources have been dedicated to our research and development activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We believe that we will continue to expend substantial resources for the foreseeable future, including, costs associated with our efforts to address the deficiencies in our NDA for the Hyperphosphatemia Indication noted by the FDA in the CRL, costs associated with the commercialization of tenapanor for any approved indication, research and development, conducting preclinical studies and clinical trials for our other programs, including RDX013, obtaining regulatory approvals, scaling our manufacturing processes for our product candidates and sales and marketing. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to address the deficiencies in our NDA for the Hyperphosphatemia Indication noted by the FDA in the CRL. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify a path to address the deficiencies noted in the CRL regarding our NDA that is achievable in terms of clinical endpoints, time and cost;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize tenapanor for any approved indication, either alone or with one or more collaboration partners;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sales price and the availability of adequate third-party reimbursement for tenapanor, if commercialized;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing costs of our product candidates, and the availability of one or more suppliers for our product candidates at reasonable costs, both for clinical and commercial supply;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the selling and marketing costs associated with tenapanor, including the cost and timing of maintaining our sales and marketing capabilities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of preclinical and discovery programs that we decide to pursue or initiate, and any clinical trials we decide to pursue for other product candidates, including RDX013;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with Solar Capital and Western Alliance Bank in May 2018, as amended in October 2020, March 2021, May 2021 and July 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our research activities, preclinical and clinical trials for our product candidates and our establishment and maintenance of sales and marketing capabilities or other activities that may be necessary to commercialize tenapanor, either alone or with collaboration partners. Additionally, our inability to access capital on a timely basis and on terms that are acceptable to us may force us to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the development or commercialization of tenapanor or certain of our product candidates through the use of alternative structures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, we entered into a loan and security agreement with Solar Capital, Ltd. and Western Alliance Bank (collectively, the &#8220;Lenders&#8221;) pursuant to which the Lenders agreed to provide us a $50.0 million term loan facility with a maturity date of November 1, 2022. In each of October 2020, March 2021, May 2021 and July 2021, we entered into an amendment to the loan and security agreement. The full amount of the loan was funded on May 16, 2018. Until we have repaid such indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, and to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are permitted to make interest only payments on the loan facility through December 1, 2021, unless we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before October 25, 2021, in which case, the period in which we are permitted to make interest only payments shall end on November 1, 2021. However, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. An event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lenders determine that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the Lenders to accelerate the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant to others&#8217; rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. The Lenders could also exercise their rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Risks Related to Our Business</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of our lead product candidate, tenapanor. In July 2021, we received a CRL from the FDA related to our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. We may not receive regulatory approval for tenapanor for such indication, and if approved, we may not be able to successfully commercialize tenapanor for hyperphosphatemia. Although we received marketing approval from the FDA for tenapanor for IBS-C in September 2019, we have not yet commercialized tenapanor for such indication, and should we elect to do so, we may not be successful in such commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have invested a significant amount of our efforts and financial resources in the research and development of tenapanor for the Hyperphosphatemia Indication and the IBS-C indication. The commercial success of tenapanor will depend on a number of factors, including whether tenapanor&#8217;s safety and efficacy profile is satisfactory to the FDA and foreign regulatory authorities to gain marketing approval for the Hyperphosphatemia Indication. On July 28, 2021, we received a CRL from the FDA regarding our NDA for tenapanor for the Hyperphosphatemia Indication. According to the CRL, the FDA has determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and unclear of clinical significance. Additionally, in the CRL, the FDA noted that in order for the NDA to be approved, we will need to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in adult patients with CKD dialysis. While we intend to request a Type A meeting as soon as possible, there can be no assurances that the Type A meeting with result in a clear path to approval of our NDA that is achievable in terms of clinical endpoints, time and cost. If following the Type A meeting we determine to pursue an additional clinical trial, there can be no assurances that results of the trial will demonstrate a clinically relevant treatment effect, noted by the FDA as being required for approval of the NDA. If we decide to appeal the issuance of the CRL, there can be no assurances that our request for appeal will be granted, or that, if granted, we will be successful in our appeal. As a result, the regulatory approval process for our NDA is highly uncertain. We may not obtain approval at all, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize tenapanor for the Hyperphosphatemia Indication, our business and our results of operations. If we are successful in obtaining approval for tenapanor for the Hyperphosphatemia Indication, and tenapanor is commercialized for such indication or for IBS-C, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the commercial success of tenapanor will depend on a number of additional factors, including the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for tenapanor for the treatment of IBS-C, and/or if approved, tenapanor for the Hyperphosphatemia Indication, particularly in light of the effects of the COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not the content and breadth of the label approved by the FDA or foreign regulatory authorities may materially and adversely impact our ability or the ability of our collaboration partners to commercialize the product for the approved indication, or for any other indication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of any clinical trials we are required to conduct to address the deficiencies noted the CRL for the Hyperphosphatemia Indication, and the timing required to conduct such clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of tenapanor;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, either alone, or with a collaboration partner, to successfully commercialize tenapanor, if approved for marketing and sale by the FDA or foreign regulatory authorities, including educating physicians and patients about the benefits, administration and use of tenapanor;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving and maintaining compliance with all regulatory requirements applicable to tenapanor;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of tenapanor as safe, effective and well-tolerated by patients and the medical community, and, with respect to tenapanor for the Hyperphosphatemia Indication, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of tenapanor as safe, effective and well-tolerated;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, alone or with collaboration partners, to manage the complex pricing and reimbursement negotiations associated with marketing the same product at different doses for separate indications for tenapanor for the treatment of IBS-C, and, if approved, for the Hyperphosphatemia Indication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of tenapanor compared to alternative and competing treatments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and sustaining an adequate level of coverage and reimbursement for tenapanor by third-party payors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcing intellectual property rights in and to tenapanor;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoiding third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of tenapanor following approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As tenapanor is a first-in-class drug, there is a higher likelihood that approval may not be attained as compared to a class of drugs with approved products. Although tenapanor met the primary endpoints in all of the three Phase 3 clinical trials evaluating tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, we received a CRL from the FDA in July 2021 indicating that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and unclear of clinical significance. We intend to request a Type A meeting as soon as possible. However, there can be no assurances that we will receive regulatory approval to market tenapanor for the Hyperphosphatemia Indication. Further, even if approved, it may not be possible to market tenapanor on the basis of certain of the benefits we believe tenapanor possesses. If the number of patients in the market for tenapanor based on the approved indication or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate coverage and reimbursement for tenapanor, we may not generate sufficient revenue from sales of tenapanor for the Hyperphosphatemia Indication, if approved, or for IBS-C, if commercialized. There can be no assurance that tenapanor will ever be successfully commercialized or that we will ever generate income from sales of tenapanor. If we are not successful in obtaining approval for tenapanor for the Hyperphosphatemia Indication, or we are not successful in commercializing tenapanor for any approved indication, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we determine to commercialize tenapanor for IBS-C, or are successful in obtaining regulatory approval for tenapanor for the Hyperphosphatemia Indication, and tenapanor is ultimately commercialized for any approved indications, tenapanor may never achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success, which will depend, in part, upon the degree of acceptance among physicians, patients, patient advocacy groups, health care payors and the medical community. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance of tenapanor for IBS-C and, in the event that marketing approval is obtained, for the Hyperphosphatemia Indication, depends on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breadth and content of the approved label, and the clinical indications for which it is approved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy demonstrated in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to tenapanor for the Hyperphosphatemia Indication, whether tenapanor, along with other oral only medications, are included in the bundled prospective payment system for the treatment of ESRD patients, and the time and manner in which such transition is achieved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects and overall safety and tolerability profile of the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advantages over new or traditional or existing therapies, including recently approved therapies or therapies that the physician community anticipate will be approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, major operators of clinics and patients of tenapanor as a safe, effective and well-tolerated treatment, and, with respect to tenapanor for the Hyperphosphatemia Indication, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of tenapanor as safe, effective and well-tolerated;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration of tenapanor;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of tenapanor over current treatment options or alternative treatments, including future alternative treatments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments and the willingness to pay for tenapanor, if approved, on the part of physicians and patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of alternative products and their ability to meet market demand; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality of our relationships with patient advocacy groups.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure of tenapanor to achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success for any approved indications would adversely affect our results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We hired sales and marketing leadership and other key employees in anticipation of the receipt of marketing approval by the FDA for tenapanor for the Hyperphosphatemia Indication. If we are not able to redeploy and retain those employees while we seek to address the deficiencies identified by the FDA in the CRL received in July 2021, and we are not able to replace any lost personnel we may not be able to commercialize tenapanor for the Hyperphosphatemia Indication, if approved, or such commercialization may be delayed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved, we currently plan to commercialize tenapanor for the Hyperphosphatemia Indication, on our own. We have hired sales leadership and sales employees with technical expertise, and we are required to train, retain and incentivize those sales personnel. Following from the receipt of a CRL from the FDA in July 2021, we executed a reduction in force during which we eliminated a portion of the sales positions that had been filled during the preceding months. Despite the receipt of the CRL and the reduction in force, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to employ sales leadership and sales employees with technical expertise. Even if we are successful in addressing the deficiencies noted in the CRL and we obtain regulatory approval to market tenapanor for the Hyperphosphatemia Indication, the commercialization of tenapanor for such indication will be substantially delayed from the time we expected when we hired our sales and marketing leadership and other key employees. There can be no assurances that we will be able to redeploy and retain our existing sales and marketing leadership or other key employees necessary for commercial launch of tenapanor for the Hyperphosphatemia Indication throughout this delay, or that we will be able to replace any such leadership or other sales personnel that may leave the Company. Redeploying, retaining and incentivizing our commercial personnel throughout this period and thereafter will continue to be expensive and time consuming. Even if we are able to redeploy and retain our key sales and marketing leadership during this delay, and tenapanor is approved for the Hyperphosphatemia Indication, we have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in managing and retaining a sales organization, including our ability to secure the capital necessary to fund such efforts on acceptable terms, provide adequate training to sales and marketing personnel, comply with regulatory requirements applicable to the marketing and sale of drug products and effectively manage a geographically dispersed sales and marketing team.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to redeploy, maintain or replace our internal sales, marketing and distribution capabilities, we may need to delay the commercialization of tenapanor for the Hyperphosphatemia Indication, if approved, or such commercialization could be adversely impacted.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party payor coverage and reimbursement status of newly-approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage and reimbursement of our product candidates, if approved, must be adequate to support a commercial infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford treatments such as tenapanor for the Hyperphosphatemia Indication, assuming approval, or tenapanor for IBS-C. In the event that tenapanor is commercialized, sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will depend substantially, both domestically and abroad, on the extent to which the costs of tenapanor will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we, or our collaboration partners, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the United States Department of Health and Human Services responsible for administering the Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increased uncertainty related to insurance coverage and reimbursement for drugs, like tenapanor for the Hyperphosphatemia Indication, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the ESRD prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014 and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents may be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on tenapanor and our business should tenapanor be brought into the bundle in 2025, or at any time,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may be unable to sell tenapanor for the Hyperphosphatemia Indication, if approved, to dialysis providers on a profitable basis if third-party payors reduce their current levels of payment, or if our costs of production are higher than levels necessary for an appropriate gross margin after payment of all discounts, rebates and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chargebacks. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, these caps may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third parties to manufacture tenapanor and our other product candidates. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of tenapanor for any approved indication and our development efforts for tenapanor, RDX013 and our other product candidates may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture tenapanor or any of other our product candidates on a commercial scale, or to manufacture our drug supplies for use in the conduct of our nonclinical and clinical studies. The facilities used by our contract manufacturers to manufacture our drug supply are subject to inspection by the FDA. Our ability to control the manufacturing process of our product candidates is limited to the contractual requirements and obligations we impose on our contract manufacturer. Although they are contractually required to so do, we are completely dependent on our contract manufacturing partners for compliance with the regulatory requirements, known as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;), for manufacture of both active drug substances and finished drug products.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment. Manufacturers of pharmaceutical products often encounter difficulties in commercial production. These problems may include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, and shortages of qualified personnel, as well as compliance with federal, state and foreign regulations and the challenges associated with complex supply chain management. Even if our contract manufacturers do not experience problems and commercial manufacturing is achieved, their maximum or available manufacturing capacities may be insufficient to meet commercial demand. Finding alternative manufacturers or adding additional manufacturers requires a significant amount of time and involves significant expense. New manufacturers would need to develop and implement the necessary production techniques and processes, which along with their facilities, would need to be inspected and approved by the regulatory authorities in each applicable territory. In addition, the raw materials necessary to make API for our products are acquired from a limited number of sources. Any delay or disruption in the availability of these raw materials could result in production disruptions, delays or higher costs with consequent adverse effects on us.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our contract manufacturers fail to adhere to applicable GMP or other regulatory requirements, experience delays or disruptions in the availability of raw materials or experience manufacturing or distribution problems, we may suffer significant consequences, including the inability to meet our product requirements for our clinical development programs, and if tenapanor is commercialized for any indication, such events could result in product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. As a result, or if maximum or available manufacturing capacities are insufficient to meet demand, our development or our commercialization efforts for tenapanor for the control of serum phosphorus or for another other related indication, if approved, may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Risks Related to Our Business and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to develop RDX013 or any other product candidates that are at an early stage of development, or expand our pipeline of product candidates, as a result of numerous factors, which may include the inability to access capital necessary to fund such efforts on acceptable terms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy has been focused on the expansion of our pipeline of product candidates utilizing our proprietary drug discovery and design platform and to advance such product candidates through clinical development. Our inability to access capital in a timely manner or on acceptable terms to fund our early stage product candidates may force us to consider certain restructuring activities to enable the funding of those early assets through the use of alternative structures. In addition, of the large number of drugs in development, only a small percentage of such drugs successfully complete the FDA regulatory approval process and are commercialized. Accordingly, even if we are able to continue to fund our research and early-stage development programs, there can be no assurance that any product candidates will reach the clinic or be successfully developed or commercialized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Although our research and development efforts to date have resulted in several development programs, we may not be able to develop product candidates that are safe, effective and well-tolerated. Our research programs may initially show promise in identifying potential product candidates, and we may select candidates for development, yet we may fail to advance product candidates to clinical development for many reasons, including the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to access sufficient capital on acceptable terms to fund the development of all of our assets and as a result we may be forced to delay or terminate the development of certain product candidates, or to consider restructuring efforts to secure alternate funding for those assets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the research methodology used and our drug discovery and design platform may not be successful in identifying potential product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective, well-tolerated or otherwise does not meet applicable regulatory or commercial criteria;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be accepted as safe, effective and well-tolerated by patients, the medical community or third-party payors, if applicable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in continuing to expand our pipeline, through our own research and development efforts, the potential product candidates that we identify or for which we acquire rights may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize a product pipeline, we may not be able to generate revenue from product sales in future periods or ever achieve profitability. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome and the results of earlier studies and trials may not be predictive of future trial results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical and clinical studies of our product candidates, including RDX013, may not be predictive of the results of later-stage clinical trials. An unexpected adverse event profile, or the results of drug-drug interaction studies, may present challenges for the future development and commercialization of a product candidate for a particular condition despite receipt of positive efficacy data in a clinical study. A number of companies in the pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials for similar indications that we are pursuing due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing RDX013 Phase 2 clinical trial or any of our other ongoing clinical trials may be impacted by the COVID-19 pandemic in a number of ways, including delays or difficulties in any planned clinical site initiation, difficulties in obtaining IRB approvals, recruiting clinical site investigators and clinical site staff, delays or difficulties in enrolling patients, interruption of planned key clinical trial activities, such as clinical trial site data monitoring due to diversion of resources at clinical sites or limitation on travel imposed by federal or state governments. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we could encounter delays if our ongoing RDX013 Phase 2 clinical trial, or any other of our clinical trials are suspended or terminated by us, by the IRBs of the institutions in which the trial is being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, identifying and qualifying patients to participate in our RDX013 Phase 2 clinical trial or any of our other clinical trials is critical to our success. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug, or our inclusion and exclusion criteria for our clinical trials may present challenges in identifying acceptable patients. As a result, the timeline for recruiting patients and conducting our RDX013 Phase 2 clinical trial or any of our other clinical trials may be delayed. These delays could result in increased costs, delays in advancing our development of our product candidates, or termination of the clinical studies altogether. Any of these occurrences may significantly harm our business, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even though we have completed our Phase 3 clinical development program for tenapanor for the control of serum phosphorus, the results may not be sufficient to obtain the desired regulatory approval for tenapanor, or if such regulatory approval is obtained, the content of the label approved by regulatory authorities may materially and adversely impact our ability to commercialize the product for the approved indication. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct some of our nonclinical studies and all of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct clinical trials and, in some cases, nonclinical studies. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue to rely, on these third parties to conduct some of our nonclinical studies and all of our clinical trials, we remain responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We, and these third parties are required to comply with current GLPs for nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;) for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (&#8220;EEA&#8221;) and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products or product candidates may cause undesirable side effects or have other properties that could delay our clinical trials, or delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval that is achieved. If we or others identify undesirable side effects caused by any product candidate following receipt of marketing approval, the ability to market such product candidate could be compromised. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Undesirable side effects caused by our products or product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, result in the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities or limit the commercial profile of an approved label. To date, patients treated with tenapanor have experienced drug-related side effects including diarrhea, nausea, vomiting, flatulence, abdominal discomfort, abdominal pain, abdominal distention and changes in electrolytes. Despite our receipt of marketing approval for tenapanor for IBS-C in adults and the completion of our Phase 3 clinical program for tenapanor for the Hyperphosphatemia Indication, in the event that future trials conducted by us with tenapanor, or trials we conduct with RDX013 or our other product candidates, reveal an unacceptable severity and prevalence of these or other side effects, such trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of tenapanor, RDX013, or any such other product candidate, for any or all targeted indications. Additionally, despite a positive efficacy profile, the prevalence and/or severity of these or other side effects could cause us to cease further development of a product candidate for a particular indication, or entirely. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we or others identify undesirable side effects caused by one of our products for which we have received regulatory approval, a number of potentially significant negative consequences could occur, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be required to recall the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) which could require creation of a Medication Guide or patient package insert outlining the risks of such side effects for distribution to patients, a communication plan to educate healthcare providers of the drugs&#8217; risks, as well as other elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us, or a collaboration partner, from achieving or maintaining market acceptance of a particular product candidate, if approved, and could result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat. If approved for marketing by the FDA or other regulatory agencies, tenapanor, as well as our other product candidates, would compete against existing treatments. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, tenapanor, if approved for the control of serum phosphorus in adult patients with CKD on dialysis or for another related indication, will compete with phosphate binders used for the same or similar indication`. If approved, our label for tenapanor for the control of serum phosphorus may include data comparing the effectiveness of tenapanor to phosphate binders used for the same indication. The various types of phosphate binders commercialized in the United States include the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Calcium carbonate (many over-the-counter brands including Tums and Caltrate);</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Calcium acetate (several prescription brands including PhosLo and Phoslyra);</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lanthanum carbonate (Fosrenol);</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sevelamer hydrochloride (Renagel);</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sevelamer carbonate (Renvela);</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sucroferric oxyhydroxide (Velphoro); and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ferric citrate (Auryxia). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the phosphate binders listed above are available as generics in the U.S., with the exception of Velphoro and Auryxia. In addition to the currently available phosphate binders, we are aware of at least two other binders in development, including fermagate (Alpharen), an iron-based binder in Phase 3 being developed by Opko Health, Inc., and PT20, an iron-based binder in Phase 3 being developed by Shield Therapeutics. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In respect of tenapanor for the treatment of IBS-C, numerous treatments exist for constipation and the constipation component of IBS-C, many of which are over-the-counter. These include psyllium husk (such as Metamucil), methylcellulose (such as Citrucel), calcium polycarbophil (such as FiberCon), lactulose (such as Cephulac), polyethylene glycol (such as MiraLax), sennosides (such as Exlax), bisacodyl (such as Ducolax), docusate sodium (such as Colace), magnesium hydroxide (such as Milk of Magnesia), saline enemas (such as Fleet) and sorbitol. These agents are generally inexpensive and work well to temporarily relieve constipation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of four prescription products marketed for certain patients with IBS-C, including Linzess (linaclotide), Amitiza (lubiprostone), Trulance (plecanatide) and Zelnorm (tegaserod maleate). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our competitors' drugs may be less expensive and more effective than our product candidates, or that will render our product candidates obsolete. It is also possible that our competitors will commercialize competing drugs or treatments before we or our collaboration partners can launch any products developed from our product candidates. We also anticipate that we will face increased competition in the future as new companies enter into our target markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing relationships with our competitors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have continued to work to optimize our management composition, personnel and systems to support our current activities for future growth, these resources may not be adequate for this purpose. Our need to effectively execute our business strategy requires that we: </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage any commercialization activities in which we may engage effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical trials effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our internal research and development efforts effectively while carrying out our contractual obligations to licensors, contractors, collaborators, government agencies and other third parties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain and motivate our remaining employees and potentially identify, recruit, and integrate additional employees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize or co-promote our product candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, medical, manufacturing, and sales and marketing personnel is critical to our success. We are highly dependent on our executives, senior management and certain other key employees. The loss of the services of our executives, senior management or other key employee could impede the achievement of our research, development and commercial objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executives, senior management and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. We may be unable to hire, train or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic regions. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our proprietary drug discovery and design platform, and, in particular, APECCS, is a new approach to the discovery, design and development of new product candidates and may not result in any products of commercial value. Furthermore, the APECCS aspects of our drug discovery and design platform may have diminished relevance to our efforts focused on the discovery of targets and therapies for the treatment of renal diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a proprietary drug discovery and design platform integrating our proprietary chemistry capabilities and our APECCs stem cell platform to enable the identification, screening, testing, design and development of new product candidates, and have developed APECCS as a component of this of this platform. We have utilized APECCS in the design of our small molecules and to identify new and potentially novel targets in the GI tract. However, there can be no assurance that APECCS will be able to identify new targets in the GI tract or that any of these potential targets or other aspects of our proprietary drug discovery and design platform will yield product candidates that could enter clinical development and, ultimately, be commercially valuable. In addition, as we focus our efforts on the discovery and design of therapies for the treatment of cardiorenal diseases, we may need to further develop our proprietary drug discovery and design platform to enhance its usefulness in the identification, screening, testing, design and development of new product candidates for the treatment of cardiorenal diseases. There can be no assurances that we will be successful in such additional development of our platform or that our platform will yield product candidates for the treatment of renal diseases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the California Consumer Privacy Act ("CCPA") on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the California Privacy Rights Act (CPRA) recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Union General Data Protection Regulation (GDPR) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom&#8217;s withdrawal from the European Economic Area and the European Union, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to further compliance risk. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We and our collaborators, CROs and other contractors and consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators, CROs, and other contractors and consultants collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and our collaborators, CROs and other contractors and consultants collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we and our collaborators, CROs and other contractors and consultants do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, CROs, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs, and/or of our efforts to commercialize tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication, if approved. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including HIPAA. Moreover, if a computer security breach affects our systems or those of our collaborators, CROs or other contractors, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have previously identified a material weakness in our internal control over financial reporting. If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us and could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, management and our independent registered public accounting firm identified a control deficiency that constituted a material weakness in our internal control over financial reporting. The material weakness was due to a failure in the design and implementation of controls over the evaluation of the terms of our clinical trial contracts for inclusion into our clinical financial model which estimates clinical trial expenses. Specifically, we had failed to properly interpret an expense in our clinical trial contracts which resulted in the over accrual of our clinical trial expenses during 2018 and the first quarter of 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed and implemented a remediation plan for this material weakness which included modifications to the design and implementation of certain internal controls, and the material weakness was remediated as of December 31, 2019. Although we have remediated this material weakness, as attested by our independent registered public accounting firm, we can give no assurance that an additional material weakness or significant deficiency in our internal controls over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal controls over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. If we cannot in the future favorably assess the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the trading price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have current collaboration partnerships for the commercialization of tenapanor in certain foreign countries, and we may form additional collaboration partnerships, create joint ventures or enter into additional licensing arrangements with third parties in the United States and abroad that we believe will complement or augment our existing business. In particular, we have formed collaboration partnerships with KKC for certain research programs and for commercialization of tenapanor for hyperphosphatemia in Japan; with Fosun Pharma for commercialization of tenapanor for hyperphosphatemia and IBS-C in China and related territories; and in Canada with Knight for commercialization of tenapanor for IBS-C and hyperphosphatemia. We face significant competition in seeking appropriate collaboration partners, and the process to identify an appropriate partner and negotiate appropriate terms is time-consuming and complex. Any delays in identifying suitable additional collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. There is no guarantee that our current collaboration partnerships or any such arrangements we enter into in the future will be successful, or that any collaboration partner will commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions. We have received a CRL from the FDA regarding our NDA for the Hyperphosphatemia Indication. While we intend to request a Type A meeting as soon as possible, there can be no assurances that the Type A meeting with result in a path to address the deficiencies noted in the CRL </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and to obtain approval of our NDA that is achievable in terms of clinical endpoints, time and cost. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval will likely result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic, or any other outbreak of epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of epidemic, pandemic, or contagious diseases, such as the current novel coronavirus (&#8220;COVID-19&#8221;) pandemic or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could disrupt our business. Business disruptions could include disruptions or restrictions on our ability to conduct our clinical trials, as planned, travel, as well as temporary closures of the facilities of our collaboration partners, suppliers or contract manufacturers. Any disruption of our clinical trial operations, collaboration partners, suppliers or contract manufacturers could adversely impact our operating results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and health conditions related to the COVID-19 pandemic in the United States and across most of the globe remain uncertain and continue to evolve. While at this point, the extent to which the coronavirus outbreak may impact our results is uncertain, it could result in delays in the manufacture of tenapanor, or in the delivery of key intermediates or raw materials required to manufacture tenapanor or delays in clinical development activities by us, or our collaboration partners. It could also materially and negatively impact our ability, either alone, or with a collaboration partner, to successfully commercialize tenapanor, if approved for marketing and sale by the FDA or foreign regulatory authorities, including our ability to educate physicians and patients about the benefits, administration and use of tenapanor. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a result of the COVID-19 pandemic, we may also experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">While our Phase 3 clinical development of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis is complete, we have ongoing and planned clinical trials for tenapanor and an ongoing Phase 2 clinical trial for RDX013, any of which may be delayed as a result the COVID-19 outbreak. Other potential impacts of the COVID-19 pandemic on our various clinical trials include delays or difficulties in any planned clinical site initiation, including difficulties in obtaining Institutional Review Board approvals, recruiting clinical site investigators and clinical site staff, delays or difficulties in enrolling patients, interruption of planned key clinical trial activities, such as clinical trial site data monitoring due to diversion of resources at clinical sites or limitation on travel imposed by federal or state governments. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited the use of our offices to essential employees and requested that most of our personnel, including all of our administrative employees, work remotely. We have restricted on-site staff to only those personnel and contractors who must perform essential activities that must be completed on-site and limited the number of staff in our research laboratories. The COVID-19 pandemic could disrupt our ability to secure supplies for our facilities and to provide personal protective equipment for our employees. The safety, health and well-being of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the novel coronavirus. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA and comparable foreign regulatory agencies may continue to experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of COVID-19, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and/or in-licensing of products, product candidates or technologies. In addition, if we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the development or commercialization of tenapanor and/or the development of RDX013 or certain of our other product candidates through the use of alternative structures. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, spin outs, collaboration partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher-than-expected acquisition and integration costs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write-downs of assets or goodwill or impairment charges;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek and obtain approval to commercialize our product candidates outside of the United States, manufacture our product candidates outside of the United States, or otherwise engage in business outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaboration partners may decide to seek marketing approval for certain of our product candidates outside the United States or otherwise engage in business outside the United States, including entering into contractual agreements with third-parties. We currently utilize contract manufacturing organizations located outside of the United States to manufacture our active drug substance for tenapanor. We are subject to additional risks related to entering these international business markets and relationships, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing United States and foreign drug import and export rules;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems, and different competitive drugs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dual headquarters and one of our facilities is located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our California facility, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. Neither we nor any of our collaboration partners is permitted to market any drug product in the United States until we receive marketing approval from the FDA. Obtaining regulatory approval of a NDA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of regulatory approval of products;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending NDAs or supplements to approved NDAs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a drug candidate in the United States or abroad, we or our collaboration partners must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such drug candidates are safe and effective for their intended uses. The number of nonclinical studies and clinical trials that will be required for FDA approval varies depending on the drug candidate, the disease or condition that the drug candidate is designed to address, and the regulations applicable to any particular drug candidate. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our drug candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering drug candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a drug candidate for any or all targeted indications. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors. The FDA and comparable foreign authorities have substantial discretion in the approval process and we may encounter matters with the FDA or such comparable authorities that requires us to expend additional time and resources and delay or prevent the approval of our product candidates. For example, on July 28, 2021, we received a CRL from the FDA regarding our NDA for tenapanor for the Hyperphosphatemia Indication. According to the CRL, the FDA has determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and unclear of clinical significance. Additionally, in the CRL, the FDA noted that in order for the NDA to be approved, we will need to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in adult patients with CKD on dialysis. While we intend to request a Type A meeting as soon as possible, there can be no assurances that the Type A meeting with result in a path to address the deficiencies noted in the CRL and to approval of our NDA that is achievable in terms of clinical endpoints, time and cost. If following the Type A meeting we determine to pursue an additional clinical trial, there can be no assurances that results of the trial will demonstrate a clinically relevant treatment effect, noted by the FDA as being required for approval of the NDA. If we decide to appeal the issuance of the CRL, there can be no assurances that our request for appeal will be granted, or that, if granted, we will be successful in our appeal. As a result, the regulatory approval process for our NDA is highly uncertain. We may not obtain approval at all, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize tenapanor for the Hyperphosphatemia Indication, our business and our results of operations. Finally, approval policies, regulations or the type and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or result in a decision not to approve an application for regulatory approval. Despite the time and expense exerted, failure can occur at any stage. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our, or our collaboration partners&#8217;, clinical studies;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which approval is sought;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the interpretation of data from preclinical studies or clinical studies;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaboration partners may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers responsible for clinical and commercial supplies; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failure and/or that of our collaboration partners to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. Additionally, if the FDA requires that we conduct additional clinical studies, places limitations in our label, delays approval to market our product candidates or limits the use of our products, our business and results of operations may be harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, any product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging, distribution, pharmacovigilance, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP regulations for any clinical trials that we conduct post-approval. As such, we and our third-party contract manufacturers will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters, fines or holds on clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of existing regulatory approvals;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our contract manufacturers&#8217; operations; or</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the results of the 2020 President election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these Executive Orders will be implemented, or whether they will be rescinded or replaced under a Biden Administration. The policies and priorities of an incoming administration are unknown, and could materially impact the regulatory framework governing our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of product candidates for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection programs. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. If tenapanor or our other product candidates receive marketing approval, we and our collaboration partners, if any, will be restricted from marketing the product outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. We are implementing compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FFDCA, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tenapanor, which has been approved by the FDA for the treatment of IBS-C in adults, and/or RDX013, and our other product candidates, if approved, may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some participants in clinical studies of tenapanor have reported adverse effects after being treated with tenapanor, including diarrhea, nausea, flatulence, abdominal discomfort, abdominal pain, abdominal distention and changes in electrolytes. If we are successful in commercializing any products, FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate any of the following: FDA regulations, including those laws that require the reporting of true, complete and accurate financial and other information to the FDA; manufacturing standards; or federal and state healthcare fraud and abuse laws and regulations. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product in the EEA (which is composed of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). Before the MA is granted, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file we may not receive necessary approvals to commercialize our products in any market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaboration partners may be subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our products, we and our collaboration partners may be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate as a commercial organization include:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician sunshine requirements under the ACA, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, certain other healthcare providers beginning in 2022, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or pricing information and marketing expenditures; and </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional clinical trials to be conducted prior to obtaining approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to manufacturing methods;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, replacement, or discontinuance of one or more of our products; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional record keeping. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. In the United States, the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act of 2017 included a provision repealing, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court's decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The Supreme Court heard argument on this case on November 10, 2020. On February 10, 2021, the Department of Justice notified the Court of the federal government&#8217;s change in position from that presented in its brief on the merits filed in the case. It is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal, or replace the ACA will impact the ACA or our business. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These new laws, among other things, included aggregate reductions of Medicare payments of 2% per fiscal year to providers that will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2020, unless additional action is taken by Congress, additional specific reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, individual states have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims alleging infringement of third parties&#8217; patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of tenapanor or our other product candidates, or prevent or delay the continued use of our drug discovery and development platform, including APECCS. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other intellectual property rights in the pharmaceutical and biotechnology industries. There can be no assurances that we will not be subject to claims alleging that the manufacture, use or sale of tenapanor or any other product candidates, or that the use of our drug discovery and development platform, including APECCS, infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending which may later result in issued patents that may be infringed by the manufacture, use or sale of tenapanor or other product candidates or by the use of APECCS. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of tenapanor or our other product candidates, or by the use of APECCS. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to third-party patent infringement claims in the future against us or our that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. In addition, if a patent infringement suit were brought against us regarding the use of aspects of our drug discovery and development platform, we could be forced to stop our use of APECCS or of other aspects of our platform, or we could be forced to modify our processes to avoid infringement, which may not be possible at a reasonable cost, if at all, and which could result in substantial delay in our use of our platform for the discovery of new product candidates or potential targets. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease our use of APECCS or some other aspect of our drug discovery and development platform or our business operations if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, or unable to maintain such licenses when granted. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our intellectual property related to our product candidates is not adequate or if we are not able to protect our trade secrets or our confidential information, we may not be able to compete effectively in our market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates, our drug discovery and development platform and our development programs. Any disclosure to or misappropriation by third parties of our confidential or proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in foreign countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the United States, Europe and other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is successfully challenged, then our ability to commercialize such product candidates could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, if we encounter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays in our clinical trials, the period of time during which we or our collaboration partners could market tenapanor or other product candidates under patent protection would be reduced. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering the product candidate, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to a product candidate, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or third parties, or by our former employees. The breach of such agreements by individuals or entities who are actively involved in the discovery and design of our potential drug candidates, or in the development of our discovery and design platform, including APECCS, could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive, and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements, our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the approval by the FDA for our NDA to market tenapanor for IBS-C, we became eligible to seek and sought patent term restoration under the Hatch-Waxman Act for one of the U.S. patents covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Despite seeking patent term extension for tenapanor or other product candidates, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee, advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us, and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of regulatory decisions regarding our NDA seeking marketing approval for tenapanor for the the Hyperphosphatemia Indication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our contract manufacturing organizations, or specific label restrictions or patient populations for tenapanor&#8217;s use, or changes or delays in the regulatory review process;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding whether tenapanor, alone or with other oral only medications, will be included in the bundled prospective payment system for the treatment of ESRD patients, and the time and manner in which such transition is achieved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results from, or any delays in, our RDX013 Phase 2 clinical trial;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to our current or future collaboration partnerships;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of therapeutic innovations or new products by us or our competitors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our product label, our clinical trials, manufacturing supply chain or sales and marketing activities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our approved products or our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our testing and clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet any of our projected timelines or goals with regard to the clinical development and commercialization of any of our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or license or discover additional product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement actions in which we may become involved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to obtain adequate intellectual property protection for our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements concerning our competitors or the pharmaceutical industry in general;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, supply or distribution shortages;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the United States;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of debt securities and sales or licensing of assets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in the United States equity markets; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of any of our key scientific or management personnel. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and, together with our management, will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares outstanding as of June&#160;30, 2021, our officers, directors and stockholders who hold at least 5% of our stock together beneficially own approximately 39.2% of our outstanding common stock. If these officers, directors, and principal stockholders or a group of our principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and control matters requiring stockholder approval, including the election of directors, amendments to our organizational documents, and approval of any merger, sale of assets or other business combination transactions. The interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders. For instance, officers, directors and principal stockholders, acting together, could cause us to enter into transactions or agreements that we would not otherwise consider. Similarly, this concentration of ownership may have the effect of delaying or preventing a change in control of our company otherwise favored by our other stockholders. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of June&#160;30, 2021, we had approximately 103.0 million shares of common stock outstanding. Of those shares, approximately 37.4 million were held by current directors, executive officers and stockholders owning 5% or more of our outstanding common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, 1.2 million shares of common stock issuable upon vesting of outstanding restricted stock units and approximately 12.5 million shares of common stock issuable upon exercise of outstanding options were eligible for sale in the public market to the extent permitted by the provisions of the applicable vesting schedules, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are issued and sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;) and the related rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) which require, among other things, our management to report on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the global economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, presidential elections, other political influences and inflationary pressures. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. We cannot anticipate all the ways in which the global economic climate and global financial market conditions could adversely impact our business in the future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if economic challenges in the United States result in widespread and prolonged unemployment, either regionally or on a national basis, or if certain provisions of the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, are repealed, a substantial number of people may become uninsured or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnities, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could restrict our ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to pay dividends, our stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union and ratified a trade and cooperation agreement governing its future relationship with the European Union. The agreement, which is being applied provisionally from January 1, 2021 until it is ratified by the European Parliament and the Council of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and may significantly reduce global market liquidity, restrict the ability of key market participants to operate in certain financial markets or restrict our access to capital. Any of these factors could have a material adverse effect on our business, financial condition and results of operations and reduce the price of our common stock.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) pursuant to which the Lenders agreed to provide us a $50.0 million term loan facility. Covenants in the loan and security agreement limit our ability to pay dividends or make other distributions. For additional information refer to &#8220;NOTE 5. BORROWING&#8221; in the notes to our unaudited condensed financial statements in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">None.</span></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_133"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits </span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1437402/000162828021011446/ardenwoodleasefifthamendme.htm">Fifth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc. and 34175 Ardenwood Venture, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20210630xex311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20210630xex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20210630xex321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of June&#160;30, 2021 and December&#160;31, 2020, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June&#160;30, 2021 and 2020, (iii) Condensed Statements of Cash Flows for the six months ended June&#160;30, 2021 and 2020, and (iv) Notes to Unaudited Condensed Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="iba274a23d3f04ea8a3bf82e7a8ef31ca_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7">Table</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iba274a23d3f04ea8a3bf82e7a8ef31ca_7"> of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:47.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ardelyx, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 13, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Chief Accounting and Principal Financial Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ardx-20210630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib2262a6616314ea08f55f2f86d43d0c3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Raab, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael Raab<br>President Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ardx-20210630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if3e0c24f43fd405b8812d423f10f8fa7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Justin Renz, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ardx-20210630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i341fb2f5b05846ffab9f3259432b1cae_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Ardelyx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June&#160;30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Michael Raab, President and Chief Executive Officer of the Company, and Justin Renz, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael Raab<br>President Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ardx-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestments" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments">
        <link:definition>2104102 - Disclosure - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsTables" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables">
        <link:definition>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails">
        <link:definition>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ardelyx.com/role/FairValueMeasurements">
        <link:definition>2108103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables">
        <link:definition>2309302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreements" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements">
        <link:definition>2111104 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsTables" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables">
        <link:definition>2312303 - Disclosure - Collaboration and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>2413405 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsDeferredRevenueDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails">
        <link:definition>2414406 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowing" roleURI="http://www.ardelyx.com/role/Borrowing">
        <link:definition>2115105 - Disclosure - Borrowing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingTables" roleURI="http://www.ardelyx.com/role/BorrowingTables">
        <link:definition>2316304 - Disclosure - Borrowing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingNarrativeDetails" roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails">
        <link:definition>2417407 - Disclosure - Borrowing - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails">
        <link:definition>2418408 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1">
        <link:definition>2418408 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiability" roleURI="http://www.ardelyx.com/role/DerivativeLiability">
        <link:definition>2119106 - Disclosure - Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityTables" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables">
        <link:definition>2320305 - Disclosure - Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityNarrativeDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails">
        <link:definition>2421409 - Disclosure - Derivative Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityChangesinFairValueDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails">
        <link:definition>2422410 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ardelyx.com/role/Leases">
        <link:definition>2123107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ardelyx.com/role/LeasesTables">
        <link:definition>2324306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails">
        <link:definition>2425411 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalLeaseInformationDetails" roleURI="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails">
        <link:definition>2426412 - Disclosure - Leases - Additional Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2427413 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails">
        <link:definition>2428414 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1">
        <link:definition>2428414 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ardelyx.com/role/StockholdersEquity">
        <link:definition>2129108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails">
        <link:definition>2430415 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.ardelyx.com/role/EquityIncentivePlans">
        <link:definition>2131109 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables">
        <link:definition>2332307 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails">
        <link:definition>2433416 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
        <link:definition>2434417 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails">
        <link:definition>2435418 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>2436419 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2437420 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ardelyx.com/role/NetLossPerShare">
        <link:definition>2138110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ardelyx.com/role/NetLossPerShareTables">
        <link:definition>2339308 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofNetLossPerCommonShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails">
        <link:definition>2440421 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>2441422 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.ardelyx.com/role/Contingencies">
        <link:definition>2142111 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.ardelyx.com/role/ContingenciesDetails">
        <link:definition>2443423 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ardelyx.com/role/SubsequentEvents">
        <link:definition>2144112 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails">
        <link:definition>2445424 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ardx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_LongTermInvestmentsFairValue" abstract="false" name="LongTermInvestmentsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_NumberOfSeparateCollaborativeAgreements" abstract="false" name="NumberOfSeparateCollaborativeAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_CollaborativeDevelopmentMember" abstract="true" name="CollaborativeDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_OtherProductOrServicesRevenueMember" abstract="true" name="OtherProductOrServicesRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFeePercentage" abstract="false" name="DebtInstrumentClosingFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ThresholdPercentageOfSalesForTieredRoyalties" abstract="false" name="ThresholdPercentageOfSalesForTieredRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_FacilityWalthamMassachusettsMember" abstract="true" name="FacilityWalthamMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ProductSupplyRevenueMember" abstract="true" name="ProductSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_PercentageOfNonRoyaltyRevenue" abstract="false" name="PercentageOfNonRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_KnightTherapeuticsIncMember" abstract="true" name="KnightTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" abstract="false" name="RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" abstract="false" name="ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialCommercializationMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" abstract="false" name="FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" abstract="false" name="FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestPaymentExtensionTerm" abstract="false" name="DebtInstrumentInterestPaymentExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_FacilityFremontCaliforniaMember" abstract="true" name="FacilityFremontCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermOfPaymentOfLicenseFeeFirstInstallment" abstract="false" name="TermOfPaymentOfLicenseFeeFirstInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_InvestmentsAndCashFairValueDisclosure" abstract="false" name="InvestmentsAndCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" abstract="false" name="RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_ResearchCollaborationAndOptionAgreementMember" abstract="true" name="ResearchCollaborationAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsAbstract" abstract="true" name="CollaborationAndLicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_PercentageOfRoyaltyRevenue" abstract="false" name="PercentageOfRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_PutativeSecuritiesClassActionLawsuitMember" abstract="true" name="PutativeSecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PaymentsOfUnchargedLicenseFees" abstract="false" name="PaymentsOfUnchargedLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AtMarketOfferingMember" abstract="true" name="AtMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_StockIssuanceCostCommissionPercent" abstract="false" name="StockIssuanceCostCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" abstract="false" name="LongTermInvestmentsAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KyowaKirinCo.LtdMember" abstract="true" name="KyowaKirinCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" abstract="false" name="CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="LongTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AstraZenecaTerminationAgreementMember" abstract="true" name="AstraZenecaTerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFee" abstract="false" name="DebtInstrumentClosingFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" abstract="false" name="ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestRateOnDefaultPercentage" abstract="false" name="DebtInstrumentInterestRateOnDefaultPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" abstract="false" name="DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_WorkforceRealignmentMember" abstract="true" name="WorkforceRealignmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LongTermInvestmentsAmortizedCost" abstract="false" name="LongTermInvestmentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ardx-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c84575bf-704c-4845-a92a-4bbdc87faa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:to="loc_us-gaap_AssetsCurrent_c84575bf-704c-4845-a92a-4bbdc87faa0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e59f077c-af7e-415e-a384-ae5f04e72010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e59f077c-af7e-415e-a384-ae5f04e72010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7fb4f649-f9c7-45d2-872e-37b1847ebf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:to="loc_us-gaap_LongTermInvestments_7fb4f649-f9c7-45d2-872e-37b1847ebf9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a956d71f-9984-4ec9-b4e6-a74a09e42fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a956d71f-9984-4ec9-b4e6-a74a09e42fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c92deedc-6205-4a31-a835-f8d8748301aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76b54b33-d449-41a3-8715-310fc1f86d47" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c92deedc-6205-4a31-a835-f8d8748301aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bbd81f99-e23f-438b-b041-17506affb68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:to="loc_us-gaap_PreferredStockValue_bbd81f99-e23f-438b-b041-17506affb68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4207ae4e-4dc9-47ee-a95f-929c5e2414b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:to="loc_us-gaap_CommonStockValue_4207ae4e-4dc9-47ee-a95f-929c5e2414b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e519796e-9b7f-491b-b8fd-16c71baa38a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e519796e-9b7f-491b-b8fd-16c71baa38a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c5133a4-c75b-4704-9f84-7259d67e54bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c5133a4-c75b-4704-9f84-7259d67e54bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bcbb16b0-27f8-41a3-97bd-c5d6365f4019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aae142ca-a7e2-4a0d-b0ec-af6037cae989" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bcbb16b0-27f8-41a3-97bd-c5d6365f4019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a7d10ea-579b-450b-ab93-48d994f5386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1896393c-fd12-4c40-a11b-765dd09f62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a7d10ea-579b-450b-ab93-48d994f5386b" xlink:to="loc_us-gaap_LiabilitiesCurrent_1896393c-fd12-4c40-a11b-765dd09f62d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_463c4521-d99f-46c0-a900-7eb2e3475d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a7d10ea-579b-450b-ab93-48d994f5386b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_463c4521-d99f-46c0-a900-7eb2e3475d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_880509cb-6d1c-4f62-a8c7-2013d323fe72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a7d10ea-579b-450b-ab93-48d994f5386b" xlink:to="loc_us-gaap_LongTermLoansPayable_880509cb-6d1c-4f62-a8c7-2013d323fe72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e8aeacc4-7d22-4043-86db-cb66e0835fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a7d10ea-579b-450b-ab93-48d994f5386b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e8aeacc4-7d22-4043-86db-cb66e0835fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_db84a547-5665-4ae6-89cd-d2496424c786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_AccountsPayableCurrent_db84a547-5665-4ae6-89cd-d2496424c786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bee1f159-07fe-48d4-b03f-84460ee56595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bee1f159-07fe-48d4-b03f-84460ee56595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_00740374-81ba-468b-8c02-4911b43c4f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_00740374-81ba-468b-8c02-4911b43c4f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_77cf50d9-8e37-48d8-a25b-dcf61382ce49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_LoansPayableCurrent_77cf50d9-8e37-48d8-a25b-dcf61382ce49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d00ae340-4f4f-4574-aaff-871981dbb549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d00ae340-4f4f-4574-aaff-871981dbb549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b66b7170-1f82-4dbd-b01b-04ba09306146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_08751370-120f-4a4e-93c0-0dc79a769b20" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b66b7170-1f82-4dbd-b01b-04ba09306146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ac9d826e-2f62-4398-b0b0-5fa9abbaa293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55dac7f3-9671-4500-9892-450891d8ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9d826e-2f62-4398-b0b0-5fa9abbaa293" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55dac7f3-9671-4500-9892-450891d8ce17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4149d8b4-2423-4fbf-af7a-f6e2fad0db06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9d826e-2f62-4398-b0b0-5fa9abbaa293" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4149d8b4-2423-4fbf-af7a-f6e2fad0db06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_373b475b-67e1-4a9a-a383-e0ab659644b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac9d826e-2f62-4398-b0b0-5fa9abbaa293" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_373b475b-67e1-4a9a-a383-e0ab659644b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c90706a-f2f4-4c7b-9ac4-46ff5cc32bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cb17d26d-c511-4527-9b5a-4edf703c12a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c90706a-f2f4-4c7b-9ac4-46ff5cc32bad" xlink:to="loc_us-gaap_Liabilities_cb17d26d-c511-4527-9b5a-4edf703c12a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7b1e1940-0471-4f9c-b97e-7afaa422489f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c90706a-f2f4-4c7b-9ac4-46ff5cc32bad" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7b1e1940-0471-4f9c-b97e-7afaa422489f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4f76dea4-107f-450c-b9cf-2557e4ce119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c90706a-f2f4-4c7b-9ac4-46ff5cc32bad" xlink:to="loc_us-gaap_StockholdersEquity_4f76dea4-107f-450c-b9cf-2557e4ce119e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eacb5f3c-8325-48ec-b397-83f9c7945c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1717bf32-a578-4f7a-b9fd-e76aef2bc2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eacb5f3c-8325-48ec-b397-83f9c7945c77" xlink:to="loc_us-gaap_CostOfRevenue_1717bf32-a578-4f7a-b9fd-e76aef2bc2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd55ead3-4f97-4cdd-a3a1-0678f8334366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eacb5f3c-8325-48ec-b397-83f9c7945c77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd55ead3-4f97-4cdd-a3a1-0678f8334366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ba14da5-64fb-4c7f-ba37-babc097110e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eacb5f3c-8325-48ec-b397-83f9c7945c77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ba14da5-64fb-4c7f-ba37-babc097110e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac33b416-52cb-4564-b4c2-9df6cf3e3ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b9aeeb46-f50f-4f0b-a3ef-62c54889c380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ac33b416-52cb-4564-b4c2-9df6cf3e3ec2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b9aeeb46-f50f-4f0b-a3ef-62c54889c380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_886cf36f-a748-430f-a29d-813e15b65366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ac33b416-52cb-4564-b4c2-9df6cf3e3ec2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_886cf36f-a748-430f-a29d-813e15b65366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2c708311-9362-4fe3-8768-b0d3b53788ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5b78b6-d560-4baf-82e8-1874e68c6046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2c708311-9362-4fe3-8768-b0d3b53788ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c5b78b6-d560-4baf-82e8-1874e68c6046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bc8be0c6-369c-4ee9-ba88-6d52d0ebb59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2c708311-9362-4fe3-8768-b0d3b53788ad" xlink:to="loc_us-gaap_CostsAndExpenses_bc8be0c6-369c-4ee9-ba88-6d52d0ebb59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbb8b9f8-7534-45d8-8102-2a445f7b696d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c02d835c-87a4-4511-a7f6-a56987ed2158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbb8b9f8-7534-45d8-8102-2a445f7b696d" xlink:to="loc_us-gaap_OperatingIncomeLoss_c02d835c-87a4-4511-a7f6-a56987ed2158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_266b2216-dbe8-4615-9436-f4f4fde0e115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbb8b9f8-7534-45d8-8102-2a445f7b696d" xlink:to="loc_us-gaap_InterestExpense_266b2216-dbe8-4615-9436-f4f4fde0e115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f9842e86-03f9-49e4-897c-185e6a9a7bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fbb8b9f8-7534-45d8-8102-2a445f7b696d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f9842e86-03f9-49e4-897c-185e6a9a7bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_270fb48f-ab10-4d73-a0c0-f6bc32d79d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d9e1d01-e092-4d00-8814-ec906defcc20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_270fb48f-ab10-4d73-a0c0-f6bc32d79d56" xlink:to="loc_us-gaap_NetIncomeLoss_9d9e1d01-e092-4d00-8814-ec906defcc20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bbd562ae-f018-4445-8842-ee1890628b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_270fb48f-ab10-4d73-a0c0-f6bc32d79d56" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bbd562ae-f018-4445-8842-ee1890628b1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0cb28326-4028-4bbe-9eeb-4305620084cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4976e70-baaa-46a9-b650-5976ae8d3691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0cb28326-4028-4bbe-9eeb-4305620084cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4976e70-baaa-46a9-b650-5976ae8d3691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a61abc83-9e0e-471a-ba4b-dd69e120ec11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0cb28326-4028-4bbe-9eeb-4305620084cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a61abc83-9e0e-471a-ba4b-dd69e120ec11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2955b42b-fccd-434b-a735-d4177c17175b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0cb28326-4028-4bbe-9eeb-4305620084cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2955b42b-fccd-434b-a735-d4177c17175b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82222ff1-2c51-4585-9069-973414089c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9860ca12-1dd1-4c7c-81b7-4317f12a8495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82222ff1-2c51-4585-9069-973414089c41" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9860ca12-1dd1-4c7c-81b7-4317f12a8495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_35b435e2-96a7-4ab3-8b81-5f34a9d75f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82222ff1-2c51-4585-9069-973414089c41" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_35b435e2-96a7-4ab3-8b81-5f34a9d75f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b61b489-f67d-43c1-b234-52f6a3e2b9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82222ff1-2c51-4585-9069-973414089c41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2b61b489-f67d-43c1-b234-52f6a3e2b9f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_046ca900-da8b-425b-b824-e046d6fb813b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f200c335-f864-4df1-8f8c-6db72dca62b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_046ca900-da8b-425b-b824-e046d6fb813b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f200c335-f864-4df1-8f8c-6db72dca62b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2df1e3b9-6533-4928-a300-91630dbfc623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_046ca900-da8b-425b-b824-e046d6fb813b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2df1e3b9-6533-4928-a300-91630dbfc623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90b30aff-57fd-4b88-bc6d-6385551cd709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_NetIncomeLoss_90b30aff-57fd-4b88-bc6d-6385551cd709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5869b219-45ab-4042-a91e-9804479d30bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_Depreciation_5869b219-45ab-4042-a91e-9804479d30bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_fe5fa566-6f25-4c28-b830-4b4c9aa598f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_fe5fa566-6f25-4c28-b830-4b4c9aa598f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_08065b9c-11da-465a-89b9-cb6b53f329a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_08065b9c-11da-465a-89b9-cb6b53f329a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3905d2c9-754f-44d1-a48b-c7a278058421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3905d2c9-754f-44d1-a48b-c7a278058421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c3c4d9bd-5ad5-4810-81cf-0e73ffef4f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c3c4d9bd-5ad5-4810-81cf-0e73ffef4f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_38160e9c-fa72-491e-bec2-586a86e96d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_ShareBasedCompensation_38160e9c-fa72-491e-bec2-586a86e96d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1f30796b-1b67-4de5-8cfc-115461730c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1f30796b-1b67-4de5-8cfc-115461730c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_11560135-5551-468f-b75d-5e77ffe48d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_11560135-5551-468f-b75d-5e77ffe48d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1a8ba56e-8aab-46f6-9ddd-f73c5a23c257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1a8ba56e-8aab-46f6-9ddd-f73c5a23c257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff855f1c-d549-4b2a-a2bb-038282b2a58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ff855f1c-d549-4b2a-a2bb-038282b2a58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_40c606d9-30a5-4a8e-9a95-fc9fa6ac3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_40c606d9-30a5-4a8e-9a95-fc9fa6ac3f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1c5839d2-b15d-43fc-9e2b-db52b040e076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1c5839d2-b15d-43fc-9e2b-db52b040e076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6a2a6e63-ae3b-4e4c-a980-7e26a1454e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6a2a6e63-ae3b-4e4c-a980-7e26a1454e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5961b77e-8a53-4e84-97ec-9a2e902aad92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37fadea9-3f84-4df0-9049-3fb099f02d13" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5961b77e-8a53-4e84-97ec-9a2e902aad92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_35aec21a-32c3-4c9c-a8c3-d35bf39d9999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_9e7f13e7-68db-486c-9c1d-1f5e98908216" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_35aec21a-32c3-4c9c-a8c3-d35bf39d9999" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_9e7f13e7-68db-486c-9c1d-1f5e98908216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_59484c75-7434-43c2-a33a-31efc9c49f21" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_35aec21a-32c3-4c9c-a8c3-d35bf39d9999" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_59484c75-7434-43c2-a33a-31efc9c49f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashFairValueDisclosure_70e4ec44-fd4e-4f48-a22d-ab141190b07b" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_35aec21a-32c3-4c9c-a8c3-d35bf39d9999" xlink:to="loc_ardx_InvestmentsAndCashFairValueDisclosure_70e4ec44-fd4e-4f48-a22d-ab141190b07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4728874c-df83-492e-9ede-84ff240b6b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4d9b27e-7805-492f-a54f-1e45ac546147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4728874c-df83-492e-9ede-84ff240b6b27" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4d9b27e-7805-492f-a54f-1e45ac546147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_516cacba-3efb-42f0-b5ce-386f1e2443b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4728874c-df83-492e-9ede-84ff240b6b27" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_516cacba-3efb-42f0-b5ce-386f1e2443b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ed1ffaa-6b75-42e8-89b8-168ad7d9e45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4728874c-df83-492e-9ede-84ff240b6b27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ed1ffaa-6b75-42e8-89b8-168ad7d9e45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAmortizedCost_62c8a5ac-1aad-4686-a7be-5e1ce72ea89a" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_5597c989-6584-467d-9d21-6d1fc3a9ce12" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_LongTermInvestmentsAmortizedCost_62c8a5ac-1aad-4686-a7be-5e1ce72ea89a" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_5597c989-6584-467d-9d21-6d1fc3a9ce12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_326e3256-66b3-4d3e-9edc-6b09b630bcbb" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_LongTermInvestmentsAmortizedCost_62c8a5ac-1aad-4686-a7be-5e1ce72ea89a" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_326e3256-66b3-4d3e-9edc-6b09b630bcbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsFairValue_f09e1aea-389f-4366-b977-0fc440d81b9e" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_LongTermInvestmentsAmortizedCost_62c8a5ac-1aad-4686-a7be-5e1ce72ea89a" xlink:to="loc_ardx_LongTermInvestmentsFairValue_f09e1aea-389f-4366-b977-0fc440d81b9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f24b8955-1552-4995-abe2-19ba1f3b5407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c3900394-6582-453d-b220-59c404e0bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f24b8955-1552-4995-abe2-19ba1f3b5407" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c3900394-6582-453d-b220-59c404e0bc09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7d5ef4-a787-469e-a524-cfe2135443e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f24b8955-1552-4995-abe2-19ba1f3b5407" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ad7d5ef4-a787-469e-a524-cfe2135443e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_5d75561b-26e3-4c00-be43-f4a46adcc283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f24b8955-1552-4995-abe2-19ba1f3b5407" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_5d75561b-26e3-4c00-be43-f4a46adcc283" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ae7fe3a3-1594-4035-80bf-fd5197ba37a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_ed031f2d-9e5c-4265-9e93-5f0a36348c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ae7fe3a3-1594-4035-80bf-fd5197ba37a9" xlink:to="loc_us-gaap_LoansPayableCurrent_ed031f2d-9e5c-4265-9e93-5f0a36348c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_9f364200-5439-497d-b238-c259de0f7e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ae7fe3a3-1594-4035-80bf-fd5197ba37a9" xlink:to="loc_us-gaap_LongTermLoansPayable_9f364200-5439-497d-b238-c259de0f7e1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_955d0e2e-cd0c-4a8d-9144-25b7ea1d4c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_955d0e2e-cd0c-4a8d-9144-25b7ea1d4c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c593800-00c0-487d-8300-bdbd879813db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c593800-00c0-487d-8300-bdbd879813db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_919c9efc-722a-413e-8fa4-7d094a8ea758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_919c9efc-722a-413e-8fa4-7d094a8ea758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_681e0351-f185-4aa3-b2f2-79478a4165be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_681e0351-f185-4aa3-b2f2-79478a4165be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_713be57b-0078-424e-b9e3-8fffdd8839b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_713be57b-0078-424e-b9e3-8fffdd8839b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c6ba1bee-27ec-4995-8fc5-13446b968a02" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f826f08a-579b-40a3-872b-c9e95179b4e1" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c6ba1bee-27ec-4995-8fc5-13446b968a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0536df86-f28a-4d66-b353-d434f9085097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf53f25c-e078-40c1-9b10-dfaa2427e39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0536df86-f28a-4d66-b353-d434f9085097" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf53f25c-e078-40c1-9b10-dfaa2427e39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a944935-018c-4fe6-9edb-d412328af219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0536df86-f28a-4d66-b353-d434f9085097" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a944935-018c-4fe6-9edb-d412328af219" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04a7e048-2ca7-48a3-a191-3224e10ddf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11af9b4-4d20-4ee5-87a4-628b7a0344ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04a7e048-2ca7-48a3-a191-3224e10ddf7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11af9b4-4d20-4ee5-87a4-628b7a0344ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5da90eca-f7ac-4f7e-aa4b-7028f491c211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04a7e048-2ca7-48a3-a191-3224e10ddf7f" xlink:to="loc_us-gaap_OperatingLeaseLiability_5da90eca-f7ac-4f7e-aa4b-7028f491c211" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ardx-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20210630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended" id="idf977bc9500146d897ec04ba3767cf7a_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9e51c9f5-4ba8-4c37-ac48-20c2e7259bf3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentType_9e51c9f5-4ba8-4c37-ac48-20c2e7259bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_282d17fe-ef1e-4c8a-a798-2627277ae92c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentQuarterlyReport_282d17fe-ef1e-4c8a-a798-2627277ae92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cefd05d1-cb8d-4a3a-822b-2d606dfddb99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentPeriodEndDate_cefd05d1-cb8d-4a3a-822b-2d606dfddb99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fd68225f-5b44-4b12-98f9-036e28121a5b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentTransitionReport_fd68225f-5b44-4b12-98f9-036e28121a5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00a4e677-6b24-4c5b-9735-f78421f1bf6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityFileNumber_00a4e677-6b24-4c5b-9735-f78421f1bf6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d6399590-98b0-42f3-9826-80dcaee66399" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityRegistrantName_d6399590-98b0-42f3-9826-80dcaee66399" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa820154-3775-49a5-8673-3bb01f6de0d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCentralIndexKey_fa820154-3775-49a5-8673-3bb01f6de0d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1ca8a62e-ecc1-4a05-9470-98252b4c4e00" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_CurrentFiscalYearEndDate_1ca8a62e-ecc1-4a05-9470-98252b4c4e00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2486d1b1-bd9e-44ef-b833-545eb424c4c3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentFiscalYearFocus_2486d1b1-bd9e-44ef-b833-545eb424c4c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_50da7561-1c7e-4719-b0fd-c8309c825eb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_50da7561-1c7e-4719-b0fd-c8309c825eb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_03a84c49-4a1f-4db0-bb74-d6963e222fed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_AmendmentFlag_03a84c49-4a1f-4db0-bb74-d6963e222fed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_efff80a0-ba35-4837-91dd-11ab293a5562" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_efff80a0-ba35-4837-91dd-11ab293a5562" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_732a4185-5ec3-4b7c-8fef-09b32335f326" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityTaxIdentificationNumber_732a4185-5ec3-4b7c-8fef-09b32335f326" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5bc294ed-3e28-4790-8289-17128e02db1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressAddressLine1_5bc294ed-3e28-4790-8289-17128e02db1d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9d7b8f49-7477-4773-a1bb-2e200a969e5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressAddressLine2_9d7b8f49-7477-4773-a1bb-2e200a969e5d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a35b8e35-ec2b-4126-ad0f-95ece2994bd8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressCityOrTown_a35b8e35-ec2b-4126-ad0f-95ece2994bd8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_817b6f2b-b590-4ed4-b434-d27a9fcc1ae1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressStateOrProvince_817b6f2b-b590-4ed4-b434-d27a9fcc1ae1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_84ef2d36-6408-46f5-aa01-a40472da3c06" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressPostalZipCode_84ef2d36-6408-46f5-aa01-a40472da3c06" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_85230d47-39b0-4af9-96bb-6445dbfbaaaa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_CityAreaCode_85230d47-39b0-4af9-96bb-6445dbfbaaaa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7b1b8742-5843-47d3-8bf2-0297f270d540" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_LocalPhoneNumber_7b1b8742-5843-47d3-8bf2-0297f270d540" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_33cfe46e-7d13-41eb-8a3b-12b7f781309f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_Security12bTitle_33cfe46e-7d13-41eb-8a3b-12b7f781309f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_390ece83-8686-4ff7-99ff-a1b621133e92" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_TradingSymbol_390ece83-8686-4ff7-99ff-a1b621133e92" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_90e9b2da-648a-4338-bb70-debef7209735" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_SecurityExchangeName_90e9b2da-648a-4338-bb70-debef7209735" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_02407c21-212b-4364-b836-fdb591e1222d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCurrentReportingStatus_02407c21-212b-4364-b836-fdb591e1222d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d4523b96-0d37-4454-9b58-70de978c0e98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityInteractiveDataCurrent_d4523b96-0d37-4454-9b58-70de978c0e98" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_85b63b0a-3e1e-402f-bbf1-f1961d8f8192" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityFilerCategory_85b63b0a-3e1e-402f-bbf1-f1961d8f8192" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_222f90b8-b835-4c6a-819d-95c3d729dc2a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntitySmallBusiness_222f90b8-b835-4c6a-819d-95c3d729dc2a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_125325b6-0ed1-4c38-968e-22a298e378de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityEmergingGrowthCompany_125325b6-0ed1-4c38-968e-22a298e378de" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e3d3cd41-80d3-414d-8d99-1b5f204cf448" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityShellCompany_e3d3cd41-80d3-414d-8d99-1b5f204cf448" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_81e902a1-a44b-4524-baaf-c9cfc801857f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_81e902a1-a44b-4524-baaf-c9cfc801857f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b6059059-d215-4c85-9918-572d65b4d613_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:to="loc_dei_AddressTypeDomain_b6059059-d215-4c85-9918-572d65b4d613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:to="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherAddressMember_1dd984db-5246-4bd8-91e2-e5f1b49f3b90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:to="loc_dei_OtherAddressMember_1dd984db-5246-4bd8-91e2-e5f1b49f3b90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="icca5865efece408b8d92d692058d0b35_CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b28498e-584a-4035-a203-0032bfe763e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b28498e-584a-4035-a203-0032bfe763e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_38168242-ba19-473e-afc9-b2c70ee79915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_CostOfRevenue_38168242-ba19-473e-afc9-b2c70ee79915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_75ae6b60-6ffd-4066-be60-361a63d11ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_75ae6b60-6ffd-4066-be60-361a63d11ac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_60af4401-cca0-4443-83e2-33fe103c80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_60af4401-cca0-4443-83e2-33fe103c80ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b9e655f9-f6a2-4f75-b60d-164b5d020895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_CostsAndExpenses_b9e655f9-f6a2-4f75-b60d-164b5d020895" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f1b6118-65a2-417b-9dfd-46680dc3b4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f1b6118-65a2-417b-9dfd-46680dc3b4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ace43c85-eb35-4bfe-9f0b-f70f20079bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_InterestExpense_ace43c85-eb35-4bfe-9f0b-f70f20079bc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5f7685fb-8a50-49d0-a065-aa927a9e2e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5f7685fb-8a50-49d0-a065-aa927a9e2e16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84cdb601-1881-47cc-b2fb-bd3aa0864ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84cdb601-1881-47cc-b2fb-bd3aa0864ee1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2a77bd9a-5ef9-4beb-bf46-bac2d1ed40b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2a77bd9a-5ef9-4beb-bf46-bac2d1ed40b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91eefbee-4b47-429c-93c0-3fc98fc64eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_NetIncomeLoss_91eefbee-4b47-429c-93c0-3fc98fc64eaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_53a9ff05-52dc-4707-80f8-39acd2d21034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_EarningsPerShareBasic_53a9ff05-52dc-4707-80f8-39acd2d21034" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_06a4aa1c-a0a5-4535-909a-83451d0bb144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_06a4aa1c-a0a5-4535-909a-83451d0bb144" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbefb560-9449-4364-97dd-34530cd790ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbefb560-9449-4364-97dd-34530cd790ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40ab9e62-ec7b-42fb-a5d6-e94be3a10ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40ab9e62-ec7b-42fb-a5d6-e94be3a10ada" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6ac2851d-ccb9-4f71-908c-a22bb25d075f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_49141fa4-a987-4e46-b4d7-d8f5bb941573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_49141fa4-a987-4e46-b4d7-d8f5bb941573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f09a2fb-9583-433c-a09b-a4a99b0961a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f09a2fb-9583-433c-a09b-a4a99b0961a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:to="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:to="loc_srt_ProductsAndServicesDomain_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:to="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_57e141d8-09f0-421d-9cfd-d44ea514f05a" xlink:href="ardx-20210630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_ardx_CollaborativeDevelopmentMember_57e141d8-09f0-421d-9cfd-d44ea514f05a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_511b4c53-b033-4547-ba1a-85952cb07a6e" xlink:href="ardx-20210630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_ardx_ProductSupplyRevenueMember_511b4c53-b033-4547-ba1a-85952cb07a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_72b22dd5-077b-4b94-a6cf-3f0723bcf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_us-gaap_LicenseMember_72b22dd5-077b-4b94-a6cf-3f0723bcf1e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="if41233494eb246c5b6b1ca15242e8a55_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ef49fd8-b6db-4337-a3e4-5918e6a8c071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockholdersEquity_5ef49fd8-b6db-4337-a3e4-5918e6a8c071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6348810b-1c56-4e7e-af08-f1a66f56cc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_SharesOutstanding_6348810b-1c56-4e7e-af08-f1a66f56cc1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_43ca3556-4968-4885-8760-7d11cfbe796d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_43ca3556-4968-4885-8760-7d11cfbe796d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c0e8078c-18c4-4d8a-b92b-8e030c47bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c0e8078c-18c4-4d8a-b92b-8e030c47bfea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_e91ad7fa-7719-4724-a0d3-cb193985b51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_e91ad7fa-7719-4724-a0d3-cb193985b51d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_76184be7-7b6d-4fe7-b088-eb3beff445e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_76184be7-7b6d-4fe7-b088-eb3beff445e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_707d5b21-c5ad-4dc8-878e-60c83ea6946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_707d5b21-c5ad-4dc8-878e-60c83ea6946a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_57af6896-377c-4428-b47e-8687d7098886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_57af6896-377c-4428-b47e-8687d7098886" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db8ec02b-3063-421d-8470-51a658af5d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db8ec02b-3063-421d-8470-51a658af5d37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0432b742-336c-4f75-84a5-8b068e303865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0432b742-336c-4f75-84a5-8b068e303865" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_299099de-46c8-4021-9338-7d399cfe40b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_299099de-46c8-4021-9338-7d399cfe40b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d27dde6a-edcc-445b-b605-5a81fe326b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d27dde6a-edcc-445b-b605-5a81fe326b1c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b07a6db2-bd73-48d1-834b-85caaaf78dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b07a6db2-bd73-48d1-834b-85caaaf78dcd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_653e01cd-e8d1-4499-b607-056ec92e8dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_NetIncomeLoss_653e01cd-e8d1-4499-b607-056ec92e8dd4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ed9e38c-8480-47f2-b0c4-50b3739e6190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bcf0c1b7-26c4-43cf-a0b7-e14aca2a59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4688d17e-9674-4422-835c-6dbbcd86fc18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:to="loc_us-gaap_EquityComponentDomain_4688d17e-9674-4422-835c-6dbbcd86fc18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:to="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c24caf17-c13a-47fd-a800-610229004dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_CommonStockMember_c24caf17-c13a-47fd-a800-610229004dd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ac647f05-6221-4415-9c19-8bd7919a595e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ac647f05-6221-4415-9c19-8bd7919a595e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bd7392a-6781-4b0c-8189-348bfa97fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_RetainedEarningsMember_3bd7392a-6781-4b0c-8189-348bfa97fa5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3909b822-f282-44f1-ae3d-c0546c02d42f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3909b822-f282-44f1-ae3d-c0546c02d42f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="ibb6cba6562d54b489f84294b91c5ae52_CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2f786e4-ae79-45d4-af14-520da6c19278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2f786e4-ae79-45d4-af14-520da6c19278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df1c1290-65f1-4b24-bcba-df9307d503bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df1c1290-65f1-4b24-bcba-df9307d503bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b20b2735-9159-4ed0-a919-ed9039116725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b20b2735-9159-4ed0-a919-ed9039116725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07088dd4-7d70-4761-a012-d6f3c030a850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07088dd4-7d70-4761-a012-d6f3c030a850" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6142a82f-2217-46b3-a390-2f9f64da2bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6142a82f-2217-46b3-a390-2f9f64da2bcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34facfde-5ae1-44e3-9d7b-4a00d84072ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34facfde-5ae1-44e3-9d7b-4a00d84072ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAmortizedCost_91648fbd-2768-4e0c-b01c-0fda46cb78e4" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAmortizedCost_91648fbd-2768-4e0c-b01c-0fda46cb78e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_10306606-9a9e-4a91-a3d6-fb5c2372b0a9" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_10306606-9a9e-4a91-a3d6-fb5c2372b0a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_2ffd1f2f-b3e1-4e86-aea9-5ef066cdfa79" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_2ffd1f2f-b3e1-4e86-aea9-5ef066cdfa79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsFairValue_5aaacc93-4b52-46c6-834e-6e204bf2f75a" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsFairValue_5aaacc93-4b52-46c6-834e-6e204bf2f75a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_901a5aa0-4915-49ad-99db-4a9f3ddfd36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_InvestmentsAndCash_901a5aa0-4915-49ad-99db-4a9f3ddfd36d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_79d6c5d2-94fa-408b-aa3a-69a558bf7626" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_79d6c5d2-94fa-408b-aa3a-69a558bf7626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_01716b77-c63f-4817-919a-63aeebef2aa1" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_01716b77-c63f-4817-919a-63aeebef2aa1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashFairValueDisclosure_dbe13399-ae93-43a0-b45d-a4f701f1bc2b" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashFairValueDisclosure_dbe13399-ae93-43a0-b45d-a4f701f1bc2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d101ceb7-430f-4d23-9346-1493caff86b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d101ceb7-430f-4d23-9346-1493caff86b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ee262834-f248-4639-86b6-7d13dc9b3643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ee262834-f248-4639-86b6-7d13dc9b3643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b2d5d545-ea94-4f6d-94bf-7dac493c8ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b2d5d545-ea94-4f6d-94bf-7dac493c8ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0df5146e-770e-41fd-becb-1fb07632b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0df5146e-770e-41fd-becb-1fb07632b1a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b65f77cb-cd54-4fd9-8e4b-67901c9c8886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b65f77cb-cd54-4fd9-8e4b-67901c9c8886" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_1e88da8d-b5e5-4180-8319-6088c6e04c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_1e88da8d-b5e5-4180-8319-6088c6e04c89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2fd8f682-daf6-4408-ae14-ccc3f74c22f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2fd8f682-daf6-4408-ae14-ccc3f74c22f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_b3f5ad7b-274d-499b-bbad-4ea4a9f01cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_CashMember_b3f5ad7b-274d-499b-bbad-4ea4a9f01cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7811b5cc-03d8-4dd8-9409-b7211f0af2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7811b5cc-03d8-4dd8-9409-b7211f0af2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14e3d4cc-2466-45ee-9a7d-041b8795e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_CommercialPaperMember_14e3d4cc-2466-45ee-9a7d-041b8795e7b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ie5c1c6dd31cb4b4f921aee57bb362a9b_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1cb03204-c366-4989-8d7e-72bf03c119cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1cb03204-c366-4989-8d7e-72bf03c119cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ebb0024a-c3ca-4516-b968-831f5cf1af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ebb0024a-c3ca-4516-b968-831f5cf1af1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b694da9-56cb-489b-96f9-e028a6bbf445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4b694da9-56cb-489b-96f9-e028a6bbf445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_33455a0b-ac3c-4617-9495-9b198408c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_33455a0b-ac3c-4617-9495-9b198408c94a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f090ade5-19f4-4867-999f-406cb33a8746_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f090ade5-19f4-4867-999f-406cb33a8746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3c9980eb-a578-4554-981b-d23d2aa5b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3c9980eb-a578-4554-981b-d23d2aa5b83c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_873b7c9d-f5d3-4724-bb86-1c709df8c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_873b7c9d-f5d3-4724-bb86-1c709df8c6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9c838c75-3d02-4cd3-9f50-8848bf42ac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9c838c75-3d02-4cd3-9f50-8848bf42ac9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d7f8b1b9-41b3-490d-adb0-e8efeca5be13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d7f8b1b9-41b3-490d-adb0-e8efeca5be13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d0a3837d-c5f1-421f-932e-8907cad3ec93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d0a3837d-c5f1-421f-932e-8907cad3ec93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0296e6c6-e0f8-4d4e-816f-5a3a3beb739c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_CommercialPaperMember_0296e6c6-e0f8-4d4e-816f-5a3a3beb739c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c23de353-289d-431b-bc1f-4ee5d9c214ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c23de353-289d-431b-bc1f-4ee5d9c214ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7fb4c03f-06cf-4f9a-a759-af0fa48cff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7fb4c03f-06cf-4f9a-a759-af0fa48cff16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cd03617-3cd1-4a5d-8819-46bfcbea79fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cd03617-3cd1-4a5d-8819-46bfcbea79fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ed3a311f-7bfe-44cc-b7a6-913d6e9766e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ed3a311f-7bfe-44cc-b7a6-913d6e9766e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e7afa2fc-99eb-41ee-af8d-7ee73cffe992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e7afa2fc-99eb-41ee-af8d-7ee73cffe992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dc4bea7f-47d1-4156-adc6-0bdc2cd67375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dc4bea7f-47d1-4156-adc6-0bdc2cd67375" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="i0947df36d644472e94a504b61d6669e6_CollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_f54d7fa1-9665-4e6a-aa5c-1d7f6a116d02" xlink:href="ardx-20210630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_f54d7fa1-9665-4e6a-aa5c-1d7f6a116d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_df12f52c-f16f-499d-9c92-98a9096b6e57" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_df12f52c-f16f-499d-9c92-98a9096b6e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_4fac8d96-d633-432c-aa83-acab63fb9aed" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_4fac8d96-d633-432c-aa83-acab63fb9aed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_8b11504e-89ab-41ce-9553-e81fbfe479c7" xlink:href="ardx-20210630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_8b11504e-89ab-41ce-9553-e81fbfe479c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_a195c334-3e3c-4210-aa31-1d5798318871" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_a195c334-3e3c-4210-aa31-1d5798318871" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_b8f067af-fae3-4924-94b0-f057ca34f4df" xlink:href="ardx-20210630.xsd#ardx_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_TermOfAgreement_b8f067af-fae3-4924-94b0-f057ca34f4df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_49945e46-f26f-498b-8c04-e4f9f5dcd7a3" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_49945e46-f26f-498b-8c04-e4f9f5dcd7a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e2aefa6-33e8-4fec-b985-5a73e2620808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e2aefa6-33e8-4fec-b985-5a73e2620808" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_cbc4ed5e-a681-403d-bdc7-17ede1a143dd" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_cbc4ed5e-a681-403d-bdc7-17ede1a143dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eccf0564-9c3c-4ecf-8486-8e053539ccd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eccf0564-9c3c-4ecf-8486-8e053539ccd1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_ac99689d-50be-4c1d-88e3-b57e51be341c" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_ac99689d-50be-4c1d-88e3-b57e51be341c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_56d23ae1-cd9e-4e21-9aaf-d4776ab09e17" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_56d23ae1-cd9e-4e21-9aaf-d4776ab09e17" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_b22c669b-348f-4ce3-bd7e-24b60ea115e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_b22c669b-348f-4ce3-bd7e-24b60ea115e1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_9b388547-b813-4c34-b1ab-4b4ba41e53b3" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_9b388547-b813-4c34-b1ab-4b4ba41e53b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_8f1b46e4-a5ca-41b8-a9f4-3f779e82e8a4" xlink:href="ardx-20210630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_8f1b46e4-a5ca-41b8-a9f4-3f779e82e8a4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_76671de8-17db-4456-9621-32814f1b48eb" xlink:href="ardx-20210630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_76671de8-17db-4456-9621-32814f1b48eb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_26c97db8-22c3-43ec-a64e-44873d0c6c1f" xlink:href="ardx-20210630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_26c97db8-22c3-43ec-a64e-44873d0c6c1f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_c4a3842a-c7bd-42fe-9e18-8e7e8c1e8d5d" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_c4a3842a-c7bd-42fe-9e18-8e7e8c1e8d5d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_9736586b-3f98-4443-b677-916c160b2611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_CostOfRevenue_9736586b-3f98-4443-b677-916c160b2611" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFees_fd06c4a2-c449-4428-bef3-9138846e9481" xlink:href="ardx-20210630.xsd#ardx_PaymentsOfUnchargedLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFees_fd06c4a2-c449-4428-bef3-9138846e9481" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdc23faf-653b-4dc4-aa57-221c3c83b40f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdc23faf-653b-4dc4-aa57-221c3c83b40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_29f911c1-93ba-4778-a596-bb49c6427564" xlink:href="ardx-20210630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_29f911c1-93ba-4778-a596-bb49c6427564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_bfff45a0-8216-453a-95ef-1a63f59fa878" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_bfff45a0-8216-453a-95ef-1a63f59fa878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_4cc4b53d-bc6c-4019-bf3d-501abc436a36" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_4cc4b53d-bc6c-4019-bf3d-501abc436a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_77c8f4bd-d6aa-4f1f-9fd0-ce6ab4202e4b" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_77c8f4bd-d6aa-4f1f-9fd0-ce6ab4202e4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_8cb148b8-1dc5-409d-8d4b-3624e82b1751" xlink:href="ardx-20210630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_8cb148b8-1dc5-409d-8d4b-3624e82b1751" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_eeb5ef01-7863-4ea8-b3a4-84aa1bf68c94" xlink:href="ardx-20210630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_eeb5ef01-7863-4ea8-b3a4-84aa1bf68c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_82741568-0f60-44a4-a042-c6e08a54dcc7" xlink:href="ardx-20210630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_82741568-0f60-44a4-a042-c6e08a54dcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_7d67c4d4-ed17-4fcb-afaf-621df77f1f4c" xlink:href="ardx-20210630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_KnightTherapeuticsIncMember_7d67c4d4-ed17-4fcb-afaf-621df77f1f4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_3f2b1b36-aeb4-4d16-9ff2-65fd0a42a66b" xlink:href="ardx-20210630.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_AstrazenecaMember_3f2b1b36-aeb4-4d16-9ff2-65fd0a42a66b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34883593-b176-49a3-b83d-765bb2c45092_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:to="loc_srt_ProductsAndServicesDomain_34883593-b176-49a3-b83d-765bb2c45092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:to="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_27f40f9d-243e-4cbf-a5e1-92b8948c636f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_us-gaap_LicenseMember_27f40f9d-243e-4cbf-a5e1-92b8948c636f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_89345957-7227-4713-821f-9dac832356ea" xlink:href="ardx-20210630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_ardx_ProductSupplyRevenueMember_89345957-7227-4713-821f-9dac832356ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OtherProductOrServicesRevenueMember_f6cffe0a-7109-4d30-b254-cf675b661a09" xlink:href="ardx-20210630.xsd#ardx_OtherProductOrServicesRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_ardx_OtherProductOrServicesRevenueMember_f6cffe0a-7109-4d30-b254-cf675b661a09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad46c20a-be3e-4f17-ad43-563f46b91d13_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:to="loc_srt_RangeMember_ad46c20a-be3e-4f17-ad43-563f46b91d13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:to="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bec31b9-54c0-4829-968c-c4cedc63be3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:to="loc_srt_MinimumMember_7bec31b9-54c0-4829-968c-c4cedc63be3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended" id="ia8f747619d2d4f80bf69339abeeb5296_CollaborationandLicensingAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2805ec7-b19c-4812-b825-4fa80fdd9835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2805ec7-b19c-4812-b825-4fa80fdd9835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_360c6f52-02e3-4845-b369-f3bcbc88a6fb" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_360c6f52-02e3-4845-b369-f3bcbc88a6fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca3eb690-ae76-454b-a4ae-ca4b4cdb80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_026d9fbf-bf02-4df6-a3bc-14b29cfd87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_026d9fbf-bf02-4df6-a3bc-14b29cfd87cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_ab1a28a4-399a-47ed-9be1-94cdcff3bf2a" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_ab1a28a4-399a-47ed-9be1-94cdcff3bf2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4c1ce90b-6309-4fc5-a602-25462ac8aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76c33591-9d97-41b1-b47c-848b9022fecd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76c33591-9d97-41b1-b47c-848b9022fecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_6edee05e-ce85-46fc-8f59-899887f0ebaf" xlink:href="ardx-20210630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_6edee05e-ce85-46fc-8f59-899887f0ebaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_b7025736-f60a-42d6-a19d-b3b743d5a608" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_b7025736-f60a-42d6-a19d-b3b743d5a608" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended" id="i7bd149c27b294337aed7185a32197784_BorrowingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_925b91ee-931f-4630-a6c5-82fdb917363d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_925b91ee-931f-4630-a6c5-82fdb917363d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_4c382425-2ae7-4423-9242-29b015f39b25" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_4c382425-2ae7-4423-9242-29b015f39b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeePercentage_611f349a-f08f-4657-8af1-6bb2e7455eb3" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentClosingFeePercentage_611f349a-f08f-4657-8af1-6bb2e7455eb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFee_4728e230-51d1-45f6-8e19-9a42c2eff9d0" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentClosingFee_4728e230-51d1-45f6-8e19-9a42c2eff9d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_30c58d41-fcce-4079-b2e7-bc6a23350901" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_30c58d41-fcce-4079-b2e7-bc6a23350901" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_3eb7ccdc-abca-46d6-8483-2036b9ebfda0" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_3eb7ccdc-abca-46d6-8483-2036b9ebfda0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_2700268d-0d5f-433d-acfb-5e1e76903917" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_2700268d-0d5f-433d-acfb-5e1e76903917" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_fd9e5ce3-b806-40c6-bb8b-bb63aa5ecf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:to="loc_us-gaap_LoansPayableMember_fd9e5ce3-b806-40c6-bb8b-bb63aa5ecf8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32c3cfa2-bf34-4073-8973-fa25ca360aa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32c3cfa2-bf34-4073-8973-fa25ca360aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d69d5baa-cfa6-430b-a54f-8fe6203a5a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d69d5baa-cfa6-430b-a54f-8fe6203a5a0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_600a2348-67ae-4dfe-9437-39ea168fec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_600a2348-67ae-4dfe-9437-39ea168fec5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2cd487f8-3d3b-4c38-ade4-ed0959569a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2cd487f8-3d3b-4c38-ade4-ed0959569a30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6ed76b9c-f2a5-4829-9c88-ef50081be900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6ed76b9c-f2a5-4829-9c88-ef50081be900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2e97e4c2-8449-47d4-9ef4-d28d7d07da61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:to="loc_us-gaap_SubsequentEventMember_2e97e4c2-8449-47d4-9ef4-d28d7d07da61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended" id="i9aec9846d0f34a628ed81174bd19e477_DerivativeLiabilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_1256789a-71ac-41b5-aec5-e747372cfe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_1256789a-71ac-41b5-aec5-e747372cfe25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_358a2dfc-fc71-40ae-b69d-7aa3f6954d9f" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_358a2dfc-fc71-40ae-b69d-7aa3f6954d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_f394f67a-ca87-4aca-93fc-03adfc6c0c26" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_f394f67a-ca87-4aca-93fc-03adfc6c0c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_752d5d28-1691-4ea2-972d-990d78766f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:to="loc_us-gaap_OtherContractMember_752d5d28-1691-4ea2-972d-990d78766f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f9b8c77a-e8ea-4d25-83fb-502341a7ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f9b8c77a-e8ea-4d25-83fb-502341a7ddc6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended" id="i284b6716c77e4a36b9aa1640cba6c4f3_DerivativeLiabilityChangesinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b28151f-ffe7-4a80-bd07-bdfc9f467893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b28151f-ffe7-4a80-bd07-bdfc9f467893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_177ce4d1-e1cd-4179-9fd9-2b85cfc37024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_177ce4d1-e1cd-4179-9fd9-2b85cfc37024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd24591a-e15e-44fc-890c-dc50add808c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a9f39df7-6725-4492-9d66-2afa2bd46b78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a9f39df7-6725-4492-9d66-2afa2bd46b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8ce802b-b003-4146-b6a7-970a8a425754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8ce802b-b003-4146-b6a7-970a8a425754" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i671e6c2430ef4826a47e7344e47fecaa_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_58bd346d-5323-4384-afbf-1790a2d0bd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_58bd346d-5323-4384-afbf-1790a2d0bd2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_568ab977-2a4f-4b2a-8e44-a202236f82db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_568ab977-2a4f-4b2a-8e44-a202236f82db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_662ffdba-8640-4718-abfe-67dfa0d8ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_662ffdba-8640-4718-abfe-67dfa0d8ccf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_a0ff429f-b2fe-4450-8526-8fedb077d549" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_a0ff429f-b2fe-4450-8526-8fedb077d549" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_be5a0fed-ad0b-4aad-b0ef-8939317fbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_be5a0fed-ad0b-4aad-b0ef-8939317fbdca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:to="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_e8ebdf51-6b3c-494c-b789-bdeafa92192c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:to="loc_us-gaap_LeaseContractualTermDomain_e8ebdf51-6b3c-494c-b789-bdeafa92192c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_45979410-cf24-49bb-96ca-51e077ce36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:to="loc_us-gaap_LeaseContractualTermDomain_45979410-cf24-49bb-96ca-51e077ce36a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:to="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_1d881520-dd54-459d-a6af-3da731646eb2_default" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:to="loc_ardx_LeaseArrangementsDomain_1d881520-dd54-459d-a6af-3da731646eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:to="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_f4e865bc-5d74-4cdc-b264-7f56d3001d84" xlink:href="ardx-20210630.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_f4e865bc-5d74-4cdc-b264-7f56d3001d84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityWalthamMassachusettsMember_86355969-a376-4854-95ce-e1d34cba7760" xlink:href="ardx-20210630.xsd#ardx_FacilityWalthamMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:to="loc_ardx_FacilityWalthamMassachusettsMember_86355969-a376-4854-95ce-e1d34cba7760" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended" id="i7752e929a9cc414a9e4ad539a2ba34cc_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_4cce9aa9-917f-4ee5-9b38-4878f8b9e787" xlink:href="ardx-20210630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_4cce9aa9-917f-4ee5-9b38-4878f8b9e787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b1a5fc3-254c-4bfe-a9ad-b4f033af4cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b1a5fc3-254c-4bfe-a9ad-b4f033af4cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8569dbef-4c3f-4a3f-99e8-56623a22e3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8569dbef-4c3f-4a3f-99e8-56623a22e3ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_6cda0b5e-2e07-49bc-8566-36db5ddfa72c" xlink:href="ardx-20210630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_6cda0b5e-2e07-49bc-8566-36db5ddfa72c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_37ceb1a0-f4e9-4cbf-9a41-ba1c2397ae9a" xlink:href="ardx-20210630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_37ceb1a0-f4e9-4cbf-9a41-ba1c2397ae9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_705981d8-25df-47ee-aab6-304673360978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:to="loc_us-gaap_ClassOfStockDomain_705981d8-25df-47ee-aab6-304673360978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:to="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d3180397-db1f-4c46-a58f-1588590b50a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:to="loc_us-gaap_CommonClassAMember_d3180397-db1f-4c46-a58f-1588590b50a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c278781-aba9-476d-94dd-e44a690a67ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c278781-aba9-476d-94dd-e44a690a67ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AtMarketOfferingMember_b70b6e42-7646-469b-9f20-804273d25975" xlink:href="ardx-20210630.xsd#ardx_AtMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:to="loc_ardx_AtMarketOfferingMember_b70b6e42-7646-469b-9f20-804273d25975" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended" id="if02cd0b6a0334373b8f32182aa79de88_EquityIncentivePlansStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73e3ae6e-b4af-4ded-997b-adb2f3761e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73e3ae6e-b4af-4ded-997b-adb2f3761e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07771c06-2574-4784-b8c5-8f005c403a5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07771c06-2574-4784-b8c5-8f005c403a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_999ece14-f039-4a56-b0b8-43105a489f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_999ece14-f039-4a56-b0b8-43105a489f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21cf68df-3fb9-4900-877c-f4c075ab4bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21cf68df-3fb9-4900-877c-f4c075ab4bd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended" id="icd612e8aaf2541a989ebe4f86d0076d5_EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06f649f3-0165-47c0-9775-e2b96edd6eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06f649f3-0165-47c0-9775-e2b96edd6eca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486c5d82-06eb-4ad6-a34e-ce8b3cd89e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486c5d82-06eb-4ad6-a34e-ce8b3cd89e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:to="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4e2b07d-ec12-4abf-beca-e878a840b6c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:to="loc_us-gaap_PlanNameDomain_d4e2b07d-ec12-4abf-beca-e878a840b6c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:to="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_8661615f-c37f-49b7-969c-003ed12acd6f" xlink:href="ardx-20210630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_8661615f-c37f-49b7-969c-003ed12acd6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:to="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ad1975-3f9e-4266-8aaa-ca5610e0a903_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_47ad1975-3f9e-4266-8aaa-ca5610e0a903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d060340e-a2bf-4daa-89f9-f53f7f144892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d060340e-a2bf-4daa-89f9-f53f7f144892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b17c64bc-2f5d-42a2-8400-e55b0ffb03c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b17c64bc-2f5d-42a2-8400-e55b0ffb03c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="ibf2caf23ac5d4db39f4fdf01e9f941c6_EquityIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a936d85f-cce6-4bc6-a26f-017e187d626b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a936d85f-cce6-4bc6-a26f-017e187d626b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ed3028e-a819-4016-bdc6-6d32d57c61fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ed3028e-a819-4016-bdc6-6d32d57c61fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4adfcd02-09a5-41c3-8845-19214d3644ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4adfcd02-09a5-41c3-8845-19214d3644ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_65e250af-a135-49b4-9264-2e7aaa96e0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_65e250af-a135-49b4-9264-2e7aaa96e0ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d25d21f-e458-41f5-a4fb-0e2f116a50e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b79c3ed3-0709-4526-b316-9eb22e4f447f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b79c3ed3-0709-4526-b316-9eb22e4f447f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1dc361b-d6bd-43e0-9153-9d58b75e740d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1dc361b-d6bd-43e0-9153-9d58b75e740d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09bcb53d-d143-422b-95ac-20b7f9c50530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09bcb53d-d143-422b-95ac-20b7f9c50530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8371683-315a-4ea0-925a-ca3fef7baa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8371683-315a-4ea0-925a-ca3fef7baa94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_85392a6c-8e8e-479a-a9c7-5184bd2a978c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:to="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60bfb197-6422-42cd-9967-88a1fa982d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60bfb197-6422-42cd-9967-88a1fa982d98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="i29fc7e7dda054a9d904c1642dd2839c5_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f5f8276a-c2f3-4754-b57b-7587c955347d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f5f8276a-c2f3-4754-b57b-7587c955347d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f2d4e9e-bb0c-4881-b85b-efff964448df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f2d4e9e-bb0c-4881-b85b-efff964448df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_25f9d8fb-b3ca-43d1-9da6-627186a07b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_25f9d8fb-b3ca-43d1-9da6-627186a07b77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ab50f816-c718-4a17-9ae2-397a76161007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_SharePrice_ab50f816-c718-4a17-9ae2-397a76161007" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0658b91e-b27e-4a9c-91f0-158ad3609ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0658b91e-b27e-4a9c-91f0-158ad3609ede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f7f24604-e9d4-4923-87e4-759dc51abb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f7f24604-e9d4-4923-87e4-759dc51abb50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_f2704070-df04-4175-bfdb-61094ff4e54e" xlink:href="ardx-20210630.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:to="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_f2704070-df04-4175-bfdb-61094ff4e54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a333293d-ece2-4c3d-8de7-a2791d5c3580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:to="loc_us-gaap_PlanNameDomain_a333293d-ece2-4c3d-8de7-a2791d5c3580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:to="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_512cb764-fe95-4198-ac62-ca0e89ece5bb" xlink:href="ardx-20210630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_512cb764-fe95-4198-ac62-ca0e89ece5bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10e36938-a20e-47e4-8676-27013e2d5ab0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10e36938-a20e-47e4-8676-27013e2d5ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_5e7a9abf-c561-45ca-afa6-4d42afdb5a6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:to="loc_srt_DirectorMember_5e7a9abf-c561-45ca-afa6-4d42afdb5a6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended" id="i556af180585a44e8ae30a4cc1df94ce7_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_9122070e-ac62-4856-89f3-deeb1ab9264e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_9122070e-ac62-4856-89f3-deeb1ab9264e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_d90680ce-6c5c-4f94-8833-3a202d6e06e3" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_d90680ce-6c5c-4f94-8833-3a202d6e06e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_41f10245-6444-4b1d-8141-15de8a19afdd" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_41f10245-6444-4b1d-8141-15de8a19afdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount_fa8cd9ff-e170-4f55-b2d8-4ff17553a3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_EffectOnFutureEarningsAmount_fa8cd9ff-e170-4f55-b2d8-4ff17553a3bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_792f2ada-26e0-43bd-ad49-f85515c67dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_792f2ada-26e0-43bd-ad49-f85515c67dab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_e7c0a193-159c-41d1-a162-09ebd3edd1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_e7c0a193-159c-41d1-a162-09ebd3edd1ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_144314af-1eee-4e62-b068-030c02da4852_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_144314af-1eee-4e62-b068-030c02da4852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f32f26b-40d0-47e4-86c2-334a0f2d5a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:to="loc_us-gaap_SubsequentEventMember_2f32f26b-40d0-47e4-86c2-334a0f2d5a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ede75f3d-1221-4a9b-882b-4a6070de1940_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:to="loc_srt_LitigationCaseTypeDomain_ede75f3d-1221-4a9b-882b-4a6070de1940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:to="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PutativeSecuritiesClassActionLawsuitMember_587ecf92-5f4d-43b8-beb4-d95aa97dd7e5" xlink:href="ardx-20210630.xsd#ardx_PutativeSecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:to="loc_ardx_PutativeSecuritiesClassActionLawsuitMember_587ecf92-5f4d-43b8-beb4-d95aa97dd7e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7e34e053-430f-480c-aab6-f7c54d060f99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:to="loc_us-gaap_LitigationStatusDomain_7e34e053-430f-480c-aab6-f7c54d060f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:to="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1cd5c5b-c491-4349-8005-c927ff6c3093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:to="loc_us-gaap_PendingLitigationMember_f1cd5c5b-c491-4349-8005-c927ff6c3093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_84c1ee73-57c4-4edd-af2a-3364724941cf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_84c1ee73-57c4-4edd-af2a-3364724941cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_a3610ed3-b1df-49e5-8b46-1325bf1b5062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:to="loc_srt_OfficerMember_a3610ed3-b1df-49e5-8b46-1325bf1b5062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_031e121c-006f-470d-8381-cf3d55d61e70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:to="loc_us-gaap_RestructuringPlanDomain_031e121c-006f-470d-8381-cf3d55d61e70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:to="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_WorkforceRealignmentMember_06efbf16-77ad-4309-bf13-bbbc47431061" xlink:href="ardx-20210630.xsd#ardx_WorkforceRealignmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:to="loc_ardx_WorkforceRealignmentMember_06efbf16-77ad-4309-bf13-bbbc47431061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_efe45eeb-0001-419d-aefd-c75d1d2624af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:to="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_efe45eeb-0001-419d-aefd-c75d1d2624af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:to="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReducedEmployeeExpensesMember_7177eaf5-e710-4b14-82f4-aa2e704fb002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReducedEmployeeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:to="loc_us-gaap_ReducedEmployeeExpensesMember_7177eaf5-e710-4b14-82f4-aa2e704fb002" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ardx-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a224c02c-e904-425a-bf99-6921674745a5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2a5d9a4f-9c34-46b6-81a6-5ca5ef790190_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7af098d8-6198-4a81-a77e-7c210930b590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_564e265f-b15a-40fb-bc78-1183766e94b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9fce8663-05f4-432c-8bed-9a27b6d10470_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2d956410-5201-4e15-910e-f6508168bcbe_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_252f85d5-9ef8-440e-aa05-50755d92e929_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_45a9608d-e559-4013-9752-4390f7b5c396_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_26fe94d8-cf18-437a-91ff-6bb6408ed1de_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d547b7f6-d1e0-4047-aa26-254ab182a7ba_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_93d9cbc5-7571-4f85-9bce-6fe48baa94c9_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate On Default, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional default interest rate on the event of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:to="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f1ea08c-ec8f-4e68-8676-7e83803ab0ea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ee67228b-99e7-4b8e-a555-0483c0c2e4ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c764649e-f5b6-4131-8ac8-690fcaec0c46_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7d63cdf0-3f52-417d-80c6-8cf874e33f8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_a200e2df-85e3-47ee-b639-2c1b30b56aa6_terseLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:to="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_cbf3ef7b-937b-4217-917f-00e866b1a17f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_d53d8799-40f5-4d22-9def-6e3995e3866a_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Additional Details of Leases</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Details of Leases [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of additional details of the leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:href="ardx-20210630.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:to="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5058b8f2-78ca-4aaa-a502-e95362ba74e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Debt Payment Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_85bcda1e-1dee-4e36-b1a0-846f0c73286a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_afbf55cd-d287-46e1-b6cb-627b1f345a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b0a8b021-bff4-4d3f-972c-39b50b564571_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_11b49be9-0d30-4120-b52c-81461f16f194_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b5a1a78-b88e-448f-a890-12c072e85403_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_02c8825c-4b3f-4f85-af60-f3206fb37fd9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining life (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_18b3684c-cf37-48e5-95d9-f4d806e21f91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_611a0c46-91f8-4487-b9ec-05490e3c844e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e073c7e6-0984-4524-a4d0-fcecb4a3d427_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AtMarketOfferingMember_4531eec0-f757-41c7-829a-3124a22849e5_terseLabel_en-US" xlink:label="lab_ardx_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market offering</link:label>
    <link:label id="lab_ardx_AtMarketOfferingMember_label_en-US" xlink:label="lab_ardx_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Offering [Member]</link:label>
    <link:label id="lab_ardx_AtMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_AtMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AtMarketOfferingMember" xlink:href="ardx-20210630.xsd#ardx_AtMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AtMarketOfferingMember" xlink:to="lab_ardx_AtMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25f0af2f-c6bd-4e77-9a8c-b6444e7410c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4d89f2b8-3e90-4b47-b097-a27f1be80aaf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c23191b5-fed8-41a7-923b-04150a328bb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_22cd52fd-297a-44f7-aeed-772f20d19073_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fa641c99-58a2-47b1-8610-ac51085a1c1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_bf5e5ada-dc17-42fc-b489-8da4f4865c0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFee_1d86bc77-572c-4c17-a147-cf32469ec8eb_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFee_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFee_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFee" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFee" xlink:to="lab_ardx_DebtInstrumentClosingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f9973b6-2d88-4eae-98e1-bc634f366cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dd0e05ce-a911-41af-85bd-68e5393910ed_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities not included in computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_91f5bdc1-b9d7-4f83-be43-2f71804243b2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4e1dc851-61d6-40c9-bc04-8c88bda768e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_555146e4-2c56-4fbf-bfc1-6c504353448f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_25e1177f-37a6-4aee-a3ac-f5863508dcf8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_daf0cf50-cff1-4f0e-b13f-4ba1b4eff325_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8da2ae9-8dc9-451c-971f-9544bd0f0028_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_be39585b-d611-4947-85ff-e8155cb5d7b6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_1520e2f7-d6ae-40e9-97ce-7bb8a603670b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02a17171-e8e4-409c-b820-e7145cfa064c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e432fe8c-a76e-4388-ac25-2369025acc42_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e1ae5155-0122-48fc-a703-402caa853a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_dd20e771-3b5c-4b27-87ad-2fbc230e048c_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable, current portion</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_53463af1-34dc-4ce1-963d-1516470bced2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable, current portion</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_eda4bddf-1e24-44fb-9bc0-0f62eb05b2a7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_7a53d14c-8ecd-4020-b1d8-206805ced124_terseLabel_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKC</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_label_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd [Member]</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_documentation_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Kyowa Kirin Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember" xlink:href="ardx-20210630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KyowaKirinCo.LtdMember" xlink:to="lab_ardx_KyowaKirinCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91def991-e33e-4267-8105-a65e5b7b0536_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea828cf4-4eb4-4c8e-8367-d54bba71a11e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7dc0ca85-f583-4315-b36c-23ac5db11d7e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_33dd0bad-91ce-4452-b278-f58af29cf056_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_345e149b-61a8-4d6d-ad3e-50875f0c319f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13c827c3-f8f3-47f5-911a-e4f6acdaccbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b3bc9bab-f598-4a91-a7aa-8bb7559ef1f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_647b6012-6466-4c96-b7d6-23623baf50e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_b380a4a1-f726-401f-ab10-9ea195ff86b3_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e2197b1-681e-4b4c-b449-eb2fa1365999_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_9e003265-bf66-4c7a-80a9-53d02ff86955_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space area (sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b6b111dc-bb6e-45cc-a1af-4adee3b49ef0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a13c43ed-b6b2-4bce-9b25-4468e6c1d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1ffac5fd-9a82-4e93-8cd2-d74d126ce88f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9186b30b-e238-46f0-85d1-c05abe62c5eb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9714d45e-0283-4b0d-8561-970e8305168f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1bb02667-1c39-4fa1-90c6-596491b8c917_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_16c27c76-905f-4801-b188-042a6203e924_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_c847e6e0-61f1-4170-b148-ea1d95d5cd5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_49ea7ca9-067e-490d-907f-671da94f46c7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1fd3726b-7682-414e-a393-2bf5b1c2557a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0a91bf8e-a016-41f3-a815-0a546c078c1b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4843c973-c341-44c1-be90-dfa821bef5b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_ccd7377b-cf96-4606-ba2d-212aecc78f5b_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue" xlink:href="ardx-20210630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b56b27b-e01e-4185-997d-d1fbfbff2f49_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f9d66ee3-c65e-493d-a484-d4ed6c8226f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7028d517-9149-4f65-9959-dc69d7c43dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2aab9e6f-6ef3-4bb6-8428-61d5d7fad5ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Exit Fee derivative liability, beginning</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_06e0e8c0-b772-4b8a-a948-5e5a4efee16c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Exit Fee derivative liability, ending</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2d573603-96de-4dd0-bce9-5e3c504f83cd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12034b5d-cbdd-4597-8c40-53a427d24fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_46158bdd-3179-4db7-8424-4d05a654922a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_fc89e509-7eca-4909-9d88-9722da1554b4_terseLabel_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated reduction in workforce as percent of total workforce</link:label>
    <link:label id="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_label_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</link:label>
    <link:label id="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_documentation_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:to="lab_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_59ebde70-a2d8-4cba-83a8-a26c97e92d02_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_21526458-6a1e-423b-ba34-e4419d87a251_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOnFutureEarningsAmount_28c70757-ed7a-41ef-a4e6-de960b2a6478_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected effect of decrease in annual compensation costs</link:label>
    <link:label id="lab_us-gaap_EffectOnFutureEarningsAmount_label_en-US" xlink:label="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on Future Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOnFutureEarningsAmount" xlink:to="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_de587011-b37b-481e-93c0-18ed9439cc0c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total repayment obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8f9a83e7-e904-4ac9-bd8a-489f3e20cd53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary through second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f7a5af04-4f5f-42d6-b9d7-6c1a2f67e9e2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d53281ed-aa24-443c-9cfa-32267c8976c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_75a30396-ff31-4016-89b5-e4c2b7e5c12b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e502812a-4eca-4f97-b176-eee7f1dbccb5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fa654747-9573-4a48-9b32-143a190c5add_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2a71156a-5603-4e51-9ac5-764410146523_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9e17e72f-9815-4096-8189-4440b1f14cad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_16fe18e7-2c03-42a9-a6b4-2c4ba85ed241_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_add372ca-1aa1-4af5-8c05-5bfe60d0979f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted cash payment obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_2e678cc3-73f2-475e-9288-85e58af1986f_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development And Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of future development and commercialization milestone under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6d30a533-35fc-4c6d-9009-4dac8bd72a3c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_aebd3311-5fdf-46ec-a901-54855b053305_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d0fa3417-5bec-4f9e-9d4d-447e91e58b69_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5eebd962-7d24-428f-906e-177b8e0293f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a9b2b679-05b1-436e-ad1c-52ef9782acda_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_baa7af4e-b8ef-4d3f-b66b-9886d46d8d9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1acd4ad0-6a65-4725-83bf-a0d0fe744a40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsAxis_892116d4-7a48-43fa-b20c-121574447b21_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_label_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsAxis" xlink:to="lab_ardx_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7adcbe51-d57a-48b7-b984-2f7f95ba7425_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4813bb23-202f-41dc-8dec-503cc902f125_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_880237c2-aa39-4883-b789-dbac42b88fe9_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability for Exit Fee</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f1c2d726-e421-4ada-a069-fc15c8ab0ace_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d7702167-75dc-48ec-b35e-4ac450a9472d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_40021754-557d-4f09-a7a3-1d28fd159fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_aa5e28bb-ee4b-46b7-8356-e8920733f9e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c1041671-edd4-4c60-b80f-f469a7947ed3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_aacb3dc5-248d-4d22-a04e-45551e7fe7df_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7e95802d-7cfa-4bde-ad24-2114ec17cf84_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b0025bd-9cfc-4491-8d89-6e5130ca4e8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8233f724-b215-40b7-8752-64807becfeb4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d2000c1e-0f4d-4dfc-a31b-e5c9559ab899_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_e883a169-7c5b-4a87-a096-580af5f61835_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_53057499-c0f6-43aa-bd68-b2751b2e2503_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_abcd79d2-87fd-4c9b-941c-123b7f8f16c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d18ed59d-f2cc-4d72-ab8f-c51d51755c5c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_72c29839-8c10-4d84-bf9a-8e3dab58535e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_105f7714-5283-4ac7-9454-efb91720a1c2_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e100aa9d-3865-4947-b970-8df4a7f5d17f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_c691c697-ef06-4b05-b998-9c83795ef126_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d98fb0c-8008-4480-bc97-a356087330c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at-the-market offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3bae17c1-feba-40db-8e38-968fae6510c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_95829456-6d9c-40b3-bf76-1669c635c041_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_b43f096d-383b-41e6-a579-6edab187adae_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_71fc4a8a-5382-4b8f-a30c-973af44122c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_00815619-2fc1-4c55-9933-89aa99bbe3d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_556d6a70-7145-41a8-b584-83f0913c3c03_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ff93d320-e8e0-47d1-af78-1ff1ebd2211a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReducedEmployeeExpensesMember_3febf78d-5524-4dc6-86cd-540db0feeb7e_terseLabel_en-US" xlink:label="lab_us-gaap_ReducedEmployeeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_ReducedEmployeeExpensesMember_label_en-US" xlink:label="lab_us-gaap_ReducedEmployeeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Employee Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReducedEmployeeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReducedEmployeeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReducedEmployeeExpensesMember" xlink:to="lab_us-gaap_ReducedEmployeeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e7a92bef-ea55-4018-a613-6d216abd636b_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_537c0a1f-c69f-4e0c-a2d5-b8c52aa10939_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c050b5bf-343e-452a-a413-a665ab526088_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aa6ac871-8ac2-4f60-a35d-1f3fcabae017_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at-the-market offering (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfAgreement_f3774f19-be48-4a62-a538-f965cabd1dda_terseLabel_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_label_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_documentation_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement" xlink:href="ardx-20210630.xsd#ardx_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfAgreement" xlink:to="lab_ardx_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_676954fb-fccd-4d7e-9d60-426cf6a45942_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_418029ca-f203-488a-a82b-55fb6c39e35e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 102,967,017 and 93,599,975 shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0ef0d410-c282-469e-99d7-6d4ce23cd729_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6055c02c-924a-4a6a-8fc8-43cf15cee55d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Vesting Period (Years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5ab6bd1-d827-4073-9fd5-2bc6d842640f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fa7c3a01-b411-4098-9224-d5bd69be0737_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_f3bb337d-cbe7-4531-ba28-766f9583547c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects on Future Earnings and Cash Flows, by Type of Effect [Domain]</link:label>
    <link:label id="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_label_en-US" xlink:label="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects on Future Earnings and Cash Flows, by Type of Effect [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain" xlink:to="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_de8e22a2-a245-4167-a128-c607fe93f5c9_terseLabel_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ca55a552-c3d7-4c3a-b82c-750dc5299104_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_86bd2283-3934-4b4d-9b44-d0793bd599bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_79ff756a-2695-46fc-85ad-17516c34aba0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payment obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_51adca82-a7ff-4e93-909d-e3e011ab9dcc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1015f221-fc02-4ac4-8dee-c6f3444023d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db86761b-9239-47ea-bf5e-872e78f57cb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_3fc420f1-c7ae-4851-8cab-a54bd447ba19_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fee payable on prepayment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_40cf3a1c-1670-4a7e-8a64-cc3f51decfc4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFees_b8ba3b98-afe8-4883-8a19-149f05cd58fc_terseLabel_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made per agreement</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFees_label_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Uncharged License Fees</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFees_documentation_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the cash outflow from payments of uncharged license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFees" xlink:href="ardx-20210630.xsd#ardx_PaymentsOfUnchargedLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PaymentsOfUnchargedLicenseFees" xlink:to="lab_ardx_PaymentsOfUnchargedLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_db2f9a3b-4700-427c-8092-ce11fd7a193b_terseLabel_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of net sales for tiered royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_label_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Percentage of Sales For Tiered Royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_documentation_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold percentage of net sales for tiered royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:href="ardx-20210630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:to="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_edb0a4bc-b662-4d1f-abac-bc5a25440f24_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9c903d0e-1d1b-4b8e-97d2-8ae2cbef796c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_69e4a944-dbf4-4abb-a4c3-e079c17971e2_terseLabel_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRSUs</link:label>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for performance-based restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:href="ardx-20210630.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_295db179-3691-4196-b529-d323c9c36757_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e7ed38be-2b4f-45e3-8065-b93c0ca680c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1565f779-dd40-403b-a1a6-e4f95c098c74_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_135e0d0c-f0cc-4124-bb72-4f5acdb5bac6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8fac3128-e614-4024-a228-e964d320197d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expenses</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_46798286-bb25-4996-b9ab-9234d6afe6ea_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_77f5006a-a1ba-4531-88d1-f18d8795430c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_e781f34d-22b1-4ed4-8b59-fd7c2195cb48_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7cd33058-c623-4ac1-b73a-4ad6cd2e0488_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d852185a-921f-4814-80db-fe2071275775_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d16c3f78-7198-49ef-a0f6-0620f7740632_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_46621d6d-19ad-416a-a1db-974955b6a9e1_terseLabel_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Pharma</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_label_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development [Member]</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Shanghai Fosun Pharmaceutical Industrial Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:href="ardx-20210630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:to="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_3c6106eb-fd36-4ec3-a1b6-b3061a8c21ba_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Canada [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4c4e74be-0b07-432b-90ab-9184b56e6fe2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6102e5e-899a-4f60-8c26-21662293539c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_475e84d2-1d9c-407f-b5ea-e2f5fa74698f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_0262cd69-1d6b-4a97-894a-62148b6c9b74_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7b979ccc-9a12-4097-8269-c3ae1a247b2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_OtherAddressMember_fe07b368-8aea-4e19-a382-0d782452f9c8_terseLabel_en-US" xlink:label="lab_dei_OtherAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Headquarter</link:label>
    <link:label id="lab_dei_OtherAddressMember_label_en-US" xlink:label="lab_dei_OtherAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherAddressMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherAddressMember" xlink:to="lab_dei_OtherAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3adc09b1-d466-41a5-9b92-33caecbf5720_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3c785903-1078-4b51-8f4b-c4f51dc92603_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2da5bf68-7503-471e-8532-2e0f810d54cb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e2622876-a97a-4133-829c-822d430eb805_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b574cdec-bdd1-40be-be15-67f3f4072744_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_766cb5ad-5f51-404e-9455-0c6282ccf4e4_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_8f654863-bb88-4845-9ff7-3d208d7e747f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d5e07071-9bbe-439c-8ba9-ce28d9babf58_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_7a1de96d-3690-4828-b7b3-2a529abdf6d9_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember" xlink:href="ardx-20210630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanMember" xlink:to="lab_ardx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5484990e-082c-4737-8d56-feeb74862d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e8b3c85d-0e1b-40be-9201-a668468a946f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_361f569e-518c-4757-b579-66b5ce8bc50c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4456ff39-c8b1-40d5-83cd-a06f1e93e948_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7ea0632a-36f7-460b-a34a-4bbc18790e17_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_a04ce02e-062d-4ca8-842a-0acaeea9149b_terseLabel_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average sales price per share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:href="ardx-20210630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a851c7af-b748-45ae-beab-e345f0306bd0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_9feaf058-e519-45cf-ad96-591f1b730f31_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_5aec146e-32ba-4336-80b2-cde51fa1ff9b_terseLabel_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice period for impacted employees cash payments and benefits</link:label>
    <link:label id="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_label_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Impacted Employees Term For Cash Payments And Benefits</link:label>
    <link:label id="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_documentation_en-US" xlink:label="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Impacted Employees Term For Cash Payments And Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:to="lab_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_b0e31302-b1c3-44ee-94b5-36a44dd8dc84_terseLabel_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_label_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement [Member]</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_documentation_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:href="ardx-20210630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:to="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c919054b-6517-46ba-866c-d3216303e8c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ece35fb5-e415-4a38-8b3c-c5651914c6b2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_a9c698a7-b0ef-4f72-ab98-28a58fe79c17_terseLabel_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fremont facility amendment</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_label_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California [Member]</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_documentation_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember" xlink:href="ardx-20210630.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityFremontCaliforniaMember" xlink:to="lab_ardx_FacilityFremontCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_73826c94-2c99-475f-9c69-8c16af063ca5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87192a59-ce86-43d1-862a-dabb030fb2fc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c906d93-59a3-421b-8ef6-f8ffed4d0c22_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a67e62c0-54b9-4206-b0b2-6c8262e536f1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_186e403d-8eb5-43e6-a397-9eb39de6cd12_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ce885140-b8ef-41d4-9704-a5b6bf254666_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1978a1c6-799d-4b9d-9a76-3e9643b705ee_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_13ee70d0-668b-42bb-9379-d1976e35f729_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of non-royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:href="ardx-20210630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_21749651-787d-4c4d-86c9-99e7678f57f7_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_63ef36b6-21ac-4a4c-b946-e312d6f5f263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6295cbb4-8c0f-4692-9531-8bae91c0044f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_834c163b-f2a5-4e7a-a797-be8012bc8310_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_40416a69-abe3-4752-96fe-3fa64c557833_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_a25bd9aa-2e7c-4e81-bf0c-d6dfce007213_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated restructuring charges expected to be incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_bd2d0449-6c24-4d33-b7c6-073b10d03e42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_5952f6f2-0ace-4b7e-ba41-49843dfe6e24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existence of option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_58bd63e2-4fdf-401b-a2b2-d83ba7a41d63_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_247b5586-7274-4e5d-8c77-10f4d06db680_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_6940cf75-15b4-4095-a257-8e96a3cd6f91_terseLabel_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product supply revenue</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_label_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue [Member]</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_documentation_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember" xlink:href="ardx-20210630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductSupplyRevenueMember" xlink:to="lab_ardx_ProductSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OtherProductOrServicesRevenueMember_e36c687e-832f-4693-b868-5fcd2e0960fe_terseLabel_en-US" xlink:label="lab_ardx_OtherProductOrServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ardx_OtherProductOrServicesRevenueMember_label_en-US" xlink:label="lab_ardx_OtherProductOrServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product Or Services Revenue [Member]</link:label>
    <link:label id="lab_ardx_OtherProductOrServicesRevenueMember_documentation_en-US" xlink:label="lab_ardx_OtherProductOrServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to revenues from other product or services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OtherProductOrServicesRevenueMember" xlink:href="ardx-20210630.xsd#ardx_OtherProductOrServicesRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OtherProductOrServicesRevenueMember" xlink:to="lab_ardx_OtherProductOrServicesRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c3f98a27-4b13-4b81-a246-e33b6d7464ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_7ee076ff-92c9-44ed-9878-f009c616d06f_terseLabel_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on sale of stock per agreement (percent)</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_label_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_documentation_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent" xlink:href="ardx-20210630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockIssuanceCostCommissionPercent" xlink:to="lab_ardx_StockIssuanceCostCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_edceebcf-ce24-4d76-b198-469c2080ab60_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6e2c96cd-cda6-4cf0-9b94-4bb7fc0a9d7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5ee548ac-eafb-493c-b2f2-796fad3e6598_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4a9227a0-4d26-4040-9528-c75768055936_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1f3f73a6-7550-4377-b352-0e63d35aed3a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8b66a759-80f9-4f9b-9a6b-a12633e39551_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_536b62b4-99e9-400a-b233-4d6533245e62_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative development revenue</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_label_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember" xlink:href="ardx-20210630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeDevelopmentMember" xlink:to="lab_ardx_CollaborativeDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_ee063cd7-c1f1-4616-a201-59183371ea04_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7e875b73-d244-498d-b76f-7f391c1f1e17_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_ca4fe995-4595-4c46-a47f-b98efcb8b63c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2327346e-0fb4-4898-87ae-eed0d59e80fe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ef75350d-ca9e-4872-9f4f-8596b2a9e9e8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2a62bfcf-1b86-4745-9380-655083361b87_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_27c2814e-7514-4088-b433-91f9a73af4b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_af0a74f8-34a3-44d0-a1d7-6fc456bddf6e_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:to="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2e2c8c4e-e0ac-4ef6-a5ae-18d48f063765_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_388cc2d7-72c6-47d9-aa34-c154f405acd3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstrazenecaMember_7de6ed95-90ff-47a6-b4f3-10642b39a36f_terseLabel_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_label_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astrazeneca [Member]</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_documentation_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember" xlink:href="ardx-20210630.xsd#ardx_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstrazenecaMember" xlink:to="lab_ardx_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_5d2d4ba3-26da-4f4d-87af-c037805db239_terseLabel_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of license fee, first installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_label_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Of License Fee, First Installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_documentation_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of first installment fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:href="ardx-20210630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:to="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_8142022a-8ad8-46e4-9df4-7de3be044fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary impairment</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_0b529b08-08d6-43bd-9740-03a2c48d35a4_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, percentage change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:to="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_611d0cae-00d9-4fef-b4cc-4e70b7b702e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_90cbf327-8149-4e64-aff0-b981bf9897b4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_f9304227-99d7-438d-b769-01d9f3dc3013_terseLabel_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_label_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Separate Collaborative Agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_documentation_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:href="ardx-20210630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:to="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e2488884-ea1c-482a-a257-b546684a227c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f980adde-1889-4a73-a506-1fff85fc6302_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_4b3ea7ca-a75d-4f8d-9556-a960fb67c30b_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98fb2ffb-d990-4cc5-b790-c16a2ebb350c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_42ea54f4-bd77-4c29-a407-9b076858ccf7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a8600d18-4811-4d84-8a86-406067ea32ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_6aaca189-4f13-42f0-b9ec-ecc03ed85498_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2cd73d2c-dc2a-4ed2-8d37-444a0ffa03a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d09f4890-a7c4-42a5-8f5b-a2f92982ce21_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c160ed1d-ad70-417c-a289-94ef54c41402_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6a6f1774-f7f6-402c-8707-8e28d8d3d4b8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_eb95eb4b-d481-4b80-9cd5-0f558968dfdf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3fc0a9d2-fb9c-4be3-9009-3bd3daf6af08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_3f88fbb4-a152-40aa-8fbe-0221283d9054_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In China [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_8bf5a5d5-3528-402d-beb5-3aea207d6dba_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred revenue</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1c8299a0-1796-464a-b936-017b0ef4589e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_88a4ab4c-8cb5-4e98-9d45-a5ddba751dd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d3f0bfee-0759-4ebf-b1f5-2960e0ed68d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_33563b3b-2004-42b0-ad74-761ae49cd700_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_7c4853d5-61c3-4c73-afae-7a5a2d4b83dd_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 KKC Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Japan [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_05f5b346-23fa-4835-b12b-778b5ca55c67_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_WorkforceRealignmentMember_9e5b7483-1dbe-4f92-8a01-5a57bee476e6_terseLabel_en-US" xlink:label="lab_ardx_WorkforceRealignmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce realignment</link:label>
    <link:label id="lab_ardx_WorkforceRealignmentMember_label_en-US" xlink:label="lab_ardx_WorkforceRealignmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Realignment [Member]</link:label>
    <link:label id="lab_ardx_WorkforceRealignmentMember_documentation_en-US" xlink:label="lab_ardx_WorkforceRealignmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Realignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_WorkforceRealignmentMember" xlink:href="ardx-20210630.xsd#ardx_WorkforceRealignmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_WorkforceRealignmentMember" xlink:to="lab_ardx_WorkforceRealignmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_02b6c377-0d61-4034-b744-ef8a5a1dd8fe_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_801891c3-663b-472e-b68d-fb3a1908dbf1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_981715db-ca17-467d-8d49-263ffa99b989_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e71d3d11-c1c0-42ac-9a26-9904daa49cce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_25b61d83-4f54-4a88-82c3-a1eec10338e5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred compensation for services</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDeferredCharges" xlink:to="lab_us-gaap_AmortizationOfDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_9f056c4f-5f2b-405d-93a2-6e4d47eb0a0d_terseLabel_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:to="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_65fe3fa6-98f8-46e0-9513-f265521818ea_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a56eaf90-204b-498b-8a55-242b0ea6da8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After second anniversary to maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a9989dda-bc1b-40c2-b180-f273facf51de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_e29e992b-f944-45fe-a9b9-5fcfbb29ae42_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest associated with debt discount accretion</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_605b34f4-3e7c-4610-a7fc-15ef5f7d828b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_05edd05b-ab9b-4a73-9ca0-487b508da7a4_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_ea729835-2b95-448e-8658-c90dabcc500a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46748389-a7d7-4f29-a76e-4d3824ac9fe1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_0b36a062-ac02-45b7-932e-3404b2302813_verboseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment due</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_61e3e791-a7f6-42fb-8611-34a09ade60ee_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced for which cash has been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32f15ef5-66c9-4ac2-806e-529d36a957b7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_d17b7010-2f91-4517-a9a8-82674fd6541a_terseLabel_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 KKC Agreement</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_label_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Option Agreement [Member]</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:href="ardx-20210630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:to="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_202790b2-c4f5-4e4d-b17d-fdad69efbdab_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d4b0917-f73f-4845-8e4c-a6985996a0d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7f2fc70c-aa90-4caf-a050-436806f0cff1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_59c51b21-fdd1-4fdd-9e6e-eb0f468494a4_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_26344d15-5238-4bf4-9444-b43cfef960df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ccea3001-7b48-4ab7-b084-f850ebf1784b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5d762a0c-e063-4ef3-bfa3-ac1eebdf9945_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_dfac02ca-ad5c-4c7f-b5bc-11b2ce46b7db_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_1190914c-4aac-4f39-9bb0-0968a7a2b67a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2af24dfe-ef12-4721-9592-833e82697ae5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c049b1f1-885e-42a5-9c31-0d361e777973_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c48b06c-8dae-4744-a6bd-6fc12bb5598c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6d6854c4-6fa4-4433-a8a2-1fb688d25278_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsDomain_265703c4-d1cb-4195-a575-f8ff82f74689_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_label_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsDomain" xlink:to="lab_ardx_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLoansPayable_98aa9cd9-81fa-407e-adc0-f45e4729ed75_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLoansPayable_label_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable" xlink:to="lab_us-gaap_LongTermLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_cb82ee13-8e09-4ee4-8916-dbe79b611a40_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d52c6eb9-6c3f-4afd-9994-eda14093183a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_66277ffe-be4c-4095-a080-29bbab836ca8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21302577-4396-4614-947c-138ae5d277ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1471bfc8-952c-430c-a2fc-38081a0576be_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_013f7e8a-be7a-45ba-88b9-f8dc029afacc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b9bcdff9-ce71-447b-8118-76e395ccf134_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e482eecf-3fe6-482b-b58e-1272407466c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_db60cf3d-e7c2-49f0-a004-729d6a04c392_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in at-the-market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b36d8169-99da-4ce3-9b41-f3bfce32cdec_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_a613ba9c-45ab-4796-8d32-86e863cdaaf5_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8e68a8f2-d2b5-4ecf-b410-69ecbbdac932_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2b2db06a-6937-4a45-ab58-ec70fa734010_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3ae1f73c-0c71-4377-ae7e-a416b659674f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_c66f53b2-2777-4b6c-89c5-79b6bfff7972_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ab6f6f3e-c505-4011-a5be-dd71e403c4c2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_13137b90-61e8-4ace-a17c-069def5e7959_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f0c06411-687e-4026-ada9-8ac418f9a012_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_01a513c4-b38f-4246-a835-31eba9653f43_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_095ddc5d-d60f-4373-8701-1f0543c9455a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_34d05270-8b78-4dc0-8321-113218a6dbb8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lease extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18406a3b-71b5-4f3c-b188-33f6fa917644_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_ff1620f7-fb61-4a83-b93e-02fcd5b59c78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_96ed7220-348b-4a27-bc7b-0ba2f28599f9_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ebdfc72a-96eb-44e4-a184-e3e6d8553ff5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ee9b93a-6068-4921-876b-98d9361a78a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_bc0ac640-7c22-4835-b3e6-25c65f01ce6e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_5ccfb965-983a-470c-9ec5-305cfa5c112b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon change of control or regulatory approval</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4d8157c0-3a96-4dbf-9813-aba6ab8feece_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c92b479c-2193-47eb-80d3-f1f1b82e90a2_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_43279a0a-15eb-4aa6-b637-f510a84b0aa2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0407b8fc-9f50-4afa-805e-47924116b75b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3b0f512b-7ca7-479e-a438-038dfad3f91e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_625acfe1-0b04-4609-8893-a2edae1f32cd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_b112609a-2374-4db5-af2f-d748cd74d0a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_fe541228-dffa-43b8-9844-26dc47c9f9fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_23b74727-287b-4e70-ac43-8fcd3e8ebcf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93191170-9fd4-40d1-9248-736df5f20d24_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13eb5e99-88f2-41ca-a637-a79092a1041b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c3d04786-d166-4fde-914d-57f0a5a0fde9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6819b447-91c7-4d2d-8beb-e354787beaec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_6716678d-3055-4523-b1dd-9c31a5c51704_terseLabel_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_label_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Knight Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember" xlink:href="ardx-20210630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KnightTherapeuticsIncMember" xlink:to="lab_ardx_KnightTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_31435c8b-00e4-42a4-b54b-3ede3c93da0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0b80d750-ddfc-4039-80c9-48dac0700f6c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_d277a917-845f-40d7-b167-578e5dc862b2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fa2e605e-0c32-4cd5-87e2-31e894a70da5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_9106c8c7-016e-4fe0-bdf9-68a735f1b333_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_8aecd2f7-c784-474e-aa32-0961d7a8a3a2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated reduction in workforce</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_da4760a4-ab3e-40ee-af63-07c5d8b866bc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_57f8c725-d63c-4465-8866-111533481458_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_56674ab5-8ab3-451d-8e34-6f8d86287c83_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_32bb76a2-5201-4b32-81d7-aa9bf2d43bcf_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3fc5d19f-6414-4523-b247-0ddcc39395a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_08fb2be7-2ae0-4fe0-a104-6f58b69270be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_90d9ef72-abe1-4777-9583-c7ce361a0f90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b09e8fed-c20e-415d-90ba-98c1313e2dc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_ffe9d30d-c765-4185-8325-02e2048e9e8e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_638898c1-0280-432e-816e-6ff10c278c03_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred revenue</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a3fcddc2-3e49-4bd5-912e-eeb24c7a0d26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_f777e0f6-3935-4a1b-a6aa-b1bf899dcf4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d191c1bb-b328-4926-b83a-43dde1f771ce_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_b30aad72-8155-4b2b-90c8-3432eefee5bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_cd8e5bae-a70f-4019-8fa2-4242b69f4f42_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f5a63383-899c-4038-a6cd-b674816127e7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_de803839-2807-4470-8348-0b3f53040a6b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_a2694aa3-261d-4924-b312-033c9ddece19_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:to="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bff2bc67-1f38-4a33-8c5d-d5a24a382d91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_641f73cc-cf1a-462f-9d34-a6dd00b0f280_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9aa223bd-0860-49e6-8875-04d8f9f81a53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7c7fab9c-fe53-4314-aa06-cf90e67f91b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_bc9f3402-93d0-43e7-bb05-de5d03c2d4f2_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential payment per agreement</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:to="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_4c518670-4e26-42ca-92aa-2fcffda9affa_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_68e7b026-76dd-429c-9d96-f37726eadc64_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PutativeSecuritiesClassActionLawsuitMember_0e3cf445-4dee-4cd1-a71a-1672ded7edfe_terseLabel_en-US" xlink:label="lab_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative securities class action lawsuit</link:label>
    <link:label id="lab_ardx_PutativeSecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_ardx_PutativeSecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Putative Securities Class Action Lawsuit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:href="ardx-20210630.xsd#ardx_PutativeSecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:to="lab_ardx_PutativeSecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_2987f6f2-7988-4cb7-a35c-27b553183229_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LongTermInvestmentsAmortizedCost_f2821912-5190-4b6e-badf-cc20653e71e6_totalLabel_en-US" xlink:label="lab_ardx_LongTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Amortized Cost</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAmortizedCost_label_en-US" xlink:label="lab_ardx_LongTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Amortized Cost</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAmortizedCost_documentation_en-US" xlink:label="lab_ardx_LongTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAmortizedCost" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LongTermInvestmentsAmortizedCost" xlink:to="lab_ardx_LongTermInvestmentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c918a96d-14a4-45ea-8370-79ab438cb96a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d0cb9171-3f7c-492f-b979-d544fe1f3c74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b537df09-67c5-4db2-aa24-dc824b5a03b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_681d671c-5459-4f7b-b5cd-638abb079245_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashFairValueDisclosure_01b024ec-0fb2-46ff-83ce-7007f7195e2b_terseLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Fair Value</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashFairValueDisclosure_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Fair Value Disclosure</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashFairValueDisclosure_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashFairValueDisclosure" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashFairValueDisclosure" xlink:to="lab_ardx_InvestmentsAndCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_7794386f-d285-4a38-8259-fd46dfaa295e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f4130771-2933-4255-b768-a88c10ff06ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2fdaeaa7-4030-4a9d-a28a-64110c960f6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9afdbe38-ce30-49bb-a71c-429be8c428ab_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_e4a27af8-8215-436b-af2f-0ee8a88ac6e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d0ddc240-7d34-4e64-8363-d60d2f4b0c99_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7a359eec-bdc0-41ef-9b5b-c860651a117c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Value at Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_731abb93-fd21-48e9-a876-36cf77750990_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b6425de2-0541-4038-9a07-23d1d47e0a2f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discount) premium on investment securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_db779a48-789e-4091-b301-a43beaaf67c9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b1a128bf-6776-48b0-a9bb-366a4a8d1c26_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_3725f239-9a04-4c7c-be1f-633bc8535839_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a49d9d1-7c98-4a3b-8c8c-e2f9f7a50bb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95f3bf44-e4bf-47a8-bac4-eca6cb492c40_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_635426c5-0570-4540-8bb1-27056121b4e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_label_en-US" xlink:label="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis" xlink:to="lab_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_405ebf3f-7c4f-4c16-b25e-9bc76428a029_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_87993aec-8a95-4359-b365-9c205685bb27_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ec4bb26a-811c-4fb4-bdcf-ee186fc113ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3fe097e6-5828-4167-ad38-0c17d652d18f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bae1bb6f-41c0-4494-a3fe-030a50785426_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b480ab18-bf10-4e59-9d22-dd98a1ca6ea2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d289a866-516d-4670-b255-43068118db51_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_25dffa44-4e40-4d56-afd4-d4c66ce1ce63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_87b88f92-2c64-46f8-af34-ca09c9a37cde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_bbc703d0-3df1-4bf8-bab1-20cd01a4dcc0_verboseLabel_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease Liability, Payments Due After Year Four</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease Liability, Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_93cde73b-3e34-4b66-8d1d-2b986f88b350_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d570ce4-99f3-4120-b5f6-303d1602d696_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_65a05e7a-60d5-48df-93d3-d548ad8ad8d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_6bb4c042-47c8-4b5c-bb65-31a66f066b76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_fc203c17-d1a8-4f72-bea0-6eb9fc02a343_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0fb4816c-e205-4480-8811-bf4360a990d2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0badc69a-bb42-49a4-9ca3-e102f0d265c9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_29002853-ad05-4ffc-8433-5071eb9287d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_731fe631-0667-40cc-9670-b286d641c293_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_e5cd1954-0e17-4264-bdef-79fa62e33bcb_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_02279af3-ea25-43bc-9c2f-801701f84313_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3306393a-0a8e-44cf-996b-21316468940b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_192c7c0a-96f7-4772-86bf-bec8ab797a98_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f8a4cb5f-1264-4a75-9182-23d24731652e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d56bcb02-c1d6-44c4-af29-4d0083f92ebd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4f5e3b58-5265-4651-8733-f4b826cecb2c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cff2ca4-b772-42b6-a999-6126cc059235_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca63b172-899c-4071-8f02-33e4b4ccf09e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_849c7e31-4d2c-4eb7-a818-33d0e01ae1bb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherContractMember_3ba0698f-9b4c-4f30-8c5e-5a0c409924f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee derivative</link:label>
    <link:label id="lab_us-gaap_OtherContractMember_label_en-US" xlink:label="lab_us-gaap_OtherContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherContractMember" xlink:to="lab_us-gaap_OtherContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LongTermInvestmentsFairValue_672a318c-bb21-4ad8-aad9-efc19089bcb8_terseLabel_en-US" xlink:label="lab_ardx_LongTermInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Fair Value</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsFairValue_label_en-US" xlink:label="lab_ardx_LongTermInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Fair Value</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsFairValue_documentation_en-US" xlink:label="lab_ardx_LongTermInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsFairValue" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LongTermInvestmentsFairValue" xlink:to="lab_ardx_LongTermInvestmentsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d236f03a-97c5-41f2-a1e6-90741fe7b66b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d788205f-a6e6-43de-8c59-640c45443d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_677747f9-e211-4755-a2ef-cab817a59585_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_2b97528e-c7bf-4159-8aee-005ce108b0e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional details</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_cf2c0b67-96e8-4eed-9658-2abd6da81ca7_negatedTerseLabel_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a122b3a3-b90d-40eb-af62-74c5aac44c8c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1a5cb8b5-0922-486d-983e-fa0921b284cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2e97f2ea-8d1e-44ab-9b8c-cde8aa3b2cd2_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_bd64b75d-2b2d-41b7-83f6-de4cc4028baa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fc45adc9-bd45-4e3e-9d6a-d8011977f0e4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityWalthamMassachusettsMember_7edeb4c4-66f1-4432-a497-6986683748f8_terseLabel_en-US" xlink:label="lab_ardx_FacilityWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham facility</link:label>
    <link:label id="lab_ardx_FacilityWalthamMassachusettsMember_label_en-US" xlink:label="lab_ardx_FacilityWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Waltham Massachusetts [Member]</link:label>
    <link:label id="lab_ardx_FacilityWalthamMassachusettsMember_documentation_en-US" xlink:label="lab_ardx_FacilityWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Waltham Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityWalthamMassachusettsMember" xlink:href="ardx-20210630.xsd#ardx_FacilityWalthamMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityWalthamMassachusettsMember" xlink:to="lab_ardx_FacilityWalthamMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_21fddedd-0b66-43e4-aaa1-77c9283fa7f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_f417cb23-94f6-407a-be40-578c263a7416_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_8c3bcded-6853-45d4-9e5d-4ebf36b53b8c_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to revenue recognized in the period for which cash has been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Liability Revenue Recognized Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01cd1a56-45b2-4104-8412-0376b6e6fbbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_0efd2d41-dcbf-4692-a3be-53c26d68ed14_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8efaad2b-3d38-44fc-8fef-3cf2b586184d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_618bac4d-fd15-441a-8085-2ab54fdfd5ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in continuous unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_235fe12f-14d4-40da-868f-e4837317f5ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_c9ca37a4-b671-4c8f-bcc6-c037fed43409_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e593788c-3f6f-4872-b74f-388d4269af44_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7d4f533e-434a-4ac9-98dc-80d6d98a6df6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7062c36c-ac3c-4fe8-abbb-34ae2f58a78b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_426f248e-2f5f-4204-8054-34dd708d6250_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_4945fd9e-fc08-4c6f-b846-8d13a5a13616_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment extension term (in months)</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Payment Extension Term</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Payment Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:to="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_911258f8-5c8e-4a09-948c-2710d220f4f7_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80a7de1e-ce5d-4cef-9e7e-d5409c5339f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bea7542c-4934-4094-8d46-9189aa27d7ca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ec4e3abf-b96b-4e28-abcf-32678546355f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_b4f9802d-da99-467c-a0dc-1d7a3db19548_negatedTerseLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:to="lab_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_10375d4c-beab-4ed6-8898-6a65090f04fd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_2aa1ccce-4e1e-426c-97b6-71a10d41e025_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFeePercentage_49a2107d-ddf3-433e-ae42-69a1a04a5911_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeePercentage" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFeePercentage" xlink:to="lab_ardx_DebtInstrumentClosingFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_09299259-f26c-44ad-9a7d-f337f4a389b3_terseLabel_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice" xlink:href="ardx-20210630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MaximumAggregateOfferingPrice" xlink:to="lab_ardx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_e1f26158-c2bb-40b2-9b1b-46c674eee3ea_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6153e9c9-778e-404d-846b-7cbb15fed59c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ardx-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:55b49626-e7f1-400f-8a34-37e828e7ca79,g:3944a7fa-d7ec-4ef2-b9dc-56ae9474db91-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_379319fc-7ea5-4c3b-8d3a-a5e94d82f39a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_379319fc-7ea5-4c3b-8d3a-a5e94d82f39a" xlink:to="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b6059059-d215-4c85-9918-572d65b4d613" xlink:to="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_OtherAddressMember_1dd984db-5246-4bd8-91e2-e5f1b49f3b90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_ad4d8fe4-b80c-4461-a69c-0d4572ddf729" xlink:to="loc_dei_OtherAddressMember_1dd984db-5246-4bd8-91e2-e5f1b49f3b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_4e2d5126-09ff-42be-8ba3-6b31faeb635c" xlink:to="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9e51c9f5-4ba8-4c37-ac48-20c2e7259bf3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentType_9e51c9f5-4ba8-4c37-ac48-20c2e7259bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_282d17fe-ef1e-4c8a-a798-2627277ae92c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentQuarterlyReport_282d17fe-ef1e-4c8a-a798-2627277ae92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cefd05d1-cb8d-4a3a-822b-2d606dfddb99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentPeriodEndDate_cefd05d1-cb8d-4a3a-822b-2d606dfddb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fd68225f-5b44-4b12-98f9-036e28121a5b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentTransitionReport_fd68225f-5b44-4b12-98f9-036e28121a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00a4e677-6b24-4c5b-9735-f78421f1bf6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityFileNumber_00a4e677-6b24-4c5b-9735-f78421f1bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d6399590-98b0-42f3-9826-80dcaee66399" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityRegistrantName_d6399590-98b0-42f3-9826-80dcaee66399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa820154-3775-49a5-8673-3bb01f6de0d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCentralIndexKey_fa820154-3775-49a5-8673-3bb01f6de0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1ca8a62e-ecc1-4a05-9470-98252b4c4e00" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_CurrentFiscalYearEndDate_1ca8a62e-ecc1-4a05-9470-98252b4c4e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2486d1b1-bd9e-44ef-b833-545eb424c4c3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentFiscalYearFocus_2486d1b1-bd9e-44ef-b833-545eb424c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_50da7561-1c7e-4719-b0fd-c8309c825eb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_50da7561-1c7e-4719-b0fd-c8309c825eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_03a84c49-4a1f-4db0-bb74-d6963e222fed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_AmendmentFlag_03a84c49-4a1f-4db0-bb74-d6963e222fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_efff80a0-ba35-4837-91dd-11ab293a5562" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_efff80a0-ba35-4837-91dd-11ab293a5562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_732a4185-5ec3-4b7c-8fef-09b32335f326" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityTaxIdentificationNumber_732a4185-5ec3-4b7c-8fef-09b32335f326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5bc294ed-3e28-4790-8289-17128e02db1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressAddressLine1_5bc294ed-3e28-4790-8289-17128e02db1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9d7b8f49-7477-4773-a1bb-2e200a969e5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressAddressLine2_9d7b8f49-7477-4773-a1bb-2e200a969e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a35b8e35-ec2b-4126-ad0f-95ece2994bd8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressCityOrTown_a35b8e35-ec2b-4126-ad0f-95ece2994bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_817b6f2b-b590-4ed4-b434-d27a9fcc1ae1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressStateOrProvince_817b6f2b-b590-4ed4-b434-d27a9fcc1ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_84ef2d36-6408-46f5-aa01-a40472da3c06" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityAddressPostalZipCode_84ef2d36-6408-46f5-aa01-a40472da3c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_85230d47-39b0-4af9-96bb-6445dbfbaaaa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_CityAreaCode_85230d47-39b0-4af9-96bb-6445dbfbaaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7b1b8742-5843-47d3-8bf2-0297f270d540" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_LocalPhoneNumber_7b1b8742-5843-47d3-8bf2-0297f270d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_33cfe46e-7d13-41eb-8a3b-12b7f781309f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_Security12bTitle_33cfe46e-7d13-41eb-8a3b-12b7f781309f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_390ece83-8686-4ff7-99ff-a1b621133e92" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_TradingSymbol_390ece83-8686-4ff7-99ff-a1b621133e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_90e9b2da-648a-4338-bb70-debef7209735" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_SecurityExchangeName_90e9b2da-648a-4338-bb70-debef7209735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_02407c21-212b-4364-b836-fdb591e1222d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCurrentReportingStatus_02407c21-212b-4364-b836-fdb591e1222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d4523b96-0d37-4454-9b58-70de978c0e98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityInteractiveDataCurrent_d4523b96-0d37-4454-9b58-70de978c0e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_85b63b0a-3e1e-402f-bbf1-f1961d8f8192" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityFilerCategory_85b63b0a-3e1e-402f-bbf1-f1961d8f8192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_222f90b8-b835-4c6a-819d-95c3d729dc2a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntitySmallBusiness_222f90b8-b835-4c6a-819d-95c3d729dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_125325b6-0ed1-4c38-968e-22a298e378de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityEmergingGrowthCompany_125325b6-0ed1-4c38-968e-22a298e378de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e3d3cd41-80d3-414d-8d99-1b5f204cf448" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityShellCompany_e3d3cd41-80d3-414d-8d99-1b5f204cf448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_81e902a1-a44b-4524-baaf-c9cfc801857f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_d704256e-b838-439d-8252-4bdf822d5db9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_81e902a1-a44b-4524-baaf-c9cfc801857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b2c6ed95-5ff6-4d53-91c5-d1f174562484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2c6ed95-5ff6-4d53-91c5-d1f174562484" xlink:to="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2629d6ad-d963-410b-b43a-a24003323b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2629d6ad-d963-410b-b43a-a24003323b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c961a828-8356-4b43-9bcc-7adddfa0ca8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c961a828-8356-4b43-9bcc-7adddfa0ca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f361b62a-2ed6-4d27-8bdb-f8cd2e437c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f361b62a-2ed6-4d27-8bdb-f8cd2e437c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_902afe71-e249-4f20-9d70-f37383e27aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d1e9ff-d930-45a0-a9f8-2bf700f5031e" xlink:to="loc_us-gaap_AssetsCurrent_902afe71-e249-4f20-9d70-f37383e27aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_79bdd241-6fb6-4af6-b7ed-83bace027879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_79bdd241-6fb6-4af6-b7ed-83bace027879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3bfa6d8f-d8ad-460a-8f5e-bc7f0c1f660a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_LongTermInvestments_3bfa6d8f-d8ad-460a-8f5e-bc7f0c1f660a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_225a84d0-be31-4b70-932d-172649f950d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_225a84d0-be31-4b70-932d-172649f950d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_688a9718-adb2-4240-a183-b3047bbe8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_688a9718-adb2-4240-a183-b3047bbe8eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_85b56109-2285-490d-96f4-9c2ea4333be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1e66cf8c-8f02-49f8-8792-cfeb87b262b7" xlink:to="loc_us-gaap_Assets_85b56109-2285-490d-96f4-9c2ea4333be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2c6ed95-5ff6-4d53-91c5-d1f174562484" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b604093-aa89-470b-afa0-bfd2f55728dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b604093-aa89-470b-afa0-bfd2f55728dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93b7388f-d6c8-4277-913e-676adf552feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93b7388f-d6c8-4277-913e-676adf552feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4477b4c9-e601-49ac-a213-8f483b888a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4477b4c9-e601-49ac-a213-8f483b888a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_b19f369a-9cd9-4b4f-90fa-8bcc04e19f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_LoansPayableCurrent_b19f369a-9cd9-4b4f-90fa-8bcc04e19f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2c490cc-a00b-4838-81f3-3a9c36ed10c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2c490cc-a00b-4838-81f3-3a9c36ed10c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e4adc4a6-b04e-42f9-8ada-2967a011ba92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e4adc4a6-b04e-42f9-8ada-2967a011ba92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_40196dc8-ddbb-44cd-8745-9e9821a5d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ca79326e-4cb2-4504-ac16-0649ee9681f3" xlink:to="loc_us-gaap_LiabilitiesCurrent_40196dc8-ddbb-44cd-8745-9e9821a5d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e69ce3bd-5411-4aa0-97f0-1befa4ca5015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e69ce3bd-5411-4aa0-97f0-1befa4ca5015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_ca5d6ecd-ba62-4971-b9de-ce87a46d89d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_LongTermLoansPayable_ca5d6ecd-ba62-4971-b9de-ce87a46d89d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e6f9f1e-f470-4494-9abb-0a537967be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e6f9f1e-f470-4494-9abb-0a537967be0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3214e9b3-289e-416e-bc4b-b7b62d68cca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_Liabilities_3214e9b3-289e-416e-bc4b-b7b62d68cca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5e2c208b-5537-4731-8744-9309cacff670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5e2c208b-5537-4731-8744-9309cacff670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e503eed3-f2c2-4766-bd94-64e50efdc1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_PreferredStockValue_e503eed3-f2c2-4766-bd94-64e50efdc1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ea2e73c5-93ce-4834-a55d-fa4d45073f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_CommonStockValue_ea2e73c5-93ce-4834-a55d-fa4d45073f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e5f4f3a8-c78a-4a8b-b677-68b89ad5430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e5f4f3a8-c78a-4a8b-b677-68b89ad5430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3c3f0ac-919c-4e90-82f4-c307254cd4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b3c3f0ac-919c-4e90-82f4-c307254cd4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e7ee595-75b7-41ae-af26-59db8dc528b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e7ee595-75b7-41ae-af26-59db8dc528b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f075a662-23c8-40d5-be61-7ce6e7030cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2cff1fa5-9e58-4bc3-85e1-a1ef1a194d20" xlink:to="loc_us-gaap_StockholdersEquity_f075a662-23c8-40d5-be61-7ce6e7030cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bf72c0ca-41ce-4126-877a-b620a509f461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e6e4ce9-f61c-43cb-9842-19f93279683b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bf72c0ca-41ce-4126-877a-b620a509f461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0f44233-2e07-4e62-bbba-96e918c11616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d0f44233-2e07-4e62-bbba-96e918c11616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d69c333d-4eeb-4b3b-9e13-640ffbb5159a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d69c333d-4eeb-4b3b-9e13-640ffbb5159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f47b3b56-a7e6-4e65-952d-34c18dba0621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f47b3b56-a7e6-4e65-952d-34c18dba0621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_040d41cd-455e-40ea-a6fe-7b19f6b93292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_040d41cd-455e-40ea-a6fe-7b19f6b93292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ef6f498c-9dfc-4be9-b500-87590ed1e719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ef6f498c-9dfc-4be9-b500-87590ed1e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_74ac09f3-1b52-48a7-bbb2-e4ebeb557135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_74ac09f3-1b52-48a7-bbb2-e4ebeb557135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_361ea0fb-30f6-410a-a30f-f391636f3a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_CommonStockSharesIssued_361ea0fb-30f6-410a-a30f-f391636f3a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec30cad8-7093-4c69-8050-aa020afcd961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c71659f-fd5f-4b74-96d2-b81c2f7c49be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec30cad8-7093-4c69-8050-aa020afcd961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cef18e1a-ad1b-49d9-bcf3-cb99bab8d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cef18e1a-ad1b-49d9-bcf3-cb99bab8d99a" xlink:to="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:to="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2ee7d3bb-2aa5-4609-bbb1-aac93d6e882b" xlink:to="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_57e141d8-09f0-421d-9cfd-d44ea514f05a" xlink:href="ardx-20210630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_ardx_CollaborativeDevelopmentMember_57e141d8-09f0-421d-9cfd-d44ea514f05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_511b4c53-b033-4547-ba1a-85952cb07a6e" xlink:href="ardx-20210630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_ardx_ProductSupplyRevenueMember_511b4c53-b033-4547-ba1a-85952cb07a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_72b22dd5-077b-4b94-a6cf-3f0723bcf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96dc49e9-fe1e-470f-84a9-487a5b0d257b" xlink:to="loc_us-gaap_LicenseMember_72b22dd5-077b-4b94-a6cf-3f0723bcf1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec6c6e05-4a8d-4e58-ac17-85161cf9e18d" xlink:to="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b28498e-584a-4035-a203-0032bfe763e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_db5519f4-e5f0-4cf0-b12d-2d23e06f9214" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5b28498e-584a-4035-a203-0032bfe763e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_38168242-ba19-473e-afc9-b2c70ee79915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_CostOfRevenue_38168242-ba19-473e-afc9-b2c70ee79915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_75ae6b60-6ffd-4066-be60-361a63d11ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_75ae6b60-6ffd-4066-be60-361a63d11ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_60af4401-cca0-4443-83e2-33fe103c80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_60af4401-cca0-4443-83e2-33fe103c80ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b9e655f9-f6a2-4f75-b60d-164b5d020895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ace8325-293f-4416-bc2b-55bee6816a7d" xlink:to="loc_us-gaap_CostsAndExpenses_b9e655f9-f6a2-4f75-b60d-164b5d020895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f1b6118-65a2-417b-9dfd-46680dc3b4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f1b6118-65a2-417b-9dfd-46680dc3b4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ace43c85-eb35-4bfe-9f0b-f70f20079bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_InterestExpense_ace43c85-eb35-4bfe-9f0b-f70f20079bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5f7685fb-8a50-49d0-a065-aa927a9e2e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5f7685fb-8a50-49d0-a065-aa927a9e2e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84cdb601-1881-47cc-b2fb-bd3aa0864ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84cdb601-1881-47cc-b2fb-bd3aa0864ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2a77bd9a-5ef9-4beb-bf46-bac2d1ed40b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2a77bd9a-5ef9-4beb-bf46-bac2d1ed40b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91eefbee-4b47-429c-93c0-3fc98fc64eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_NetIncomeLoss_91eefbee-4b47-429c-93c0-3fc98fc64eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_53a9ff05-52dc-4707-80f8-39acd2d21034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_EarningsPerShareBasic_53a9ff05-52dc-4707-80f8-39acd2d21034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_06a4aa1c-a0a5-4535-909a-83451d0bb144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_06a4aa1c-a0a5-4535-909a-83451d0bb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbefb560-9449-4364-97dd-34530cd790ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bbefb560-9449-4364-97dd-34530cd790ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40ab9e62-ec7b-42fb-a5d6-e94be3a10ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_40ab9e62-ec7b-42fb-a5d6-e94be3a10ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4db9cb01-396d-4fd0-a283-b35feb850ca6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6ac2851d-ccb9-4f71-908c-a22bb25d075f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:to="loc_us-gaap_NetIncomeLoss_6ac2851d-ccb9-4f71-908c-a22bb25d075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_49141fa4-a987-4e46-b4d7-d8f5bb941573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_49141fa4-a987-4e46-b4d7-d8f5bb941573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f09a2fb-9583-433c-a09b-a4a99b0961a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_54c2e89b-f749-4573-80b4-a4ad9aaedd0f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f09a2fb-9583-433c-a09b-a4a99b0961a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5478c327-19c4-4be1-a19d-8e2f20cac05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5478c327-19c4-4be1-a19d-8e2f20cac05b" xlink:to="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4688d17e-9674-4422-835c-6dbbcd86fc18" xlink:to="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c24caf17-c13a-47fd-a800-610229004dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_CommonStockMember_c24caf17-c13a-47fd-a800-610229004dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ac647f05-6221-4415-9c19-8bd7919a595e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ac647f05-6221-4415-9c19-8bd7919a595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3bd7392a-6781-4b0c-8189-348bfa97fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_RetainedEarningsMember_3bd7392a-6781-4b0c-8189-348bfa97fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3909b822-f282-44f1-ae3d-c0546c02d42f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8ea9cd57-4839-4868-8835-309b070dbb31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3909b822-f282-44f1-ae3d-c0546c02d42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0bfd5fc5-e8c7-46db-8d23-ccbe4eddd13b" xlink:to="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ef49fd8-b6db-4337-a3e4-5918e6a8c071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockholdersEquity_5ef49fd8-b6db-4337-a3e4-5918e6a8c071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6348810b-1c56-4e7e-af08-f1a66f56cc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_SharesOutstanding_6348810b-1c56-4e7e-af08-f1a66f56cc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_43ca3556-4968-4885-8760-7d11cfbe796d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_43ca3556-4968-4885-8760-7d11cfbe796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c0e8078c-18c4-4d8a-b92b-8e030c47bfea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c0e8078c-18c4-4d8a-b92b-8e030c47bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_e91ad7fa-7719-4724-a0d3-cb193985b51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_e91ad7fa-7719-4724-a0d3-cb193985b51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_76184be7-7b6d-4fe7-b088-eb3beff445e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_76184be7-7b6d-4fe7-b088-eb3beff445e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_707d5b21-c5ad-4dc8-878e-60c83ea6946a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_707d5b21-c5ad-4dc8-878e-60c83ea6946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_57af6896-377c-4428-b47e-8687d7098886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_57af6896-377c-4428-b47e-8687d7098886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db8ec02b-3063-421d-8470-51a658af5d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db8ec02b-3063-421d-8470-51a658af5d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0432b742-336c-4f75-84a5-8b068e303865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0432b742-336c-4f75-84a5-8b068e303865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_299099de-46c8-4021-9338-7d399cfe40b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_299099de-46c8-4021-9338-7d399cfe40b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d27dde6a-edcc-445b-b605-5a81fe326b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d27dde6a-edcc-445b-b605-5a81fe326b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b07a6db2-bd73-48d1-834b-85caaaf78dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b07a6db2-bd73-48d1-834b-85caaaf78dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_653e01cd-e8d1-4499-b607-056ec92e8dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_NetIncomeLoss_653e01cd-e8d1-4499-b607-056ec92e8dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ed9e38c-8480-47f2-b0c4-50b3739e6190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_StockholdersEquity_7ed9e38c-8480-47f2-b0c4-50b3739e6190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bcf0c1b7-26c4-43cf-a0b7-e14aca2a59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5680957a-7c47-4a8a-a24d-b7e79560cd7c" xlink:to="loc_us-gaap_SharesOutstanding_bcf0c1b7-26c4-43cf-a0b7-e14aca2a59c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20210630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12cd6492-00ab-4dfb-9f0b-13be616da786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:to="loc_us-gaap_NetIncomeLoss_12cd6492-00ab-4dfb-9f0b-13be616da786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c5925468-8014-4d94-91b9-60a9fe845c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_Depreciation_c5925468-8014-4d94-91b9-60a9fe845c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_87ee97f5-c0cb-47b0-8013-21fc2f2205f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_87ee97f5-c0cb-47b0-8013-21fc2f2205f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_aad17ee2-4aee-4ee7-bcad-1a4e619c3a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_aad17ee2-4aee-4ee7-bcad-1a4e619c3a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a02f450b-6f85-43e4-bb5f-6fd1d2f7197b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a02f450b-6f85-43e4-bb5f-6fd1d2f7197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_17efc45c-60fc-44cf-8ed9-8699c183a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_17efc45c-60fc-44cf-8ed9-8699c183a9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3bea63fb-5e01-4eba-8456-ff69760430ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_ShareBasedCompensation_3bea63fb-5e01-4eba-8456-ff69760430ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9edc4526-e1aa-4dbd-a701-035b4f40c83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9edc4526-e1aa-4dbd-a701-035b4f40c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e0da19f2-3575-4f41-908c-aa3fe9ea0655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f71707c7-73c9-46dc-818d-f07d0c2bffbd" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e0da19f2-3575-4f41-908c-aa3fe9ea0655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6d9519d2-9003-45ee-93b1-e24b5b45f694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6d9519d2-9003-45ee-93b1-e24b5b45f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_383f16c8-35fa-4b3c-a8da-64f39ad8d235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_383f16c8-35fa-4b3c-a8da-64f39ad8d235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7a00666a-18d6-462d-931d-3ca7443c8822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7a00666a-18d6-462d-931d-3ca7443c8822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0ff2db-0f62-4a03-98d9-2619e395998b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0ff2db-0f62-4a03-98d9-2619e395998b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_db807b14-e34d-4f5d-aa16-abb2cccb2a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_db807b14-e34d-4f5d-aa16-abb2cccb2a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6599a32e-9134-413f-bad6-79eb6984fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_760027b4-39f7-4243-9daa-bd6babba04f1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6599a32e-9134-413f-bad6-79eb6984fe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_894220e2-20e7-4457-9260-15fe0a88dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ae67d96-620a-45e9-a358-a7888fb5da8e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_894220e2-20e7-4457-9260-15fe0a88dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_631fba82-bc60-4d38-952c-86cbf67a79d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_631fba82-bc60-4d38-952c-86cbf67a79d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_508d9eb2-1552-4db5-8cef-123ca5149b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_508d9eb2-1552-4db5-8cef-123ca5149b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_098419bc-2478-424c-aec1-cdcdef3fcbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_098419bc-2478-424c-aec1-cdcdef3fcbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b50c7215-facb-4e44-a12c-1b89f57ee1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13075225-103e-40ca-954f-70977a8d333f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b50c7215-facb-4e44-a12c-1b89f57ee1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9283af5-51eb-4d1e-9609-1fc1ee9af661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9283af5-51eb-4d1e-9609-1fc1ee9af661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7fc3d946-ace1-499f-9344-7c99d7a64c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9283af5-51eb-4d1e-9609-1fc1ee9af661" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7fc3d946-ace1-499f-9344-7c99d7a64c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_90aec91a-edd0-4a96-95e6-5408659f132d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9283af5-51eb-4d1e-9609-1fc1ee9af661" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_90aec91a-edd0-4a96-95e6-5408659f132d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54ee1918-edaa-493c-b623-5a435eafa175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b9283af5-51eb-4d1e-9609-1fc1ee9af661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54ee1918-edaa-493c-b623-5a435eafa175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_89caa815-6284-4f8b-a398-ec871920b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_89caa815-6284-4f8b-a398-ec871920b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08f3bfbd-f753-47bc-827a-bb9dea72c432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08f3bfbd-f753-47bc-827a-bb9dea72c432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_282065a2-0f42-402f-8847-0f985ff4f928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_282065a2-0f42-402f-8847-0f985ff4f928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2917d61f-bc76-4b38-92ee-d8751757fe35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2917d61f-bc76-4b38-92ee-d8751757fe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_137d5dfe-d295-486e-a99a-62fd252e5909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2917d61f-bc76-4b38-92ee-d8751757fe35" xlink:to="loc_us-gaap_InterestPaidNet_137d5dfe-d295-486e-a99a-62fd252e5909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_d6610ece-1b5d-4734-ac30-07b5678f0d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2917d61f-bc76-4b38-92ee-d8751757fe35" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_d6610ece-1b5d-4734-ac30-07b5678f0d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8a3b5d01-a140-4b15-b4f1-babffb0c3ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aae26f18-372b-459a-9410-f225bfae0171" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8a3b5d01-a140-4b15-b4f1-babffb0c3ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5e661262-d2e7-4599-8c4f-3aef59ebf552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8a3b5d01-a140-4b15-b4f1-babffb0c3ddb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5e661262-d2e7-4599-8c4f-3aef59ebf552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_c62e065f-2e5b-4d7a-86ed-689fb589e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8a3b5d01-a140-4b15-b4f1-babffb0c3ddb" xlink:to="loc_us-gaap_StockIssued1_c62e065f-2e5b-4d7a-86ed-689fb589e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="ardx-20210630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_432d81d5-877a-4d8c-892c-7441ac77fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5255bd4e-85e4-4878-ae40-8912bff07124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_432d81d5-877a-4d8c-892c-7441ac77fea9" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5255bd4e-85e4-4878-ae40-8912bff07124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="ardx-20210630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97a37e93-e65a-413b-9762-3816891e6c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1a3ce053-4968-4e3a-a4d4-789545948aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97a37e93-e65a-413b-9762-3816891e6c4a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1a3ce053-4968-4e3a-a4d4-789545948aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d31195e7-4d19-4b0a-bf30-e9d6b4e5d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97a37e93-e65a-413b-9762-3816891e6c4a" xlink:to="loc_us-gaap_UseOfEstimates_d31195e7-4d19-4b0a-bf30-e9d6b4e5d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2c86ed6d-49ae-4a85-9377-4957d607b165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97a37e93-e65a-413b-9762-3816891e6c4a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2c86ed6d-49ae-4a85-9377-4957d607b165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a69722a2-65bb-4291-b641-c80ba6540a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97a37e93-e65a-413b-9762-3816891e6c4a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a69722a2-65bb-4291-b641-c80ba6540a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab9a7d03-0ecd-4264-9293-9ae1a26c88b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bc5ef134-3af8-4c3d-a0c1-74e44068e989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab9a7d03-0ecd-4264-9293-9ae1a26c88b8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bc5ef134-3af8-4c3d-a0c1-74e44068e989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c1797510-53bc-4833-8269-af1004f03508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab9a7d03-0ecd-4264-9293-9ae1a26c88b8" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_c1797510-53bc-4833-8269-af1004f03508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_de5e86fa-5353-4ce3-b9b2-d6a17fc1e5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_de4dc1cd-11a6-4fd2-90b6-b25eb921c6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_de5e86fa-5353-4ce3-b9b2-d6a17fc1e5d2" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_de4dc1cd-11a6-4fd2-90b6-b25eb921c6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f6064d10-fee9-4c57-8b8b-728b508b5541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1ea393d9-adea-4eee-b735-735a0226bf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f6064d10-fee9-4c57-8b8b-728b508b5541" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1ea393d9-adea-4eee-b735-735a0226bf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_8a47bc29-e089-4b1a-bbba-8c148dec111e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8a47bc29-e089-4b1a-bbba-8c148dec111e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d101ceb7-430f-4d23-9346-1493caff86b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ee262834-f248-4639-86b6-7d13dc9b3643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ee262834-f248-4639-86b6-7d13dc9b3643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b2d5d545-ea94-4f6d-94bf-7dac493c8ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b2d5d545-ea94-4f6d-94bf-7dac493c8ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0df5146e-770e-41fd-becb-1fb07632b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_0df5146e-770e-41fd-becb-1fb07632b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b65f77cb-cd54-4fd9-8e4b-67901c9c8886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b65f77cb-cd54-4fd9-8e4b-67901c9c8886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_1e88da8d-b5e5-4180-8319-6088c6e04c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e758d12b-2bec-46f3-bac4-d5d4251ec6d4" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_1e88da8d-b5e5-4180-8319-6088c6e04c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2fd8f682-daf6-4408-ae14-ccc3f74c22f9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_b3f5ad7b-274d-499b-bbad-4ea4a9f01cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_CashMember_b3f5ad7b-274d-499b-bbad-4ea4a9f01cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7811b5cc-03d8-4dd8-9409-b7211f0af2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7811b5cc-03d8-4dd8-9409-b7211f0af2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_14e3d4cc-2466-45ee-9a7d-041b8795e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47e288c2-fc4d-4948-b878-99af784156ff" xlink:to="loc_us-gaap_CommercialPaperMember_14e3d4cc-2466-45ee-9a7d-041b8795e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3bf7b923-da94-4dc2-a39d-f66a280cd306" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2f786e4-ae79-45d4-af14-520da6c19278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2f786e4-ae79-45d4-af14-520da6c19278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df1c1290-65f1-4b24-bcba-df9307d503bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_26e5f0c5-db6a-494e-aa01-798da165cc95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df1c1290-65f1-4b24-bcba-df9307d503bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b20b2735-9159-4ed0-a919-ed9039116725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b20b2735-9159-4ed0-a919-ed9039116725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07088dd4-7d70-4761-a012-d6f3c030a850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07088dd4-7d70-4761-a012-d6f3c030a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6142a82f-2217-46b3-a390-2f9f64da2bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6142a82f-2217-46b3-a390-2f9f64da2bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34facfde-5ae1-44e3-9d7b-4a00d84072ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_7cd0034e-f7f1-47bb-940c-711ac7128124" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_34facfde-5ae1-44e3-9d7b-4a00d84072ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAmortizedCost_91648fbd-2768-4e0c-b01c-0fda46cb78e4" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAmortizedCost_91648fbd-2768-4e0c-b01c-0fda46cb78e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_10306606-9a9e-4a91-a3d6-fb5c2372b0a9" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain_10306606-9a9e-4a91-a3d6-fb5c2372b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_2ffd1f2f-b3e1-4e86-aea9-5ef066cdfa79" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss_2ffd1f2f-b3e1-4e86-aea9-5ef066cdfa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LongTermInvestmentsFairValue_5aaacc93-4b52-46c6-834e-6e204bf2f75a" xlink:href="ardx-20210630.xsd#ardx_LongTermInvestmentsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_d13d5ff9-e955-4e8c-b533-1c8103b12a8b" xlink:to="loc_ardx_LongTermInvestmentsFairValue_5aaacc93-4b52-46c6-834e-6e204bf2f75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_901a5aa0-4915-49ad-99db-4a9f3ddfd36d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_us-gaap_InvestmentsAndCash_901a5aa0-4915-49ad-99db-4a9f3ddfd36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_79d6c5d2-94fa-408b-aa3a-69a558bf7626" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain_79d6c5d2-94fa-408b-aa3a-69a558bf7626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_01716b77-c63f-4817-919a-63aeebef2aa1" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss_01716b77-c63f-4817-919a-63aeebef2aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashFairValueDisclosure_dbe13399-ae93-43a0-b45d-a4f701f1bc2b" xlink:href="ardx-20210630.xsd#ardx_InvestmentsAndCashFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5b32cbce-4507-4731-9577-e35e919f53ba" xlink:to="loc_ardx_InvestmentsAndCashFairValueDisclosure_dbe13399-ae93-43a0-b45d-a4f701f1bc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CashCashEquivalentsandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6d15685d-2428-4ce4-9335-8de9c8c7f206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_967f52fc-0642-4862-ae59-bba2a3cdf70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6d15685d-2428-4ce4-9335-8de9c8c7f206" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_967f52fc-0642-4862-ae59-bba2a3cdf70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_933cb4cf-87f6-4b87-83f2-1d7d756233fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6d15685d-2428-4ce4-9335-8de9c8c7f206" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_933cb4cf-87f6-4b87-83f2-1d7d756233fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ardx-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ae6c08f-472d-4dc3-a3fe-150c06ce03dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_aee50621-d945-4a86-9f21-99073602eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ae6c08f-472d-4dc3-a3fe-150c06ce03dd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_aee50621-d945-4a86-9f21-99073602eaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e5f23ec-6d4d-4dc8-8cdb-ca091c69c760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_632e2b5e-e562-4e51-9678-6dc4833b2e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e5f23ec-6d4d-4dc8-8cdb-ca091c69c760" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_632e2b5e-e562-4e51-9678-6dc4833b2e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba7a4dd5-0600-4ddb-bba1-e6ba03e454c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba7a4dd5-0600-4ddb-bba1-e6ba03e454c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4b694da9-56cb-489b-96f9-e028a6bbf445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_33455a0b-ac3c-4617-9495-9b198408c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e250ed7-13b9-494e-8e40-4ffd7e0665c9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_33455a0b-ac3c-4617-9495-9b198408c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f090ade5-19f4-4867-999f-406cb33a8746" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3c9980eb-a578-4554-981b-d23d2aa5b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3c9980eb-a578-4554-981b-d23d2aa5b83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_873b7c9d-f5d3-4724-bb86-1c709df8c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_873b7c9d-f5d3-4724-bb86-1c709df8c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9c838c75-3d02-4cd3-9f50-8848bf42ac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d06c786c-a70d-498e-a129-08fa4347975c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9c838c75-3d02-4cd3-9f50-8848bf42ac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7f8b1b9-41b3-490d-adb0-e8efeca5be13" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d0a3837d-c5f1-421f-932e-8907cad3ec93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d0a3837d-c5f1-421f-932e-8907cad3ec93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0296e6c6-e0f8-4d4e-816f-5a3a3beb739c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_CommercialPaperMember_0296e6c6-e0f8-4d4e-816f-5a3a3beb739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c23de353-289d-431b-bc1f-4ee5d9c214ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c23de353-289d-431b-bc1f-4ee5d9c214ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7fb4c03f-06cf-4f9a-a759-af0fa48cff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7fb4c03f-06cf-4f9a-a759-af0fa48cff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cd03617-3cd1-4a5d-8819-46bfcbea79fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2cd03617-3cd1-4a5d-8819-46bfcbea79fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ed3a311f-7bfe-44cc-b7a6-913d6e9766e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_893b1935-d928-4e87-bb10-94aa2690dba7" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ed3a311f-7bfe-44cc-b7a6-913d6e9766e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e7afa2fc-99eb-41ee-af8d-7ee73cffe992" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dc4bea7f-47d1-4156-adc6-0bdc2cd67375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2eadd0b7-78b7-47d6-b271-db041ea28d17" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_dc4bea7f-47d1-4156-adc6-0bdc2cd67375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3de2bb8e-91ff-4426-9c8b-00edaeb2ed60" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1cb03204-c366-4989-8d7e-72bf03c119cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3659c434-a0ab-4593-8939-873ca0c18bdf" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1cb03204-c366-4989-8d7e-72bf03c119cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c875994f-1c8c-45b2-b6f2-e67b497f1af9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ebb0024a-c3ca-4516-b968-831f5cf1af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e55cacf0-38c4-4703-b158-cd45812b13af" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ebb0024a-c3ca-4516-b968-831f5cf1af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_c85dc9a2-b2d4-4e9f-9e53-a51648067b5a" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f73be9d3-46e1-4873-ab08-44e8385799d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_c85dc9a2-b2d4-4e9f-9e53-a51648067b5a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f73be9d3-46e1-4873-ab08-44e8385799d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_78edfaef-7097-4557-8c6c-77542d290397" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b720bf55-8218-40eb-ab0c-ce4f7c49bcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_78edfaef-7097-4557-8c6c-77542d290397" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b720bf55-8218-40eb-ab0c-ce4f7c49bcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_1921b9ab-8392-4fd2-aa2d-b4aef469ceb7" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_1921b9ab-8392-4fd2-aa2d-b4aef469ceb7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdc23faf-653b-4dc4-aa57-221c3c83b40f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_29f911c1-93ba-4778-a596-bb49c6427564" xlink:href="ardx-20210630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_29f911c1-93ba-4778-a596-bb49c6427564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_bfff45a0-8216-453a-95ef-1a63f59fa878" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_bfff45a0-8216-453a-95ef-1a63f59fa878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_4cc4b53d-bc6c-4019-bf3d-501abc436a36" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_4cc4b53d-bc6c-4019-bf3d-501abc436a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_77c8f4bd-d6aa-4f1f-9fd0-ce6ab4202e4b" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_77c8f4bd-d6aa-4f1f-9fd0-ce6ab4202e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_8cb148b8-1dc5-409d-8d4b-3624e82b1751" xlink:href="ardx-20210630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa502ced-42d3-44cb-b029-82b63bfc5f8f" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_8cb148b8-1dc5-409d-8d4b-3624e82b1751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0f33ab83-9a13-4f03-b9dc-516aaf2fa14c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_eeb5ef01-7863-4ea8-b3a4-84aa1bf68c94" xlink:href="ardx-20210630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_eeb5ef01-7863-4ea8-b3a4-84aa1bf68c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_82741568-0f60-44a4-a042-c6e08a54dcc7" xlink:href="ardx-20210630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_82741568-0f60-44a4-a042-c6e08a54dcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_7d67c4d4-ed17-4fcb-afaf-621df77f1f4c" xlink:href="ardx-20210630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_KnightTherapeuticsIncMember_7d67c4d4-ed17-4fcb-afaf-621df77f1f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_3f2b1b36-aeb4-4d16-9ff2-65fd0a42a66b" xlink:href="ardx-20210630.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e89a81-e2b9-4bfd-991a-9329ee42da05" xlink:to="loc_ardx_AstrazenecaMember_3f2b1b36-aeb4-4d16-9ff2-65fd0a42a66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_34883593-b176-49a3-b83d-765bb2c45092" xlink:to="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_27f40f9d-243e-4cbf-a5e1-92b8948c636f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_us-gaap_LicenseMember_27f40f9d-243e-4cbf-a5e1-92b8948c636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_89345957-7227-4713-821f-9dac832356ea" xlink:href="ardx-20210630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_ardx_ProductSupplyRevenueMember_89345957-7227-4713-821f-9dac832356ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OtherProductOrServicesRevenueMember_f6cffe0a-7109-4d30-b254-cf675b661a09" xlink:href="ardx-20210630.xsd#ardx_OtherProductOrServicesRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0fd80c17-2639-4f86-a180-4c0d618f0928" xlink:to="loc_ardx_OtherProductOrServicesRevenueMember_f6cffe0a-7109-4d30-b254-cf675b661a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ad46c20a-be3e-4f17-ad43-563f46b91d13" xlink:to="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bec31b9-54c0-4829-968c-c4cedc63be3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6bbf08d-c84f-44ee-aaf2-0a12d4727485" xlink:to="loc_srt_MinimumMember_7bec31b9-54c0-4829-968c-c4cedc63be3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65d21f3d-ba78-47f8-a0db-2f81a0cb43a6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_f54d7fa1-9665-4e6a-aa5c-1d7f6a116d02" xlink:href="ardx-20210630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_f54d7fa1-9665-4e6a-aa5c-1d7f6a116d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_df12f52c-f16f-499d-9c92-98a9096b6e57" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_df12f52c-f16f-499d-9c92-98a9096b6e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_4fac8d96-d633-432c-aa83-acab63fb9aed" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_4fac8d96-d633-432c-aa83-acab63fb9aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_8b11504e-89ab-41ce-9553-e81fbfe479c7" xlink:href="ardx-20210630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_8b11504e-89ab-41ce-9553-e81fbfe479c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_a195c334-3e3c-4210-aa31-1d5798318871" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_a195c334-3e3c-4210-aa31-1d5798318871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_b8f067af-fae3-4924-94b0-f057ca34f4df" xlink:href="ardx-20210630.xsd#ardx_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_TermOfAgreement_b8f067af-fae3-4924-94b0-f057ca34f4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_49945e46-f26f-498b-8c04-e4f9f5dcd7a3" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_49945e46-f26f-498b-8c04-e4f9f5dcd7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e2aefa6-33e8-4fec-b985-5a73e2620808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e2aefa6-33e8-4fec-b985-5a73e2620808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_cbc4ed5e-a681-403d-bdc7-17ede1a143dd" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_cbc4ed5e-a681-403d-bdc7-17ede1a143dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eccf0564-9c3c-4ecf-8486-8e053539ccd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eccf0564-9c3c-4ecf-8486-8e053539ccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_ac99689d-50be-4c1d-88e3-b57e51be341c" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_ac99689d-50be-4c1d-88e3-b57e51be341c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_56d23ae1-cd9e-4e21-9aaf-d4776ab09e17" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_56d23ae1-cd9e-4e21-9aaf-d4776ab09e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_b22c669b-348f-4ce3-bd7e-24b60ea115e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_b22c669b-348f-4ce3-bd7e-24b60ea115e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_9b388547-b813-4c34-b1ab-4b4ba41e53b3" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_9b388547-b813-4c34-b1ab-4b4ba41e53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_8f1b46e4-a5ca-41b8-a9f4-3f779e82e8a4" xlink:href="ardx-20210630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_8f1b46e4-a5ca-41b8-a9f4-3f779e82e8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_76671de8-17db-4456-9621-32814f1b48eb" xlink:href="ardx-20210630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_76671de8-17db-4456-9621-32814f1b48eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_26c97db8-22c3-43ec-a64e-44873d0c6c1f" xlink:href="ardx-20210630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_26c97db8-22c3-43ec-a64e-44873d0c6c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_c4a3842a-c7bd-42fe-9e18-8e7e8c1e8d5d" xlink:href="ardx-20210630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_c4a3842a-c7bd-42fe-9e18-8e7e8c1e8d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_9736586b-3f98-4443-b677-916c160b2611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_us-gaap_CostOfRevenue_9736586b-3f98-4443-b677-916c160b2611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFees_fd06c4a2-c449-4428-bef3-9138846e9481" xlink:href="ardx-20210630.xsd#ardx_PaymentsOfUnchargedLicenseFees"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88b687f4-0b16-4c72-ada3-6dffb663213a" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFees_fd06c4a2-c449-4428-bef3-9138846e9481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_b36ac5cc-5d9c-4ffb-8b7e-f93d4577fe87" xlink:href="ardx-20210630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_b36ac5cc-5d9c-4ffb-8b7e-f93d4577fe87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76c33591-9d97-41b1-b47c-848b9022fecd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_6edee05e-ce85-46fc-8f59-899887f0ebaf" xlink:href="ardx-20210630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_6edee05e-ce85-46fc-8f59-899887f0ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_b7025736-f60a-42d6-a19d-b3b743d5a608" xlink:href="ardx-20210630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35304241-0186-4c14-806c-d36021e7a048" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_b7025736-f60a-42d6-a19d-b3b743d5a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f4d9d08e-b454-418e-97d1-81a9f392f474" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2805ec7-b19c-4812-b825-4fa80fdd9835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d2805ec7-b19c-4812-b825-4fa80fdd9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_360c6f52-02e3-4845-b369-f3bcbc88a6fb" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_360c6f52-02e3-4845-b369-f3bcbc88a6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca3eb690-ae76-454b-a4ae-ca4b4cdb80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_cc0d00ef-196c-4add-aca7-968e061cf27a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca3eb690-ae76-454b-a4ae-ca4b4cdb80cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:href="ardx-20210630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6a8fca85-d723-4cf6-a748-146ac032acba" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_026d9fbf-bf02-4df6-a3bc-14b29cfd87cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_026d9fbf-bf02-4df6-a3bc-14b29cfd87cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_ab1a28a4-399a-47ed-9be1-94cdcff3bf2a" xlink:href="ardx-20210630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_ab1a28a4-399a-47ed-9be1-94cdcff3bf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4c1ce90b-6309-4fc5-a602-25462ac8aafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_29bf1717-09c7-4b08-9fe6-5839034b3db6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4c1ce90b-6309-4fc5-a602-25462ac8aafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Borrowing" xlink:type="simple" xlink:href="ardx-20210630.xsd#Borrowing"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Borrowing" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d19fcdb9-2008-45d9-b34a-7208c2d9c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_503f8c9c-4948-4cc3-9e95-790505cffa76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d19fcdb9-2008-45d9-b34a-7208c2d9c15c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_503f8c9c-4948-4cc3-9e95-790505cffa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3f7e76b8-e768-4cf6-b6f5-cce00b5dd367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_365dfa09-64b7-49aa-8c9f-b2e21c2c65a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3f7e76b8-e768-4cf6-b6f5-cce00b5dd367" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_365dfa09-64b7-49aa-8c9f-b2e21c2c65a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f370e01-1f37-461b-bdac-25b7a733ef57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f370e01-1f37-461b-bdac-25b7a733ef57" xlink:to="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05d4c069-6b39-4ab3-9fd0-c2d7bac60c0a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_fd9e5ce3-b806-40c6-bb8b-bb63aa5ecf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f8ab42f0-6eb1-4d4b-b3bc-ea6db6a68dfb" xlink:to="loc_us-gaap_LoansPayableMember_fd9e5ce3-b806-40c6-bb8b-bb63aa5ecf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32c3cfa2-bf34-4073-8973-fa25ca360aa5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d69d5baa-cfa6-430b-a54f-8fe6203a5a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d69d5baa-cfa6-430b-a54f-8fe6203a5a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_600a2348-67ae-4dfe-9437-39ea168fec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_600a2348-67ae-4dfe-9437-39ea168fec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2cd487f8-3d3b-4c38-ade4-ed0959569a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4b882dce-1df2-49e5-8015-d10e29766cd7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2cd487f8-3d3b-4c38-ade4-ed0959569a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6ed76b9c-f2a5-4829-9c88-ef50081be900" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2e97e4c2-8449-47d4-9ef4-d28d7d07da61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_65039766-77b8-4616-808e-4fc07fa174ae" xlink:to="loc_us-gaap_SubsequentEventMember_2e97e4c2-8449-47d4-9ef4-d28d7d07da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98e62e15-304e-4885-b31a-5d4dd90e3e83" xlink:to="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_925b91ee-931f-4630-a6c5-82fdb917363d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_925b91ee-931f-4630-a6c5-82fdb917363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_4c382425-2ae7-4423-9242-29b015f39b25" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_4c382425-2ae7-4423-9242-29b015f39b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeePercentage_611f349a-f08f-4657-8af1-6bb2e7455eb3" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentClosingFeePercentage_611f349a-f08f-4657-8af1-6bb2e7455eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFee_4728e230-51d1-45f6-8e19-9a42c2eff9d0" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentClosingFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentClosingFee_4728e230-51d1-45f6-8e19-9a42c2eff9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_30c58d41-fcce-4079-b2e7-bc6a23350901" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_30c58d41-fcce-4079-b2e7-bc6a23350901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_3eb7ccdc-abca-46d6-8483-2036b9ebfda0" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_3eb7ccdc-abca-46d6-8483-2036b9ebfda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_2700268d-0d5f-433d-acfb-5e1e76903917" xlink:href="ardx-20210630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_23d162d8-1de3-4d98-86b7-4982ea9a16f6" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_2700268d-0d5f-433d-acfb-5e1e76903917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d2cdfb5d-036e-4267-8bd8-7f41b6c43ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d2cdfb5d-036e-4267-8bd8-7f41b6c43ec1" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5260154d-1d65-46e8-8922-30f9cf84e99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5260154d-1d65-46e8-8922-30f9cf84e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_14fbe879-2864-4eef-8b7e-5078f1d08747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_14fbe879-2864-4eef-8b7e-5078f1d08747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_09091d28-ada9-4473-8f1e-08ec596a809e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_09091d28-ada9-4473-8f1e-08ec596a809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_900c7e5e-9287-49e5-be8a-aba2b6aecdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_LongTermDebt_900c7e5e-9287-49e5-be8a-aba2b6aecdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_8aa967cf-b8b3-410b-a25e-cec6630f2866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_LoansPayableCurrent_8aa967cf-b8b3-410b-a25e-cec6630f2866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_196b98d6-fef0-4243-adde-0410db336137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_3531812c-e2f0-4286-9398-4a94f854ccb0" xlink:to="loc_us-gaap_LongTermLoansPayable_196b98d6-fef0-4243-adde-0410db336137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20210630.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_001e6c9a-add2-4a33-bbc7-f56c796ccc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_be569e3e-97a8-4cab-b6bd-27955f873b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_001e6c9a-add2-4a33-bbc7-f56c796ccc87" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_be569e3e-97a8-4cab-b6bd-27955f873b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5b27ca3-48ed-43f2-964b-c05d49dce9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_39a6fedf-59b4-4202-ab98-c7c2449ab4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5b27ca3-48ed-43f2-964b-c05d49dce9bc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_39a6fedf-59b4-4202-ab98-c7c2449ab4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_71ccdfe9-577b-4482-9316-6485811b9a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_71ccdfe9-577b-4482-9316-6485811b9a46" xlink:to="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c3b0fde-c69e-4a7c-86e2-a9d9bbd26828" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherContractMember_752d5d28-1691-4ea2-972d-990d78766f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_64966e86-f6d2-442d-9354-bca39978ea77" xlink:to="loc_us-gaap_OtherContractMember_752d5d28-1691-4ea2-972d-990d78766f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ff20753-8bf4-45fc-87f8-ec9d3d0f8860" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f9b8c77a-e8ea-4d25-83fb-502341a7ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73360178-d9c9-4c45-a706-877df90f0939" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f9b8c77a-e8ea-4d25-83fb-502341a7ddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_3fd03313-0f29-4d10-93d9-10fdb7914a24" xlink:to="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_1256789a-71ac-41b5-aec5-e747372cfe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_1256789a-71ac-41b5-aec5-e747372cfe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_358a2dfc-fc71-40ae-b69d-7aa3f6954d9f" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_358a2dfc-fc71-40ae-b69d-7aa3f6954d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_f394f67a-ca87-4aca-93fc-03adfc6c0c26" xlink:href="ardx-20210630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0cc18745-66d9-404a-864c-4c0f2f6f5d3e" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_f394f67a-ca87-4aca-93fc-03adfc6c0c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e9ae384f-44ec-4721-81e5-fc0525804372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e9ae384f-44ec-4721-81e5-fc0525804372" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_a9f39df7-6725-4492-9d66-2afa2bd46b78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8ce802b-b003-4146-b6a7-970a8a425754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e59a096f-e2b9-49aa-b0b0-3e102f017f7c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8ce802b-b003-4146-b6a7-970a8a425754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c4a90b1-f502-4122-8136-ca0e6394bc1c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb8782f2-9965-44ae-aae0-67fd4414c318" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b28151f-ffe7-4a80-bd07-bdfc9f467893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b28151f-ffe7-4a80-bd07-bdfc9f467893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_177ce4d1-e1cd-4179-9fd9-2b85cfc37024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_177ce4d1-e1cd-4179-9fd9-2b85cfc37024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd24591a-e15e-44fc-890c-dc50add808c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_984c2c60-85bd-4d85-99db-9c0c3523e60b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fd24591a-e15e-44fc-890c-dc50add808c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Leases" xlink:type="simple" xlink:href="ardx-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0d4f0c99-b9fd-4f5d-9e62-0c1a21058055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b70288b5-6cc4-4915-9141-41f18a38b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d4f0c99-b9fd-4f5d-9e62-0c1a21058055" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b70288b5-6cc4-4915-9141-41f18a38b5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_27cdad42-839b-4af2-9d78-f8e581656664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_f3c27567-dc95-4a10-a05f-0298cf7a67d1" xlink:href="ardx-20210630.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27cdad42-839b-4af2-9d78-f8e581656664" xlink:to="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_f3c27567-dc95-4a10-a05f-0298cf7a67d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a9753cd2-d1e3-469e-bfd6-5d41d8446e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27cdad42-839b-4af2-9d78-f8e581656664" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a9753cd2-d1e3-469e-bfd6-5d41d8446e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_74a68324-5cf2-46e0-9849-754b49cae5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27cdad42-839b-4af2-9d78-f8e581656664" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_74a68324-5cf2-46e0-9849-754b49cae5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bcbac060-38aa-4aff-8b8b-50bcbc56f9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcbac060-38aa-4aff-8b8b-50bcbc56f9b6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:to="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_45979410-cf24-49bb-96ca-51e077ce36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_e8ebdf51-6b3c-494c-b789-bdeafa92192c" xlink:to="loc_us-gaap_LeaseContractualTermDomain_45979410-cf24-49bb-96ca-51e077ce36a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:to="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:href="ardx-20210630.xsd#ardx_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsAxis_1d881520-dd54-459d-a6af-3da731646eb2" xlink:to="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_f4e865bc-5d74-4cdc-b264-7f56d3001d84" xlink:href="ardx-20210630.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_f4e865bc-5d74-4cdc-b264-7f56d3001d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityWalthamMassachusettsMember_86355969-a376-4854-95ce-e1d34cba7760" xlink:href="ardx-20210630.xsd#ardx_FacilityWalthamMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_53be5efa-18ac-496e-b27b-9af3925ecfff" xlink:to="loc_ardx_FacilityWalthamMassachusettsMember_86355969-a376-4854-95ce-e1d34cba7760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7d4d9be3-e86a-4752-8916-7be5d0c377ce" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_58bd346d-5323-4384-afbf-1790a2d0bd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_58bd346d-5323-4384-afbf-1790a2d0bd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_568ab977-2a4f-4b2a-8e44-a202236f82db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_568ab977-2a4f-4b2a-8e44-a202236f82db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_662ffdba-8640-4718-abfe-67dfa0d8ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_662ffdba-8640-4718-abfe-67dfa0d8ccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_a0ff429f-b2fe-4450-8526-8fedb077d549" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_a0ff429f-b2fe-4450-8526-8fedb077d549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_be5a0fed-ad0b-4aad-b0ef-8939317fbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_19b121c7-6533-4a09-b14b-b84c23db60b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_be5a0fed-ad0b-4aad-b0ef-8939317fbdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesAdditionalLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7ecaba5b-617f-455f-9ae4-5266e03f2db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ecaba5b-617f-455f-9ae4-5266e03f2db3" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a145f482-b61a-4b26-a97a-e6a2a8a82abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a145f482-b61a-4b26-a97a-e6a2a8a82abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_04c98d29-04d5-4c9c-b7f6-9ec4f3597ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_04c98d29-04d5-4c9c-b7f6-9ec4f3597ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f45c33bd-7c95-4753-bc6f-85b87f6e1e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f45c33bd-7c95-4753-bc6f-85b87f6e1e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_33a87dc3-c162-48e8-abae-572778e2a435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_944cf80e-c9d3-4f5d-8a5a-0be33bc856a8" xlink:to="loc_us-gaap_OperatingLeaseLiability_33a87dc3-c162-48e8-abae-572778e2a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_915d8e7d-7c56-43a4-87a6-7afb19b7c0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ecaba5b-617f-455f-9ae4-5266e03f2db3" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_915d8e7d-7c56-43a4-87a6-7afb19b7c0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89cf65d6-821b-4861-95b8-0df337e3e128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_915d8e7d-7c56-43a4-87a6-7afb19b7c0bc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89cf65d6-821b-4861-95b8-0df337e3e128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dba91650-1aea-412d-9207-97e4cb3eff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_915d8e7d-7c56-43a4-87a6-7afb19b7c0bc" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dba91650-1aea-412d-9207-97e4cb3eff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b4a500a3-9070-4deb-a395-aadbb57bc5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_c2026964-e52d-489b-aa7a-3fc01b266f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b4a500a3-9070-4deb-a395-aadbb57bc5ed" xlink:to="loc_us-gaap_LeaseCostAbstract_c2026964-e52d-489b-aa7a-3fc01b266f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_00291594-a056-4800-a7ea-684a7d40f60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c2026964-e52d-489b-aa7a-3fc01b266f33" xlink:to="loc_us-gaap_OperatingLeaseCost_00291594-a056-4800-a7ea-684a7d40f60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_dc6c2532-bab1-4ce9-95e2-c4f875320750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c2026964-e52d-489b-aa7a-3fc01b266f33" xlink:to="loc_us-gaap_OperatingLeasePayments_dc6c2532-bab1-4ce9-95e2-c4f875320750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3061ca7d-627d-44b5-93e6-b634385cdc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3061ca7d-627d-44b5-93e6-b634385cdc87" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ac66020-ecde-4ba2-a681-f4a5b727bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ac66020-ecde-4ba2-a681-f4a5b727bc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f6c6dc9-57fa-44ec-b317-e93701d9c17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f6c6dc9-57fa-44ec-b317-e93701d9c17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f322cc40-9137-45d2-8999-a0c4d10001b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f322cc40-9137-45d2-8999-a0c4d10001b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8fcf750b-fbfe-4d4c-a159-c7282cc0f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8fcf750b-fbfe-4d4c-a159-c7282cc0f1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_86cf854c-71cf-4f6d-a679-73f006fdbbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_86cf854c-71cf-4f6d-a679-73f006fdbbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_df35bc35-8653-4f55-860e-d5982c5e5681" xlink:href="ardx-20210630.xsd#ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_df35bc35-8653-4f55-860e-d5982c5e5681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63dbebb1-41bc-46d2-9799-52ae18bfa78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63dbebb1-41bc-46d2-9799-52ae18bfa78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0af67a51-1f27-4f11-b25f-bcdd9ad94851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0af67a51-1f27-4f11-b25f-bcdd9ad94851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f0bcac8d-3144-4ccd-b7a5-44068abb44eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_OperatingLeaseLiability_f0bcac8d-3144-4ccd-b7a5-44068abb44eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c1f094c-09c6-441a-8621-d0e877ba9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c1f094c-09c6-441a-8621-d0e877ba9d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_af2898e5-8a1a-4dc2-9bea-42670a9df104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7b63b934-c090-4bba-a317-80565c717e49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_af2898e5-8a1a-4dc2-9bea-42670a9df104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20210630.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ardx-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_98e98b14-01a9-4fe3-8cc6-3e32c37e76b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_739de35a-4b8f-405b-b336-e3cb52806abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_98e98b14-01a9-4fe3-8cc6-3e32c37e76b6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_739de35a-4b8f-405b-b336-e3cb52806abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7f83bcf4-0fac-4b34-b1de-9bedce157e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7f83bcf4-0fac-4b34-b1de-9bedce157e40" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_705981d8-25df-47ee-aab6-304673360978" xlink:to="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d3180397-db1f-4c46-a58f-1588590b50a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_88a1021f-bce7-4def-9c1c-b78630519001" xlink:to="loc_us-gaap_CommonClassAMember_d3180397-db1f-4c46-a58f-1588590b50a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c278781-aba9-476d-94dd-e44a690a67ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AtMarketOfferingMember_b70b6e42-7646-469b-9f20-804273d25975" xlink:href="ardx-20210630.xsd#ardx_AtMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5929b59-ff01-4785-a757-8a8afa756cf7" xlink:to="loc_ardx_AtMarketOfferingMember_b70b6e42-7646-469b-9f20-804273d25975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c555080d-73b7-4c07-aa85-455d0ac2469a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_4cce9aa9-917f-4ee5-9b38-4878f8b9e787" xlink:href="ardx-20210630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_4cce9aa9-917f-4ee5-9b38-4878f8b9e787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b1a5fc3-254c-4bfe-a9ad-b4f033af4cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b1a5fc3-254c-4bfe-a9ad-b4f033af4cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8569dbef-4c3f-4a3f-99e8-56623a22e3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8569dbef-4c3f-4a3f-99e8-56623a22e3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_6cda0b5e-2e07-49bc-8566-36db5ddfa72c" xlink:href="ardx-20210630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_6cda0b5e-2e07-49bc-8566-36db5ddfa72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_37ceb1a0-f4e9-4cbf-9a41-ba1c2397ae9a" xlink:href="ardx-20210630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_97141925-ad21-42a3-82b2-f5814eae48b7" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_37ceb1a0-f4e9-4cbf-9a41-ba1c2397ae9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea111846-2594-4873-acc2-35fd8e6c00fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3255109-249f-4f7f-ae86-193102260864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea111846-2594-4873-acc2-35fd8e6c00fd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3255109-249f-4f7f-ae86-193102260864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f361716-d846-41b5-9821-2f0ad7ac59be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bdf3aebc-64b3-4af2-98ab-2f6a10a872ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f361716-d846-41b5-9821-2f0ad7ac59be" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bdf3aebc-64b3-4af2-98ab-2f6a10a872ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_0d68cd1a-b96d-412b-be23-27af8830aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f361716-d846-41b5-9821-2f0ad7ac59be" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_0d68cd1a-b96d-412b-be23-27af8830aaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3925abc4-4ca4-48b1-a057-3d64c0a1e1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f361716-d846-41b5-9821-2f0ad7ac59be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3925abc4-4ca4-48b1-a057-3d64c0a1e1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7aae1e46-f622-441a-adf1-5dca2227ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f361716-d846-41b5-9821-2f0ad7ac59be" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_7aae1e46-f622-441a-adf1-5dca2227ce62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4c8a105-06c7-4043-90bb-6b03bef840f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4c8a105-06c7-4043-90bb-6b03bef840f1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_07771c06-2574-4784-b8c5-8f005c403a5a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_999ece14-f039-4a56-b0b8-43105a489f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_999ece14-f039-4a56-b0b8-43105a489f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21cf68df-3fb9-4900-877c-f4c075ab4bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ff4cc28d-e667-48eb-9ae8-4b1cd696030e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_21cf68df-3fb9-4900-877c-f4c075ab4bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3492a522-95fd-452f-8dab-b2977bcf66c6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73e3ae6e-b4af-4ded-997b-adb2f3761e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_50bcda1f-d1de-4045-9e99-ba7b4344c9ff" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73e3ae6e-b4af-4ded-997b-adb2f3761e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56d30777-a499-4523-9a34-91899743c4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56d30777-a499-4523-9a34-91899743c4cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:to="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d4e2b07d-ec12-4abf-beca-e878a840b6c9" xlink:to="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_8661615f-c37f-49b7-969c-003ed12acd6f" xlink:href="ardx-20210630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_df359348-3434-4d01-9557-9024ecc232e7" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_8661615f-c37f-49b7-969c-003ed12acd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:to="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47ad1975-3f9e-4266-8aaa-ca5610e0a903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d060340e-a2bf-4daa-89f9-f53f7f144892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d060340e-a2bf-4daa-89f9-f53f7f144892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b17c64bc-2f5d-42a2-8400-e55b0ffb03c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0279a2dc-a706-47f3-a39c-8718e86b0658" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b17c64bc-2f5d-42a2-8400-e55b0ffb03c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3e7b47e-07e7-412e-97d0-a0da0533b8fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06f649f3-0165-47c0-9775-e2b96edd6eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06f649f3-0165-47c0-9775-e2b96edd6eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486c5d82-06eb-4ad6-a34e-ce8b3cd89e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed71ce3d-e9da-47c7-9776-0250a3700e49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_486c5d82-06eb-4ad6-a34e-ce8b3cd89e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1337845a-4004-40ee-933c-edb0422c8498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1337845a-4004-40ee-933c-edb0422c8498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14184b17-62e4-49f9-8ad3-b849cba9a624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14184b17-62e4-49f9-8ad3-b849cba9a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b48bc131-8f4f-4d5f-b246-ede11946058b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b48bc131-8f4f-4d5f-b246-ede11946058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41080a79-11d2-4d44-8be6-d8fe06c85a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41080a79-11d2-4d44-8be6-d8fe06c85a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e7f3a365-2d9f-4e63-9473-a1e7fb4fd0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e7f3a365-2d9f-4e63-9473-a1e7fb4fd0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a280914a-67af-48b4-a6dc-4075082c00bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_27f9de49-cc95-4015-b632-98f11da4c7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a280914a-67af-48b4-a6dc-4075082c00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2dd4b1b8-d3d7-4c7e-a8da-f86741d434ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1337845a-4004-40ee-933c-edb0422c8498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2dd4b1b8-d3d7-4c7e-a8da-f86741d434ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1337845a-4004-40ee-933c-edb0422c8498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84a3a0c9-ca0f-416c-8551-2d5529bade7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84a3a0c9-ca0f-416c-8551-2d5529bade7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1d40632c-c719-4984-8eed-45bcc74a2998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1d40632c-c719-4984-8eed-45bcc74a2998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fabfb6e7-165e-459d-95e9-a4e7e16b1d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fabfb6e7-165e-459d-95e9-a4e7e16b1d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a86b4283-38bd-467f-b11a-d8e5463d53bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a86b4283-38bd-467f-b11a-d8e5463d53bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69abdfb1-4e50-4a6b-94d8-71e7262834cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a682050f-cf1c-4c2f-9c30-bd5755426ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69abdfb1-4e50-4a6b-94d8-71e7262834cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b7d60b1-964d-4c64-9b0f-3a0ae5766843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1337845a-4004-40ee-933c-edb0422c8498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b7d60b1-964d-4c64-9b0f-3a0ae5766843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73102453-7cad-448c-81a1-843767bee86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73102453-7cad-448c-81a1-843767bee86b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:to="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dbdbcc66-bcae-4b9a-83bd-5a68d76d2b46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60bfb197-6422-42cd-9967-88a1fa982d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6a18db8-4da0-4ae4-8dda-3509bc7831e1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60bfb197-6422-42cd-9967-88a1fa982d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_121b8ee6-dc36-49f2-b720-7132195b129c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a936d85f-cce6-4bc6-a26f-017e187d626b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a936d85f-cce6-4bc6-a26f-017e187d626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ed3028e-a819-4016-bdc6-6d32d57c61fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ed3028e-a819-4016-bdc6-6d32d57c61fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4adfcd02-09a5-41c3-8845-19214d3644ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4adfcd02-09a5-41c3-8845-19214d3644ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_65e250af-a135-49b4-9264-2e7aaa96e0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_65e250af-a135-49b4-9264-2e7aaa96e0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d25d21f-e458-41f5-a4fb-0e2f116a50e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98ed304c-c97d-4631-99ee-3f6fb6618ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0d25d21f-e458-41f5-a4fb-0e2f116a50e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b44ae52a-4d9c-4a92-aaaa-68ffd5c95df3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b79c3ed3-0709-4526-b316-9eb22e4f447f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b79c3ed3-0709-4526-b316-9eb22e4f447f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1dc361b-d6bd-43e0-9153-9d58b75e740d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1dc361b-d6bd-43e0-9153-9d58b75e740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09bcb53d-d143-422b-95ac-20b7f9c50530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_09bcb53d-d143-422b-95ac-20b7f9c50530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8371683-315a-4ea0-925a-ca3fef7baa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f8371683-315a-4ea0-925a-ca3fef7baa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_85392a6c-8e8e-479a-a9c7-5184bd2a978c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a3ecfc8-a658-4c19-a789-6a2afa2af281" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_85392a6c-8e8e-479a-a9c7-5184bd2a978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71d06346-4779-47b2-9e70-6f63c337d5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71d06346-4779-47b2-9e70-6f63c337d5fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06d54bcb-e8c0-4bce-bba6-4f3674dad5d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_f2704070-df04-4175-bfdb-61094ff4e54e" xlink:href="ardx-20210630.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e485979c-c8fb-4b9c-9cba-43dd4346e00d" xlink:to="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_f2704070-df04-4175-bfdb-61094ff4e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a333293d-ece2-4c3d-8de7-a2791d5c3580" xlink:to="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_512cb764-fe95-4198-ac62-ca0e89ece5bb" xlink:href="ardx-20210630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2fc24252-250f-4b81-ab35-da0b6868b806" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_512cb764-fe95-4198-ac62-ca0e89ece5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10e36938-a20e-47e4-8676-27013e2d5ab0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_5e7a9abf-c561-45ca-afa6-4d42afdb5a6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_277c0d7a-72e7-4962-b92f-98996858d9e2" xlink:to="loc_srt_DirectorMember_5e7a9abf-c561-45ca-afa6-4d42afdb5a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e4659b8-2d51-47f6-ad7a-aa87558592a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f5f8276a-c2f3-4754-b57b-7587c955347d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f5f8276a-c2f3-4754-b57b-7587c955347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f2d4e9e-bb0c-4881-b85b-efff964448df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3f2d4e9e-bb0c-4881-b85b-efff964448df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_25f9d8fb-b3ca-43d1-9da6-627186a07b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_25f9d8fb-b3ca-43d1-9da6-627186a07b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ab50f816-c718-4a17-9ae2-397a76161007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_SharePrice_ab50f816-c718-4a17-9ae2-397a76161007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0658b91e-b27e-4a9c-91f0-158ad3609ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0658b91e-b27e-4a9c-91f0-158ad3609ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f7f24604-e9d4-4923-87e4-759dc51abb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5726f840-3662-485d-9f4d-c2e841f0347f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f7f24604-e9d4-4923-87e4-759dc51abb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ardx-20210630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0295a47c-71f8-45bc-8e82-f8228a52d261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c1c5a4a8-90ec-4ad2-bf2a-277f12a86081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0295a47c-71f8-45bc-8e82-f8228a52d261" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c1c5a4a8-90ec-4ad2-bf2a-277f12a86081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ardx-20210630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70fd948b-4418-4793-b39d-d6583d35dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5c9b6f7f-b92f-48d9-b7c4-e930d6a248a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70fd948b-4418-4793-b39d-d6583d35dcfc" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5c9b6f7f-b92f-48d9-b7c4-e930d6a248a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#NetLossPerShareComputationofNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_76b1096f-c625-439c-b616-e5bfd74cf39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_2ba1c30c-fb62-4810-bd31-ccd7cced0c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76b1096f-c625-439c-b616-e5bfd74cf39c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_2ba1c30c-fb62-4810-bd31-ccd7cced0c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0142d2b-fb28-4496-b365-46ff32ce0e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_2ba1c30c-fb62-4810-bd31-ccd7cced0c14" xlink:to="loc_us-gaap_NetIncomeLoss_d0142d2b-fb28-4496-b365-46ff32ce0e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ef4895c3-b4e1-4c3e-ae49-c44dd0fde82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76b1096f-c625-439c-b616-e5bfd74cf39c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ef4895c3-b4e1-4c3e-ae49-c44dd0fde82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_506dc4fb-0fc4-4506-82c9-d79c2451af5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ef4895c3-b4e1-4c3e-ae49-c44dd0fde82d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_506dc4fb-0fc4-4506-82c9-d79c2451af5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4986887-d7bf-42dc-a352-80d38918dc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_ef4895c3-b4e1-4c3e-ae49-c44dd0fde82d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4986887-d7bf-42dc-a352-80d38918dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6964e06d-f98b-4c0d-944c-6527f53a0669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76b1096f-c625-439c-b616-e5bfd74cf39c" xlink:to="loc_us-gaap_EarningsPerShareBasic_6964e06d-f98b-4c0d-944c-6527f53a0669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c203679e-577d-4951-8772-c4e315a0e20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76b1096f-c625-439c-b616-e5bfd74cf39c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c203679e-577d-4951-8772-c4e315a0e20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc33be59-4fe5-4bde-b2a8-f881dcdaea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_154bd636-bd30-495e-b6f5-80cc99977309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc33be59-4fe5-4bde-b2a8-f881dcdaea0a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_154bd636-bd30-495e-b6f5-80cc99977309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Contingencies" xlink:type="simple" xlink:href="ardx-20210630.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5118f60-7421-4603-91d6-75778f358e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6d22e331-0c8e-4bcb-9fc3-92b40be47d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5118f60-7421-4603-91d6-75778f358e36" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6d22e331-0c8e-4bcb-9fc3-92b40be47d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1f90c62-7b90-439d-813b-4e582274d1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b6f96202-76e9-431a-8ff2-01f84832884c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1f90c62-7b90-439d-813b-4e582274d1f4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b6f96202-76e9-431a-8ff2-01f84832884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ardx-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_31521c4a-cb44-46ca-b0e9-53d84c2e6435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ac90ad01-94ac-4494-8c7a-698c8edd4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_31521c4a-cb44-46ca-b0e9-53d84c2e6435" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ac90ad01-94ac-4494-8c7a-698c8edd4b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20210630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3cd9690b-0e16-43fc-84f6-9f2b6d3a9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3cd9690b-0e16-43fc-84f6-9f2b6d3a9fbf" xlink:to="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_144314af-1eee-4e62-b068-030c02da4852" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2f32f26b-40d0-47e4-86c2-334a0f2d5a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_434b4f86-0bf6-4d17-9f9a-79af9bc04ba2" xlink:to="loc_us-gaap_SubsequentEventMember_2f32f26b-40d0-47e4-86c2-334a0f2d5a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ede75f3d-1221-4a9b-882b-4a6070de1940" xlink:to="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PutativeSecuritiesClassActionLawsuitMember_587ecf92-5f4d-43b8-beb4-d95aa97dd7e5" xlink:href="ardx-20210630.xsd#ardx_PutativeSecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_780360e5-b06c-416d-8893-91a4cb5f73d7" xlink:to="loc_ardx_PutativeSecuritiesClassActionLawsuitMember_587ecf92-5f4d-43b8-beb4-d95aa97dd7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_7e34e053-430f-480c-aab6-f7c54d060f99" xlink:to="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1cd5c5b-c491-4349-8005-c927ff6c3093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_8313c596-f110-4c5a-a788-9790143e224e" xlink:to="loc_us-gaap_PendingLitigationMember_f1cd5c5b-c491-4349-8005-c927ff6c3093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_84c1ee73-57c4-4edd-af2a-3364724941cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_a3610ed3-b1df-49e5-8b46-1325bf1b5062" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce1c91d5-67ce-448b-8b60-da6716b9007e" xlink:to="loc_srt_OfficerMember_a3610ed3-b1df-49e5-8b46-1325bf1b5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_031e121c-006f-470d-8381-cf3d55d61e70" xlink:to="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_WorkforceRealignmentMember_06efbf16-77ad-4309-bf13-bbbc47431061" xlink:href="ardx-20210630.xsd#ardx_WorkforceRealignmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f82ef380-e335-4b5b-8975-1dfc3625115d" xlink:to="loc_ardx_WorkforceRealignmentMember_06efbf16-77ad-4309-bf13-bbbc47431061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis_efe45eeb-0001-419d-aefd-c75d1d2624af" xlink:to="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReducedEmployeeExpensesMember_7177eaf5-e710-4b14-82f4-aa2e704fb002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReducedEmployeeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain_9e23132c-c27f-4510-8f60-3de4531663f8" xlink:to="loc_us-gaap_ReducedEmployeeExpensesMember_7177eaf5-e710-4b14-82f4-aa2e704fb002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c8d1cba8-67ff-49d7-9b46-b5f3f5ccf912" xlink:to="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_9122070e-ac62-4856-89f3-deeb1ab9264e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_9122070e-ac62-4856-89f3-deeb1ab9264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_d90680ce-6c5c-4f94-8833-3a202d6e06e3" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce_d90680ce-6c5c-4f94-8833-3a202d6e06e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_41f10245-6444-4b1d-8141-15de8a19afdd" xlink:href="ardx-20210630.xsd#ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits_41f10245-6444-4b1d-8141-15de8a19afdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount_fa8cd9ff-e170-4f55-b2d8-4ff17553a3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_EffectOnFutureEarningsAmount_fa8cd9ff-e170-4f55-b2d8-4ff17553a3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_792f2ada-26e0-43bd-ad49-f85515c67dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_792f2ada-26e0-43bd-ad49-f85515c67dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_e7c0a193-159c-41d1-a162-09ebd3edd1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b9acfb65-afd6-42f2-858c-dfe8359686ba" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_e7c0a193-159c-41d1-a162-09ebd3edd1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ardx-20210630_g1.jpg
<TEXT>
begin 644 ardx-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3B1N/?\ 2L6\_P""N&DHY^S^"M0E7'!DU!(SG\$;\Z\JIXE\,T_BQ<?DI/\
M*+/5I^&G$U3X<)+YN*_.2/L"BOBNZ_X*[S/%^Y\ QQOGJ^M%QCZ" ?SJG<?\
M%<-6:%A#X)T^.3LSZB[*/PV#^=<<O%CA=;8AO_MRI^L4=D?"?BA[X=+_ +?I
M_I(^X**^%?\ A[7XB_Z%'1?_  )EH_X>U^(O^A1T7_P)EK'_ (BYPS_S^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC6HU*4W2JIQDG9IJS371H****T,PHHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI]Q;R6EQ)%+&\<L;%'1UVLC#@@CL1Z4ROYEVT9_35[ZH**** "BBB@ HHHH
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MX/\ >-?:DOL^D7OWEZ:E%%%?N1^&A1110 4444 %%%% !1110 4444 %%%%
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MDTULT]FC^/<1AZE"K*C6BXRBVFGNFMTPHHHK8Q"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7;?LZ_"F3XU_&CP_P"'%5VM[ZY#7;*<;+=/GE.>QV*P'N0.]<37VA_P2?\
MA3QXB\:7$7II5BQ'TDF(_P#(0R/]H5]5P3D?]KYU0P4E>+=Y?X8ZO[[6]6?*
M\;9Y_9&2U\;%VDE:/^*6B^Z]_1,^S;:WCL[>.&&-8XHE"(BC"HHX  ]!3Z**
M_N+;1'\.WOJPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H[JUCOK:2&:-)89E*.CC<KJ1@@CN"*DHH
M>NC!-K5'Y/\ [4/P;D^!'QMUK0 K"Q27[1I[$YWVTGS1\]RO*D^J&O/Z^^?^
M"H_P8_X2KX9V'C"TAW7OAN3R+HJ.7M96 R?79)MQZ"1S7P-7\2\?<._V-G57
M"P5J<O>A_AET^3O'Y']M< \1?VSDM+%3=ZD?=G_BCU^:M+YA1117QI]D%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7T1_P3Z_:A_P"%+>/_ /A'M6N-OAGQ%,JLSMA;
M&Y/RK+Z!6X5O8*?X>?G>BO6R/.<3E6.IX_"NTH._DUU3\FM'_F>3GF38?-<#
M4P&*5XS5O-/HUYIZK_(_:"BOG7_@GI^TV?C+\._^$=U>X\SQ)X;C5"SME[VV
MZ)+ZEEX1CS_"2<M7T57]P9'G.'S7 T\?A7[LU?S3ZI^:>C/X?SS)L1E6.J8#
M%+WH.WDUT:\FM4%%%%>L>2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=W_!1
M;]I3_A;7Q(_X1G2[C?X?\,RLC,C?+=W?W7?W"<HO_ R,AA7U'^W=^T9_PH7X
M0R0Z?/Y?B+Q#NM+#:?FMUQ^\G_X"" /]IU/8U^9I.37\_P#C-Q=R161866KM
M*I;MO&/S^)^7+W9_0/@SPCSR>>XJ.BO&G?OM*7R^%>?-V04445_.9_184444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 J(TKJJJ69C@ #))K]9?V:?A8OP9^
M!WAWP^4"75K:B2[P.MQ)\\GUPS$#V K\]_V&OA5_PMG]I'0;>6/S+'2'.JW?
M'&R$@J#[-(8U/LQK]0J_HSP-R/EIU\VFM_<CZ*SE][Y5\F?SGXY9YS5*&4P>
MWOR]7=1^Y<S^:"BBBOZ /Y_"BBB@ HHHH **** "BBB@ HHHH **** "BBJN
MIZW9Z+%OO+RUM$QG=-*L8_,FIE)15Y.R*C%R=HJ[+5%4]+\1:?K@_P!!OK.\
MX)_<3+)T^A-7*(SC)7B[H)1E%VDK,****HD**** "BBB@ HHHH **** "BBB
M@ HHHH SO%WA>S\;^%=2T;4(_-L=4MI+2=?5'4J<>^#P>QK\BOB/X&O/AGX]
MUCP_?+BZTB[DM7.,!]IP&'LPPP]B*_8:OA#_ (*I?"#^P?'^D^,K6+;;Z[%]
MCO& X%Q$/D8GU:/  _Z9&OQ?QIR#ZSED,SIKWJ+L_P#!+3\)6]$V?M'@MG_U
M;,YY;4?NUE=?XXZ_C&_JTCY.HHHK^6S^I HHHH **** "BBB@ HHHH ****
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MZLK ^%G@&W^%OPXT3P[:;6AT>SCMMX&/-91\SX]6;+'W-;]?W5PKDJRG*:&
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M_+T'Q,4LKO<?EAER1#+[88[2>RNQ[5^E=?V?X=\5+/,IC5J/][3]V?JMI?\
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M["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV@N;_MYZ1_5K_"?D_C%GGU+)/JD'[U=\O_;JUE^B?^(]"HHHK^M#^2PHHHH
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MO^V[>/;8>+(?M8P,*MPF$F'X_(Y]Y#7X7XW9#[;!4LUIK6F^67^&6S^4M/\
MMX_=/!'/O8XVKE51Z5%S1_Q1W2]8Z_\ ;I\ZT445_,Y_3 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /3OV._BQ_P *<_:%\/ZI))Y5A<S?
M8+XDX7R)OD+-[(Q5_P#@%?JE7XOU^K7[)OQ3/QB_9^\-ZU+()+W[,+6\.<MY
M\1\MR?=MH?Z.*_HCP-SS2OE,W_T\C^$9?^VO[S^=_'+([.AFT%_T[E^,H_\
MMR^X]&HHHK^A#^>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*_P!M/XFGX5?LW>)+Z*0QWEY!_9UJ0<,))ODR#ZJI=O\
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MBBB@ HHHH *^SO\ @DW\3\2^)O!LTGW@NKVBG\(IO_:/'L:^,:](_9'^)/\
MPJG]HGPOJSMMM3=BTNB3A1%,#$Q/LN[=]5%?6<#9Q_9F>8?%-VCS<LO\,O=?
MW7O\CY/CK)_[3R/$85*\N7FC_BC[R^^UOF?JQ1117]P'\/A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445R/Q[^('_"K/@QXF\0
M!MLNFZ?+) ?68C;$/QD91^-<^*Q,,/1GB*ND8)R?HE=G1A<-/$5H8>EK*;45
MZMV1^:W[7GQ&_P"%I?M&^*M41]]LEX;.V(.5,4($2D>S;-W_  *O-J5F+L68
MEF8Y)/>DK^!\PQM3&8JIBZOQ5).3]6[G]\9?@H8/"T\)2^&G%17HE8****XS
ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OT-_X)A_"K_A#/@7-X@GBV
M7GBJY,JDC#?9XB4C'KRWF-[AA7P-X'\)77C[QEI6AV*[KO5KN*TBXR SL%!/
ML,Y/L*_7OPAX8M?!/A33='L4\NSTJUCM(%]$10H_' K]O\$<C]OF%7,YK2DN
M6/\ BE_E&Z?^)'XAXW9Y[#+Z660>M5\TO\,=OODTU_A9HT445_3I_,04444
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MUZ+XE_X#=^J1^E>%.??V=GU.G-VA6]Q^K^%_^!67HV?GG1117\>G]A!1110
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M9:4[S?\ VZM/_)G$^9:***_C<_L@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /IK_@EW\*O^$O\ C9>>)+B/=:^%;4M&2./M$P9$^N$$I]B%K]!J
M\/\ ^">_PI_X5C^S=I<TT?EW_B1CJL^1\P5P!$,^GEJC8[%S7N%?VAX:Y'_9
MF04:<E:=3WY>LMONC9>J/XO\2L\_M//ZU2+O"G[D?2._WRN_1A1117WA\&%%
M%% !1110 4444 %%%% !1110 5Q?[17Q/7X.?!/Q'XBW!9K"T86V>\[X2(?3
M>RY]LUVE?'?_  5A^*1M-%\.>#;>3#7CMJMXHZ[%S'$/H6,A^J"OE^-,Z_LK
M)<1C4[24;1_Q2TC]S=_1'U'!>2_VKG6'P35XN5Y?X8ZR^]*WJSXD=VE=F9BS
M,<DDY)-)117\-G]R!1110 4444 %%%% !1110 4444 %%%% !1110!]P?\$H
M?BM]O\.>(/!EQ+F33Y!J=FI.3Y3X24#T"N$/UE-?8%?E/^R3\5O^%-_M ^'=
M8DD\NQ:X%G>DGY1!+\C,?]W(?ZH*_5BOZV\'\\^NY&L+-^_0?+_VZ]8O\XK_
M  G\D^,&1_4<\>*@O<KKF_[>6DE^4G_B"BBBOU8_*0HHHH **** "BBB@ HH
MHH **** "J/BCPY:>,?#6H:3?Q^;8ZI;26MPG]Z-U*L/R)J]14SA&<7":NGH
MT53J2A)3@[-:I^9^//Q&\#W?PT\>:QX?OA_I6CW<EJYQ@/M8@,/9A@CV(K%K
MZK_X*H_"7_A'OB9I7BZWBQ;^((/LUTP'2XA  )_WHRH'_7,U\J5_"O%62RRG
M-:^ >T).WG%ZQ?W-?,_NKA7.HYME5#'K><5?RDM)+[T_D%%%%?/GT 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'T%_P31\>GPC^TM;Z>\FVW\16<UDP/W=ZCS4
M/US&5'^_7Z/5^/GPO\9R?#OXCZ#KT>[=H]_#=D#^((X8K^(!'XU^P%O<)=01
MRQL'CD4,K#HP/(-?U!X'YI[7*ZV!D]:<[KTFO\XM_,_E_P <,L]EFE''16E2
M%GZP?^4HKY#Z***_;#\3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OR8_:8\;?\ "Q/C_P"+M85O,BN=3F2!O[T49\N/_P <1:_47XO>
M,?\ A7OPJ\2:YNVMI.FW%TGNZQL5'XM@?C7Y DY-?S[X[9A:&%P*ZN4W\K1C
M^<C^@O G+[SQ6/?11@OG>4ORB%%%%?SJ?T4%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=5\#OAM-\7_BWX?\-Q;L:I>)',R]4A'S2M^"!C^%<K7UY_P2
MB^%/]I>*M?\ &5Q'F+38AIMF3T,LF&D(]U0*/I*:^FX/R5YMG%# M>[*5Y?X
M5K+\$UZM'S7&&=+*<GKXY/WHQM'_ !/2/XM/T3/M^RLH=-LH;>WC6&"W18XT
M485% P /8 5+117]RI)*R/X9;;=V%%%%,04444 %%%% !1110 4444 %%%%
M!7Y4_M>?%,?&#]H7Q)JT4GF6,=Q]CLR#E?)A_=J1[,07_P"!U^B'[67Q3/P=
M_9^\2:U%)Y=[]F-K9G/S>?*?+0CW7<7^B&OREK^>O'+.M,/E,'_T\E^,8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_5+]CSX4_\ "G?V>?#NES1^7?7$'V^]!7#":;YRK>Z
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M/DFBBBOXG/[8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_ KZ=$T?V-X6Y]_:60TU-WG2]Q_+X7_ . VUZM,****_.3]&"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^W?^"1VK^=X=\<6'_/O<VEP/^!K*O_M.OL.OA;_@DIJ?
ME?$+Q=9\?Z1IT,V,?W)".O\ VTK[IK^Q_"FO[3AC#I_9YU_Y/+]&C^./%:A[
M/B?$/^;D?_DD?U3"BBBOT4_.@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^=?\ @I_?_8_V8_+X_P!*U:VBZXZ"1_Q^[7T57R[_ ,%8+S9\"-!M]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M])GDV6/BJ V+ GY1.OSPGZDAD'_72OT<K^R?"_//[2R"ESN\Z7[N7_;OP_\
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M?>^&,K<3X1^<O_2)'PO1117\8G]GA1110 4444 %%%% !1110 4444 %%%%
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M117 =X4J(TKJJJ69C@ #))I*]@_86^%7_"U_VD="AFC\RPT=SJMWE<KMA(*
M^S2&-3GL3UZ5Z&59?4Q^,I8*C\522BOF[7^6[//S7,*> P=7&UOAIQ<G\E>W
MJ]D?H1^S=\+E^#7P/\.>'BFRXL[17N^G-Q)^\EY[X=F ]@*[BBBO[SP>%IX7
M#PPU%6C!**]$K(_@S&8NIBL1/$UG>4VY/U;NPHHHKI.8**** "BBB@ HHHH
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M6O\ P&BH_P"'2GAW_H;M:_\  :*C_B$?$W_/E?\ @<?\P_XBYPS_ ,_G_P"
M2_R/A6BONR'_ ()+>&EE7S/%FN-'GD+!$I/X\_RJW_PZ;\&?]#)XG_.#_P"-
MU4?"'B5[THK_ +?C_F3+Q>X:6U63_P"W)?Y'P117WO\ \.F_!G_0R>)_S@_^
M-UY5^V'^PMX=_9S^$T?B#2]8UJ^N7OXK0QW1B\O:ZN2?E4'/RCO7'F7A?GV
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M_GZT7_P7K_C1_P /,_BE_P _6B_^"]?\:^?:*/\ 7CB#_H,J?^!,/]1^'_\
MH#I_^ H^@O\ AYG\4O\ GZT7_P %Z_XT?\/,_BE_S]:+_P""]?\ &OGVBC_7
MCB#_ *#*G_@3#_4?A_\ Z Z?_@*/H+_AYG\4O^?K1?\ P7K_ (UX%?7LVI7L
MUQ<2--/<.TDDC'+.Q.23[DFHJ*\O,\^S',5%8ZM*IRWMS-NU][7[V1ZF69#E
MV7.3P-&-/FM?E25[;7MVNPHHHKR3U@HHHH _1[_@GK^SQ9_"CX/6?B"ZMT;Q
M#XH@6ZEF9<M!;-\T42GL"NUV]6.#G:,?059_A&VCLO"FEPQ+MCAM(D1?0!
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MK_Z$:^@J^??^"F?_ ":W=?\ 81M?_0C7RO''_)/XS_KW+\CZK@?_ )*#!_\
M7R'YH_.&BBBOX=/[B"BBB@ HHHH **** "BBB@ HHHH ^R_^"3_Q7\J[\1>"
M[B3B4#5K)2>XVQS ?4>4<?[+'UK[5K\E/V=?BBWP9^-?AWQ%N9;>QNU%T!D[
MK=_DE&.YV,V/<"OUIAF6XB62-EDCD 964Y# ]"#7]7^#>>?7,F>"F_>H.W_;
MLM8_CS+T2/Y1\9<C^IYRL;!>[75_^WHV4OPY7ZMCJ***_73\A"BBB@ HHHH
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M .@M7M<-_P#(VPO_ %\A_P"E(\;B+_D4XK_KW/\ ])9^J5%%%?WD?P8%%%%
M!1110 4444 %%%% !1110 5\*_\ !6O_ )*)X1_[!TO_ *-K[JKX5_X*U_\
M)1/"/_8.E_\ 1M?FGBY_R3-;UA_Z6C],\(_^2FH^D_\ TEGR31117\?']@!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?L-
M\-_^2=Z#_P!@ZW_]%+6U6+\-_P#DG>@_]@ZW_P#12UM5_H)@_P"!#T7Y'^?>
M+_CS]7^84445T'.%%%% !1110 4444 %%%% !7S[_P %,_\ DUNZ_P"PC:_^
MA&OH*OGG_@IU=+;_ +,$B-NW3ZI;(N/7YV_DIKY7CIVX?QE_^?<OR/JN!DWQ
M!@[?\_(_F?G+1117\.G]Q!1110 4444 %%%% !1110 4444 %?IU^P5\5?\
MA:G[-FBM-)YE]H0.D7.>N8@/+/J<Q&,D]SFOS%KZB_X)9_%;_A&/B]J/A>XD
MVVOB:U\R!3_S\0 L/IF,R9]=JU^F^$V>?V?GT*4W[E9<C]7K'_R96^;/S/Q9
MR/\ M#(9U8+WZ+YUZ+27_DK;^2/OZBBBOZ_/X_"BBB@ HHHH **** "BBB@
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M$N;]3^'N.L5[?B#&5/\ IY)?^ OE_0****^K/E HHHH **** "BBB@ HHHH
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M,8_[C_'0^P\/X\W$6#7]]'Y]T445_$9_;@4444 %%%% !1110 4444 %%%%
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MGM4BF_)[-?)W7R"BBBO'/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBKWA?0Y/%'B;3M-BXDU&ZBM4^KN%'\ZJ
M$)3DH1W>A,YJ$7.6RU/U?_9T\._\(I\!/!NG[=KV^C6OF#_;,2L__CQ-=G3+
M:W2SMXX8U"1Q*$11_"!P!3Z_T!P>'6'P\*$=HQ2^Y6/\_<9B'B,1.O+>3;^]
MW"BBBNDYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B_\ X*W^
M%CM\%ZVB\?Z38S-_W[>,?^C*^+Z_1W_@IGX1/B3]F"YO%7<V@ZA;WN1U"DF
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MKQ.=82CWJ0OZ<R;_  N?/\68I8;)<77[4YV]>5I?C8_2&BBBO[L/X3"BBB@
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MX@<;UW/$Q]ROF#)[(HK[:K@?VG?A0OQJ^!GB'0%C$EY/;&:R]1<1_/'@]LL
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MYX^DM;?*5U\C^U/#G/?[5R&C6D[S@N27K'2_SC9_,****^&/N HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+P;X9G\:^+]
M*T>U_P"/C5KR*SBX_BD<(/U-?L-I6F0Z+I=M9VZ^7;VD2PQ+_=50 !^0K\V?
M^"=G@/\ X3?]J'1YGC\RWT&&74Y>. 579&?PD=#^%?I=7]->!N6>SR_$8^2U
MJ245Z05_SD_N/YE\<LS]IF&'P$7I3BY/UF[?E%/YA1117[D?AH4444 %%%%
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MD,WS-8?#2O2HW2:V<G\37=:)+TNM&%%%%?J1^6A1110 4444 %%%% !1110
M4444 !.!7X[_ !"\1?\ "7^/]<U;.[^U-0N+O///F2,_?GOWK]7?CKXJ_P"$
M'^"_BO5MRJ]AI-S+'DXS((VV#\6P/QK\BJ_G;QVQEYX3"+HIR?SY4OR9_17@
M3@[0Q>+?5PBOES-_F@HHHK^?#^@@HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ A1\RT445_,)_3P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #/Z]\(\X^N\/PHR?O46X/TWC^#M\@HHHK\P/T\**** "BBB@ HHHH ****
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MX)KU/F>,LX_LO)<1C4[2C%J/^*7NQ_%I^A]T ;1@4445_<Q_#(4444 %%%%
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MW(6BBBOZ,/YS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]0E?_MV5D_QY7Z)GV%1117]6'\IA1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!F98"K@<74P=;XJ<G%^J=O\ A@HHHKN.$**** "BBB@ HHHH **** "BBB@
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M445XY[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+[D[KS2/R/HJ2ZM9+&ZDAF1HYH6*.C#!5@<$'Z&HZ_AMW6C/[D3NKH****
M"BBB@ HHHH **** "BBB@ HHHH *]!_9@^"4_P ?OC+I6@JK_8=_VG49%X\F
MV0@N<]BV0@/]YQ7GU?HG_P $W/@(WPO^$+>(K^'9J_BP)<+N'S0V@&8E]MV2
MY]0R^E?;>'_#+SO.(4)K]U'WI_X5T_[>=EZ-OH?$^('$RR3)YUX/][+W8?XG
MU_[=5WZI+J?1-G9Q:=9PV]O&D,$""..-!A44#  'H!4E%%?VLDDK(_BEMMW8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\8_\%2/V?=RV?Q$TVW^[LLM8V#MTAF/_HLGWC'K
M7V=6;XQ\)6/CWPKJ&BZI"+C3]4@>WGC/=6&#CT(Z@]B :^;XMX=IYWE=3 3W
M:O%]I+9_H_)M'TG"7$57),TIX^GLG:2[Q>Z_5>:3/QQHKK/C=\)=0^!_Q.U7
MPWJ 9I+"4^3+C"W,)YCD'^\N#CL<CJ*Y.OX>Q6&JX>M+#UERRBVFGT:T:/[A
MPN)I8BC'$4'S0DDTUU3U3"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "O0O@7^T_XP_9ZU'S- U$FQD??/IUR#):3GW7(*M_M(5;@<XXKSVBNK
M X[$8.LL1A9N$X[-.S_K\SEQV!P^,HO#XJ"G"6Z:NOZ_(_2+X"?\%#O!7Q>2
M&SU:9?"FN287R+V0?9IF_P"F<W"\^C[3DX&>M>^JP=0RD,K#(([U^,%>H_!3
M]L3QY\"?)M]*U9KS2HN!IM^#/; >BC(9/^ ,M?NG#/C94@E1SNGS+^>"2?\
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M@?C5I^FS1L=%T\B]U1\<>2I'[OZNV%]0"3VK]2H($M8$CC18XXU"HBC"J!P
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M_A?G;JS^CO!GB[GIO(L3+6-Y4[]5O*/R^)>5^B1XO1117X"?OP4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5J>$O&VL> M56^T/5-0TF\
M7CSK2=H7(]"5(R/8\&LNBM*=2=.2G3;36S6C7S(J4X5(N%1)I[IZI_(^C/AO
M_P %.?B%X/$<.L+IOB>V7 )N8?(N,>@>/ _%E8U[Q\/_ /@J;X%\1>7'KVGZ
MQX<F;[S[!>6Z_P# DPY_[]U^?=%?>93XH<18"T57]I%=)KF_'XO_ "8^"S;P
MOX=Q]Y.A[.3ZTWR_A\/_ )*?K7X*_:-\!_$0*-'\6:'>22?=A-TL<Q_[9OA_
MTKM:_%^NC\(_&#Q7X!VC1/$FN:4J\;+6^DC0CT*@X(]B*_0\O\=IK3'85/SA
M*W_DK3_]*/SS,/ F+UP.*?I.-_\ R9-?^DGZ^T5^9GAC_@H;\5_#>Q6\11:E
M"G2.]LH9,_5E4.?^^J[WP_\ \%8O&%H%&I^'/#E\JX!-OYUNS=.N7<9Z]!CG
MI7V&#\9N'JO\7GI^L;_^DN1\?B_!CB&E_"Y*GI*W_I2B?>U%?'.C?\%<K*50
M-0\#W4+ <M;ZFLN3]&C7'TR?QKI],_X*N> ;@A;K1?%ELQ.,K!!(H'J3YH/Y
M U[]#Q*X9J_#BXKU4H_G%'@5_#7B:E\6$D_1QE^4F?3]%?/5G_P4Y^%]RBEY
MM>MR3C$EADCW^5C6BG_!1WX2NZJ=>O%!."QTRXP/R2O2AQMP_+58RE\YQ7YL
M\V?!/$$='@ZORA)_DCW2BO%_^'A7P?\ ^AN_\I5[_P#&:/\ AX5\'_\ H;O_
M "E7O_QFMO\ 6[(O^@VC_P"#(?\ R1C_ *HY[_T!5O\ P7/_ .1/:**\7_X>
M%?!__H;O_*5>_P#QFH;O_@HG\(K95*>)YKC)Y$>EW8Q_WU&*'QAD25_KM+_P
M9#_,%P?GS=OJ57_P7/\ R/;J*\%N_P#@I1\*;95*:KJ5QD\B/3I1C_OH"LC4
M?^"I?PULMWEVOBF\P<#R;*(9]_GE6N:IQUP]#?&4_E)/\KG33X%XAG\.#J?.
M+7YV/I&BODW5O^"M'A>$-]A\*Z]<GG'GS10Y]/NEZY77/^"N.H3!AIO@FSM^
MRM<ZDTWKR0L:>W&?7FO*Q'BEPQ1WQ*;\HS?Y1M^)ZN'\+>)ZNV&:7G*"_.5_
MP/MRBOSK\1_\%0OB9K.X6B^'M(4_=-M9&1@/K*[@G\/PKSSQ5^V!\3O&087O
MC77%5LAEM)A9J0>H(A"#'M7S>,\;<DIZ4*=2;]$E][=_P/I,'X)9W4UKU*<%
MZMO[DK?B?J/XB\5Z7X0LOM.K:EI^EV_/[V[N$A3CKRQ KR?QW_P4 ^%O@7>G
M_"0?VQ<)_P LM+A:XW?1^(__ !^OS/U+5+K6;MKB\N+BZG?[TDTAD=OJ3S5>
MOB\R\<\?4NL#AXP\Y-R?X<J_,^TRWP,P%.SQV(E/RBE%?CS/\C[*^(G_  5H
MN)1)%X3\*Q0\_+<ZK,7)'_7*/&#_ -M#7S[\3_VM_B%\7?,CU?Q-?+9R9!L[
M1OLMOM/\)6/&X?[^XUYO17YOG''.>YFG'%XF7*_LKW8_-1LG\[GZ1D_ V198
MU+"8>/,OM/WI?)RNU\K!1117R9]8%%%% !1110 4444 %%%% !1110 4444
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M ?CFJO\ PLCP[_T'M%_\#HO_ (JOQYHJ9>/%;I@U_P"!O_Y J/@/1^UC'_X
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M/!G_ $-WAC_P:0?_ !5?D-12_P"([8O_ *!(_P#@3_R'_P 0)PG_ $%R_P#
M5_F?K1XP^(G@+QOX3U/1K[Q9X9>SU:UDM)P-4@SL=2IQ\W7!K\I/$FBMX;\1
M:AIS36]RVGW,EL9H'#Q2E&*[E8<%3C((Z@U2HKX'C;CB7$;I2JT%3E3OJFW=
M.VCNELUIZL^]X)X'CPXJL:5=U(U+.S25FKZJS>]]?1!1117P9]X%%%% !111
M0 4444 %%%% !7T7_P $Z?V<O^%M_%'_ (2/4H-V@^%I%EPP^6ZN^L<?N%^^
MWT4'AJ\(\$>#-0^(GB[3]#TF!KG4=4G6"",=V/<GLH&23V )K]7O@7\(-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>NWEJ_GGCOPC=Y8_(8^<J7ZP_P#D?_ >D3^AN!/%Q/EP&?2\HU?TG_\ )?\
M@75GP+15[Q+X9U#P;KMSIFJV=QI^H6;^7-;SH4DC/N#^>>A'-4:_GV<)0DX3
M5FM&GNF?T%"I&<5.#NGJFMF@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVV[MA11174<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"KK.B6?B+39+/4+.UOK.8;9(+B)98Y!Z%6!!_&OG_XM_\
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M5I'_ ,!5E\VK^84445](?-A1110 4444 %%%% !1110 4444 %%%% !1110
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MKK:\O_ I7E^)^<YMQ?G.976-Q,I)]+VC_P" QM'\ HHHKZ0^;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *J:OH-CX@M_)O[*TOHO[EQ"LB_DP/I5NBIE&,ERR5T5&4HOFB[,\_P#$
M'[*7PU\3;C=>"/#>Y_O-!9);L>O.8PISSUZ]/05Q>N?\$X_A/K#,T6AWFG,W
M)-MJ,_7GH'9@.O0#' KW2BO$Q7"^3XC^/A:<O-PC?[[7/;PO%&<8?2ABJD5V
M4Y6^Z]CY>UC_ ()1^!+K<UEKGBFS9LX#RP3(OIQY8/ZUS.J?\$C+.0G[%XZN
M8>>!/I2R?AD2K^>/PK['HKPJ_AGPS5^+"1^3E'\I(]VAXE\34OAQ<OFHR_.+
M/A?4?^"2?B"+=]D\8:/-QQYUI)%D_@6_.L:]_P""47Q B9O(UOPC,H&1NN+A
M&)],>21^M?H#17E5/!_AJ7PTY1])R_5L]6GXO\2Q^*I&7K"/Z)'YTW?_  2_
M^)UM&&3_ (1VX.<;8[]@1[_,@%4[K_@FE\5+>+<NGZ3,V?NIJ,8/_CV!^M?I
M%17%+P6X?>SJ+_MY?K%G;'QIX@6ZIO\ [=?Z21^:G_#N#XL_] *R_P#!E;__
M !='_#N#XL_] *R_\&5O_P#%U^E=%9_\02R#_GY5_P# H_\ R!I_Q&W/_P"2
ME_X#+_Y,_-FT_P"";'Q6N9"KZ3IMN,9W2:E$0?;Y235RU_X)B_%"XEVM%H,*
M_P!Y[_(_\=4G]*_1JBKCX*\/K>51_P#;R_2*(EXU<0/:--?]NO\ 63/SUM/^
M"5?Q'N4)?4O"-N0<8DO)R3_WS":VK+_@DQXJ<M]H\4^'XNF/+CFDSZ]56OO"
MBNNGX.\-Q^*$I>LW^ECDJ>,/$DOAG&/I!?K<^+=,_P""13%MUYX\4#)RD.D9
MR,<?,9N.?8UTFD?\$F?"<.W^T/%'B*YX&?LZ0P9XY^\K]Z^KJ*]2CX7\,4M8
MX5/UE-_G)H\NMXH<3U=)8IKTC!?E%'SYHG_!,KX6Z4%^T6NMZEC_ )^=0*YZ
M?\\PGI^I]J[+0/V*_A7X;*_9_!6D2;>GVK?=?GYK-G\:]1HKW,-PCD>'UHX2
MFGWY(M_>U<\/$\79YB-*N+J-=N>27W)V,;P[\.?#WA +_9.@Z-I>WI]DLHX,
M?]\J/0?E6S117O4J-.G'EIQ279*QX-2M4J2YJC;?=NX4445H9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ardx-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ardx="http://www.ardelyx.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ardx-20210630.xsd" xlink:type="simple"/>
    <context id="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib8ff198d368245179917bda45ce11447_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:OtherAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic2a86335175446c3b31159227a07237e_I20210810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="i7ce11e50673c4ce593372c02d75ba21d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i62f4c36f4b554b9b8908a7e166a96117_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5169c85622a346fb9062ffb6b012fd12_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic844400b43a7400da61df183e26a583f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9b324fd57d14e27bcd90f57c095fb22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44aa89a05a754d1b891d684b45030896_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70adb02e2ed84dbfbb84ecc59e237f22_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46815f43fb5147de827a675a8e9bff26_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie3f93c6e57284dcdb9ba529c830b9ddc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74d70bc74d694a89afe4beef05f285a0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifefc52610f304fc29c70ee02bfdad54f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f6dc4b98bc94f80aee011fe441527d8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i63cbe2d3588447c6a15715bc02d7d4c5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i305ca64104904718823ba7cb678ddb2d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia91cafc3f3d549f29a542a11fe2aef57_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icfe4795385734cbb8a81bf1b0bcd78a5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i65a85d71d0204688a7b741f604983349_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7e91b1a5dd24c928910e0eb927abf63_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i996b9b49c28f44a59ede689736e3c19b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80b5a2b6ba734b409098fe1a0d30c5e2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6bd017782e8d453ca3fbb2a862a9ba90_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a5b6508dc384cedb263a3547a372fce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i83ff1f828c934f0f88513250a9fcec8e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if0080ccb444c45f6820630de940835f5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i18cceea8b49b4f9996c4425728df8ddb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3e3cd82573141db8cb46c3d4aff5c1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia40995d012e245ab8f368eab46de01fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9599acbfae04ff2926fa311f5b1fa11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefa2601d5c60400197dae7d0b451836e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4740541ee7924fea863cb9f577326fd3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia909a04442314115a14cb637f127f9a0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iab525b262fba48b39730d896423dd7fe_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2175ce28f9d54b8083c2d9170d124b24_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i521561e365cb4f9aa0c62af71fc32133_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if512d3ccb798492096508a8d2449275e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i055e0b998d064537b3d88828cb52ae44_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1f1fb8a7c88e498f92aa1aae68c2fea8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia3c73b1263494577a798b153956f45fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5481c5ac22b441f1a636dc6115281e1d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37628ae924f0472da65e1caaf4ca8ce8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie74c05e19ce74538b7ea429c28d19a88_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic53ee417fef84d79a20f0137c9009129_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdb8a5ab08814d09a475fc45cb62c355_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf0bc9463f684e9b8d4d88cb346673ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe50953188ac47108208481d704ce612_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd41c948817d46d799997c58b6d1030b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib52df4b25bae450697308ad35e1759ba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i783b4aad17a142a08d4f48f537af01a4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5b98058de4da42c294fa91c66eeb6e89_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i35ad3f3857994eafbf8092a727a20054_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibccabbde714945ec89a64f78f0954426_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2ad7361da3114524894d528d36761938_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7acd89d799254005a61260d4785cc411_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3cd17446ca75477084ef05a6506f3a4d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if07744061b93432eb1154ad3a3a36816_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2251a0841514418a8a29bca5526a858_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b26e91f4014480084d27170ccd8c8fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91b9eea8333f47a1b077cabf000e2716_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66a0e0f970d3480faac49ec39d277a5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80c54e2862a942258157af583a390e08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied42e28071324f2ebd2db962a44477e1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6f276be494047f297ca9e5088e20b96_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3e74d17c420a47afaac9eca94b5c23eb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3063806f84794b4ca0e47322baed68bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0cf01a41f9d048ed926937a9e81f57f5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5acef194906f40c4b0bc625b1fe030d8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia89a5f8f089048d695069dfd0f3ddb1e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia16d7277926b4ae1a8bf1f8ccc7f5fdd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1e6b406bbf6f45849047db8c4c1bd725_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia7317f8962714c4b83d096692d77f4c5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9635984f4f30476f8f150e932200d84f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7de92fed80134bcdb3a7fc397526ea81_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6a1f62f1e1524a1bb1796ea45572aa13_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i64a8a52b89c442b0802c08887c2a4136_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id37c22c74c3a41568c43be19dee6db9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie4d0ce291981454e84664b7d247bbd2e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i331cc003c0d04f078a6a32154ebd1c19_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8b5fb96fe51e419887a5821e069bbb56_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61c3ad7f462746299218071393ac1e76_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaec0006dbb884a2688382b808984430a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie3f9b87841b6410e833b3c2aec531508_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i77e6a25c0cce4489942fd3fe7e7c649b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia9e9e314500242078338cfabc68e7044_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iad2604c61a3d4a84a43dc5a5223d046b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibf133615c36b4ab3a3e102804e0b1395_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55f163fd764f4b419a6b868c74be4819_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic67057377152479a8f17df5a513c8a7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i343e1acc71bd421f93de6475da3bff62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3066659e3a14837b312644f5691a4bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f1a8fad572045d6bef48f3a3f6b19e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib83afd2bc4c346a6981483552dc69b41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a252b2bdcfa4716b77eb9c9da774c15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i359ed40755d742d598b2a7d817c16d1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99fa54e72d4843718c001d9ccb44924b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i777ba44fc4ef4475b9a38bc841b0576d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i718d02cc72e24371be1e76266dcf5064_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib84bae8c4960433d93fdb8f2d7158729_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85a26be08aec4aeea36c9609cfd1b404_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8614004f13e5407d91653ae48dae6571_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d8f87376786455daba169deb2cd6918_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id472a845edd54c8788fc87a0d47191f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c27facfc44a42718fa0b68303467103_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie506d6ee79ea43278c382f43160888b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6c71f6dc2c144e6bde1f09a7d4d318c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaafed114ecbb40428246f042c26c16d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0667655fab5c49cc8a9064756e708041_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75ed11eb6d6e4fd99e38e05050686318_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffd4156d88704e5dbe480f29b020b4b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ed64ecd7425451a846dd9c27093960b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2769548737144611a050277733a53d55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb0206150a344137a26fa4bb438d55b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i428867f600214f18bfdfb49712d4abf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9f52e3ac5894f0d82d3246f26b4426f_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="if971ec15d09646659e6f792d4e0c33c1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc9980b470ca44ceb2a1da9962e99de8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6882c8ec77184cfc83073e6f4ae139de_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i891ee02e0c064d5fac9eef456b775d16_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8f8816a7551b42f7b0f4ee113d914fe6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if032ba3b809943c691949710d1c0d6e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i69ac419220864a3e96c1c6f85f0e3d6c_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="ifd7ffc17c4ea41b8942ca8c90aef5985_D20171101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1534860e131847dd8b0713fab040d16d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ca092a95ab44a3fbec59b1d0b8dead2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i283b29715ca94bd7bff20ea912e2dc44_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2ed442c04974d718d23c4fab2737e51_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc13520e38174911bb24b8da85289f37_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2816086d585e4b8ab2a5d4fcf91cc35b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78360eebb07744fe9d6aa96a4bb1ccec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33e4b72e7e4047f7963dc1ef571b8610_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9445347caff444659496b5c488ed0fa2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:OtherProductOrServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i98776866f5974807b9f5978a8f14c768_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:OtherProductOrServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7f5d2add0495488f81876f95890d813f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if14136718f7645a09e5144e34b83338e_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i988b12581c6e42f6b02b04fe7c54a484_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5c99d81bd754260871242f4e771916c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="idcc25084bb364545944e03f1663c5e5e_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a52e2793ccc45d7acd1aa68fc3d6d54_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0bf132b0a9774bdc872ca3d86d11edd7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2fc36ba0cdfe49288d9249c20ff9f953_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c458d292e4c40c6a13a0002a7985e5c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8e8922e9c354c27894a0e726cd808d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie588300a61314fd1a511fc90bc57b89c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94f983056a234617bb02529bdab92604_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c3eac47e3784f54a4d7c86adfabdc2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i822c7141162e4b328f9131de3d247ea5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3fc7bd2e9a8044539a1c899e40063725_I20180516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-16</instant>
        </period>
    </context>
    <context id="ibcaf515abe2840c282d0b24ba36d7735_D20201009-20201009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-09</startDate>
            <endDate>2020-10-09</endDate>
        </period>
    </context>
    <context id="i090b2bbf6d4a488396b2cfe21eb06705_I20201009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-09</instant>
        </period>
    </context>
    <context id="i7210d52700b243169235360a519811d9_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i23709eda801d451e8c51e46f71e084aa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iabae158ea16a4d0db01673f4d02bd862_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iac7f10228e774928bcb37829f399cf64_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic930520ff3b24850b76418b4769ee010_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iabd06b4585e1420e94a3a1bc12e8bde5_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0977925bb314a0d989a37372b6e92e9_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ia4b9f41836824ed3b567440b012e50ee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7a442e4da84048eda09938d7030e2b4c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OtherContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63131bdabbd8434aaf8c26325f068bd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae411fbdd0534f02bc4fdf3a5d2ca8a5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i013c596cde5f4e4195fb7311188973d7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id7c87d785bda4e47beed917e20627d9a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3f3cfb47f314559af19e068ea3c36e7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib702c69d1490476d80c3cd108100c164_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9190bfc1045649fbbed0e5bf15c56905_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c2e99912d72427fa13d8d0bf46271f8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityWalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie2170430801c4c239779ff73419a0839_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityWalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3dc7ec6f5ed4386a5ff6d842b738934_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i5a4fc789a9b84f18b38090c85e7db5bc_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i785930e859ee4be7bb7b7fb96ea4cb11_D20201113-20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2021-02-19</endDate>
        </period>
    </context>
    <context id="ifdc1fab5cf114d6a87de78c84c48449b_D20210511-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i3e4e511a9eaa4a259b6f2af0a9346f02_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90d3b6aaec8145c3b159056fc132c464_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3795671d1695460f9521163c5473a1b8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9edc45d4a609489c93f139ccdfc04755_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie94913409dc945679a54fb334278a1a4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id449269d05cb4a7bb376cb25ae99695c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iee13a843486b4b1dba0ef49f9b47772a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd939d4bd73a4f909c2aade26597c328_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iedd803553a9b495da7e99b9a2beac824_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia11f4aa0f44f40bd8da00137040b43e3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e8bc56233124f56814734f35647572c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if7650d015d8f4d54b605259abc29e66e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie6de6db9967249b18554b23602a09e1a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic6421afe2e3a4ee69726ba784046ad51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57135135174447be98ce98bf5cae8472_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7334dc0c28ed479ea8dd4c7d8a181fcd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4477929b6b09482994b251a77283960d_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ie5f1bc8e4fe941348afc91140237ac09_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ie2465ac8d53a4afba2b987515d381da9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="i131c578fa03b4050ae8b161b42ffff16_D20210802-20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis">us-gaap:ReducedEmployeeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="i12c10d6ea1834cf0a59df57076605afc_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ardx:WorkforceRealignmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="icfc6f67e8c63440689c94f063c69ad9f_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:PutativeSecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ardx:segment</measure>
    </unit>
    <unit id="investment">
        <measure>ardx:investment</measure>
    </unit>
    <unit id="item">
        <measure>ardx:item</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal_option">
        <measure>ardx:renewal_option</measure>
    </unit>
    <unit id="position">
        <measure>ardx:position</measure>
    </unit>
    <unit id="defendant">
        <measure>ardx:defendant</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18wLTEtMS0xLTA_7d35fc13-65ba-440a-8b6b-270bbc0a4877">0001437402</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18xLTEtMS0xLTA_da76370e-e275-4f8f-b649-493cadc2f76e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18yLTEtMS0xLTA_82a67bf6-450a-42ac-b7a7-a4b4d094671e">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM18zLTEtMS0xLTA_4c5270d4-2ba4-4e4d-9f46-510a96d0b603">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80L2ZyYWc6ZDUzMTNjZTc3Yzg2NGY0Zjk4MzBjODI3ZTJmYjVlMDMvdGFibGU6ZDY5Mjk5YjU5ZjIxNGM2NmIyZjA5YTkyMjBmYWM3YzMvdGFibGVyYW5nZTpkNjkyOTliNTlmMjE0YzY2YjJmMDlhOTIyMGZhYzdjM180LTEtMS0xLTA_df3685f3-f59f-4152-904e-6c964ad6e6de">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg1_398bc0a4-7173-484f-a113-c2a5f5003da9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6OWZkYjQ1NjA4NjQyNGQ0ZWJlOGE5NzJjM2Y4MmYxMGYvdGFibGVyYW5nZTo5ZmRiNDU2MDg2NDI0ZDRlYmU4YTk3MmMzZjgyZjEwZl8wLTAtMS0xLTA_de4d30b3-1489-4cb4-9103-dcd96c606537">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8xMzg_b5efa580-5613-4c4f-89cb-20975e5ccdb7">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NDc1ZDJiNzM4YTUxNDBkN2E2MTAxM2Y5NWM3OGI4ZGQvdGFibGVyYW5nZTo0NzVkMmI3MzhhNTE0MGQ3YTYxMDEzZjk1Yzc4YjhkZF8wLTAtMS0xLTA_05600940-1ab1-4b85-989e-d23bc859c252">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY4_7179742b-9114-46e7-a7e7-50df64f6114b">001-36485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYy_73ff9288-2ed8-4c07-b16a-90ebc90c0a1f">ARDELYX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MmE0NGJkZmZmYmVlNGZkNjljYmVmNTA5MDYxZDBkZjMvdGFibGVyYW5nZToyYTQ0YmRmZmZiZWU0ZmQ2OWNiZWY1MDkwNjFkMGRmM18wLTAtMS0xLTA_8927e623-0d89-492a-adc8-7eb40e767868">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MmE0NGJkZmZmYmVlNGZkNjljYmVmNTA5MDYxZDBkZjMvdGFibGVyYW5nZToyYTQ0YmRmZmZiZWU0ZmQ2OWNiZWY1MDkwNjFkMGRmM18wLTEtMS0xLTA_a631d98d-ea5b-44bc-9102-ab860d702533">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc2_96a696f2-227a-488d-be85-edcb912e756b">34175 Ardenwood Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY5_9f304a78-d91c-4a40-914f-7dc6492eb3bb">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc0_04943293-6fe1-42f4-a2cc-fa8dbe3bc5f6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYz_39868989-8731-4547-ac3a-26ee68c2007e">94555</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressAddressLine1
      contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg2_10e4d35e-c52d-4bf0-8770-9e7b1ace80c1">400 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc4_97aa1d6e-e314-4de6-82b0-4df2e49d09e8">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY1_03f09e46-4760-47c8-b408-d356df72ff93">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTc5_3a5ca8c9-a762-4820-af9a-730f387d2063">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib8ff198d368245179917bda45ce11447_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTgz_d666f259-f000-4f9c-a8f9-1c3871f553b5">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY2_31e16897-0c96-4fcd-8f4c-839a79ec55a6">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTg0_c2ba2d7f-f149-43fc-a0df-5d1b0d18946c">745-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTAtMS0xLTA_be8f25a3-c2d2-48ca-b9b7-f65ebbf09419">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTItMS0xLTA_f89aa78c-86c1-47d9-99ed-6e273fb0d7d2">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6MGVhNTdmYjNlN2Y4NDFlMjkwMDcxY2JhZDdhZDgxNTQvdGFibGVyYW5nZTowZWE1N2ZiM2U3Zjg0MWUyOTAwNzFjYmFkN2FkODE1NF8xLTQtMS0xLTA_98afac7f-e0e6-4aa8-99d2-531a3325152b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTY3_964bd75b-3b63-48ed-a101-7ead07354627">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTgw_2aa30d2e-9f9b-4db8-9410-b84de551f263">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF8yLTEtMS0xLTA_a6a696a2-a9da-45f0-837f-741dd8fa5f02">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF8yLTUtMS0xLTA_b338a941-ec9b-4825-84d4-043075a2a358">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGFibGU6NjNkNzZjYWYwMDgxNDk1NmEyNWVhMzc3Y2EyMDEyNTgvdGFibGVyYW5nZTo2M2Q3NmNhZjAwODE0OTU2YTI1ZWEzNzdjYTIwMTI1OF80LTUtMS0xLTA_05617856-13e7-4582-af02-3591a0a7ac69">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTYw_18c4f7f3-12e8-4e57-a235-f6008ba7067a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic2a86335175446c3b31159227a07237e_I20210810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xL2ZyYWc6ZWVlZjQzOTA5ZGIzNDMzMDkxOTJmMjgyOWVlMjQzNDkvdGV4dHJlZ2lvbjplZWVmNDM5MDlkYjM0MzMwOTE5MmYyODI5ZWUyNDM0OV8yMTU0_8e25e63d-2013-434b-b7c8-d12fb033fa5f"
      unitRef="shares">103119010</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMy0xLTEtMS0w_de70d7e0-a598-4e36-a39e-e529400b7c0c"
      unitRef="usd">86745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMy0zLTEtMS0w_06292eaa-95d7-4802-9f69-73ca19304d34"
      unitRef="usd">91032000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNC0xLTEtMS0w_5d14d30d-cfb7-4b79-b5b1-5756cfb68824"
      unitRef="usd">85064000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNC0zLTEtMS0w_b3329f02-e5d8-4a25-8100-4a64a4ee8b70"
      unitRef="usd">95452000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNi0xLTEtMS0w_c23c05fc-ce4a-4e99-b884-216901031929"
      unitRef="usd">14683000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNi0zLTEtMS0w_087b2038-0c42-4f3d-a5ec-ee22c8bd5729"
      unitRef="usd">8202000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNy0xLTEtMS0w_e1f45e4c-9158-4d50-ab11-a40fe73ecfab"
      unitRef="usd">186492000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfNy0zLTEtMS0w_48aaf61c-f8df-4337-aa19-175b0be383c9"
      unitRef="usd">194686000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOC0xLTEtMS0w_29d363a3-6c16-4f7b-bdb3-f98f026faa44"
      unitRef="usd">2666000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOC0zLTEtMS0w_085a3337-cf67-4377-9eab-cbe9637676eb"
      unitRef="usd">1936000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOS0xLTEtMS0w_9dbbb4c0-cf02-4ffd-acad-5757442c6e90"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfOS0zLTEtMS0w_e94670c8-7c5f-4f46-ad56-1dc3bfd06cfe"
      unitRef="usd">2114000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTAtMS0xLTEtMA_38d64189-0a38-4461-9453-ef70b147a15c"
      unitRef="usd">14519000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTAtMy0xLTEtMA_93732216-2263-411c-8296-86e9eacdf612"
      unitRef="usd">2274000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTEtMS0xLTEtMA_e40c4648-98d4-4c31-864e-491936b9972e"
      unitRef="usd">1305000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTEtMy0xLTEtMA_f7d4cbd3-6047-4fbd-859d-20939ca2e801"
      unitRef="usd">552000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTItMS0xLTEtMA_509fd983-8044-4b11-aeec-e828fedb9a7e"
      unitRef="usd">204982000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTItMy0xLTEtMA_fc5fca9b-50aa-446a-ac4a-caf2fc6fe9f9"
      unitRef="usd">201562000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTUtMS0xLTEtMA_34efdf2c-3424-4bfd-bd8f-9fe26e6bec1f"
      unitRef="usd">2587000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTUtMy0xLTEtMA_e5e45c04-5ce6-412a-a070-c2cc846f4f02"
      unitRef="usd">5626000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTYtMS0xLTEtMA_f8ef0c18-0d77-4104-88a1-694fe850c3ba"
      unitRef="usd">5939000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTYtMy0xLTEtMA_4a85110d-7dc8-4025-b2d8-2c4d6be0a0f2"
      unitRef="usd">5672000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTctMS0xLTEtMA_807d19d4-b405-4ab9-af68-8dc317b8f820"
      unitRef="usd">3184000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTctMy0xLTEtMA_0bad859b-0375-4e8e-b1ee-42a566fd53b9"
      unitRef="usd">2117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTgtMS0xLTEtMA_4a7b7805-ca46-440a-9f60-3d1bef7e591b"
      unitRef="usd">36111000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTgtMy0xLTEtMA_ae189a5b-7dd9-42d9-aecf-b51c76bf7a37"
      unitRef="usd">4167000</us-gaap:LoansPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTktMS0xLTEtMA_cecd03ca-5271-4264-9ecf-b9f06ce3b371"
      unitRef="usd">1412000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMTktMy0xLTEtMA_a1dc81fa-836f-4fdb-b1f3-cf6b4a656d6e"
      unitRef="usd">4177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjAtMS0xLTEtMA_78aa114c-4020-4d78-9af3-00edf29daeae"
      unitRef="usd">8552000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjAtMy0xLTEtMA_8d508ac1-7f8d-4682-9656-dd5e3cae373d"
      unitRef="usd">6657000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjEtMS0xLTEtMA_78e0a6d2-17e1-4331-9418-f78aeb065198"
      unitRef="usd">57785000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjEtMy0xLTEtMA_b65486a8-61ef-4fe9-9d02-2c6e28278c5c"
      unitRef="usd">28416000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjItMS0xLTEtMA_0f4e655a-04f0-4223-a936-d2dad1c54074"
      unitRef="usd">11548000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjItMy0xLTEtMA_7663f15f-f5c5-4ada-bd08-22529f89604d"
      unitRef="usd">413000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjMtMS0xLTEtMA_91e36da4-0887-4863-bda4-212ceace6503"
      unitRef="usd">15133000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjMtMy0xLTEtMA_e8240558-a103-49dc-ba96-3b8011256486"
      unitRef="usd">46621000</us-gaap:LongTermLoansPayable>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjQtMS0xLTEtMA_de45f1ef-fe8d-4579-9a4e-d31b47cca415"
      unitRef="usd">2947000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjQtMy0xLTEtMA_faafe729-9674-4b36-9be2-a75706d18d85"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjUtMS0xLTEtMA_028c3138-d4d7-43e5-add2-5bc42cd63141"
      unitRef="usd">87413000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjUtMy0xLTEtMA_888950a1-1355-4baa-a4cd-6799ba17b81e"
      unitRef="usd">75450000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjYtMS0xLTEtMA_14334b63-0bca-4423-9522-e085dfc55cb1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjYtMy0xLTEtMA_bbe8d74f-2cc8-4fad-a614-989078739ae2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzIx_2bda0c15-c022-4859-acdf-8be51c225e4a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzIx_cde8418f-febe-4dd3-b58e-7ea459e3b09e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzM1_3d843ac7-9488-41d6-a8a7-eb40909b51dc"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzM1_699cb8cc-8706-4e25-a509-36053be31cbe"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_19ba2a5e-3e5c-4386-96f7-f2017ad1faae"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_2ba06891-eed7-4736-9cab-85d8a05710e3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_585ffe2a-4c57-419a-bc79-ffda4939acae"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjg1NzhlZWEzYjYzZjQ4MjFhNjBmYWVhMTY5NzRlNjY2XzU3_e8122fc6-4e3e-4223-b80f-045c26cbd13a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMS0xLTEtMA_b514ee2f-9441-49db-9112-b56119f202b3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjgtMy0xLTEtMA_11b0ab8e-8a5c-44ff-a58c-f5abf034e5a8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzE4_29760cbc-ef6f-4802-b350-61b4af6ab853"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzE4_a143fd69-aa1b-4750-8d18-76977182a0b7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzMy_39c23a65-0380-4a1a-abb8-875bc7f9dbbf"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzMy_3e7394ad-502a-4344-ae01-4d361ea6bcea"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzU0_90ae7b79-60c5-4ade-b18e-edcd1c7b8c26"
      unitRef="shares">102967017</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzU0_db8c89f0-3c32-4c8e-bbae-df42af31636d"
      unitRef="shares">102967017</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzYx_91fbc735-dd1b-4ab3-ad9e-ec8c3b882c48"
      unitRef="shares">93599975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmIzYjJmMmMwODRlYTQyMDBiMWM2NDBiZjVjMzBlNjI2XzYx_eea31663-41c2-4bc4-b345-208a5a6f01ce"
      unitRef="shares">93599975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMS0xLTEtMA_bb7d0c57-617e-4afd-8972-2893ff0458a2"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMjktMy0xLTEtMA_59320495-d0d2-4ea9-a7ad-0e7b4201a3e4"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzAtMS0xLTEtMA_d0e6d3bc-fe28-4f3b-aae4-b2ef9f73e91d"
      unitRef="usd">750664000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzAtMy0xLTEtMA_491de9ce-4a84-4023-ab6f-1f28a3e80b69"
      unitRef="usd">680872000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzEtMS0xLTEtMA_a039fc75-1ec1-43e3-9935-25896faf50bd"
      unitRef="usd">-633109000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzEtMy0xLTEtMA_b29f888a-d20b-4ac0-b08e-a5f82fb7e685"
      unitRef="usd">-554765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzItMS0xLTEtMA_2b0ce254-134f-4391-bcfc-f90ec18637dc"
      unitRef="usd">4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzItMy0xLTEtMA_3374ff7e-48d1-4232-846c-22e3c663fe71"
      unitRef="usd">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzMtMS0xLTEtMA_fd420e3a-de02-4776-8ea6-5a8ef99c81b2"
      unitRef="usd">117569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzMtMy0xLTEtMA_fc83ec89-984a-45d8-9e8f-a1fef6493272"
      unitRef="usd">126112000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzQtMS0xLTEtMA_c4652467-999f-4154-bea1-c760a00623c5"
      unitRef="usd">204982000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xNi9mcmFnOjgzNWU5ZDJhZGI2OTRmYThhNzQyZjViZDQ3ODM1ZjEzL3RhYmxlOjhjZWY2NmRkZTlhZDRlMjVhN2Y5Yjk0ZDBjZDIzN2JmL3RhYmxlcmFuZ2U6OGNlZjY2ZGRlOWFkNGUyNWE3ZjliOTRkMGNkMjM3YmZfMzQtMy0xLTEtMA_2951c3ce-01d0-4581-b2d2-e871d7c3df7d"
      unitRef="usd">201562000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5169c85622a346fb9062ffb6b012fd12_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy0xLTEtMS0w_0e675c44-a596-4213-9ab4-f529be20a307"
      unitRef="usd">1310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic844400b43a7400da61df183e26a583f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy0zLTEtMS0w_be67838b-3bda-4d48-8a4e-ea923d6cc76b"
      unitRef="usd">1125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9b324fd57d14e27bcd90f57c095fb22_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy01LTEtMS0w_755e5607-58d2-41d7-a4e7-b899503742ea"
      unitRef="usd">2764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44aa89a05a754d1b891d684b45030896_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMy03LTEtMS0w_9c2c69db-737f-44fd-844a-9417622c7a95"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70adb02e2ed84dbfbb84ecc59e237f22_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC0xLTEtMS0w_c0e6dfdc-11d3-411b-88a6-c869c83ca216"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46815f43fb5147de827a675a8e9bff26_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC0zLTEtMS0w_38a66b4d-f612-4c0f-83a7-7519c49d2a43"
      unitRef="usd">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3f93c6e57284dcdb9ba529c830b9ddc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC01LTEtMS0w_41e56a80-0648-4181-afb2-e6b08e0abba7"
      unitRef="usd">126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74d70bc74d694a89afe4beef05f285a0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNC03LTEtMS0w_e631ced3-d881-4deb-804f-80136435bc98"
      unitRef="usd">43000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifefc52610f304fc29c70ee02bfdad54f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS0xLTEtMS0w_c9af0644-4ea8-41bd-b01b-2f163c12ee19"
      unitRef="usd">3000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f6dc4b98bc94f80aee011fe441527d8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS0zLTEtMS0w_04965215-fe18-4629-bb09-e47137e31179"
      unitRef="usd">706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63cbe2d3588447c6a15715bc02d7d4c5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS01LTEtMS0w_2034d4cd-0c00-48be-9d34-1f687e2f31e0"
      unitRef="usd">5005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i305ca64104904718823ba7cb678ddb2d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNS03LTEtMS0w_c01c08bf-8b8f-47a1-8543-55425087eb24"
      unitRef="usd">706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi0xLTEtMS0w_043ffa85-1125-4a71-a3bd-677c92c14ad7"
      unitRef="usd">1313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi0zLTEtMS0w_fae0c03a-afdb-4286-a0b1-6eadc0c74ab4"
      unitRef="usd">1836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi01LTEtMS0w_1f289167-a77b-4b08-8d84-d5e3ccc7109c"
      unitRef="usd">7895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfNi03LTEtMS0w_f33ebe0f-8f51-4f04-adaa-fae4b0719dbf"
      unitRef="usd">3049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC0xLTEtMS0w_987d149f-86ea-42d9-a7c6-dcf905cfdf09"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC0zLTEtMS0w_44e22628-6e3b-4862-9f35-87b43b634be6"
      unitRef="usd">141000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC01LTEtMS0w_ac7f83a7-9974-464f-9a33-8b8fc1ddf951"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOC03LTEtMS0w_8a4192bc-8044-4734-97df-e6c42b34e2aa"
      unitRef="usd">141000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS0xLTEtMS0w_d86b7c29-6fd4-4617-94b4-60ebc1ecdac5"
      unitRef="usd">26021000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS0zLTEtMS0w_87c2b0a7-8d5c-480c-b6ed-f9ee8d14ed54"
      unitRef="usd">18864000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS01LTEtMS0w_3b110c36-1500-43a3-89f1-e74d581042fa"
      unitRef="usd">46477000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfOS03LTEtMS0w_5e7fa451-e7d4-42f8-9086-edadd3d040cf"
      unitRef="usd">34708000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtMS0xLTEtMA_2f26f59f-6711-4d94-9335-e05deaf89346"
      unitRef="usd">20124000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtMy0xLTEtMA_5614b2b9-427b-446a-baf2-24dc0c84c4ec"
      unitRef="usd">7038000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtNS0xLTEtMA_2465003f-41c4-40a6-abcc-32e055b76ef7"
      unitRef="usd">37255000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTAtNy0xLTEtMA_1675071a-87e4-4fc3-bc26-ceed7bb071b1"
      unitRef="usd">14176000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtMS0xLTEtMA_b5e772cc-9390-4143-9a34-c4901fbf0969"
      unitRef="usd">46145000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtMy0xLTEtMA_8f92de22-a0b5-4b4d-8063-30a3e7c1e8ee"
      unitRef="usd">26043000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtNS0xLTEtMA_6a460265-e4ef-4055-b908-9f66062ec1d0"
      unitRef="usd">84732000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTEtNy0xLTEtMA_255aeb46-a71d-4aec-b6d8-cf9270ad56a0"
      unitRef="usd">49025000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItMS0xLTEtMA_d6654d33-e899-4fa1-bb3d-24e668219396"
      unitRef="usd">-44832000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItMy0xLTEtMA_d86ce272-1eaa-4ce7-a02b-ace3fe495f2e"
      unitRef="usd">-24207000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItNS0xLTEtMA_46cc345f-06dc-48f8-8126-bb4f16fb1111"
      unitRef="usd">-76837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTItNy0xLTEtMA_f10d5e0c-2e3f-437a-b389-5cbd0056551a"
      unitRef="usd">-45976000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtMS0xLTEtMA_e5483768-6deb-4955-930e-fbb8e5fda75a"
      unitRef="usd">1202000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtMy0xLTEtMA_84362921-dc32-4b38-99d9-7195812b82fc"
      unitRef="usd">1226000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtNS0xLTEtMA_7f0c2e0c-1419-4cfe-aaaf-cdb8080c05b7"
      unitRef="usd">2302000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTMtNy0xLTEtMA_f1aaf233-a36f-41a4-8af8-e7787fa5afcf"
      unitRef="usd">2583000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtMS0xLTEtMA_52435d31-d31f-44f7-bd58-246acdef732c"
      unitRef="usd">847000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtMy0xLTEtMA_24931e9e-b650-4efd-87a6-e2f519651cb3"
      unitRef="usd">477000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtNS0xLTEtMA_a95cfbb0-2a9c-4164-a86d-16cdc5db5f88"
      unitRef="usd">798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTQtNy0xLTEtMA_88230f70-9b29-4e12-bce6-a5ba30a91ac6"
      unitRef="usd">1230000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtMS0xLTEtMA_78b1c04a-7671-4864-9a9b-2652614e100e"
      unitRef="usd">-45187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtMy0xLTEtMA_965f6a75-83ee-4276-8b8e-f4c93e09ff7f"
      unitRef="usd">-24956000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtNS0xLTEtMA_15a04e0d-556a-435d-ae03-a53ab94e4e27"
      unitRef="usd">-78341000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTUtNy0xLTEtMA_2d1fd419-4266-405f-bd37-1bff4c35dfbf"
      unitRef="usd">-47329000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtMS0xLTEtMA_bffdd046-7b66-406f-a056-e41ce490cef0"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtMy0xLTEtMA_b883faa6-f4b4-47dc-b200-feb5e8774bc8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtNS0xLTEtMA_a881bf87-adef-4c41-81e3-82b4bbb91f5b"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTYtNy0xLTEtMA_37f35cee-99e2-437b-9a78-65dc8b1bc094"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctMS0xLTEtMA_36b1a710-f49a-4252-bb30-be22204d3ebc"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctMy0xLTEtMA_c0031e41-f89b-4230-86a9-8347f3e680e2"
      unitRef="usd">-24956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctNS0xLTEtMA_6670e331-2aa3-4a4c-b0fa-285f531ae058"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTctNy0xLTEtMA_fe2daaae-b1f4-4653-a48b-5cb9626a6084"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMS0xLTEtMA_3231ae0b-5441-4177-bace-c718a4904339"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMS0xLTEtMA_4f1d2145-46a1-4e54-a23c-f9b91939bf80"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMy0xLTEtMA_66675b4a-0cf1-46bf-ad2c-71de9f816993"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtMy0xLTEtMA_ed339dfc-d849-4ac0-9ce4-970f9375bc17"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNS0xLTEtMA_69bbd04b-1e46-47a4-8ac5-078b4c590e1e"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNS0xLTEtMA_e7ddc54e-7d66-4532-981c-f6f47089aced"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNy0xLTEtMA_30fc0c2d-8e1b-4ee6-adf3-e95ce3969b1b"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTgtNy0xLTEtMA_4da18ea2-bc6b-4ed9-9b3d-bbbdfa1449be"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMS0xLTEtMA_309d9cec-93a9-48bd-ac93-de27612209cb"
      unitRef="shares">100040083</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMS0xLTEtMA_87805e5a-9d0f-4d6d-b26f-a3c78249d983"
      unitRef="shares">100040083</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMy0xLTEtMA_bdea2ffa-a104-4572-bcef-3bf4ee31db46"
      unitRef="shares">89080046</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktMy0xLTEtMA_ee7940d2-cb9a-40f6-ba2f-739c5d2bc2e9"
      unitRef="shares">89080046</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNS0xLTEtMA_db96cfd9-54a7-4b15-b75e-01f7115ee3ac"
      unitRef="shares">98617564</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNS0xLTEtMA_f642723b-6388-4104-aa02-40917d4416fc"
      unitRef="shares">98617564</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNy0xLTEtMA_ec9fb02d-e882-4fcd-8a1a-44e82cee4ec4"
      unitRef="shares">88890353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMTktNy0xLTEtMA_f2a77d11-8532-417d-8a35-ee2d18d692dd"
      unitRef="shares">88890353</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtMS0xLTEtMA_9adfd863-b8bf-4b65-b923-12c4994f1957"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtMy0xLTEtMA_618c0c18-2db9-4e4a-aae7-09b6419a1d88"
      unitRef="usd">-24956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtNS0xLTEtMA_9809d3b9-cecb-425f-92c4-934a9a424935"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjEtNy0xLTEtMA_43580f25-4af8-42e9-9484-0b1afbeb9aaa"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItMS0xLTEtMA_9da9d98c-383a-4e26-bd23-ac2bca5fbfd9"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItMy0xLTEtMA_626baee1-16b1-4733-ac7e-21922505607e"
      unitRef="usd">361000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItNS0xLTEtMA_c7279384-0b3b-4905-970a-f2748909f8b4"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjItNy0xLTEtMA_000e65b6-a063-44d1-915c-f0df91551230"
      unitRef="usd">297000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtMS0xLTEtMA_5c1a8bbc-1223-4f75-ba97-f7b20bc27df9"
      unitRef="usd">-45178000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtMy0xLTEtMA_4cd72bfe-df2b-4a7e-94b3-1c7aca5a69f1"
      unitRef="usd">-24595000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtNS0xLTEtMA_cb4fc910-2b6c-4cba-8183-e235e47c2985"
      unitRef="usd">-78336000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8xOS9mcmFnOmM2ZmIwMjU1NzNiMDQ2NzM5ODdmNjc1MjY1NDFmM2FjL3RhYmxlOjMxNjE2M2YxMzZjNTQxMGY5YWMyOWQxZjM1ZmUxZTA0L3RhYmxlcmFuZ2U6MzE2MTYzZjEzNmM1NDEwZjlhYzI5ZDFmMzVmZTFlMDRfMjMtNy0xLTEtMA_f8077811-0942-4d99-978d-7e387d0e749c"
      unitRef="usd">-47032000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ia91cafc3f3d549f29a542a11fe2aef57_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0xLTEtMS0w_3ade4308-c436-4ec1-9a80-6ad9fa8b8a99"
      unitRef="shares">98688577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia91cafc3f3d549f29a542a11fe2aef57_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0zLTEtMS0w_6eb70f2f-0a47-445c-88b7-8fcd7c328375"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfe4795385734cbb8a81bf1b0bcd78a5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy01LTEtMS0w_db749189-2a68-4285-85f1-5ac7fbcf1df1"
      unitRef="usd">718728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65a85d71d0204688a7b741f604983349_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy03LTEtMS0w_126f0859-b951-4785-b23b-9e0bdf935c25"
      unitRef="usd">-587920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7e91b1a5dd24c928910e0eb927abf63_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy05LTEtMS0w_3d789782-fac7-4c63-8a0f-627e4e72c100"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i996b9b49c28f44a59ede689736e3c19b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMy0xMS0xLTEtMA_7841acdd-31de-4199-8653-4164ba3273f0"
      unitRef="usd">130811000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi0xLTEtMS0w_3926987e-0fc1-40db-9335-cf15b284c417"
      unitRef="shares">194799</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi01LTEtMS0w_460eb337-fa77-48d4-89c7-6382315dc8ff"
      unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNi0xMS0xLTEtMA_2cd2beaf-c5ef-4dd5-85f1-33a1011a023c"
      unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfNy0xLTEtMS0w_af4d65b5-c264-484b-a66f-a5c510571321"
      unitRef="shares">44684</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib3cf83b47db14a139f4efefe1953ef41_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC0xLTEtMS0w_d00c5d8c-6d18-49be-ad71-aa1b77c19c50"
      unitRef="shares">4038957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC01LTEtMS0w_db0f200a-f670-468f-82e2-7a79811bc75c"
      unitRef="usd">28174000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOC0xMS0xLTEtMA_2ed488b6-99e3-4969-b232-4bcc76e01633"
      unitRef="usd">28174000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i296853fafb024267aa5af41bb60e0f37_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOS01LTEtMS0w_fd5f7821-e20c-4b2d-8f41-51d741952d78"
      unitRef="usd">3219000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfOS0xMS0xLTEtMA_f62b7572-1d9c-4f88-98f1-47e30d851917"
      unitRef="usd">3219000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i80b5a2b6ba734b409098fe1a0d30c5e2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTAtOS0xLTEtMA_9dcf393c-84c4-4fa4-861c-10ddfafc36df"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTAtMTEtMS0xLTA_e28e3acc-f485-45ab-945f-b958bc374bc8"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6bd017782e8d453ca3fbb2a862a9ba90_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTEtNy0xLTEtMA_96c42f62-1159-40db-bd2b-9c202c088baf"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTEtMTEtMS0xLTA_f0c432e8-39f0-4808-9fe1-aa41e07640ca"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMS0xLTEtMA_9a3513f0-b0e9-4e66-84a8-42001b2d1ed8"
      unitRef="shares">102967017</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMy0xLTEtMA_2553b5af-77bc-4009-ad95-729268d8e6d8"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83ff1f828c934f0f88513250a9fcec8e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItNS0xLTEtMA_2096f7fa-71a6-422e-8dc7-93ca55e1e6ef"
      unitRef="usd">750664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItNy0xLTEtMA_8e47effe-7cf4-47ea-99b4-6d4dc69a2151"
      unitRef="usd">-633109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0080ccb444c45f6820630de940835f5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItOS0xLTEtMA_caf248a3-afd4-4bc0-9441-0796789a1635"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmJjN2NhYjE4OTdmMjRlZDRhZTgyMWZiYTVlOTQ4MTg1L3RhYmxlcmFuZ2U6YmM3Y2FiMTg5N2YyNGVkNGFlODIxZmJhNWU5NDgxODVfMTItMTEtMS0xLTA_8704aa2a-7298-42d4-8e62-04ba713896f2"
      unitRef="usd">117569000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i18cceea8b49b4f9996c4425728df8ddb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0xLTEtMS0zOA_3fd02609-484b-49f6-be4c-de309ca3cb02"
      unitRef="shares">93599975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i18cceea8b49b4f9996c4425728df8ddb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0zLTEtMS0zOA_07d4ec43-454a-42a3-ab84-4e0231c09e15"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3e3cd82573141db8cb46c3d4aff5c1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy01LTEtMS0zOA_bd11b23e-f929-41f0-87df-4071dca7f399"
      unitRef="usd">680872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia40995d012e245ab8f368eab46de01fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy03LTEtMS0zOA_61967fca-4075-4b45-b8b7-d003e58aaa10"
      unitRef="usd">-554765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9599acbfae04ff2926fa311f5b1fa11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy05LTEtMS0zOA_d0e95b0e-c6fc-4e27-8595-c17b99bb4fb7"
      unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMy0xMS0xLTEtMzg_6f55765a-99ac-4b3f-94d1-3413909595b3"
      unitRef="usd">126112000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC0xLTEtMS0zOA_9b1c6cd8-4680-484b-ba80-2a04b15b51ce"
      unitRef="shares">102208</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC01LTEtMS0zOA_f8ffa616-ee7a-42ba-bb9e-9a6f2c01f74f"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNC0xMS0xLTEtMzg_773e4eb2-3395-4cc1-baa5-df51d3658442"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi0xLTEtMS0zOA_e136aa98-28b0-47fe-a638-14aec0a2d1da"
      unitRef="shares">205306</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi01LTEtMS0zOA_b642e51b-8043-4bd2-b231-d39445453b00"
      unitRef="usd">563000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNi0xMS0xLTEtMzg_cff54803-4056-46a8-ab58-210a1cfa0fe0"
      unitRef="usd">563000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfNy0xLTEtMS0zOA_b734bf82-91a7-498a-b570-eab6f60e978b"
      unitRef="shares">79784</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0xLTEtMS0zOA_a6ecd68b-2e97-4116-a1fe-cc122a845ac0"
      unitRef="shares">8979744</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3042268d89ee48e28a8fe4d397c84d5c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0zLTEtMS0zOA_2614dee2-ebc4-45c0-a901-195d0d4c2831"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC01LTEtMS0zOA_30d0b047-90dd-493a-acef-ba6080d412ac"
      unitRef="usd">62445000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOC0xMS0xLTEtMzg_4dbc6e68-d276-462f-b21d-522764d11342"
      unitRef="usd">62446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i49ef3d735ed9467480d387259bef8fb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOS01LTEtMS0zOA_88acb922-5b6e-4e29-8973-07fd00cb6189"
      unitRef="usd">6306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfOS0xMS0xLTEtMzg_f31492c1-5f97-4fed-8341-434ceaaf1b81"
      unitRef="usd">6306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iefa2601d5c60400197dae7d0b451836e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTAtOS0xLTEtMzg_736ceb70-2afd-4777-b6e8-c444183156db"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTAtMTEtMS0xLTM4_e3e19890-ae8d-448d-86ed-b5768eef6417"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i4740541ee7924fea863cb9f577326fd3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTEtNy0xLTEtMzg_bc15edec-9889-4388-97f2-4ad7eb2eeaea"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTEtMTEtMS0xLTM4_c262b52a-c56d-4544-bbe3-5599caf6e6f2"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMS0xLTEtMzg_6c3034c1-2bac-401f-b032-71d96771278a"
      unitRef="shares">102967017</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a5b6508dc384cedb263a3547a372fce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMy0xLTEtMzg_97f6a539-800e-4cb2-9321-4a8e425d470b"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83ff1f828c934f0f88513250a9fcec8e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItNS0xLTEtMzg_d9611c55-c0ff-44f7-8efb-dead6f26dbc3"
      unitRef="usd">750664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6fa6b621654ccfb01e0d454b7f2766_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItNy0xLTEtMzg_b680cfbf-abea-4891-b0b5-1967ae85729f"
      unitRef="usd">-633109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0080ccb444c45f6820630de940835f5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItOS0xLTEtMzg_e80c649b-5d0f-4bc9-af5c-a3894a5df45f"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOmNkNjIxNmMyMzk2NDRhYmViZjcxNjg3NTU5NmQ5YTk3L3RhYmxlcmFuZ2U6Y2Q2MjE2YzIzOTY0NGFiZWJmNzE2ODc1NTk2ZDlhOTdfMTItMTEtMS0xLTM4_6f74a787-7f48-4b40-857a-9eb6ad9589ef"
      unitRef="usd">117569000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0xLTEtMS0w_5d0aa610-7f99-4760-a508-62c75bd1bfcf"
      unitRef="shares">89035096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iccdc16ed512f4d0d8f097c8825fdf1e9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0zLTEtMS0w_f7c4680d-b825-42c8-8d46-2a9e0362eebb"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia909a04442314115a14cb637f127f9a0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy01LTEtMS0w_da00833a-bef6-4b75-b096-f97d531b51f4"
      unitRef="usd">650617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab525b262fba48b39730d896423dd7fe_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy03LTEtMS0w_6bb0bf41-4091-414f-a2f4-2ef5d3e70804"
      unitRef="usd">-482825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2175ce28f9d54b8083c2d9170d124b24_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy05LTEtMS0w_fdefc506-fc0a-4509-9c10-8d958f3c4b98"
      unitRef="usd">-44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i521561e365cb4f9aa0c62af71fc32133_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMy0xMS0xLTEtMA_b52aebdd-bc67-4697-82d7-9114d5d78aad"
      unitRef="usd">167757000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if512d3ccb798492096508a8d2449275e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS0xLTEtMS0w_d26eb4a3-b510-4bb4-ba60-be7974f31e3d"
      unitRef="shares">42403</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS01LTEtMS0w_7b90328d-4608-4863-bebb-30fa25ba125d"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNS0xMS0xLTEtMA_aee3a60d-e7b9-485c-943c-9129c5badba3"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if512d3ccb798492096508a8d2449275e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi0xLTEtMS0w_23fb46f6-761c-4c59-91b3-aef7a6a83c2a"
      unitRef="shares">63064</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi01LTEtMS0w_641fa403-7786-4e3c-9e15-afd8d43d00ba"
      unitRef="usd">204000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfNi0xMS0xLTEtMA_704b5255-ac13-4ee9-909f-67f7eacc7589"
      unitRef="usd">204000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7fb2f2c30763452d9271f600a2c4b255_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOC01LTEtMS0w_c069e09e-697b-4bc6-9640-ff3ca45ddd90"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOC0xMS0xLTEtMA_40d3fb05-01e4-48cd-a570-95fbd4a97812"
      unitRef="usd">2674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i055e0b998d064537b3d88828cb52ae44_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOS05LTEtMS0w_f7230cd9-dc36-436d-adf2-f13cc96fc47d"
      unitRef="usd">361000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfOS0xMS0xLTEtMA_32155cf0-038c-470b-9d48-4c7e33f46be1"
      unitRef="usd">361000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i1f1fb8a7c88e498f92aa1aae68c2fea8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTAtNy0xLTEtMA_8145fbe8-06cf-467e-ab70-4f9d7d4c9288"
      unitRef="usd">-24956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTAtMTEtMS0xLTA_83b7497f-0438-45a8-8ba3-4208de0fb441"
      unitRef="usd">-24956000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMS0xLTEtMA_9a85ad53-a22d-453a-9792-a9479d73f099"
      unitRef="shares">89140563</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMy0xLTEtMA_a528c7cf-feb4-43c3-864e-3d4a4ad62872"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3c73b1263494577a798b153956f45fc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtNS0xLTEtMA_68207679-7158-47f8-8c26-dd01a6a71f0a"
      unitRef="usd">653805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5481c5ac22b441f1a636dc6115281e1d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtNy0xLTEtMA_bac5860d-c7a1-46c4-8629-24234e2f0735"
      unitRef="usd">-507781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37628ae924f0472da65e1caaf4ca8ce8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtOS0xLTEtMA_37c58149-9f39-46b7-8666-7aff6f22f475"
      unitRef="usd">317000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjY4MzZkNDA2ZTk5MDQwMDQ4ZDI0NDE2MjE4NWQ3NTU4L3RhYmxlcmFuZ2U6NjgzNmQ0MDZlOTkwNDAwNDhkMjQ0MTYyMTg1ZDc1NThfMTEtMTEtMS0xLTA_9de8bb7a-1f17-4c31-95ae-73addde050d8"
      unitRef="usd">146350000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic53ee417fef84d79a20f0137c9009129_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0xLTEtMS01NA_a667c1cc-a7d7-4588-bcd5-943af553ac25"
      unitRef="shares">88817741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic53ee417fef84d79a20f0137c9009129_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0zLTEtMS01NA_b24ae5cd-99e2-48f4-9256-9c553c3c3028"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdb8a5ab08814d09a475fc45cb62c355_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy01LTEtMS01NA_e8c7cbe2-b762-4fb4-b641-1ddf5a7fd19e"
      unitRef="usd">647078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf0bc9463f684e9b8d4d88cb346673ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy03LTEtMS01NA_a9ef80a7-d2ea-4d43-9719-2e0c3e030fff"
      unitRef="usd">-460452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe50953188ac47108208481d704ce612_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy05LTEtMS01NA_34c13332-8bc0-4333-92c2-dc83d90a4a8a"
      unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd41c948817d46d799997c58b6d1030b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMy0xMS0xLTEtNTQ_3e03af83-b7b4-479e-a02a-8ebabbc9396f"
      unitRef="usd">186655000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC0xLTEtMS01NA_8ffc9252-0aa8-452f-b122-2becf3f3f7a0"
      unitRef="shares">75804</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC01LTEtMS01NA_31bc9d8d-456a-47a6-932d-03c4c3ae6389"
      unitRef="usd">375000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNC0xMS0xLTEtNTQ_5a8cf86c-7e38-48ce-aeea-b83d49b49b53"
      unitRef="usd">375000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS0xLTEtMS01NA_0ffb8daf-cc23-4242-a452-32756b9ac017"
      unitRef="shares">42403</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS01LTEtMS01NA_ac778148-281f-4b7a-89ee-8e6a75df1302"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNS0xMS0xLTEtNTQ_750f73a5-0074-4108-b5ee-4f7633e71f41"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9b84f83ce712474e8b9f431e111ea597_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi0xLTEtMS01NA_39fd2c6e-fd92-4499-9e4a-43777118991a"
      unitRef="shares">204615</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi01LTEtMS01NA_03eb4f03-8b1b-40c3-a247-c0503afda12d"
      unitRef="usd">420000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfNi0xMS0xLTEtNTQ_66506489-bf45-44b5-b975-53574bf0834a"
      unitRef="usd">420000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9188bdc05a5493cb605dd6eba7ea75e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOC01LTEtMS01NA_63059854-f104-4ad7-be9e-8f26c16ad574"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOC0xMS0xLTEtNTQ_8acde3ad-4c28-4169-8191-f7ec938e7c0e"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib52df4b25bae450697308ad35e1759ba_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOS05LTEtMS01NA_74dc79a9-9330-4963-9090-0836101ce1b5"
      unitRef="usd">297000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfOS0xMS0xLTEtNTQ_8a95803c-232c-4311-a76d-635e8605d6e6"
      unitRef="usd">297000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i783b4aad17a142a08d4f48f537af01a4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTAtNy0xLTEtNTQ_0942bd3f-8dca-4173-a32d-79bec39777aa"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTAtMTEtMS0xLTU0_94ae78e4-fba7-47f6-9de9-856d35752777"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMS0xLTEtNTQ_d89dca5b-28a4-4baa-ac2e-ccc6a778dd63"
      unitRef="shares">89140563</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd4fadc03d8248e2b92d9369a7dc4798_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMy0xLTEtNTQ_78b25a28-bdb9-49f8-a223-ebdcc5aa7d9e"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3c73b1263494577a798b153956f45fc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtNS0xLTEtNTQ_d56d0bd8-f725-4b4e-905a-bc260ca72ab1"
      unitRef="usd">653805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5481c5ac22b441f1a636dc6115281e1d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtNy0xLTEtNTQ_f6da4004-a20c-4f13-bd78-43850cdc05ac"
      unitRef="usd">-507781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37628ae924f0472da65e1caaf4ca8ce8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtOS0xLTEtNTQ_8d569947-02c5-4039-a710-65ec0ca9c43b"
      unitRef="usd">317000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yMi9mcmFnOjc5MWVkNTBiYTZjNzRiNGQ5NTRjY2FiZGE1NTRjNjAzL3RhYmxlOjE3ZTQwYzFiYWUzYTQxYjU5MmVlYmFjNzZlNjU4NDQwL3RhYmxlcmFuZ2U6MTdlNDBjMWJhZTNhNDFiNTkyZWViYWM3NmU2NTg0NDBfMTEtMTEtMS0xLTU0_a5caabdd-ef46-4b8b-89d2-74a0e051975a"
      unitRef="usd">146350000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMy0xLTEtMS0w_69e15acc-5dca-41d1-ac1c-f02a25430863"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMy0zLTEtMS0w_b7cdebd4-8ab8-469e-bda2-31752cfc586f"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNS0xLTEtMS0w_67fcb4df-f622-4b5d-b1aa-da627476ae87"
      unitRef="usd">787000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNS0zLTEtMS0w_0228565a-0169-4eec-8ffa-916c1abdee1f"
      unitRef="usd">960000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNi0xLTEtMS0w_f684add3-45ae-4c2b-8d45-abc6ecb1ec14"
      unitRef="usd">316000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNi0zLTEtMS0w_022189f8-dd08-43ec-bf5d-9b7999c37c5f"
      unitRef="usd">282000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNy0xLTEtMS0w_c917fa18-c2a5-4b48-9cf3-9ecd3d1d1d15"
      unitRef="usd">145000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNy0zLTEtMS0w_479edd39-ad86-4d80-b8fd-f0396c442726"
      unitRef="usd">158000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOC0xLTEtMS0w_0867fad5-d3ae-4825-8323-a9da96a6f3f5"
      unitRef="usd">-274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOC0zLTEtMS0w_a5d6ecd4-178b-4511-82df-1641b28fefd2"
      unitRef="usd">227000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOS0xLTEtMS0w_9e753b2a-f65d-4447-84d3-ddc5166a1110"
      unitRef="usd">1318000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfOS0zLTEtMS0w_3259ef6b-b083-4f91-b0f1-4f027cb7bf24"
      unitRef="usd">1025000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTAtMS0xLTEtMA_ba8e266a-1050-4170-ab3e-583204f8fc92"
      unitRef="usd">6306000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTAtMy0xLTEtMA_47ce6392-48d4-4ef7-8536-b136aa1981b4"
      unitRef="usd">5622000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTEtMS0xLTEtMA_55874ec5-2958-4c69-b5a6-48bbc2b111c6"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTEtMy0xLTEtMA_18a67405-d298-4109-a271-2efa99988825"
      unitRef="usd">152000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTItMS0xLTEtMA_0baa630a-bc39-4a7f-aa58-f6c0136340ed"
      unitRef="usd">141000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTItMy0xLTEtMA_7af055aa-65c3-43da-a0fa-307ce60eb273"
      unitRef="usd">257000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTUtMS0xLTEtMA_1d3e29a4-dc5c-452a-b89f-fb406c13008f"
      unitRef="usd">7379000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTUtMy0xLTEtMA_ec7e7246-34a9-4d82-9033-07c95bb6ab62"
      unitRef="usd">2144000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTYtMS0xLTEtMA_bff629b1-8a45-4b46-bba9-f08f1ce8e281"
      unitRef="usd">-3039000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTYtMy0xLTEtMA_1488f539-82d3-4f8d-a25a-80840831ea1d"
      unitRef="usd">2025000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTctMS0xLTEtMA_eb2c0c74-8f1c-435d-bdcd-acf5410f6f0c"
      unitRef="usd">267000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTctMy0xLTEtMA_3f8ff4fd-9e89-4706-9a17-11516e51c907"
      unitRef="usd">-1372000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTgtMS0xLTEtMA_25e2f592-dde4-4830-b233-7edc6a0ed1b1"
      unitRef="usd">-1361000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTgtMy0xLTEtMA_bbf0c2f3-64e5-4a68-a04c-72d8a080c12a"
      unitRef="usd">-1251000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTktMS0xLTEtMA_fbe73f6f-fb81-4af7-abac-eaa7eaf0b142"
      unitRef="usd">2607000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMTktMy0xLTEtMA_9348747c-7d3a-468b-9734-e37b965f0841"
      unitRef="usd">174000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjAtMS0xLTEtMA_3734a759-03c2-4275-b8d7-dec12062bcc6"
      unitRef="usd">182000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjAtMy0xLTEtMA_607bc570-ec96-406e-8fca-b5a64a501709"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjEtMS0xLTEtMA_4fe02038-f6ec-4c3b-95fb-9cec40cbf758"
      unitRef="usd">-78493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjEtMy0xLTEtMA_db776a38-649d-4570-8860-1a878262b21e"
      unitRef="usd">-43968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjMtMS0xLTEtMA_96fd7ccb-455c-4799-b43b-aa2ca0d88117"
      unitRef="usd">60550000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjMtMy0xLTEtMA_ea23a441-f358-48c0-81b6-1c2214c97640"
      unitRef="usd">25519000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjQtMS0xLTEtMA_d9123c6c-d447-4134-8026-e7ae0d618dd2"
      unitRef="usd">48314000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjQtMy0xLTEtMA_fc8f2c51-6454-4128-ac7d-1e2fb4d4422c"
      unitRef="usd">62960000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjUtMS0xLTEtMA_ce4065d3-8bc5-41b5-a442-8560af394d3c"
      unitRef="usd">1517000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjUtMy0xLTEtMA_e6e6117e-c0bb-4d2c-b74d-9bfc5d84e916"
      unitRef="usd">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjYtMS0xLTEtMA_5a814ff3-c832-4d63-b514-c1e30ac02090"
      unitRef="usd">10719000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMjYtMy0xLTEtMA_63f2971f-8068-4c8e-8c3c-9ba940c1ba29"
      unitRef="usd">-37466000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzAtMS0xLTEtMA_110bc062-1688-4821-a771-6fd5710d5d20"
      unitRef="usd">62446000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzAtMy0xLTEtMA_9ccc520a-ef6e-4e7a-9a49-367566e324a2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzEtMS0xLTEtMA_9002e238-4fe9-4420-9a29-aa8a8446cc60"
      unitRef="usd">1041000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzEtMy0xLTEtMA_304975d2-eaee-427a-a9c7-541f6c81525d"
      unitRef="usd">795000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzMtMS0xLTEtMA_dadbf070-6906-4714-aa73-eca5f9446db8"
      unitRef="usd">63487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzMtMy0xLTEtMA_18079268-0b81-4b0e-8a16-c9296f87ef31"
      unitRef="usd">795000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzQtMS0xLTEtMA_91896fc0-d1d9-4388-a400-5e821519be97"
      unitRef="usd">-4287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzQtMy0xLTEtMA_420578b9-60a3-4725-a4b6-141a6a121fc9"
      unitRef="usd">-80639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzUtMS0xLTEtMA_ae59333b-fcf3-4e54-8373-576b922fa340"
      unitRef="usd">91032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icd41c948817d46d799997c58b6d1030b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzUtMy0xLTEtMA_84236673-f80b-4aae-af8e-dbc4cb146335"
      unitRef="usd">181133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzYtMS0xLTEtMA_73b85d62-ac9e-4c56-8933-8e7103f84341"
      unitRef="usd">86745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzYtMy0xLTEtMA_a13ab9e4-c0b8-4dc8-aa87-425d3285b3f9"
      unitRef="usd">100494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzgtMS0xLTEtMA_17c5846d-ea2b-4529-80c9-5dba787ecae8"
      unitRef="usd">1936000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzgtMy0xLTEtMA_07fc3d2e-1904-400f-a2eb-e78e57281abd"
      unitRef="usd">2146000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzktMS0xLTEtMA_f7a490f0-97eb-46bc-a824-8dd099b88e82"
      unitRef="usd">3000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfMzktMy0xLTEtMA_d33fc9e7-fd61-49d0-ab62-5c007440f0b4"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDEtMS0xLTEtMA_19a240bf-a985-40c5-b87b-29b9259be28b"
      unitRef="usd">14379000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDEtMy0xLTEtMA_11f9042c-4680-40ab-8caf-23dc85aff44a"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDItMS0xLTEtMA_1059c51e-6bf4-426a-99d6-0e7fb74e3b7e"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8yNS9mcmFnOjk0NDkxNzdlNTRhMjRhYmViMGQ2OGFmYzg0NDU4NTkwL3RhYmxlOjA3ZDg5ZTBiMDFhNzRjOGFhMGYyMmM4ZmVkMDY4ZjkzL3RhYmxlcmFuZ2U6MDdkODllMGIwMWE3NGM4YWEwZjIyYzhmZWQwNjhmOTNfNDItMy0xLTEtMA_fee1cd0e-2601-4632-8dc6-0a0e245d6142"
      unitRef="usd">311000</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1NQ_b1378a5b-4ec9-48eb-9209-caacd14603aa">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ardelyx, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment, which is the research, development and commercialization of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position at&#160;June&#160;30, 2021&#160;and results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods ended&#160;June&#160;30, 2021&#160;and&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2020. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2021, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities of approximately $171.8 million. We believe our current available cash, cash equivalents marketable securities will be sufficient to fund our planned expenditures and meet our obligations for at least 12 months following the filing of this Report on Form 10-Q. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 28, 2021, we received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding our New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis in which the FDA noted additional requirements would need to be met in order to obtain approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. On July 29, 2021 we entered into a Fourth Amendment to our Term Loan Agreement which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021, provided, however, if the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on or before October 25, 2021, then the interest-only period will expire and principal repayments will be required to begin on November 1, 2021. Further, on July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. For additional information see Note 12, Subsequent Events.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Failure to raise sufficient capital when needed or generate product revenue will further impact our ability to pursue our business strategies and could require us to further delay, scale back or discontinue one or more of our product development programs, commercialization efforts, or other aspects of our business plans. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. On June 30, 2021, our public float exceeded $700 million and therefore, on December 31, 2021, we will no longer qualify as a &#x201c;smaller reporting company&#x201d; and will instead be considered a large accelerated filer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We expect to adopt Topic 326 in the fourth quarter of 2021. We do not expect the adoption of ASU 2016-13 to have a material impact on our financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfMzIy_c57f9308-7e18-4d69-8a31-3893bdfbad5e"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1Ng_6181fcaa-a6cf-4654-96bd-e6d1713b8764">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position at&#160;June&#160;30, 2021&#160;and results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods ended&#160;June&#160;30, 2021&#160;and&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2020. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2021, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1Nw_5c0a5ced-c6e5-4b65-ab79-a923b01c6a57">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfMjUzNA_f12101bb-693d-4df7-9bad-45733c3b37cf"
      unitRef="usd">171800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zMS9mcmFnOmZiZTI3NWE3NzQyYzQxMmNhYjNkYTE2MDQ0MTkxOTVmL3RleHRyZWdpb246ZmJlMjc1YTc3NDJjNDEyY2FiM2RhMTYwNDQxOTE5NWZfNDc1NA_e9d8f8ce-27bf-41c9-8318-306c857933dd">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. On June 30, 2021, our public float exceeded $700 million and therefore, on December 31, 2021, we will no longer qualify as a &#x201c;smaller reporting company&#x201d; and will instead be considered a large accelerated filer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We expect to adopt Topic 326 in the fourth quarter of 2021. We do not expect the adoption of ASU 2016-13 to have a material impact on our financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTg2Mg_24870e53-d8c3-4136-ba52-db80fe3b2bfe">CASH, CASH EQUIVALENTS AND INVESTMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of June&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest excess cash in marketable securities with high credit ratings. These securities consist primarily of money market funds, commercial paper, corporate bonds, asset-backed securities, and U.S. treasury and agency securities and are classified as &#x201c;available-for-sale.&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All available-for-sale securities held as of June&#160;30, 2021 had contractual maturities of less than one&#160;year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when the fair value of that security is less than its carrying cost, in which case we would further evaluate the investment to determine whether the security is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition or creditworthiness of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write the investment down through the statement of operations to its fair value and establishes that value as the new cost basis for the investment. Management has determined that none of our available-for-sale securities were other-than-temporarily impaired in any of the periods presented, and as of June&#160;30, 2021, no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that investments in a loss position will be held until maturity or a forecasted recovery of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTg2Mw_27466f41-0f4a-4363-80ea-98902e1cf439">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of June&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b98058de4da42c294fa91c66eeb6e89_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNC0xLTEtMS0w_e06b3ec2-9b16-4728-a46f-854bae3f2f93"
      unitRef="usd">845000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5b98058de4da42c294fa91c66eeb6e89_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNC03LTEtMS0w_a19a028a-8ccd-475c-9a31-894d13ef0bc2"
      unitRef="usd">845000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i35ad3f3857994eafbf8092a727a20054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNS0xLTEtMS0w_b1a52901-b57c-4c6f-9581-396f9b9fb2ea"
      unitRef="usd">84650000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i35ad3f3857994eafbf8092a727a20054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNS03LTEtMS0w_3cfb826a-bfc2-4ead-9336-7a2e439279f3"
      unitRef="usd">84650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibccabbde714945ec89a64f78f0954426_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNi0xLTEtMS0w_a2450eef-fcb0-48cc-9dae-4f2b84ddf076"
      unitRef="usd">1250000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibccabbde714945ec89a64f78f0954426_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfNi03LTEtMS0w_89373bff-e329-4f8e-b489-9bb5e86d1d2e"
      unitRef="usd">1250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfOC0xLTEtMS0w_9c622cbf-432b-4fd0-a902-31a2b6fd2be6"
      unitRef="usd">86745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfOC03LTEtMS0w_8a904b49-7b15-48cf-8e96-0d31bab3ecf5"
      unitRef="usd">86745000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ad7361da3114524894d528d36761938_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtMS0xLTEtMA_bd6db30b-8a9b-429c-8e80-992cc18e4a17"
      unitRef="usd">62719000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ad7361da3114524894d528d36761938_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtMy0xLTEtMA_ed6069bc-099c-4134-bed5-63de7b0c6819"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ad7361da3114524894d528d36761938_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtNS0xLTEtMA_1a7ad0fb-9a03-49a7-b7b6-63bc7a575041"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ad7361da3114524894d528d36761938_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTAtNy0xLTEtMA_9521ea6f-b2e8-492d-a730-fb5a0e52b6c5"
      unitRef="usd">62725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7acd89d799254005a61260d4785cc411_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtMS0xLTEtMA_aae22df4-226c-438a-9c2e-24fd14d4dbb4"
      unitRef="usd">16964000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7acd89d799254005a61260d4785cc411_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtMy0xLTEtMA_c3d968b4-95b8-44ed-8fd2-7103cfa985ea"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7acd89d799254005a61260d4785cc411_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtNS0xLTEtMA_73a20545-b816-4882-9577-7b8631fea109"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7acd89d799254005a61260d4785cc411_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTEtNy0xLTEtMA_f4fef0df-a32a-4dc6-b4c7-c2fa58ce1d58"
      unitRef="usd">16964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtMS0xLTEtMA_76474513-1e28-472a-9d33-b1a4c740b4c3"
      unitRef="usd">5376000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtMy0xLTEtMA_af2f6de5-d5b7-4d80-8bb0-414a13eb3af2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtNS0xLTEtMA_235788fb-5cbf-406b-bc6c-edfeb6a06d77"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cd17446ca75477084ef05a6506f3a4d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTMtNy0xLTEtMA_1176f6d8-a348-439a-9a9d-811ef580c50f"
      unitRef="usd">5375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtMS0xLTEtMA_e7646119-b61d-4253-8daa-c327e889316d"
      unitRef="usd">85059000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtMy0xLTEtMA_11793310-5a42-4680-8353-ff0046443998"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtNS0xLTEtMA_591d99c8-744f-45af-9f60-d78e9179fb10"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTUtNy0xLTEtMA_c63c3974-7c1f-4e94-a248-a2ace870493f"
      unitRef="usd">85064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsAndCash
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtMS0xLTEtMA_f7f52f9e-83cc-499e-a8c5-c445a8c709da"
      unitRef="usd">171804000</us-gaap:InvestmentsAndCash>
    <ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtMy0xLTEtMA_6bb3a7a1-5103-499d-9312-f3af8b0dd325"
      unitRef="usd">7000</ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain>
    <ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtNS0xLTEtMA_438f8516-bf19-44bb-9c53-262176f2e11a"
      unitRef="usd">2000</ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss>
    <ardx:InvestmentsAndCashFairValueDisclosure
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOjljYzI5MGM5YmE0NDRlM2E5NmFlYjNhMzJjMzBkNGM3L3RhYmxlcmFuZ2U6OWNjMjkwYzliYTQ0NGUzYTk2YWViM2EzMmMzMGQ0YzdfMTYtNy0xLTEtMA_ed5d506b-0dd4-44e7-a81d-661c5ac79e86"
      unitRef="usd">171809000</ardx:InvestmentsAndCashFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNC0xLTEtMS0w_08cc1e00-b370-43bb-b74f-0a2d360b7dbb"
      unitRef="usd">781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i136a779aa2ad4f8bb2f99a26b48e48b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNC03LTEtMS0w_8c16ba4a-1bcc-45e7-836c-55a17ec5836b"
      unitRef="usd">781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if07744061b93432eb1154ad3a3a36816_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNS0xLTEtMS0w_a8ff797c-1ec7-43ff-b828-b88ef840c605"
      unitRef="usd">88151000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if07744061b93432eb1154ad3a3a36816_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNS03LTEtMS0w_4eae09e2-1dd0-47b9-bd83-d479882da460"
      unitRef="usd">88151000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib2251a0841514418a8a29bca5526a858_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNi0xLTEtMS0w_01bd2b9e-5d93-41c3-bb9f-a5ab149867f8"
      unitRef="usd">2100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2251a0841514418a8a29bca5526a858_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfNi03LTEtMS0w_153bd4e0-4c81-438a-8d85-ce3c882b4f62"
      unitRef="usd">2100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfOC0xLTEtMS0w_b8560561-8227-4dfc-9c3d-74072e4e7210"
      unitRef="usd">91032000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfOC03LTEtMS0w_6384e6b8-421e-4ec0-a57b-d03b646daa88"
      unitRef="usd">91032000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtMS0xLTEtMA_02b8ea16-ab6c-455c-a824-3be5c698c5c6"
      unitRef="usd">60631000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtMy0xLTEtMA_5c2c54d0-656a-4a1e-a069-c0d7ca334f94"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtNS0xLTEtMA_c8176768-7d2c-474f-94f8-ff69f8f9f503"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b26e91f4014480084d27170ccd8c8fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTAtNy0xLTEtMA_a66a5eb1-d046-482b-8bf5-17eaeb65704e"
      unitRef="usd">60629000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtMS0xLTEtMA_74cc1227-fc6a-4226-9285-cd2f73812db7"
      unitRef="usd">24547000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtMy0xLTEtMA_52deab03-ad92-4e49-bc26-ffdcd532529b"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtNS0xLTEtMA_ed1b15ae-c08d-4043-8966-a092793669c7"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTEtNy0xLTEtMA_329d597c-940a-4424-8712-aa84719df357"
      unitRef="usd">24544000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItMS0xLTEtMA_980c8de6-7b88-4472-b70b-843ad9ece312"
      unitRef="usd">9277000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItMy0xLTEtMA_b1f0ed6b-cffa-4275-b03d-17800d2b9f79"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItNS0xLTEtMA_86fe8b1a-2a74-42d7-8975-8cb1e14bfc8a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66a0e0f970d3480faac49ec39d277a5d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTItNy0xLTEtMA_3a6c19e7-5514-446c-b99b-2037842644ab"
      unitRef="usd">9279000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80c54e2862a942258157af583a390e08_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtMS0xLTEtMA_8134d00c-e36f-4b5d-bebc-3fe87b7e7db5"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80c54e2862a942258157af583a390e08_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtMy0xLTEtMA_ee534029-7cb4-4885-aea8-e15e488ff21c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80c54e2862a942258157af583a390e08_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtNS0xLTEtMA_3956043b-5e31-44a8-b668-5594a1f51499"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80c54e2862a942258157af583a390e08_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTMtNy0xLTEtMA_e76fa941-caf9-4155-8de3-5790b4141b95"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtMS0xLTEtMA_9785b19b-dc3f-45e7-ae16-26f7b8584ac8"
      unitRef="usd">95455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtMy0xLTEtMA_57686541-5a13-465d-98d7-1259c9f3c723"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtNS0xLTEtMA_83ecafe7-6a3f-4dba-bb41-890ba0602029"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTQtNy0xLTEtMA_bf7824ce-260c-415b-8b43-663d05ebf7c2"
      unitRef="usd">95452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:LongTermInvestmentsAmortizedCost
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtMS0xLTEtMA_407791e3-d9f3-4e31-9b8f-273c1adefcf1"
      unitRef="usd">2115000</ardx:LongTermInvestmentsAmortizedCost>
    <ardx:LongTermInvestmentsAccumulatedGrossUnrealizedGain
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtMy0xLTEtMA_7f63260c-9a94-4382-87da-6f4e85510eba"
      unitRef="usd"
      xsi:nil="true"/>
    <ardx:LongTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtNS0xLTEtMA_10c7d8dc-ca2a-4d91-8471-48ccd6000756"
      unitRef="usd">1000</ardx:LongTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <ardx:LongTermInvestmentsFairValue
      contextRef="i91b9eea8333f47a1b077cabf000e2716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTYtNy0xLTEtMA_f33bbe9d-fe7d-4996-be62-0fac9d1f6f81"
      unitRef="usd">2114000</ardx:LongTermInvestmentsFairValue>
    <us-gaap:InvestmentsAndCash
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctMS0xLTEtMA_8bd84e46-2304-4d69-9932-403b57e955f6"
      unitRef="usd">188602000</us-gaap:InvestmentsAndCash>
    <ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctMy0xLTEtMA_9c15477e-f0d6-4543-bad4-4dcdc88c1599"
      unitRef="usd">7000</ardx:InvestmentsAndCashAccumulatedGrossUnrealizedGain>
    <ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctNS0xLTEtMA_1cae3403-62ba-496a-b701-ef31681a9497"
      unitRef="usd">11000</ardx:InvestmentsAndCashAccumulatedGrossUnrealizedLoss>
    <ardx:InvestmentsAndCashFairValueDisclosure
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RhYmxlOmI2YjU4NDVmMTRhNDRmMGRiN2M5NWY2NjBhNGEwOTYxL3RhYmxlcmFuZ2U6YjZiNTg0NWYxNGE0NGYwZGI3Yzk1ZjY2MGE0YTA5NjFfMTctNy0xLTEtMA_0203fbff-5ac8-43d6-8dec-29d8fbb4ab65"
      unitRef="usd">188598000</ardx:InvestmentsAndCashFairValueDisclosure>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_760fd7e8-0911-41c6-bbf8-feb9b7292e26"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_844b7221-92e3-4c42-9b4a-8e55d4c901a4"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_894f5ec5-29e1-4eec-a5b9-fb028fea8573"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTUxNg_d2f6bcc2-b50a-44b2-a904-1dd58d0df351"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNC9mcmFnOmM5ZmZlNDJlNmFiNTRmODViZTYyYmViNjNjNjdhNjE2L3RleHRyZWdpb246YzlmZmU0MmU2YWI1NGY4NWJlNjJiZWI2M2M2N2E2MTZfMTY0MA_f84d0018-d99d-4c38-9a02-05ce4b20a2b3"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5MQ_6248fdd5-34cf-417b-9181-ab019172ce3f">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, asset-backed securities and foreign currency derivative contracts as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities such as the Exit Fee, as defined and discussed in Note 6, are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2021 and December&#160;31, 2020, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at June&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5Mg_a74af059-6cec-422e-a13f-596daa982f63">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RleHRyZWdpb246NzZjMTFjYTkwMWU1NGU0OWIxNWUzZmZiYTgzMzcyYTVfMTk5Mw_839906e5-a3af-434c-a826-5c08a88ab55f">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ied42e28071324f2ebd2db962a44477e1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy0xLTEtMS0w_c0d1d318-8462-4dd4-abb0-15dd01db45ae"
      unitRef="usd">84650000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6f276be494047f297ca9e5088e20b96_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy0zLTEtMS0w_d276be21-3176-4c0c-87ca-20164c95e042"
      unitRef="usd">84650000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e74d17c420a47afaac9eca94b5c23eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy01LTEtMS0w_c4b13013-5b8a-4018-bf1e-5a6461a27e06"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3063806f84794b4ca0e47322baed68bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMy03LTEtMS0w_f001eebc-8ff6-46ce-82da-827aa3563694"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0cf01a41f9d048ed926937a9e81f57f5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC0xLTEtMS0w_8626ac59-cb34-494d-8473-fb6a994685aa"
      unitRef="usd">63975000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5acef194906f40c4b0bc625b1fe030d8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC0zLTEtMS0w_87315b95-71e3-4a3f-8710-b20e256beb20"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia89a5f8f089048d695069dfd0f3ddb1e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC01LTEtMS0w_2425f9ba-da4d-46fd-b72d-bf6e3bb787ed"
      unitRef="usd">63975000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia16d7277926b4ae1a8bf1f8ccc7f5fdd_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNC03LTEtMS0w_c02aad11-ce23-4a4f-8ce0-c7feef3962ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1e6b406bbf6f45849047db8c4c1bd725_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS0xLTEtMS0w_d127c00a-31e6-4676-8d02-1b4e19e458a8"
      unitRef="usd">16964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7317f8962714c4b83d096692d77f4c5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS0zLTEtMS0w_64e17a19-a68d-4405-956c-ce42b3b6833e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9635984f4f30476f8f150e932200d84f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS01LTEtMS0w_23f0b2e7-a6b0-4069-add5-f147ca128191"
      unitRef="usd">16964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7de92fed80134bcdb3a7fc397526ea81_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNS03LTEtMS0w_f788d024-2361-44ad-9449-fefa41ffed35"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a1f62f1e1524a1bb1796ea45572aa13_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy0xLTEtMS0w_ea39f226-e60e-41d5-b479-56c91db9b6e1"
      unitRef="usd">5375000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i64a8a52b89c442b0802c08887c2a4136_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy0zLTEtMS0w_33650c3b-dba1-4024-92e0-1889c66912a6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id37c22c74c3a41568c43be19dee6db9b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy01LTEtMS0w_22ca5838-42b4-47eb-9890-f320ed1e3cbd"
      unitRef="usd">5375000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie4d0ce291981454e84664b7d247bbd2e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfNy03LTEtMS0w_61db5840-383e-42db-90f0-df8c14c4e570"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i331cc003c0d04f078a6a32154ebd1c19_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS0xLTEtMS0w_c2eea0d9-fb28-4647-905a-6f4eb1af3316"
      unitRef="usd">170964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b5fb96fe51e419887a5821e069bbb56_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS0zLTEtMS0w_62a7b499-8005-4474-8e1f-cca6adb23627"
      unitRef="usd">84650000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i61c3ad7f462746299218071393ac1e76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS01LTEtMS0w_f01d83f8-6763-479f-af5b-87c96e6649ed"
      unitRef="usd">86314000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaec0006dbb884a2688382b808984430a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfOS03LTEtMS0w_0a6c50c4-07e3-4492-984e-b3760fda0900"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie3f9b87841b6410e833b3c2aec531508_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItMS0xLTEtMA_5611d9eb-08b4-4edc-8a82-b7c2414015ae"
      unitRef="usd">663000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i77e6a25c0cce4489942fd3fe7e7c649b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItMy0xLTEtMA_6477c9aa-8d16-4e52-83ca-47f927fa63ea"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia9e9e314500242078338cfabc68e7044_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItNS0xLTEtMA_935b55ca-d72a-41a2-91c7-b0ae1b597015"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iad2604c61a3d4a84a43dc5a5223d046b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTItNy0xLTEtMA_7d76a8e6-1a57-4ef3-9cad-0c7938c0f96f"
      unitRef="usd">663000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i331cc003c0d04f078a6a32154ebd1c19_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtMS0xLTEtMA_42c4e38a-334b-4705-b0fe-f71bab546615"
      unitRef="usd">663000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8b5fb96fe51e419887a5821e069bbb56_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtMy0xLTEtMA_24fb7439-d78d-48a2-a737-b44af469bd6d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i61c3ad7f462746299218071393ac1e76_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtNS0xLTEtMA_9e20a044-5164-49f5-a6a4-05281cabe952"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaec0006dbb884a2688382b808984430a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOjMzNzQyMjdkMzVmMDQ5ZWE4NGY2NTVkMjA5NmUwYTcyL3RhYmxlcmFuZ2U6MzM3NDIyN2QzNWYwNDllYTg0ZjY1NWQyMDk2ZTBhNzJfMTMtNy0xLTEtMA_d9df1cc4-5c14-438d-9a9b-f66de7c0fe6e"
      unitRef="usd">663000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf133615c36b4ab3a3e102804e0b1395_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy0xLTEtMS0w_be7c12b9-074b-4fc4-9035-2bf3083f6d57"
      unitRef="usd">88151000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55f163fd764f4b419a6b868c74be4819_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy0zLTEtMS0w_1042230c-4b34-4cff-9c80-956ef21f4b84"
      unitRef="usd">88151000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic67057377152479a8f17df5a513c8a7c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy01LTEtMS0w_f4b66a61-94ea-476c-b787-93d9b6d7be05"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i343e1acc71bd421f93de6475da3bff62_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMy03LTEtMS0w_5702fd5b-3e43-479c-ab7e-b08b3d364d94"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3066659e3a14837b312644f5691a4bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC0xLTEtMS0w_48afa3fa-32b3-4add-9f49-7610ea6459c5"
      unitRef="usd">62729000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f1a8fad572045d6bef48f3a3f6b19e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC0zLTEtMS0w_fdfb4eb6-211a-4af8-a781-ca82c25cbfee"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib83afd2bc4c346a6981483552dc69b41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC01LTEtMS0w_9fa17897-96bc-45c4-84ab-a69dd64b8a7b"
      unitRef="usd">62729000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a252b2bdcfa4716b77eb9c9da774c15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNC03LTEtMS0w_fd5efb70-ee14-4b36-bc5b-226a4891d8c2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i359ed40755d742d598b2a7d817c16d1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS0xLTEtMS0w_4faa9216-c4c8-4ddb-a002-02f561963783"
      unitRef="usd">26658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i99fa54e72d4843718c001d9ccb44924b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS0zLTEtMS0w_6456a38c-4c3d-489b-90b0-fe5af18fbe30"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i777ba44fc4ef4475b9a38bc841b0576d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS01LTEtMS0w_ef865ec5-33a2-4425-b275-0ead39b8fe70"
      unitRef="usd">26658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i718d02cc72e24371be1e76266dcf5064_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNS03LTEtMS0w_ff8c29cd-1850-4742-bc90-11d85909e5b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib84bae8c4960433d93fdb8f2d7158729_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi0xLTEtMS0w_68944bdf-2602-4ac0-b01c-65b872da3f4b"
      unitRef="usd">9279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85a26be08aec4aeea36c9609cfd1b404_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi0zLTEtMS0w_4f0515dd-6d7e-45e5-8e83-c8927ad6d0e2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8614004f13e5407d91653ae48dae6571_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi01LTEtMS0w_29b9a978-b3a3-430a-9706-8102de4f8c77"
      unitRef="usd">9279000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d8f87376786455daba169deb2cd6918_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNi03LTEtMS0w_700bf53e-f9d9-432b-9b12-d53473cdb81a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id472a845edd54c8788fc87a0d47191f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy0xLTEtMS0w_07aad0bc-ca34-483e-91ec-f68c5b99f530"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c27facfc44a42718fa0b68303467103_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy0zLTEtMS0w_5369677b-69e6-4b78-9502-e388fc52c288"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie506d6ee79ea43278c382f43160888b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy01LTEtMS0w_ce411956-bc03-43cf-9b17-9142354555da"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6c71f6dc2c144e6bde1f09a7d4d318c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfNy03LTEtMS0w_7d45db1e-5546-49ed-87c4-c3dddf985819"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaafed114ecbb40428246f042c26c16d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC0xLTEtMS0w_00c2dd8b-6b31-4c42-a716-0c4afe9bd9e8"
      unitRef="usd">187817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0667655fab5c49cc8a9064756e708041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC0zLTEtMS0w_82ae12d3-7b7a-47db-9a6f-d445838671b2"
      unitRef="usd">88151000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75ed11eb6d6e4fd99e38e05050686318_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC01LTEtMS0w_013d475e-5607-4fd7-bd7d-80143cbc8fd4"
      unitRef="usd">99666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iffd4156d88704e5dbe480f29b020b4b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfOC03LTEtMS0w_d4229fcf-4530-4ce8-a225-1dc9fc0d8de5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6ed64ecd7425451a846dd9c27093960b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtMS0xLTEtMA_d14bcc46-e4d2-4361-bfa3-aef6d8cd5a96"
      unitRef="usd">1376000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2769548737144611a050277733a53d55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtMy0xLTEtMA_f85239d9-671f-46cd-9847-dd6bb92a851f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ieb0206150a344137a26fa4bb438d55b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtNS0xLTEtMA_e39c486c-7456-4ddf-8141-44ea87fb6663"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i428867f600214f18bfdfb49712d4abf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTEtNy0xLTEtMA_7690fa52-c1ac-48d7-988a-6648107475fc"
      unitRef="usd">1376000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iaafed114ecbb40428246f042c26c16d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItMS0xLTEtMA_bf1aee31-f776-45d3-b520-443f6bba0edf"
      unitRef="usd">1376000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0667655fab5c49cc8a9064756e708041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItMy0xLTEtMA_89656c89-2948-4780-8960-094cab657012"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i75ed11eb6d6e4fd99e38e05050686318_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItNS0xLTEtMA_a7d30f69-a512-4978-87f9-6b99adc2255b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iffd4156d88704e5dbe480f29b020b4b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV8zNy9mcmFnOjc2YzExY2E5MDFlNTRlNDliMTVlM2ZmYmE4MzM3MmE1L3RhYmxlOmQ2NDc5MGU1N2I4ZDQ3ZTNhM2EwZTc5YjU4ZGZhZjBlL3RhYmxlcmFuZ2U6ZDY0NzkwZTU3YjhkNDdlM2EzYTBlNzliNThkZmFmMGVfMTItNy0xLTEtMA_69bdc66d-57ca-40cc-81c6-49ff58c8795e"
      unitRef="usd">1376000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTI3Mw_5c08c736-583e-4e29-bac0-4119f229025b">COLLABORATION AND LICENSING AGREEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kyowa Kirin Co., Ltd. (&#x201c;KKC&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we entered into a research collaboration and option agreement with KKC (the &#x201c;2019 KKC Agreement&#x201d;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#x201c;DCs&#x201d;), with one compound inhibiting the first undisclosed target (&#x201c;Program 1&#x201d;), and a second inhibiting the second undisclosed target (&#x201c;Program 2&#x201d;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0 million within 30 days of November 11, 2019 (the &#x201c;Effective Date&#x201d;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, we recognized $1.3 million and $2.8 million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. During the three and six months ended June&#160;30, 2020, we recognized $1.1 million and $2.3 million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. The aggregate amount of the transaction price allocated to our partially unsatisfied performance obligations as of June&#160;30, 2021 and December&#160;31, 2020 was $1.4 million and $4.2 million, respectively, which is presented in the accompanying condensed balance sheet as deferred revenue. As of June&#160;30, 2021, we expect to recognize the remaining transaction price allocated to our partially unsatisfied performance obligations over the remaining research terms, which is currently expected to extend through the end of 2021. There were no significant changes in estimates associated with the 2019 KKC Agreement during the six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, we entered into an exclusive license agreement with KKC (the &#x201c;2017 KKC Agreement&#x201d;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#x2019;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606) and related amendments (&#x201c;ASC 606&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30.0 million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the up-front license fee received of $30.0 million, we may be entitled to receive up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.0&#160;million in total development milestones, of which $10.0 million has been received and recognized as revenue as of June&#160;30, 2021, and approximately &#xa5;8.5 billion for commercialization milestones, or approximately $76.5&#160;million at the currency exchange rate on June&#160;30, 2021, as well as reimbursement of costs plus a reasonable overhead for the supply of product and high-teen royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 we recognized zero and $5.0&#160;million, respectively, as licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2020, we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized no licensing revenue upon the achievement of development milestones. The $5.0&#160;million development milestone recognized during the three months ended March 31, 2021 related to the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2021, we recognized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $0.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2020,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized $5.0 thousand and $43.0 thousand&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as product supply revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 we received a $2.9 million prepayment from KKC for the manufacturing of tenapanor drug substance. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun Pharma&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we entered into an exclusive license agreement with Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Fosun Agreement&#x201d;),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IBS-C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.0 million in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license fees which was recognized as revenue when the agreement was executed. Based on&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;management&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we determined&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the license and the manufacturing supply services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represented the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material performance obligations at the inception of the agreement, and as such,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each of the performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;distinct. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be entitled to additional development and commercialization milestones of up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue during the three and six months ended June&#160;30, 2021 related&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Knight Therapeutics, Inc. (&#x201c;Knight&#x201c;) &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, we entered into an exclusive license agreement with Knight (the &#x201c;Knight Agreement&#x201d;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#x2019;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $17.9 million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, we entered into a termination agreement with AstraZeneca (the &#x201c;AstraZeneca Termination Agreement&#x201d;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of June&#160;30, 2021, to date in aggregate, we have recognized $11.6 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $10.6 million. For the three and six months ended June&#160;30, 2021 we recognized and recorded as cost of revenue zero and $1.0 million related to the AstraZeneca Termination Agreement. For the three and six months ended June&#160;30, 2020 we recognized $0.1 million cost of revenue related to the AstraZeneca Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balance is attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ardx:NumberOfSeparateCollaborativeAgreements
      contextRef="id9f52e3ac5894f0d82d3246f26b4426f_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjU4_6b546ba7-c117-4cc1-a499-11df4107d95b"
      unitRef="item">1</ardx:NumberOfSeparateCollaborativeAgreements>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTE5_a49a399c-f37c-4215-849b-cbd1f72e7cf0"
      unitRef="usd">10000000.0</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
      contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTY4_b336618f-ad2c-44c0-b97a-40a561dde70e"
      unitRef="usd">5000000.0</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment>
    <ardx:TermOfPaymentOfLicenseFeeFirstInstallment
      contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTc4_3bcef376-a81f-4d2a-bf98-31ac5f06c390">P30D</ardx:TermOfPaymentOfLicenseFeeFirstInstallment>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
      contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA1Ng_c18f0484-74cd-4c9a-bcad-e88a4e1ad4ff"
      unitRef="usd">5000000.0</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment>
    <ardx:TermOfAgreement
      contextRef="i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTI5Ng_3e4ef167-203a-4bc7-be37-dd7f5af25480">P2Y</ardx:TermOfAgreement>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="if971ec15d09646659e6f792d4e0c33c1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTYxNQ_a7896006-e5d4-4752-bce4-6ba4fa63022e"
      unitRef="usd">1300000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="ibc9980b470ca44ceb2a1da9962e99de8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzM2MA_52f7979c-9923-4844-bca6-4297a93e4274"
      unitRef="usd">2800000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i6882c8ec77184cfc83073e6f4ae139de_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzY4NA_eed63e22-1307-4ad1-8617-13dd9de4286b"
      unitRef="usd">1100000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i891ee02e0c064d5fac9eef456b775d16_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzY5OQ_91a0242a-e3d4-43bd-b0bf-283ea0b4c806"
      unitRef="usd">2300000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8f8816a7551b42f7b0f4ee113d914fe6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzODA5OA_cdcbabdf-335e-4539-a037-9c903d99561a"
      unitRef="usd">1400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if032ba3b809943c691949710d1c0d6e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzODEwMg_780a8dde-330d-4c13-8cd3-76f56745bdc5"
      unitRef="usd">4200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMzY1Ng_05ba0c04-e2bd-479f-a838-4d99c4141048"
      unitRef="usd">30000000.0</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i366600b773664265a8f62dc28a6a75b7_D20171101-20171130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDA1Mg_05ba0c04-e2bd-479f-a838-4d99c4141048"
      unitRef="usd">30000000.0</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i69ac419220864a3e96c1c6f85f0e3d6c_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDA5Mg_5f4f72d6-0b0a-4b25-8890-37f63916b396"
      unitRef="usd">55000000.0</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd7ffc17c4ea41b8942ca8c90aef5985_D20171101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDEzNw_155d1188-6775-4093-bf0e-9b4ca7db36b3"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i1534860e131847dd8b0713fab040d16d_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDIyNA_f0e151b2-8918-4a2a-9bf9-2c55bc2ad5bb"
      unitRef="jpy">8500000000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i1534860e131847dd8b0713fab040d16d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDI3OA_75f3f8ea-7a31-455d-921d-ab3e8aa7dcee"
      unitRef="usd">76500000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ca092a95ab44a3fbec59b1d0b8dead2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzE1Mg_b4c11dec-9a89-4540-af65-b7587583ca36"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i283b29715ca94bd7bff20ea912e2dc44_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzM3MA_77fdb7bc-0f13-429a-97e7-bcd6f0ed0f3d"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2ed442c04974d718d23c4fab2737e51_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDcwOA_7ba9e921-9eaf-4f5c-b6c9-ddc7c1826ab5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc13520e38174911bb24b8da85289f37_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNDcwOA_b677d1e4-1cb4-4e67-9d67-67c9d5a5de70"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2816086d585e4b8ab2a5d4fcf91cc35b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMzI5ODUzNDg5Mjg4Ng_71e4f3ab-48b1-411c-81de-d1d7e6716491"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78360eebb07744fe9d6aa96a4bb1ccec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTAyOA_74de27fc-82e2-4468-93bd-c59ad24ccec4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33e4b72e7e4047f7963dc1ef571b8610_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzcxMA_9ca83ab2-6bd5-4829-92d9-9491cea7ac30"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9445347caff444659496b5c488ed0fa2_D20200401-20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc1Nw_c5c7fe5e-7bff-4774-a756-6b6c0df9a458"
      unitRef="usd">5000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98776866f5974807b9f5978a8f14c768_D20200101-20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc2OQ_3e4771f5-fc9c-4a4b-bd8c-d977cb74e75c"
      unitRef="usd">43000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i7f5d2add0495488f81876f95890d813f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTI5Nw_a02128db-7e59-4287-902c-13818b34290f"
      unitRef="usd">2900000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNTI5Nw_f5f4923f-1fcf-46bd-89bd-026168161d82"
      unitRef="usd">2900000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="if14136718f7645a09e5144e34b83338e_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjAyMA_f850f617-e456-4857-b955-857d4065d2a9"
      unitRef="usd">12000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjQ1MA_7a3b324c-5c39-44a2-8c6e-58b0c562b994"
      unitRef="usd">110000000.0</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:ThresholdPercentageOfSalesForTieredRoyalties
      contextRef="i3d1b64fa883d4b70bf80a72fa2648ce7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjYwNA_2e1b9604-cc34-4a36-8e80-8c5fd8880468"
      unitRef="number">0.20</ardx:ThresholdPercentageOfSalesForTieredRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i988b12581c6e42f6b02b04fe7c54a484_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjc5NA_c32a21fd-fd60-4b3d-a2e2-15b4cdf75a1f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5c99d81bd754260871242f4e771916c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNjc5NA_da3d9c0a-4513-4c5a-85d0-013bcab7694c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNzU0MA_46db6a67-957a-4bf7-a878-b26883e625e4"
      unitRef="usd">2300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="ida84e0b6304046d691e9479167fc07c6_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfNzcwMQ_1a6fb242-c515-421f-844a-55ddd2869133"
      unitRef="usd">17900000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODI0MA_c005b14c-4744-4e4f-9f77-b209629336ed"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="iedc25f8b7f474fdcb91abf065d028bc1_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODMyNQ_4d6416de-1fdd-4056-8911-f839eea37854"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="idcc25084bb364545944e03f1663c5e5e_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODUzNA_1e8df4fa-09d4-4e0f-bdbd-052bc97dcd05"
      unitRef="usd">75000000.0</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <us-gaap:CostOfRevenue
      contextRef="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODYxOQ_dcddabd9-16ff-422a-b55f-33511177eb28"
      unitRef="usd">11600000</us-gaap:CostOfRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="idcc25084bb364545944e03f1663c5e5e_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODYyOQ_1e8df4fa-09d4-4e0f-bdbd-052bc97dcd05"
      unitRef="usd">75000000.0</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:PaymentsOfUnchargedLicenseFees
      contextRef="i6b803670398d42948359c492b8c8c7ed_D20150601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODcwMw_81dcf31c-82bc-4324-84e7-681e1d6f4cfa"
      unitRef="usd">10600000</ardx:PaymentsOfUnchargedLicenseFees>
    <us-gaap:CostOfRevenue
      contextRef="i0a52e2793ccc45d7acd1aa68fc3d6d54_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODc4MA_cf5dd3cb-2e31-4fb7-9dbf-81c1932ebe58"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i0bf132b0a9774bdc872ca3d86d11edd7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfMTA5OTUxMTYzNzc5NA_f1da356b-1c53-4be0-a3bb-f46ed04ac83c"
      unitRef="usd">1000000.0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i2fc36ba0cdfe49288d9249c20ff9f953_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODg3NA_11b71e67-a4b6-4f97-adc1-0bd849495ebb"
      unitRef="usd">100000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9c458d292e4c40c6a13a0002a7985e5c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfODg3NA_63828beb-9ddd-4176-b1f4-7c197d2bc176"
      unitRef="usd">100000</us-gaap:CostOfRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RleHRyZWdpb246Njc5ZTAzZGZlYjU0NDlhNGI3YjgxOWRjOTAyMDY1ZjFfOTI3Mg_a1c77ab2-f243-447f-8533-bf0f2a66ab76">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balance is attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib8e8922e9c354c27894a0e726cd808d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfMS0xLTEtMS0w_3f44e983-9300-40e3-ae67-2c59a7e14160"
      unitRef="usd">4177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="ie588300a61314fd1a511fc90bc57b89c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfMy0xLTEtMS0w_9d3fe2c7-4c7d-4177-bef0-60536b5aa915"
      unitRef="usd">2765000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i94f983056a234617bb02529bdab92604_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmQ3ZTljOWM0ZDdlNTQyNWJhOTU0MWY3NGQ3YTA4YjhhL3RhYmxlcmFuZ2U6ZDdlOWM5YzRkN2U1NDI1YmE5NTQxZjc0ZDdhMDhiOGFfNS0xLTEtMS0w_08af3b71-84d8-4a74-b6e9-ae1614a3a84d"
      unitRef="usd">1412000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7c3eac47e3784f54a4d7c86adfabdc2d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfMS0xLTEtMS0w_363f5cc5-b75e-45ab-b959-5a7428639539"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i9e7eadf4c3104be1bc673428af6c4149_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfMy0xLTEtMS0w_05bb5bd1-8aa5-49b8-8e7f-a4f619a18cef"
      unitRef="usd">2947000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i822c7141162e4b328f9131de3d247ea5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80MC9mcmFnOjY3OWUwM2RmZWI1NDQ5YTRiN2I4MTlkYzkwMjA2NWYxL3RhYmxlOmMyZDBmN2JlN2VkYzQyNDg4NWNhMTdkMjdmZjkxOWI0L3RhYmxlcmFuZ2U6YzJkMGY3YmU3ZWRjNDI0ODg1Y2ExN2QyN2ZmOTE5YjRfNi0xLTEtMS0w_e2410c60-87b5-459a-9973-724c344a64b2"
      unitRef="usd">2947000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDM2MA_728087af-a400-427f-b426-6da89ad560ba">BORROWING &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solar Capital and Western Alliance Bank Loan Agreement&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;16, 2018, we entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;), with Solar Capital Ltd. and Western Alliance Bank (collectively the &#x201c;Lenders&#x201d;). The Loan Agreement provides for a $50.0 million term loan facility with a maturity date of November&#160;1, 2022 (the &#x201c;Term Loan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 9, 2020, we and the Lenders entered into an amendment to the Loan Agreement (&#x201c;the 2020 Amendment&#x201d;) to extend the date through which we are permitted to make interest-only payments on the Term Loan by twelve months to December 1, 2021. The 2020 amendment also required that if either the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issues a CRL with respect to our NDA Number 213931, then we are to begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issues us a CRL. On April 29, 2021, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis by three months to July 29, 2021, making it unlikely that the FDA would approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May and July 2021, we and the Lenders entered into additional amendments to the Loan Agreement (&#x201c;the 2021 Amendments&#x201d;) which together extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. As of June 30, 2021, we have classified our loan payable, current to include all principal payments that would have been due beginning on June 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We paid a closing fee of 1% of the Term Loan, or $0.5 million, upon the closing of the Term Loan, $0.1 million upon closing of the 2020 Amendment and $0.1 million upon closing of the 2021 Amendments. Under the Term Loan, we are also obligated to pay a final fee equal to 4.95% of the Term Loan upon the earliest to occur of the maturity date, the acceleration of the Term Loan, the prepayment or repayment of the Term Loan or the termination of the Loan Agreement. We may voluntarily prepay the outstanding Term Loan, subject to a prepayment premium of (i)&#160;3% of the principal amount of the Term Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii)&#160;2% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii)&#160;1% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The Term Loan is secured by substantially all our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the Term Loan, we entered into the Exit Fee Agreement, as discussed in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement also contains customary events of default that entitle the Lender to cause us indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term Loan, including our cash.&#160;Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all amounts owed under the Loan Agreement. As of June&#160;30, 2021, to our knowledge, there were no facts or circumstances in existence that would give rise to an event of default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Loan payable, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjgx_4f081b21-af24-456d-b17c-1bf184e770fe"
      unitRef="usd">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <ardx:DebtInstrumentInterestPaymentExtensionTerm
      contextRef="ibcaf515abe2840c282d0b24ba36d7735_D20201009-20201009"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNTc2_537c73e6-648c-46bc-9910-a726d2b86628">P12M</ardx:DebtInstrumentInterestPaymentExtensionTerm>
    <ardx:DebtInstrumentClosingFeePercentage
      contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjQ5OQ_6b0db210-efd4-402b-a4f6-8006aef47f11"
      unitRef="number">0.01</ardx:DebtInstrumentClosingFeePercentage>
    <ardx:DebtInstrumentClosingFee
      contextRef="i3fc7bd2e9a8044539a1c899e40063725_I20180516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjUyMw_4606dd79-41ce-4c0f-ac25-342e610e037e"
      unitRef="usd">500000</ardx:DebtInstrumentClosingFee>
    <ardx:DebtInstrumentClosingFee
      contextRef="i090b2bbf6d4a488396b2cfe21eb06705_I20201009"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjU2Ng_9858cca4-4221-4981-8273-bf011dcdbed4"
      unitRef="usd">100000</ardx:DebtInstrumentClosingFee>
    <ardx:DebtInstrumentClosingFee
      contextRef="i7210d52700b243169235360a519811d9_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMTA5OTUxMTY0MDI3MQ_617446eb-4c26-4a9b-9ca7-050d4face06c"
      unitRef="usd">100000</ardx:DebtInstrumentClosingFee>
    <ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage
      contextRef="i23709eda801d451e8c51e46f71e084aa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjY3Ng_f3f68a51-a2c0-497c-adf2-4f3e8467f68e"
      unitRef="number">0.0495</ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="iabae158ea16a4d0db01673f4d02bd862_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMjk1OQ_66b0e372-5f20-4715-ab07-7ba7575bc047"
      unitRef="number">0.03</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="iac7f10228e774928bcb37829f399cf64_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMzA3Nw_fc740e18-151c-4a17-9dc3-37064022dceb"
      unitRef="number">0.02</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="ic930520ff3b24850b76418b4769ee010_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfMzI1NQ_0a042985-e119-4868-930c-b85925a07441"
      unitRef="number">0.01</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentInterestRateOnDefaultPercentage
      contextRef="iabd06b4585e1420e94a3a1bc12e8bde5_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDAyMQ_c4f6dc1b-8d00-4408-b995-f6263cf7b8a9"
      unitRef="number">0.04</ardx:DebtInstrumentInterestRateOnDefaultPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RleHRyZWdpb246YTZhYmU5YTUyNmFkNDExZTgzOWZhMTkwYmY0MmQzYjdfNDM2MQ_f74d962e-13b8-48d8-8ac0-0681321cfbe9">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Loan payable, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMC0xLTEtMS0w_2b164d23-cbdd-4f68-a5f0-efa04b41018a"
      unitRef="usd">52475000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMS0xLTEtMS0w_e92dbaef-1061-4691-9c09-52d6a5419529"
      unitRef="usd">378000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMi0xLTEtMS0w_c637cd39-afa6-417a-8078-5bc6e65b7d32"
      unitRef="usd">853000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfMy0xLTEtMS0w_7eb18bdf-8b8c-4be4-b4c0-8c647ed92c2c"
      unitRef="usd">51244000</us-gaap:LongTermDebt>
    <us-gaap:LoansPayableCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfNC0xLTEtMS0w_17445426-a460-4c08-afa3-c956332ec8b5"
      unitRef="usd">36111000</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80My9mcmFnOmE2YWJlOWE1MjZhZDQxMWU4MzlmYTE5MGJmNDJkM2I3L3RhYmxlOmZiODc1MmUyNWY2YTQ3MzI4ZGQ4NTZjZGI4MzVmZDU1L3RhYmxlcmFuZ2U6ZmI4NzUyZTI1ZjZhNDczMjhkZDg1NmNkYjgzNWZkNTVfNS0xLTEtMS0w_b62b873b-0a51-4755-ab04-096ec43eb8ba"
      unitRef="usd">15133000</us-gaap:LongTermLoansPayable>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjQ4OA_a647e5be-6e37-4755-bc3c-8d68e8797421">DERIVATIVE LIABILITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in connection with entering into the Loan Agreement, as defined and discussed in Note 5, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#x201c;Exit Fee&#x201d;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (&#x201c;IBS-C&#x201d;), which was obtained on September 12, 2019 when the FDA approved IBSRELA&#xae; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#x201c;Exit Fee Agreement&#x201d;). Notwithstanding the prepayment or termination of the Term Loan, as defined and discussed in Note 5, our obligation to pay the Exit Fee will expire on May 16, 2028. We concluded that the Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5&#160;million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the six months ended June&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exit Fee derivative liability at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exit Fee derivative liability at June 30&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended June 30, 2021 we reduced the value of the derivative liability due the receipt of the CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib0977925bb314a0d989a37372b6e92e9_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjEx_5b6d8c65-392c-494d-8ec3-23dcfe5d92f4"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ia4b9f41836824ed3b567440b012e50ee_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMTY0OA_d35ef541-2db6-421a-a335-7521b2ba7007"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i7a442e4da84048eda09938d7030e2b4c_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjEwMw_aad13f77-88af-422d-92a5-0064ea3becb5"
      unitRef="number">0.10</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation
      contextRef="i7a442e4da84048eda09938d7030e2b4c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjIzNw_9395203b-b702-422d-8873-b972826d0fc3"
      unitRef="usd">100000</ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RleHRyZWdpb246MzJiN2IwMzlmZDQwNGIyZThjN2RjYTM5MjY5N2IyMmJfMjQ4OQ_1159a123-e82f-43f1-8ee7-fadd8801ed11">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the six months ended June&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exit Fee derivative liability at January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Exit Fee derivative liability at June 30&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMi0xLTEtMS0w_c25f717b-00a7-4108-a0f9-57c5eba59415"
      unitRef="usd">1376000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i63131bdabbd8434aaf8c26325f068bd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMi0zLTEtMS0w_e6d7d465-2d8c-4d8e-a5be-d3d801d159c7"
      unitRef="usd">969000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iae411fbdd0534f02bc4fdf3a5d2ca8a5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMy0xLTEtMS0w_3087fa3b-0b6c-4b58-8d82-4007d9904998"
      unitRef="usd">-713000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i013c596cde5f4e4195fb7311188973d7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfMy0zLTEtMS0w_db44bfff-bf7d-47b4-9e92-2204c217fdce"
      unitRef="usd">152000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id7c87d785bda4e47beed917e20627d9a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfNC0xLTEtMS0w_c35c0ae1-4a5d-4e8b-b6da-2180708a8bea"
      unitRef="usd">663000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib3f3cfb47f314559af19e068ea3c36e7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80Ni9mcmFnOjMyYjdiMDM5ZmQ0MDRiMmU4YzdkY2EzOTI2OTdiMjJiL3RhYmxlOjUxNDMwYzE2YTU2ZTRlNTE4Zjk1MzYxMDdlMTVkYTJkL3RhYmxlcmFuZ2U6NTE0MzBjMTZhNTZlNGU1MThmOTUzNjEwN2UxNWRhMmRfNC0zLTEtMS0w_f6844cbb-9535-4338-a814-415f90b26b57"
      unitRef="usd">1121000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYx_3805fdfd-cf91-4c74-b65a-cd0b012db0e0">LEASES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, we entered into an amendment to the lease for our Fremont, California facility that extended the term of the lease to March 2025. The office space consists of 72,500 square feet with the lease terminating in September 2025. We increased the right-of-use asset and lease liability by $11.9&#160;million for the Fremont lease upon commencement of the amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, we recorded a right-of-use operating lease asset for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of 12,864 square feet with the lease terminating in June 2026. We have an option to extend the lease term for one additional five year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $1.6&#160;million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in the condensed balance sheet as of June&#160;30, 2021 (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,519&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,732&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ib702c69d1490476d80c3cd108100c164_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTgwNw_d00c18c7-3636-465d-9ed6-786e9a169a2c"
      unitRef="sqft">72500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9190bfc1045649fbbed0e5bf15c56905_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTQzMg_81eeb9fc-8b9a-4dbe-a28f-780298a92dfa"
      unitRef="usd">11900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTYzOQ_3fec378c-55ce-4bf2-a2f7-2a810939c736"
      unitRef="sqft">12864</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="ie2170430801c4c239779ff73419a0839_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzI1NA_352b325d-eeba-4db6-a1ad-8729d0cd41a9">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <ardx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzI0Ng_54cadd6b-5d17-450e-9fe5-630f678b8cc0"
      unitRef="renewal_option">1</ardx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8c2e99912d72427fa13d8d0bf46271f8_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMzI5ODUzNDg4NzM2Nw_8ce7dc6e-75e1-462a-a1b3-93e2349730b6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie2170430801c4c239779ff73419a0839_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfMTA5OTUxMTYzMTY2Nw_c25b7ded-ca94-4169-83da-489bc477b915"
      unitRef="usd">1600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYy_21d56ca5-d01d-4edb-86c5-e342e652caa4">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in the condensed balance sheet as of June&#160;30, 2021 (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,519&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,184&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,732&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfMS0xLTEtMS0w_fc09795f-b732-4432-9a3a-bfc72b99e7ce"
      unitRef="usd">14519000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfMy0xLTEtMS0w_98a1f99b-106f-46e0-86e7-e318ac3be840"
      unitRef="usd">3184000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNC0xLTEtMS0w_e640687a-4d91-4481-aaa1-c5ab76b65dff"
      unitRef="usd">11548000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNS0xLTEtMS0w_55599071-605e-4ed4-bee4-5ed2a354e359"
      unitRef="usd">14732000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfNy0xLTEtMS0w_4f88955f-5ea7-44b8-bd56-626462e237cb">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUzMmFjYmM3YjMyMzQzZjA4NTY5MDUxYjJiYzljNDk4L3RhYmxlcmFuZ2U6ZTMyYWNiYzdiMzIzNDNmMDg1NjkwNTFiMmJjOWM0OThfOC0xLTEtMS0w_6d27b8c7-78aa-4ba1-a723-e679589d6fb3"
      unitRef="number">0.0687</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzYz_1805e486-516a-4e3d-ac77-ab4d70c4c961">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi0xLTEtMS0w_d45ea9dc-5cfd-4214-b3d8-9a53ac93a54b"
      unitRef="usd">837000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi0zLTEtMS0w_3aa34f8c-28f5-47ff-a809-863c09a6b4c9"
      unitRef="usd">648000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi01LTEtMS0w_6466592c-f7d6-455b-ada7-616ba16ef92f"
      unitRef="usd">1510000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMi03LTEtMS0w_17ac8d8e-bfed-4de2-a134-ea8eb6354fed"
      unitRef="usd">1296000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy0xLTEtMS0w_edbbc89e-2efc-4234-8e7d-f3f78c9ec182"
      unitRef="usd">766000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy0zLTEtMS0w_fb7bd8f2-f42f-4fc5-8030-a5dc3c316839"
      unitRef="usd">761000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy01LTEtMS0w_445e9274-e9e9-4666-898e-d7a034f69330"
      unitRef="usd">1554000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOmUxOTA4OGRhYWU5ZDQyYzA4YjkzNWI2Y2E3NzliNmJmL3RhYmxlcmFuZ2U6ZTE5MDg4ZGFhZTlkNDJjMDhiOTM1YjZjYTc3OWI2YmZfMy03LTEtMS0w_c874fd01-0ec2-4f05-bdec-95209311cacb"
      unitRef="usd">1521000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RleHRyZWdpb246YzBjYjcwOWJmNzlkNDc2NGJiZDg5YzgxNThkOWYxNDVfNzY0_6c2d52a2-ba68-4201-9ab3-4684adb248ab">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMC0xLTEtMS0w_ac89da76-c2e7-4f39-9a02-9790c63d8c55"
      unitRef="usd">1978000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMS0xLTEtMS0xOTk3_f515e64f-ee00-4f20-91a1-66c6a1761618"
      unitRef="usd">4292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMi0xLTEtMS0xOTk3_86028669-4297-4acd-8e71-54dcc2f86c18"
      unitRef="usd">4440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMy0xLTEtMS0xOTk3_1e87fca7-1466-4a2c-86c4-9d0707a9ccb0"
      unitRef="usd">4589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNC0xLTEtMS0xOTk3_d9ca83f9-d656-4f36-a264-283e5d2e5b84"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ardx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMS0xLTEtMS0w_efa0ceef-a7ea-40d2-8002-aca55f7547f8"
      unitRef="usd">252000</ardx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMi0xLTEtMS0w_abf33c2e-7b64-4276-b6c8-cf830f941d0c"
      unitRef="usd">16872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfMy0xLTEtMS0w_d3c14124-afe7-4e81-9efb-588ebacc9007"
      unitRef="usd">2140000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNC0xLTEtMS0w_6123e94d-53f6-4367-84a6-1a6bc9f6d3c0"
      unitRef="usd">14732000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNS0xLTEtMS0w_f1a75b19-8fdd-4cdc-8253-909e8c6c89fd"
      unitRef="usd">3184000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV80OS9mcmFnOmMwY2I3MDliZjc5ZDQ3NjRiYmQ4OWM4MTU4ZDlmMTQ1L3RhYmxlOjk5ODdhMmExZDM5YzRlZDJhZGFjMjJjYjJkZWVlNDJlL3RhYmxlcmFuZ2U6OTk4N2EyYTFkMzljNGVkMmFkYWMyMmNiMmRlZWU0MmVfNi0xLTEtMS0w_7fccc18d-2d40-41da-aae3-2c455ca3f670"
      unitRef="usd">11548000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTI5Mg_4e198037-3013-4b9b-ac5e-3b1d301ef42b">STOCKHOLDERS&#x2019; EQUITYAt the Market Offerings AgreementIn July 2020, we filed a Form S-3 registration statement, which became effective in August 2020, containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC, deemed to be &#x201c;at the market offerings.&#x201d; During the six months ended June&#160;30, 2021 we sold 9.0 million shares of our common stock for aggregate gross proceeds of $63.8 million at a weighted average price of $7.10 per share under the Open Market Sales Agreement. We sold 8.2&#160;million shares of our common stock between the dates of November 13, 2020 through February 19, 2021 and 4.0&#160;million shares between the dates of May 11, 2021 through June 18, 2021 for a cumulative total of 12.2&#160;million shares and gross proceeds of $85.4 million at a weighted average sales price of approximately $6.98 per share during the life of the Open Market Sales Agreement. Pursuant to the Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the Open Market Sales Agreement.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="if3dc7ec6f5ed4386a5ff6d842b738934_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMjg3_228ac5c7-ab89-4ff6-9a9e-c204e27acb21"
      unitRef="usd">250000000.0</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i5a4fc789a9b84f18b38090c85e7db5bc_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNTM0_28402d25-0503-4ddd-9f53-8672dbf9289d"
      unitRef="usd">100000000.0</ardx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNzMx_930279c3-25c9-4ede-abc2-67cbe73dd1c1"
      unitRef="shares">9000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfNzkz_ac008554-cab1-417b-9728-ed5c9fb671da"
      unitRef="usd">63800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfODI3_aceeb3f0-80af-4f84-a22c-07712abde3eb"
      unitRef="usdPerShare">7.10</ardx:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i785930e859ee4be7bb7b7fb96ea4cb11_D20201113-20210219"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA5OTUxMTYyOTYxOA_0f61b430-d56e-4662-9cd5-3aff929d5b53"
      unitRef="shares">8200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifdc1fab5cf114d6a87de78c84c48449b_D20210511-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA5OTUxMTYyOTYzMg_2c52c716-f6db-4697-bb67-02fe18a00bf3"
      unitRef="shares">4000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfOTcx_5b150f80-0558-453e-a70f-de89d019c39d"
      unitRef="shares">12200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTAyMw_1f1a2192-0462-4069-a3c3-03936560e0af"
      unitRef="usd">85400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="ic8c30b33f5d5468d98c8e1fc172a2a92_D20201113-20210618"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTA3Nw_2d7179bc-de4f-4d25-a303-9c6e93373b32"
      unitRef="usdPerShare">6.98</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="ie40ca68854bc43c7abd93ccd8eb49b60_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81Mi9mcmFnOmE3OGM1ZTJmZDUzYjRkYjNhMmRlYWJiOWY1M2ZlYWViL3RleHRyZWdpb246YTc4YzVlMmZkNTNiNGRiM2EyZGVhYmI5ZjUzZmVhZWJfMTE5NA_04dcaf56-e695-4784-8ac7-531e9a2c8fa8"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMjAxOA_b09c7fbe-596f-48c3-bdee-035e9f316c1b">EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining&lt;br/&gt;&#160;Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Value at Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued no PRSUs during the six months ended June&#160;30, 2021 and we have no PRSUs outstanding as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we sold approximately 0.2 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $5.84 per share resulting in proceeds to us of approximately $1.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance of Common Stock for Services&lt;/span&gt;&lt;/div&gt;Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2021, we issued no shares of our common stock to members of the board of directors in accordance with the program.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMQ_760073ec-3fb9-4ddf-af6e-109dc7e0e0ba">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e4e511a9eaa4a259b6f2af0a9346f02_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi0xLTEtMS0yMDE2_d1b3876f-01cb-416c-9f1c-42d876a2a03b"
      unitRef="usd">1087000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i90d3b6aaec8145c3b159056fc132c464_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi0zLTEtMS0yMDE2_515ae6e0-f099-4e78-9bb8-c36f8179aed8"
      unitRef="usd">1144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3795671d1695460f9521163c5473a1b8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi01LTEtMS0yMDE2_8cc4d1de-2791-45e4-bb42-24705475c50f"
      unitRef="usd">2179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9edc45d4a609489c93f139ccdfc04755_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMi03LTEtMS0yMDE2_61361f07-aed8-4288-8587-7b0c314bb351"
      unitRef="usd">2202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie94913409dc945679a54fb334278a1a4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy0xLTEtMS0yMDE2_1320f2dd-29f6-45f1-881e-2860f559d367"
      unitRef="usd">2132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id449269d05cb4a7bb376cb25ae99695c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy0zLTEtMS0yMDE2_2c9a061d-999e-4158-9adc-cf862d09e653"
      unitRef="usd">1530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee13a843486b4b1dba0ef49f9b47772a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy01LTEtMS0yMDE2_eaf5930d-9707-4be5-9ac5-749a6bab174d"
      unitRef="usd">4127000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd939d4bd73a4f909c2aade26597c328_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfMy03LTEtMS0yMDE2_baaf64e1-acc5-43e4-98a5-6d53deea8de5"
      unitRef="usd">3420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC0xLTEtMS0yMDE2_3c3b389a-1591-4af9-b17f-79d427b31076"
      unitRef="usd">3219000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC0zLTEtMS0yMDE2_b10fde2e-f8f5-4814-bc08-f2972ba415ae"
      unitRef="usd">2674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC01LTEtMS0yMDE2_1d3c6dc2-e7d1-4326-8e85-254276a1bcd6"
      unitRef="usd">6306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjRiM2YzZTE5ZmJjYTQ0ZGU5NGZjZjYyN2ZlZjhmY2RlL3RhYmxlcmFuZ2U6NGIzZjNlMTlmYmNhNDRkZTk0ZmNmNjI3ZmVmOGZjZGVfNC03LTEtMS0yMDE2_6a97f215-e534-4e38-98d0-fc2955930609"
      unitRef="usd">5622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMA_0529aff1-f976-4efb-95be-3f3a01f08f94">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation&lt;br/&gt;&#160;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining&lt;br/&gt;&#160;Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMS0xLTEtMS0yMDE2_8182f4d1-71f1-4f3d-af5f-e5a0f1b46259"
      unitRef="usd">25267000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iedd803553a9b495da7e99b9a2beac824_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMS0zLTEtMS0yMDE2_51841598-99bc-4f98-82a3-1c0d4033f011">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMi0xLTEtMS0yMDE2_f9fe85f2-d8ae-431c-b7ff-30af9e25dd41"
      unitRef="usd">6978000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMi0zLTEtMS0yMDE2_1dc4eb3b-efe4-459d-8ae0-79bc832074da">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if7650d015d8f4d54b605259abc29e66e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMy0xLTEtMS0yMDE2_77eb8890-2a58-4f51-80b2-456deb301250"
      unitRef="usd">151000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie6de6db9967249b18554b23602a09e1a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOjIxMzE3ZDliZWQ4ZTQ4ZWNiOWExZDZmN2FjOWNiNzBmL3RhYmxlcmFuZ2U6MjEzMTdkOWJlZDhlNDhlY2I5YTFkNmY3YWM5Y2I3MGZfMy0zLTEtMS0yMDE2_f1f79bce-1410-43f8-96b5-2e35db09046e">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMg_9d6f98ad-d7ed-4303-b2ca-8b902f598ae1">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMS0xLTEtMS0xNzIy_5a8a4ed2-e2db-4ac0-bcef-0d3149552bff"
      unitRef="shares">9790000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i62f4c36f4b554b9b8908a7e166a96117_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMS0yLTEtMS0xNzIy_337efab1-e5c6-4955-94fe-952debe86c5d"
      unitRef="usdPerShare">6.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMi0xLTEtMS0xNzIy_e60ca25d-d15a-40f5-ad83-b5b33f0854e1"
      unitRef="shares">3328000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMi0yLTEtMS0xNzIy_dad6560b-c28b-4e02-b0e5-07ae35bbc536"
      unitRef="usdPerShare">6.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMy0xLTEtMS0xNzIy_48258814-0b8f-4512-ad56-e20f2c407593"
      unitRef="shares">205000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfMy0yLTEtMS0xNzIy_c0646bc5-877d-4b2e-ba66-bb38480f3bbc"
      unitRef="usdPerShare">2.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNC0xLTEtMS0xNzIy_6a562e3a-f2ce-4af7-8f3c-52e600f5df87"
      unitRef="shares">401000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNC0yLTEtMS0xNzIy_64e91a0b-9b78-4ad8-b3a7-2d9e4b2f87cc"
      unitRef="usdPerShare">7.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNS0xLTEtMS0xNzIy_bcdfe088-da69-4ff7-af97-f6f51d033e23"
      unitRef="shares">12511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNS0yLTEtMS0xNzIy_04630478-5569-4c59-96ea-4fc69526a06d"
      unitRef="usdPerShare">6.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNi0xLTEtMS0xNzIy_a604576b-0491-4160-9d5e-01078fedd910"
      unitRef="shares">6043000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmM1OWIxYjkwOGQxMzRhYjA5ZTIwMGFkNzNiYWQzZTg4L3RhYmxlcmFuZ2U6YzU5YjFiOTA4ZDEzNGFiMDllMjAwYWQ3M2JhZDNlODhfNi0yLTEtMS0xNzIy_e5138da8-3a32-4d1a-a894-74c5b195c138"
      unitRef="usdPerShare">7.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMzI5ODUzNDg5MzYzMw_73126498-bb88-4e5c-8ce6-7ffaad6fff15">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Value at Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic6421afe2e3a4ee69726ba784046ad51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMS0xLTEtMS0xNzk4_61730083-322e-4fca-b14c-066d6f70ecb3"
      unitRef="shares">159000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic6421afe2e3a4ee69726ba784046ad51_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMS0zLTEtMS0xNzk4_b1635f00-aeb1-41c6-864f-b5e67b9945d9"
      unitRef="usdPerShare">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMi0xLTEtMS0xNzk4_04951e44-b6c0-44ef-8a82-84989a1448dc"
      unitRef="shares">1088000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMi0zLTEtMS0xNzk4_28b992d9-aba1-43c5-bc33-91603dfeb3c3"
      unitRef="usdPerShare">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMy0xLTEtMS0xNzk4_0d4603ca-8834-4d4a-a181-16ca1f0405c8"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfMy0zLTEtMS0xNzk4_fc6d6aa7-341f-4627-af98-ae1e90ab0c10"
      unitRef="usdPerShare">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNC0xLTEtMS0xNzk4_ffb05304-5ba5-4a3b-9d83-5afe8b94183d"
      unitRef="shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5e8bc56233124f56814734f35647572c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNC0zLTEtMS0xNzk4_0ba6e623-2cd7-4d61-b495-6487a4930583"
      unitRef="usdPerShare">6.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNS0xLTEtMS0xNzk4_565e1a3b-7561-4203-af11-f3596bf44f5c"
      unitRef="shares">1135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia11f4aa0f44f40bd8da00137040b43e3_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RhYmxlOmFkMjQyMDMzYzMzZDQ4MTk5ZWVhZDA4ZDU2YzZkOTZjL3RhYmxlcmFuZ2U6YWQyNDIwMzNjMzNkNDgxOTllZWFkMDhkNTZjNmQ5NmNfNS0zLTEtMS0xNzk4_f7246cef-1078-4f92-9a71-16a4e0a5ce1b"
      unitRef="usdPerShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i57135135174447be98ce98bf5cae8472_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNzE1NA_8fc8bb0e-0bf4-4507-8f7b-396f0e572f1d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7334dc0c28ed479ea8dd4c7d8a181fcd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNzE1OQ_5372cd08-6bc2-4aad-9cd5-6972cc17301f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4477929b6b09482994b251a77283960d_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA1OA_21642820-1ea0-4d39-a9a5-6cebea20aebb"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SharePrice
      contextRef="ie5f1bc8e4fe941348afc91140237ac09_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTIwNg_f2eab088-f31c-4f2a-8bce-dd320d1721f6"
      unitRef="usdPerShare">5.84</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4477929b6b09482994b251a77283960d_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTI2NA_217cf695-c510-47f2-a8b8-6acae590d732"
      unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ie2465ac8d53a4afba2b987515d381da9_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81NS9mcmFnOjcwYTI5N2MwODkwMzQ0NTc4NWE3YTk5MTA0OGZhYTJjL3RleHRyZWdpb246NzBhMjk3YzA4OTAzNDQ1Nzg1YTdhOTkxMDQ4ZmFhMmNfMTA5OTUxMTYzNjk0OQ_b6952b5f-7016-4a6f-8392-52cc05f77218"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMzI5ODUzNDg4NDY2Nw_6b9ad0f4-c4de-4aa9-970f-df2ff99f693d">NET LOSS PER SHARE&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three and six months ended June&#160;30, 2021 and 2020, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of net loss per common share (in thousands, except per share amounts):&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.8 million and 13.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2020, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 11.5 million and 11.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTIwOQ_dfafec6c-90e1-4ab9-884b-7288808cac2c">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy0xLTEtMS0w_b6f38ecf-e6fe-478f-baf1-e2aee0fc4187"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy0zLTEtMS0w_8150c461-88c2-493a-b7c1-3a1427a8d43a"
      unitRef="usd">-24956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy01LTEtMS0w_b459609f-28d1-4f65-90ce-e4599c91bbc7"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfMy03LTEtMS0w_6b5f1e4d-a6d1-4934-9d37-5f46911f9f3d"
      unitRef="usd">-47329000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0xLTEtMS0w_6330ff13-4ad6-47ab-9b70-a6af7d98bcf9"
      unitRef="shares">100040000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0xLTEtMS0w_deb887ef-8516-4125-a545-ab1f9bb12d73"
      unitRef="shares">100040000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0zLTEtMS0w_39418405-4a38-4a43-9ed4-b874ffc302f0"
      unitRef="shares">89080000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS0zLTEtMS0w_665a46a1-2caf-49a8-9b5c-0760fb8a6afc"
      unitRef="shares">89080000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS01LTEtMS0w_06cfcbfc-fb58-4f99-b440-69bd135d3668"
      unitRef="shares">98618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS01LTEtMS0w_f6435e9d-429a-48ce-8e1b-f72273836752"
      unitRef="shares">98618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS03LTEtMS0w_3622bfc2-6400-4cd9-8b3a-39e614e88784"
      unitRef="shares">88890000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNS03LTEtMS0w_e36229bc-223b-4086-953d-0288f106bc14"
      unitRef="shares">88890000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0xLTEtMS0w_32c6255d-fdf6-435d-863d-56e7f1ca01dd"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0xLTEtMS0w_66c3ce86-a45c-438d-b90e-4fd778d4a074"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0zLTEtMS0w_578efa1b-c945-4bb8-92e1-6c1b2c5723c6"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi0zLTEtMS0w_98a544fc-6e73-4e39-9c4b-9574c952ddd4"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi01LTEtMS0w_d5272259-749f-44dd-83f3-c4c9aa937675"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi01LTEtMS0w_f9013a83-a98e-4b31-bdf6-a9f0ce5f3222"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi03LTEtMS0w_6af24a4b-fab2-4283-a008-425ba7b505cb"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RhYmxlOmU0MDZiZDg3OGFiMjQyY2RhZmI2MjMwYTk0MDJhOTQ3L3RhYmxlcmFuZ2U6ZTQwNmJkODc4YWIyNDJjZGFmYjYyMzBhOTQwMmE5NDdfNi03LTEtMS0w_8f5990db-7a4e-48ab-a6e7-2498339df7fe"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfOTUw_bc204ad2-35a3-4fc8-8819-8b7a0cc2c06f"
      unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTA5OTUxMTYyOTA2Nw_adb5c09c-a716-49db-8125-20600ee84cfb"
      unitRef="shares">13400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i676eb29d3f5a423f92e6c8fa51d453ee_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTIwNg_dcbd63b3-d919-40ea-be43-536773d48d99"
      unitRef="shares">11500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic21515d387d441f4b73aabcb98bd7fed_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV81OC9mcmFnOjA2ZmRkZTlhZWMzMjQ4ZDQ5MzM4ZTk0Nzc1NDhhZTdhL3RleHRyZWdpb246MDZmZGRlOWFlYzMyNDhkNDkzMzhlOTQ3NzU0OGFlN2FfMTA5OTUxMTYyOTAzMA_d208ab6c-4f7f-49cb-9bc4-f79f35fb4ed5"
      unitRef="shares">11700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfNDA2_cf11a402-f498-41f0-8ecd-63bd85f5eafa">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us would not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of June&#160;30, 2021 or 2020.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7ce11e50673c4ce593372c02d75ba21d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfMzUz_8784310a-fe9b-4728-93fc-ba9cf3710f1e"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ie74c05e19ce74538b7ea429c28d19a88_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82NC9mcmFnOjBjZjI3YzJkZjhjNjQ5YjE4OGI4OGQ0MWJlZGUzOTE5L3RleHRyZWdpb246MGNmMjdjMmRmOGM2NDliMTg4Yjg4ZDQxYmVkZTM5MTlfMzUz_c9bf59d6-0455-4982-acaf-656dd75d23fe"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfNTc0_545f862f-cba9-41e1-a562-d9f869247880">SUBSEQUENT EVENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 28, 2021, we received a CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#x201c;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis,&#x201d; the FDA characterizes the magnitude of the treatment effect as &#x201c;small and of unclear clinical significance.&#x201d; Additionally, the FDA noted that for the application to be approved, we will need &#x201c;to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis.&#x201d; There were no safety, clinical pharmacology/biopharmaceutics, chemistry, manufacturing, and controls or non-clinical issues identified in the CRL. We intend to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 29, 2021, we entered into a Fourth Amendment to the Loan Agreement (the &#x201c;Amendment&#x201d;) which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. The restructuring plan is expected to be completed in August 2021. Under the restructuring plan, we are reducing our workforce by approximately 83 employees (approximately 33%). Impacted employees will receive cash payments equal to their base pay for a notice period of sixty (60) days and Company funded COBRA premiums through such notice period. In addition, impacted employees are eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#x2019;s execution (and non-revocation) of a separation agreement, which includes a general release of claims against the Company. We expect that the workforce reduction will decrease our annual cash compensation costs by approximately $17&#160;million. In connection with the restructuring, we estimate that we will incur restructuring charges of approximately $3.4&#160;million, which will be recorded primarily in the third quarter of 2021, related to one-time termination notice and severance payments and other employee-related costs. The cash payments related to the reduction in workforce will be paid primarily during the third quarter of 2021. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 30, 2021, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiff seeks to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiff seeks damages and interest, and an award of costs, including attorneys&#x2019; fees. We believe the plaintiff&#x2019;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTA4MQ_4f44c270-077e-4b5f-8c76-1de8c3ee09e0"
      unitRef="position">83</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <ardx:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce
      contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTExMA_d39d429f-ac81-4550-89f7-926555e24635"
      unitRef="number">0.33</ardx:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce>
    <ardx:RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits
      contextRef="ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTIxNg_17418573-ff42-4df4-971d-685babfdd319">P60D</ardx:RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits>
    <us-gaap:EffectOnFutureEarningsAmount
      contextRef="i131c578fa03b4050ae8b161b42ffff16_D20210802-20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTY3NQ_4ff8253c-ced0-40d5-9e72-8110ef882eea"
      unitRef="usd">17000000</us-gaap:EffectOnFutureEarningsAmount>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1
      contextRef="i12c10d6ea1834cf0a59df57076605afc_I20210802"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMTA5OTUxMTY1MTc4OA_90967a24-ab6b-49c0-9517-d7041e08b142"
      unitRef="usd">3400000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="icfc6f67e8c63440689c94f063c69ad9f_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhMjc0YTIzZDNmMDRlYThhM2JmODJlN2E4ZWYzMWNhL3NlYzpiYTI3NGEyM2QzZjA0ZWE4YTNiZjgyZTdhOGVmMzFjYV82Ny9mcmFnOjM3ZDY4MjQ5MTFhYjQzNDI5NTZiYjNlNTQ4ZTRhZmFmL3RleHRyZWdpb246MzdkNjgyNDkxMWFiNDM0Mjk1NmJiM2U1NDhlNGFmYWZfMzI5ODUzNDkxNzQyMQ_4d904c95-0bbc-475f-b3cf-c88a3dd3d721"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119306840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Cover</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">34175 Ardenwood Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,119,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember', window );">Co-Headquarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Cover</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Fifth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119163352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,745<span></span>
</td>
<td class="nump">$ 91,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">85,064<span></span>
</td>
<td class="nump">95,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,683<span></span>
</td>
<td class="nump">8,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">186,492<span></span>
</td>
<td class="nump">194,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">204,982<span></span>
</td>
<td class="nump">201,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">5,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,939<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">3,184<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable, current portion</a></td>
<td class="nump">36,111<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,552<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,785<span></span>
</td>
<td class="nump">28,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">11,548<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of current portion</a></td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">46,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">87,413<span></span>
</td>
<td class="nump">75,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 102,967,017 and 93,599,975 shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">750,664<span></span>
</td>
<td class="nump">680,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(633,109)<span></span>
</td>
<td class="num">(554,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">117,569<span></span>
</td>
<td class="nump">126,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 204,982<span></span>
</td>
<td class="nump">$ 201,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115191192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">102,967,017<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">102,967,017<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685118814088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="nump">$ 7,895<span></span>
</td>
<td class="nump">$ 3,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,021<span></span>
</td>
<td class="nump">18,864<span></span>
</td>
<td class="nump">46,477<span></span>
</td>
<td class="nump">34,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,124<span></span>
</td>
<td class="nump">7,038<span></span>
</td>
<td class="nump">37,255<span></span>
</td>
<td class="nump">14,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,145<span></span>
</td>
<td class="nump">26,043<span></span>
</td>
<td class="nump">84,732<span></span>
</td>
<td class="nump">49,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(44,832)<span></span>
</td>
<td class="num">(24,207)<span></span>
</td>
<td class="num">(76,837)<span></span>
</td>
<td class="num">(45,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,202)<span></span>
</td>
<td class="num">(1,226)<span></span>
</td>
<td class="num">(2,302)<span></span>
</td>
<td class="num">(2,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(45,187)<span></span>
</td>
<td class="num">(24,956)<span></span>
</td>
<td class="num">(78,341)<span></span>
</td>
<td class="num">(47,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,189)<span></span>
</td>
<td class="num">$ (24,956)<span></span>
</td>
<td class="num">$ (78,344)<span></span>
</td>
<td class="num">$ (47,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share - basic</a></td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">89,080,046<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
<td class="nump">88,890,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share - diluted</a></td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">89,080,046<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
<td class="nump">88,890,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,189)<span></span>
</td>
<td class="num">$ (24,956)<span></span>
</td>
<td class="num">$ (78,344)<span></span>
</td>
<td class="num">$ (47,329)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(45,178)<span></span>
</td>
<td class="num">(24,595)<span></span>
</td>
<td class="num">(78,336)<span></span>
</td>
<td class="num">(47,032)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember', window );">Collaborative development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
<td class="nump">$ 5,005<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116372216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 186,655<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 647,078<span></span>
</td>
<td class="num">$ (460,452)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,817,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">146,350<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">653,805<span></span>
</td>
<td class="num">(507,781)<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,140,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">167,757<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">650,617<span></span>
</td>
<td class="num">(482,825)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,035,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">146,350<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">653,805<span></span>
</td>
<td class="num">(507,781)<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,140,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">126,112<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">680,872<span></span>
</td>
<td class="num">(554,765)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">205,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at-the-market offering</a></td>
<td class="nump">$ 62,446<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">62,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at-the-market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,979,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">117,569<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">750,664<span></span>
</td>
<td class="num">(633,109)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,967,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">130,811<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">718,728<span></span>
</td>
<td class="num">(587,920)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,688,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at-the-market offering</a></td>
<td class="nump">28,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at-the-market offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains on available-for-sale securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 117,569<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 750,664<span></span>
</td>
<td class="num">$ (633,109)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,967,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116496312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,344)<span></span>
</td>
<td class="num">$ (47,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred compensation for services</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of (discount) premium on investment securities</a></td>
<td class="nump">274<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="nump">5,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in derivative liabilities</a></td>
<td class="num">(713)<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest associated with debt discount accretion</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(7,379)<span></span>
</td>
<td class="num">(2,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,039)<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">267<span></span>
</td>
<td class="num">(1,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(78,493)<span></span>
</td>
<td class="num">(43,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of investments</a></td>
<td class="nump">60,550<span></span>
</td>
<td class="nump">25,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(48,314)<span></span>
</td>
<td class="num">(62,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">10,719<span></span>
</td>
<td class="num">(37,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at-the-market offering, net of issuance costs</a></td>
<td class="nump">62,446<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">63,487<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(4,287)<span></span>
</td>
<td class="num">(80,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">91,032<span></span>
</td>
<td class="nump">181,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">86,745<span></span>
</td>
<td class="nump">100,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">14,379<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685209539624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, which is the research, development and commercialization of biopharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position at&#160;June&#160;30, 2021&#160;and results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods ended&#160;June&#160;30, 2021&#160;and&#160;2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2020. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2021, or for any other interim period or future year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents and marketable securities of approximately $171.8 million. We believe our current available cash, cash equivalents marketable securities will be sufficient to fund our planned expenditures and meet our obligations for at least 12 months following the filing of this Report on Form 10-Q. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding our New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis in which the FDA noted additional requirements would need to be met in order to obtain approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. On July 29, 2021 we entered into a Fourth Amendment to our Term Loan Agreement which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021, provided, however, if the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on or before October 25, 2021, then the interest-only period will expire and principal repayments will be required to begin on November 1, 2021. Further, on July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. For additional information see Note 12, Subsequent Events.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to raise sufficient capital when needed or generate product revenue will further impact our ability to pursue our business strategies and could require us to further delay, scale back or discontinue one or more of our product development programs, commercialization efforts, or other aspects of our business plans. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. On June 30, 2021, our public float exceeded $700 million and therefore, on December 31, 2021, we will no longer qualify as a &#8220;smaller reporting company&#8221; and will instead be considered a large accelerated filer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to adopt Topic 326 in the fourth quarter of 2021. We do not expect the adoption of ASU 2016-13 to have a material impact on our financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114713368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND INVESTMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest excess cash in marketable securities with high credit ratings. These securities consist primarily of money market funds, commercial paper, corporate bonds, asset-backed securities, and U.S. treasury and agency securities and are classified as &#8220;available-for-sale.&#8221;  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All available-for-sale securities held as of June&#160;30, 2021 had contractual maturities of less than one&#160;year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when the fair value of that security is less than its carrying cost, in which case we would further evaluate the investment to determine whether the security is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition or creditworthiness of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write the investment down through the statement of operations to its fair value and establishes that value as the new cost basis for the investment. Management has determined that none of our available-for-sale securities were other-than-temporarily impaired in any of the periods presented, and as of June&#160;30, 2021, no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that investments in a loss position will be held until maturity or a forecasted recovery of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113367976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,964&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,314&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, asset-backed securities and foreign currency derivative contracts as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities such as the Exit Fee, as defined and discussed in Note 6, are classified as Level 3.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2021 and December&#160;31, 2020, due to their short-term nature. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate of our term loan facility approximates the rate at which we could obtain alternative financing. Therefore, the carrying amount of the term loan facility approximated its fair value at June&#160;30, 2021 and December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114749624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text">COLLABORATION AND LICENSING AGREEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0 million within 30 days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The term of the 2019 KKC Agreement commenced on the Effective Date and ends on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, we recognized $1.3 million and $2.8 million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. During the three and six months ended June&#160;30, 2020, we recognized $1.1 million and $2.3 million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. The aggregate amount of the transaction price allocated to our partially unsatisfied performance obligations as of June&#160;30, 2021 and December&#160;31, 2020 was $1.4 million and $4.2 million, respectively, which is presented in the accompanying condensed balance sheet as deferred revenue. As of June&#160;30, 2021, we expect to recognize the remaining transaction price allocated to our partially unsatisfied performance obligations over the remaining research terms, which is currently expected to extend through the end of 2021. There were no significant changes in estimates associated with the 2019 KKC Agreement during the six months ended June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0 million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the up-front license fee received of $30.0 million, we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development milestones, of which $10.0 million has been received and recognized as revenue as of June&#160;30, 2021, and approximately &#165;8.5 billion for commercialization milestones, or approximately $76.5&#160;million at the currency exchange rate on June&#160;30, 2021, as well as reimbursement of costs plus a reasonable overhead for the supply of product and high-teen royalties on net sales throughout the term of the agreement. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 we recognized zero and $5.0&#160;million, respectively, as licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2020, we </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized no licensing revenue upon the achievement of development milestones. The $5.0&#160;million development milestone recognized during the three months ended March 31, 2021 related to the initiation by KKC of phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2021, we recognized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">zero</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2020,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized $5.0 thousand and $43.0 thousand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as product supply revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 we received a $2.9 million prepayment from KKC for the manufacturing of tenapanor drug substance. The prepayment is reflected within prepaid and other current assets and deferred revenue, non-current on our condensed balance sheet as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fees which was recognized as revenue when the agreement was executed. Based on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we determined</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the license and the manufacturing supply services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material performance obligations at the inception of the agreement, and as such,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of the performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distinct. &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three and six months ended June&#160;30, 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on management&#8217;s assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement, and as such, each of the performance obligations is distinct. Under the terms of the agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million nonrefundable, one-time upfront payment in March 2018 and are eligible to receive additional development and commercialization milestone payments worth up to $17.9 million. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of June&#160;30, 2021, to date in aggregate, we have recognized $11.6 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $10.6 million. For the three and six months ended June&#160;30, 2021 we recognized and recorded as cost of revenue zero and $1.0 million related to the AstraZeneca Termination Agreement. For the three and six months ended June&#160;30, 2020 we recognized $0.1 million cost of revenue related to the AstraZeneca Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balance is attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:81.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119350024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowing</a></td>
<td class="text">BORROWING <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;16, 2018, we entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;), with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;Lenders&#8221;). The Loan Agreement provides for a $50.0 million term loan facility with a maturity date of November&#160;1, 2022 (the &#8220;Term Loan&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2020, we and the Lenders entered into an amendment to the Loan Agreement (&#8220;the 2020 Amendment&#8221;) to extend the date through which we are permitted to make interest-only payments on the Term Loan by twelve months to December 1, 2021. The 2020 amendment also required that if either the FDA does not approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issues a CRL with respect to our NDA Number 213931, then we are to begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issues us a CRL. On April 29, 2021, the FDA extended the Prescription Drug User Fee Act ("PDUFA") date for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis by three months to July 29, 2021, making it unlikely that the FDA would approve our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May and July 2021, we and the Lenders entered into additional amendments to the Loan Agreement (&#8220;the 2021 Amendments&#8221;) which together extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. As of June 30, 2021, we have classified our loan payable, current to include all principal payments that would have been due beginning on June 1, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We paid a closing fee of 1% of the Term Loan, or $0.5 million, upon the closing of the Term Loan, $0.1 million upon closing of the 2020 Amendment and $0.1 million upon closing of the 2021 Amendments. Under the Term Loan, we are also obligated to pay a final fee equal to 4.95% of the Term Loan upon the earliest to occur of the maturity date, the acceleration of the Term Loan, the prepayment or repayment of the Term Loan or the termination of the Loan Agreement. We may voluntarily prepay the outstanding Term Loan, subject to a prepayment premium of (i)&#160;3% of the principal amount of the Term Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii)&#160;2% of the principal amount of the Term Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii)&#160;1% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The Term Loan is secured by substantially all our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the Term Loan, we entered into the Exit Fee Agreement, as discussed in Note 6.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement also contains customary events of default that entitle the Lender to cause us indebtedness under the Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term Loan, including our cash.&#160;Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all amounts owed under the Loan Agreement. As of June&#160;30, 2021, to our knowledge, there were no facts or circumstances in existence that would give rise to an event of default.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Loan payable, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115058472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liability</a></td>
<td class="text">DERIVATIVE LIABILITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the Loan Agreement, as defined and discussed in Note 5, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#8220;Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;), which was obtained on September 12, 2019 when the FDA approved IBSRELA&#174; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;Exit Fee Agreement&#8221;). Notwithstanding the prepayment or termination of the Term Loan, as defined and discussed in Note 5, our obligation to pay the Exit Fee will expire on May 16, 2028. We concluded that the Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5&#160;million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the six months ended June&#160;30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at June 30</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended June 30, 2021 we reduced the value of the derivative liability due the receipt of the CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114810056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, we entered into an amendment to the lease for our Fremont, California facility that extended the term of the lease to March 2025. The office space consists of 72,500 square feet with the lease terminating in September 2025. We increased the right-of-use asset and lease liability by $11.9&#160;million for the Fremont lease upon commencement of the amendment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, we recorded a right-of-use operating lease asset for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of 12,864 square feet with the lease terminating in June 2026. We have an option to extend the lease term for one additional five year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $1.6&#160;million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in the condensed balance sheet as of June&#160;30, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,519</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,184</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,732</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:44.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115057912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITYAt the Market Offerings AgreementIn July 2020, we filed a Form S-3 registration statement, which became effective in August 2020, containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC, deemed to be &#8220;at the market offerings.&#8221; During the six months ended June&#160;30, 2021 we sold 9.0 million shares of our common stock for aggregate gross proceeds of $63.8 million at a weighted average price of $7.10 per share under the Open Market Sales Agreement. We sold 8.2&#160;million shares of our common stock between the dates of November 13, 2020 through February 19, 2021 and 4.0&#160;million shares between the dates of May 11, 2021 through June 18, 2021 for a cumulative total of 12.2&#160;million shares and gross proceeds of $85.4 million at a weighted average sales price of approximately $6.98 per share during the life of the Open Market Sales Agreement. Pursuant to the Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the Open Market Sales Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685227948632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:44.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation<br/>&#160;Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining<br/>&#160;Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Value at Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued no PRSUs during the six months ended June&#160;30, 2021 and we have no PRSUs outstanding as of June&#160;30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we sold approximately 0.2 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $5.84 per share resulting in proceeds to us of approximately $1.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div>Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2021, we issued no shares of our common stock to members of the board of directors in accordance with the program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115448104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three and six months ended June&#160;30, 2021 and 2020, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of net loss per common share (in thousands, except per share amounts):</span><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2021, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 13.8 million and 13.4 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2020, the total number of securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because the effect would have been antidilutive was 11.5 million and 11.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113411656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us would not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of June&#160;30, 2021 or 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115988888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 28, 2021, we received a CRL from the FDA regarding our NDA for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#8220;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis,&#8221; the FDA characterizes the magnitude of the treatment effect as &#8220;small and of unclear clinical significance.&#8221; Additionally, the FDA noted that for the application to be approved, we will need &#8220;to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect on serum phosphorus or an effect on the clinical outcome thought to be caused by hyperphosphatemia in CKD patients on dialysis.&#8221; There were no safety, clinical pharmacology/biopharmaceutics, chemistry, manufacturing, and controls or non-clinical issues identified in the CRL. We intend to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 29, 2021, we entered into a Fourth Amendment to the Loan Agreement (the &#8220;Amendment&#8221;) which extended the period of time that we are permitted to make interest-only payments on the Term Loan to December 1, 2021; provided that if we have not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period will expire and principal repayments shall be required to begin on November 1, 2021. If principal repayments are required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment shall include all payments that would have been due if monthly principal repayment had begun on June 1, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 29, 2021, our Board of Directors approved, and on August 2, 2021 we began implementing, a restructuring plan to better align our workforce and anticipated commercial and development spend with our capital resources and the needs of our business following the receipt of the CRL. The restructuring plan is expected to be completed in August 2021. Under the restructuring plan, we are reducing our workforce by approximately 83 employees (approximately 33%). Impacted employees will receive cash payments equal to their base pay for a notice period of sixty (60) days and Company funded COBRA premiums through such notice period. In addition, impacted employees are eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#8217;s execution (and non-revocation) of a separation agreement, which includes a general release of claims against the Company. We expect that the workforce reduction will decrease our annual cash compensation costs by approximately $17&#160;million. In connection with the restructuring, we estimate that we will incur restructuring charges of approximately $3.4&#160;million, which will be recorded primarily in the third quarter of 2021, related to one-time termination notice and severance payments and other employee-related costs. The cash payments related to the reduction in workforce will be paid primarily during the third quarter of 2021. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction in workforce.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 30, 2021, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiff seeks to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiff seeks damages and interest, and an award of costs, including attorneys&#8217; fees. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685117173528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position at&#160;June&#160;30, 2021&#160;and results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods ended&#160;June&#160;30, 2021&#160;and&#160;2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2020. The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2021, or for any other interim period or future year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For smaller reporting companies the guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. On June 30, 2021, our public float exceeded $700 million and therefore, on December 31, 2021, we will no longer qualify as a &#8220;smaller reporting company&#8221; and will instead be considered a large accelerated filer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to adopt Topic 326 in the fourth quarter of 2021. We do not expect the adoption of ASU 2016-13 to have a material impact on our financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Examples of assets and liabilities utilizing Level 1 inputs are certain money market funds, U.S. treasuries and trading securities with quoted prices on active markets.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113196520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2021 and December&#160;31, 2020 are summarized below (in thousands):</span><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113430232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,964&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,314&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113423208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balance is attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:81.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113501112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Debt Payment Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our future payment obligations related to the Term Loan, excluding interest payments and the Exit Fee, are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Loan payable, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113435496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Derivative Liability</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the six months ended June&#160;30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Exit Fee derivative liability at June 30</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114966184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock', window );">Summary of Additional Details of Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in the condensed balance sheet as of June&#160;30, 2021 (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,519</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,184</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,732</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:44.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.891%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of additional details of the leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685117932888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:44.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation<br/>&#160;Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining<br/>&#160;Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,328&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2021 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Value at Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113429112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114853432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities | $</a></td>
<td class="nump">$ 171.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116372952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 86,745<span></span>
</td>
<td class="nump">$ 91,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">86,745<span></span>
</td>
<td class="nump">91,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">85,059<span></span>
</td>
<td class="nump">95,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">85,064<span></span>
</td>
<td class="nump">95,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments, Amortized Cost</a></td>
<td class="nump">171,804<span></span>
</td>
<td class="nump">188,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain', window );">Total cash equivalents and investments, Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss', window );">Total cash equivalents and investments, Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_InvestmentsAndCashFairValueDisclosure', window );">Total cash equivalents and investments, Fair Value</a></td>
<td class="nump">171,809<span></span>
</td>
<td class="nump">188,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">84,650<span></span>
</td>
<td class="nump">88,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">84,650<span></span>
</td>
<td class="nump">88,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">62,719<span></span>
</td>
<td class="nump">60,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">62,725<span></span>
</td>
<td class="nump">60,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">16,964<span></span>
</td>
<td class="nump">24,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">16,964<span></span>
</td>
<td class="nump">24,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LongTermInvestmentsAmortizedCost', window );">Long-term investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain', window );">Long-term investments, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Long-term investments, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LongTermInvestmentsFairValue', window );">Long-term investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="nump">5,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">$ 5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LongTermInvestmentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LongTermInvestmentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LongTermInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LongTermInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685117939192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Investment in continuous unrealized loss position for more than one year | investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116046328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 170,964<span></span>
</td>
<td class="nump">$ 187,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative liability for Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,650<span></span>
</td>
<td class="nump">88,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">63,975<span></span>
</td>
<td class="nump">62,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">16,964<span></span>
</td>
<td class="nump">26,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,650<span></span>
</td>
<td class="nump">88,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Derivative liability for Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,650<span></span>
</td>
<td class="nump">88,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">86,314<span></span>
</td>
<td class="nump">99,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Derivative liability for Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">63,975<span></span>
</td>
<td class="nump">62,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">16,964<span></span>
</td>
<td class="nump">26,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative liability for Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685110098200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Narrative (Details)<br> &#165; in Billions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">44 Months Ended</th>
<th class="th" colspan="1">73 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,412,000<span></span>
</td>
<td class="nump">$ 1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,177,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,836,000<span></span>
</td>
<td class="nump">7,895,000<span></span>
</td>
<td class="nump">$ 3,049,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
<td class="nump">5,005,000<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,000<span></span>
</td>
<td class="nump">1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,177,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment', window );">First installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment', window );">Term of payment of license fee, first installment</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment', window );">Second installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement | KKC | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_NumberOfSeparateCollaborativeAgreements', window );">Number of separate collaborative agreements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced', window );">Prepayment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones', window );">Potential commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,500,000<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="nump">&#165; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement | Fosun Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties', window );">Threshold percentage of net sales for tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember', window );">Knight Agreement | Knight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember', window );">AstraZeneca Termination Agreement | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PaymentsOfUnchargedLicenseFees', window );">Payments made per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, First Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of future development and commercialization milestone under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Amounts Invoiced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NumberOfSeparateCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of separate collaborative agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NumberOfSeparateCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PaymentsOfUnchargedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cash outflow from payments of uncharged license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PaymentsOfUnchargedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of payment of first installment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfPaymentOfLicenseFeeFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of net sales for tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ThresholdPercentageOfSalesForTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_OtherProductOrServicesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_OtherProductOrServicesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119039816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Non-current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Decreases due to revenue recognized in the period for which cash has been received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Non-current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced', window );">Increases to amounts invoiced for which cash has been received</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 2,947<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Current, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Noncurrent, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Amounts Invoiced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685118954232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Narrative (Details) - Term Loan - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 09, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>May 16, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentInterestPaymentExtensionTerm', window );">Interest-only payment extension term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFeePercentage', window );">Closing fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFee', window );">Closing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage', window );">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage', window );">Additional default interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFee', window );">Closing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Prior to first anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">After first anniversary through second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">After second anniversary to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestPaymentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Payment Extension Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestPaymentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional default interest rate on the event of default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestRateOnDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee payable on prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685209956568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Future Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Future payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total repayment obligations</a></td>
<td class="nump">$ 52,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized discount and debt issuance costs</a></td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan payable</a></td>
<td class="nump">51,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable, current portion</a></td>
<td class="num">(36,111)<span></span>
</td>
<td class="num">$ (4,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of current portion</a></td>
<td class="nump">$ 15,133<span></span>
</td>
<td class="nump">$ 46,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115878280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liability - Narrative (Details) - Exit Fee derivative - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon change of control or regulatory approval</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation', window );">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OtherContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685113380216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability - Changes in Fair Value (Details) - Exit Fee derivative liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of Exit Fee derivative liability, beginning</a></td>
<td class="nump">$ 1,376<span></span>
</td>
<td class="nump">$ 969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value of derivative liability</a></td>
<td class="num">(713)<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of Exit Fee derivative liability, ending</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116126568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 14,379<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember', window );">Fremont facility amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft) | ft&#178;</a></td>
<td class="nump">72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityWalthamMassachusettsMember', window );">Waltham facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft) | ft&#178;</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend | renewal_option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityWalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityWalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685115567784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 2,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">3,184<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">11,548<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 14,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Additional details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining life (years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685117915512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 1,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685199790760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Cash Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 1,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">4,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">16,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest expenses</a></td>
<td class="num">(2,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">14,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(3,184)<span></span>
</td>
<td class="num">$ (2,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 11,548<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease Liability, Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119371800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 18, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,446,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_AtMarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at-the-market offering (shares)</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Commission on sale of stock per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock | At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Cost, Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685200415144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 2,674<span></span>
</td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 5,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,132<span></span>
</td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="nump">$ 3,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119024392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 25,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 6,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119650824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding balance, beginning (shares)</a></td>
<td class="nump">9,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">3,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding balance, ending (shares)</a></td>
<td class="nump">12,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="nump">6,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding balance, beginning (in dollars per share)</a></td>
<td class="nump">$ 6.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">7.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding balance, ending (in dollars per share)</a></td>
<td class="nump">6.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119631160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock Units (Details) - RSUs<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, beginning (shares) | shares</a></td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, ending (shares) | shares</a></td>
<td class="nump">1,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Value at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">6.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">6.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">6.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119296504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Proceeds from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued under ESPP</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Proceeds from ESPP</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685119594648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,189)<span></span>
</td>
<td class="num">$ (24,956)<span></span>
</td>
<td class="num">$ (78,344)<span></span>
</td>
<td class="num">$ (47,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">89,080,046<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
<td class="nump">88,890,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">89,080,046<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
<td class="nump">88,890,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114962600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685114944712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139685116059544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>defendant</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Workforce realignment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Estimated reduction in workforce | position</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce', window );">Estimated reduction in workforce as percent of total workforce</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits', window );">Notice period for impacted employees cash payments and benefits</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated restructuring charges expected to be incurred</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Workforce realignment | Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOnFutureEarningsAmount', window );">Expected effect of decrease in annual compensation costs</a></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Putative securities class action lawsuit | Pending litigation | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Impacted Employees Term For Cash Payments And Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOnFutureEarningsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The quantified amount of the future effect on earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOnFutureEarningsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ardx_WorkforceRealignmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ardx_WorkforceRealignmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis=us-gaap_ReducedEmployeeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis=us-gaap_ReducedEmployeeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ardx_PutativeSecuritiesClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ardx_PutativeSecuritiesClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &= #5,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !G0 U3MM797>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VE!)'1[6?&D(+B@> O)[&ZP^4,RTN[;V\;=+J(/X#$SOWSS
M#4RGH]0AX7,*$1-9S#>3&WR6.F[8D2A*@*R/Z%2NYX2?F_N0G*+YF0X0E?Y0
M!X2&\UMP2,HH4K  J[@26=\9+75"12&=\4:O^/B9A@(S&G! AYXRB%H ZY>)
M\30-'5P!"XPPN?Q=0+,22_5/;.D .R>G;-?4.([UV);<O(. MZ?'E[)N97TF
MY37.O[*5=(JX89?)K^WV?O? ^H8WHN)WE6AWHI&\E9R_+ZX__*["+AB[M__8
M^"+8=_#K+OHO4$L#!!0    ( &= #5.97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M^>MF[ Z#;(NBQ_QAX_PSV%MGMFY:+K_G)+!OEM62<[VW7N*?E@O; W=Z]?O
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M;LT7,DXYDGRVS1.5P-V9 FK)W%D"&-8S-]( R%1F (3V@Y8P-,*,NH69O99
MGK ("T*3*RC"?/,H90SA=/;-<YD('%?O46D+[4:$4;<(&Q6=YUE4&^CC$P3X
MS.1TE$;_4/?ISCG'8;01&-0M,-X^$*/ 40LCYL$.A"+42I&-HH%5Y2 4PRW"
MD3;*@;J5@];(\^U,(;G=;-)?Y^2D:< T_/.<--V*GG-"X<R)W0>LA-@0*QM
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MWC2'8)V:YDSN*ZN@G"K8BS6HC#ZDX,&J.>9J;K3<VI.BI=1:%O9RPQFPNA&
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M:QF]9(FT$@WV<@ 8P8JULZC=3(\3'2:]?SF%9!Q2(O>VQ#L@(?(!.@HZ,N+
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M'_KBEV ;_G%M84.P-7]<P^_*T0*\I[OC_(4.Z'YM??,_4$L#!!0    ( &=
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M5GCHPB\JW=ON]ZC+\#-,OSW\F'4CS9W"T)C3"D>GXZ/#D3#A!Z*P<+KR/\H
M4J<+_YBARI#A#?B^TB!^LV %W:]T%_\#4$L#!!0    ( &= #5.^V0OC?0T
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M%O],96&0D FH%;8XY6WQX;WZ9<E&)4IF#U9Y Z%L15!)/O]GM1%"=["4M16
M27%U\RZH@:M*I"5;WT#\4'D?3*/9*]8!V:)Q-U:M: -$I5%%K$KD_:Z'29I,
M01RF@,9([*!8*V,= OK "_B#][Y0>4XPQ7%QK%$IGE#ZL8>7=XRH:CM\FBX
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M!7HHSVV#MBMB&N%J*90C$*F)"PM0/V]<[&[L5,J/Z#W6@FN%[8NM>M.7G^&
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M')!+=]3T$FP=[X60>MPRXV.):[UT/ 'C2PMY;U]X@<T?"L[^ %!+ P04
M" !G0 U3_R(+A.$%  !^#@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6R=5]MNXS80_17"2($$<&Q+EB\)$@-)=A?=(HLNDFWWH>@#+5$644I422J.
M^_4]0\KR)=ELMR^V+C.',V?.#*FKM39_V4((QYY+5=GK7N%<?3D<VK00);<#
M78L*;W)M2NYP:U9#6QO!,^]4JF$\&DV')9=5;W'EGWTVBRO=."4K\=DPVY0E
M-YM;H?3ZNA?UM@\>Y*IP]&"XN*KY2CP*]UO]V>!NV*%DLA25E;IB1N37O9OH
M\C8A>V_PNQ1KNW?-*).EUG_1S<?LNC>B@(02J2,$CK\G<2>4(B"$\7>+V>N6
M),?]ZRWZ!Y\[<EER*^ZT^BHS5USWYCV6B9PWRCWH]<^BS6=">*E6UO^R=;"-
M8)PVUNFR=48$I:S"/W]N>=ASF(^^X1"W#K&/.RSDHWS''5]<&;UFAJR!1A<^
M5>^-X&1%17ET!F\E_-SB7B E>S5TP*(GP[3UNPU^\3?\INR3KEQAV?LJ$]FA
M_Q Q=('$VT!NXS<!?VFJ 1N/^BP>Q=$;>.,NL;''&[^9&/OC9FF=0>W_? ,S
MZ3 3CYG\,%EO^E%C7=J:I^*ZA\ZQPCR)WN+^_<WC^T=VHQ33.=.-82J$S(U@
M:#K#G:Q6W<,J8X*G!4M!.WJMU0;Z"*U1.29LRA7W0D\5;^ R8'?">%/ NT)L
MD0K^)-A2NR(\\,B5KL[#7:K+6E= A/]7$8Q]"XF,.8TF2G6#Y3 -0CA6U!R1
MMN@[=P]+J[X&S;BU.I6<0-<2D;B"NY<(L&,6'*B7Z+0^!W/(U5)22+&!$(W:
M$&?TC!)XUQBZI3"L?&9E4*P@Q3+H371ZZ[,UTJR<,'@C*TH4 P.S)RMI-=QW
M!/JEJ5H?C"# /KOC2N)A)3G+>2J5=)N0D'AV82UR!G9Y4 E"_<0-.$0$DP'[
M@A<ZSV6*8$DK5&DKK?/)S>+^9#3"S&I('3E-ZY:X#@WXL@J:0<T?1>U$N12F
M14<M994:,@WQ&!I7YSH_;T@#1)@O60!3DB]#(LL-.XFBP05FCU*D+DJ?_-OT
M6X>F)N'I$G2EPG/6IMJ1^*/5,"+5AE[QPU"/.J,-W>N!5=@$NA* A*]<H1!E
M'SQ;"[7"WX%/KQ28MP K(T+(!P+(0K3O1-K1. J<=UK<)9M!RG;K<E,;J3R9
MG_C&)_2=XD9Q?SY-?J"XGBT 3W<]"KWJVK<_8@_"._(/PH4CSS))EERQ'#LB
MVPAN&%B5.J- I?TN4H'6K+1C2R$JDI5J,D^;M\,<2IMV%*%[*=?&T(Q2&_]>
M/ N32JID4$B[F*2ZI.W$:H<'-F@-1C*J3^97K(U>\J42/O$]B9Q$@VDGT?\H
M[:V26Y5\3\G^=:ADKA4.,U[,% Q%]20SFM([:C.!3)3=SO9.ENT4]OM Y?9H
MTU!E1=VYQ" GVL*AC'N(@_Y@IQD"X,8&7]U8I&?/+MF'L(@$_L,+#BP[85'2
MGT07["X4A-7:>.ZQP"$YA##N1_.$_7K4;AU]?72;YR8] HNB_B29LR_:@06_
MY&P<HUP4D,C.(5:#TQZ*1T=&#RQSP4Y)A?:,C0<7HY?&F;1AW_%;S70PG[&?
MV'W;A^@B3(Q"8I)2_^SK<3<LQ'--['K*J![6 :GTFQ%5*-BA)VGV&&*L+;)E
MIT<D?RDP+PY./[OJ/&*NO?[&U\W/D-W5,;=MC"!M/I[A=PH:02!*-O+_\<44
MFXTM6,UE%MKY^)APPF;3J?^-@NLD"?]8\S7EAK.X_(>V4+""R=@RC=C3L-0F
M-,%2R56@J-L!CT?QOGI>E>T1DP]> C2+8>HM*-2+V9QN8I8@X9@NQ[A,$L]<
M@LO)_,)O:K =A[2PK>6.9O0D;G5WD,AQG&U.ED73_GP6LX]EW81.I/EOW4XL
MIW$_2D9G+>A;^;8ROQ?67K[67]_RW;!3WVAG_Z/33K:]]MK1=KCW35 *L_)?
M/I9Y3L+G0?>T^[BZ"=\4._/P9893RDJB[DKD<!T-9I->F+';&Z=K_X6!4R7.
MI/ZRP >B,&2 ][G6;GM#"W2?G(M_ 5!+ P04    " !G0 U3P"KZ45H$  !A
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RU5FUOVS80_BL'-^LZ
MP-.;G<1I' /.2]%D29/%[8IAV =:.DM$)%$EJ3C^][NC9-D%G*3#L"^V^'+/
M/??<'<GQ4ND'DR%:>"KRTIST,FNK][YOX@P+83Q584DK"Z4+86FH4]]4&D7B
MC(K<CX+@P"^$+'N3L9N[TY.QJFTN2[S38.JB$'IUBKE:GO3"WGKB7J:9Y0E_
M,JY$BC.T7ZH[32._0TED@:61J@2-BY/>-'Q_.N3];L,?$I=FZQLXDKE2#SRX
M3$YZ 1/"'&/+"(+^'O$,\YR!B,:W%K/7N63#[>\U^@<7.\4R%P;/5/Y5)C8[
MZ8UZD.!"U+F]5\N/V,:SSWBQRHW[A66S=W#8@[@V5A6M,3$H9-G\BZ=6ARV#
M4?",0=0:1(YWX\BQ/!=63,9:+4'S;D+C#Q>JLR9RLN2DS*RF54EV=C*S*G[(
M5)Z@-C_#Q;=:VM78MX3,ZW[<HIPV*-$S* =PHTJ;&;@H$TR^M_>)44<K6M,Z
MC5X$O*I+#P9!'Z(@"E_ &W1A#AS>X%^$"9^41?AK.C=64W'\_8*;8>=FZ-P,
M_Z.:KZ!\OCW[[>/M]?G%_>SMFU$4'A[#Q>]?+C__.;5@,X0;H1^H7V\7"]2R
M3 U,4XU(K6(O2[BJ\Q7+1N(M$18RQP0$< G#[-<!-5(J.6#7$\8*Z^QH;R;C
M#.88BP(!"=FU"\@2IG5*==A"QI1G:G7R"N_D+P3,+0&55J8BB]H G1..HVK)
M]4$:4XLR1A!E D;D"/,5T$ZU@+H"JPB$"EH6=0$BI4!2XM29$[2,>0A[T7[@
M!=0#><[4:4;5FO@4A0N$A._39B0S31&W$PG.+1B,:RVM1$-A"JU%:0V3\8EJ
M74I+TPNM"K!TVC ?]T^!JY(<:RB4WO QQRZ,=](%OQ6WJ:LJ=UK^CQ*$P2L2
MD%]A"6M%F71>.?GLDVIR1Y1]BI]JE=PS*1)E74=T"MD,KM!1H(7KZS,6D]82
MMB5P+LPH.!9-119-178J>6XY/(;SVH7 >XQ\(BW=,8%\3%"EEOCV37@0'*\[
MG2N6J<+15I@F$QK-SFA9Z8U@*67#<$YBQ,09[!T,O%$'1%P%>>!SFF5Y1$W7
MSI:ZAUX80$5R.(^M-,S\EJ[ ==/-G%!=PWGPM:4\\J(FF!_@/4>[1,)D\(2H
MNUV?U",6<W(9#IP: 2UK5:<9?,"YKNG*A/"HU8ES.O2"G0YW@M]0281A:[W&
MY01 .&IGG9ATYQ1U+ESO6V5%SL9A]$QL3&.'ZJ-];_B*ZDV]==J+B@"H 8@N
MG5Y[!][1:"L3R::(<KEP!J^FY:[6W'/6E?K+F_N;0N^#,"Y=ZWYPRQIC)$$,
MRT-II+YJVZ]IWH$7_+3FU*BQ'1W+NBF%[\K U<V/E=FNR\G?NO8+U*E[W!AR
M49>V>0%TL]W[:=H\&S;;F\<7>4UE:2#'!9D&WN%^#W3SH&D&5E7N$3%7EIXD
M[C.C-R!JWD#K"T67:3M@!]VK<O(/4$L#!!0    ( &= #5/_;N.A7 4  )(,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;,U7W6_;-A#_5PY"'A)
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M;FQ9<#4O2\?-%JYX=EAA:2-1U&YF,@$7&WNG"3R5 P]^ SR%/HA*GV*>XM:
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M:8Z9Z(\WKC@2?S0*ID-N>4X&#TYZ.+*C!!JR+D7,-/5@:*PU+RT^BH)A9W(
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M 6]T!.^6:<GE:B])^.-J8:RFGOCS#?Q\BY\'_/P_%?%?,&Z_PN??YG.XOWV
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MU:LR]8]@%@NP"FR%\("ZAAO%9 BXS45;N!? I442L7L" TP6/OQJRRU<(X;
MB)\9*)6@=C8PX)("5&LHT@PG\* L$R3VGH4C&"=A=CJ&&S1F H^2U4I;_I=<
M%?3?J);BG6#AJL>-:9G,$7)ER,@@/3T;O@+S7*/+YIF)UA>^Y))T2T08G(W3
MH4_-I>&>-(SC,,FR'?KP)J0.T]KY;)P3&A*#]"2,XWCX)DS2="25M]%'$(_#
M.$WAO6<4'31EC7KM1X\!GV?7G_UI/]W.NZ9^#>]&XRW3:TX5%%@2='1\.@Y
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MMAP%%P'D6+!:V&>UOL.VGC/'EREA_"^LF]@^!6>UL:IJP:2@XK(9V:8]AQW
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MZ?E9 +JQPF9AU=+;SUQ9,C,_+>G? [4+H.^%4G:[< FZ_Z/Q'U!+ P04
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M^XV>"EFK@Z;K..%AH2PM"/TH_TN_%@.QI6"[#0IVH6#O*N &!:=0<$P52*%
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MX@G<I.^,O*2L_,G=DHJ0 DZ[BK'=?6G87476+DS6&^[:=.V"39E\D6Y/X:*
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M<U *&:ZH>N:;[]#X&1J^):?27M&FB?4<M*RDXF4#U@I*PNH[_FCJT %HGGY
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MN-(CSRX+_5,"80+T\XQSM=V8!.UO+OD+4$L#!!0    ( &= #5,IGZUL70,
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MP/M1Y O@B"W1W/C; MFO(/L&LM\ ^5!((56X"%VI1Z5"'L,%6L"*4*J7SLK
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M& ,  "L*   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;*66;6_:,!"
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MIKLY%&:#_C[E7"TGQD#3'PY_ U!+ P04    " !G0 U3J_^W;8@#  #@"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6S-5MMNVS ,_17"V$,+;/$E
MSJ5#$B"7#NNP#4&S;@_#'A1;B87:4B;)S?KWHV3'\;I$*["7]J&1:)VC0]*D
M.=H+>:\R2C7\*G*NQEZF]>ZM[ZLDHP51';&C')]LA"R(QJW<^FHG*4DMJ,C]
M* CZ?D$8]R8C:UO*R4B4.F><+B6HLBB(?)S17.S'7N@=#+=LFVEC\">C'=G2
M%=5WNZ7$G=^PI*R@7#'!0=+-V)N&;Q=AWP#LB:^,[E5K#<:5M1#W9G.3CKW
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M:IRL-EKL[("U%AK'-;O,< 2GTAS YQLA]&%C+FB&^LEO4$L#!!0    ( &=
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M/Q]0U@'/-U*:_<8&Z']GV1]02P,$%     @ 9T -4Y\3QG?T 0  800  !D
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !G0 U37'U^9E<$  #R(0
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M_G]2G2_WQOOCK\O;R<%+N.(<X(?TRS=02P,$%     @ 9T -4RBT:!/# 0
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M4$L! A0#%     @ 9T -4[;5V5WM    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 9T -4YE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !G0 U3%=&>@:8%   $&0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 9T -4X2R7 $R!@  T!@
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M965T-BYX;6Q02P$"% ,4    " !G0 U38O\<]_\+  !Y'0  &
M    @($Z+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M9T -4QF.I(*%!@  NQ   !@              ("!;SD  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &= #5-V"#;F< <  +$3   8
M          " @2I   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !G0 U3OMD+XWT-  #:+@  &0              @('01P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &= #5.\GK3T4@@  %@6
M   9              " @815  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ 9T -4^\TH;3'!@  -!   !D              ("!#5X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !G0 U3_R(+
MA.$%  !^#@  &0              @($+90  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( &= #5/ *OI16@0  &$*   9
M  " @2-K  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M9T -4_]NXZ%<!0  D@P  !D              ("!M&\  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !G0 U3TJG)^U $  #F"@  &0
M            @(%'=0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( &= #5.0F&NRT0(  .@%   9              " @<YY  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 9T -4]S0?R,="0
M:A4  !D              ("!UGP  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !G0 U3&\FA;B@*  #U&@  &0              @($J
MA@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &= #5/K
M#+_%]0,  "4*   9              " @8F0  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ 9T -4]UHOL*? P  !PD  !D
M     ("!M90  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &= #5,'U:2U! 4   X-   9              "
M@5>F  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 9T -
M4[7%U,C1 @  ( 8  !D              ("!DJL  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !G0 U3M.KSAV<"  !%!0  &0
M        @(&:K@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( &= #5/RG#%32@8  ),E   9              " @3BQ  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 9T -4X?BDIZN @  I@<
M !D              ("!N;<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !G0 U33.!,>/H&   5+P  &0              @(&>N@
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &= #5,>JH=^
M'@@  &$Q   9              " @<_!  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ 9T -4[7@;25A P  7PP  !D
M ("!),H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !G
M0 U3O).HG+,#  #K#0  &0              @(&\S0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &= #5/+N/HJM@(  %$'   9
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M970S.2YX;6Q02P$"% ,4    " !G0 U3>SEKN8L"  !M!P  &0
M    @('EX   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M &= #5,,A5M.&@,  *X)   9              " @:?C  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ 9T -4[92]?'O P  S X  !D
M             ("!^.8  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !G0 U38\8QEPL#   Y"@  &0              @($>ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &= #5/Y3U;1_0(
M /<)   9              " @6#N  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ 9T -4_/>.F@M P  PPH  !D              ("!
ME/$  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !G0 U3
M/!K+5Q@#   K"@  &0              @('X]   >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( &= #5.K_[=MB ,  . +   9
M      " @4?X  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ 9T -4\35H25, P  40L  !D              ("!!OP  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !G0 U3K=/ED(H"  #:!@
M&0              @(&)_P  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( &= #5.?$\9W] $  &$$   9              " @4H" 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 9T -4X[VLA%7
M P  P@D  !D              ("!=00! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " !G0 U34+3/R3H#   .%   #0
M@ $#" $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &= #5.7BKL<P    !,"
M   +              "  6@+ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &=
M#5-<?7YF5P0  /(A   /              "  5$, 0!X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " !G0 U3H9?JE,D!  "@'@  &@              @ '5
M$ $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !G0 U3
M*+1H$\,!  ")'@  $P              @ '6$@$ 6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     .P [ !00  #*% $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Borrowing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Borrowing</Role>
      <ShortName>Borrowing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaboration and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables</Role>
      <ShortName>Collaboration and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Borrowing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingTables</Role>
      <ShortName>Borrowing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Borrowing</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DerivativeLiability</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/EquityIncentivePlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Borrowing - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingNarrativeDetails</Role>
      <ShortName>Borrowing - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Borrowing - Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails</Role>
      <ShortName>Borrowing - Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Derivative Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails</Role>
      <ShortName>Derivative Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails</Role>
      <ShortName>Derivative Liability - Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Leases - Additional Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails</Role>
      <ShortName>Leases - Additional Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails</Role>
      <ShortName>Leases - Undiscounted Cash Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/StockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Contingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ardx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/SubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ardx-20210630.htm">ardx-20210630.htm</File>
    <File>ardx-20210630.xsd</File>
    <File>ardx-20210630_cal.xml</File>
    <File>ardx-20210630_def.xml</File>
    <File>ardx-20210630_lab.xml</File>
    <File>ardx-20210630_pre.xml</File>
    <File>ardx-20210630xex311.htm</File>
    <File>ardx-20210630xex312.htm</File>
    <File>ardx-20210630xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "ardx-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ardx-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ardx-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 439,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 39,
   "keyStandard": 279,
   "memberCustom": 19,
   "memberStandard": 35,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Collaboration and Licensing Agreements",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Borrowing",
     "role": "http://www.ardelyx.com/role/Borrowing",
     "shortName": "Borrowing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Derivative Liability",
     "role": "http://www.ardelyx.com/role/DerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Leases",
     "role": "http://www.ardelyx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stockholders' Equity",
     "role": "http://www.ardelyx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Equity Incentive Plans",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Net Loss Per Share",
     "role": "http://www.ardelyx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Contingencies",
     "role": "http://www.ardelyx.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Subsequent Events",
     "role": "http://www.ardelyx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables",
     "shortName": "Cash, Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaboration and Licensing Agreements (Tables)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables",
     "shortName": "Collaboration and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Borrowing (Tables)",
     "role": "http://www.ardelyx.com/role/BorrowingTables",
     "shortName": "Borrowing (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Derivative Liability (Tables)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityTables",
     "shortName": "Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Leases (Tables)",
     "role": "http://www.ardelyx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i331cc003c0d04f078a6a32154ebd1c19_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i331cc003c0d04f078a6a32154ebd1c19_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Collaboration and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i379743fcd22a40f794bbafd0cd543dbc_D20191101-20191130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i62f4c36f4b554b9b8908a7e166a96117_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7c3eac47e3784f54a4d7c86adfabdc2d_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i3fc7bd2e9a8044539a1c899e40063725_I20180516",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Borrowing - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
     "shortName": "Borrowing - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i3fc7bd2e9a8044539a1c899e40063725_I20180516",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Borrowing - Future Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
     "shortName": "Borrowing - Future Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ia4b9f41836824ed3b567440b012e50ee_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Derivative Liability - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
     "shortName": "Derivative Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ia4b9f41836824ed3b567440b012e50ee_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Derivative Liability - Changes in Fair Value (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
     "shortName": "Derivative Liability - Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i1f1306d091b348d48ad7cdf0e9c4fa89_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ib702c69d1490476d80c3cd108100c164_I20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Leases - Additional Lease Information (Details)",
     "role": "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
     "shortName": "Leases - Additional Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.ardelyx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails",
     "shortName": "Leases - Undiscounted Cash Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.ardelyx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ifdc1fab5cf114d6a87de78c84c48449b_D20210511-20210618",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i5bbdebf8d9dd41499f65ab0fde441e1a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i62f4c36f4b554b9b8908a7e166a96117_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i62f4c36f4b554b9b8908a7e166a96117_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ic6421afe2e3a4ee69726ba784046ad51_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Equity Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ic6421afe2e3a4ee69726ba784046ad51_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ie2465ac8d53a4afba2b987515d381da9_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "if3d569d2a6cd4e0ea66e338aa49b1424_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "icd41c948817d46d799997c58b6d1030b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "icd41c948817d46d799997c58b6d1030b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Contingencies (Details)",
     "role": "http://www.ardelyx.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i7ce11e50673c4ce593372c02d75ba21d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.ardelyx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "ifa8413b5cc0f4289938dc8f8f656a4a0_D20210802-20210802",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash, Cash Equivalents and Investments",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments",
     "shortName": "Cash, Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Fair Value Measurements",
     "role": "http://www.ardelyx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20210630.htm",
      "contextRef": "i9f175adc8a3e4159ae98f6a7c542b38e_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "ardx_AstraZenecaTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca Termination Agreement",
        "label": "AstraZeneca Termination Agreement [Member]",
        "terseLabel": "AstraZeneca Termination Agreement"
       }
      }
     },
     "localname": "AstraZenecaTerminationAgreementMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca.",
        "label": "Astrazeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to At the market offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Current, Rollforward",
        "label": "Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]",
        "terseLabel": "Current deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Noncurrent, Rollforward",
        "label": "Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]",
        "terseLabel": "Non-current deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaboration and Licensing Agreements",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsAbstract",
     "nsuri": "http://www.ardelyx.com/20210630",
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFees",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "terseLabel": "First installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "terseLabel": "Second installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Commercialization Milestones",
        "label": "Collaborative Arrangement, Potential Commercialization Milestones",
        "terseLabel": "Potential commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of future development and commercialization milestone under collaborative arrangements.",
        "label": "Collaborative Arrangement, Potential Development And Commercialization Milestones",
        "terseLabel": "Potential development and commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Development Milestones",
        "label": "Collaborative Arrangement, Potential Development Milestones",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentMilestones",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "label": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "terseLabel": "Maximum potential payment per agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Development [Member]",
        "label": "Collaborative Development [Member]",
        "terseLabel": "Collaborative development revenue"
       }
      }
     },
     "localname": "CollaborativeDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "label": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "terseLabel": "Increases to amounts invoiced for which cash has been received",
        "verboseLabel": "Prepayment due"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForAmountsInvoiced",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.",
        "label": "Contract with Customer Liability Revenue Recognized Cash Received",
        "negatedTerseLabel": "Decreases due to revenue recognized in the period for which cash has been received",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedCashReceived",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee",
        "label": "Debt Instrument, Closing Fee",
        "terseLabel": "Closing fee"
       }
      }
     },
     "localname": "DebtInstrumentClosingFee",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee, Percentage",
        "label": "Debt Instrument, Closing Fee, Percentage",
        "terseLabel": "Closing fee (percent)"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeePercentage",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "label": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "terseLabel": "Final fee due upon maturity, acceleration, prepayment, or termination (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentInterestPaymentExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Payment Extension Term",
        "label": "Debt Instrument, Interest Payment Extension Term",
        "terseLabel": "Interest-only payment extension term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentExtensionTerm",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_DebtInstrumentInterestRateOnDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional default interest rate on the event of default.",
        "label": "Debt Instrument, Interest Rate On Default, Percentage",
        "terseLabel": "Additional default interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateOnDefaultPercentage",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fee payable on prepayment of debt.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FacilityFremontCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility, Fremont California",
        "label": "Facility, Fremont California [Member]",
        "terseLabel": "Fremont facility amendment"
       }
      }
     },
     "localname": "FacilityFremontCaliforniaMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FacilityWalthamMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility, Waltham Massachusetts",
        "label": "Facility, Waltham Massachusetts [Member]",
        "terseLabel": "Waltham facility"
       }
      }
     },
     "localname": "FacilityWalthamMassachusettsMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "label": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "terseLabel": "Fair value analysis, percentage change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "label": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "terseLabel": "Fair value analysis, effect on fair value based on 10% change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_InvestmentsAndCashAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain",
        "label": "Investments And Cash, Accumulated Gross Unrealized Gain",
        "terseLabel": "Total cash equivalents and investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_InvestmentsAndCashAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss",
        "label": "Investments And Cash, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash equivalents and investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_InvestmentsAndCashFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Fair Value Disclosure",
        "label": "Investments And Cash, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents and investments, Fair Value"
       }
      }
     },
     "localname": "InvestmentsAndCashFairValueDisclosure",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc [Member]",
        "terseLabel": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KyowaKirinCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co. Ltd [Member]",
        "terseLabel": "KKC"
       }
      }
     },
     "localname": "KyowaKirinCo.LtdMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease Liability, Payments Due After Year Four",
        "label": "Lessee, Operating Lease Liability, Payments Due After Year Four",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Canada [Member]",
        "terseLabel": "Knight Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.",
        "label": "License Agreement Development Commercialization Distribution In China [Member]",
        "terseLabel": "Fosun Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInChinaMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Japan [Member]",
        "terseLabel": "2017 KKC Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInJapanMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LongTermInvestmentsAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_LongTermInvestmentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments, Accumulated Gross Unrealized Gain",
        "label": "Long Term Investments, Accumulated Gross Unrealized Gain",
        "terseLabel": "Long-term investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "LongTermInvestmentsAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LongTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_LongTermInvestmentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Long Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Long-term investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "LongTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LongTermInvestmentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments, Amortized Cost",
        "label": "Long Term Investments, Amortized Cost",
        "totalLabel": "Long-term investments, Amortized Cost"
       }
      }
     },
     "localname": "LongTermInvestmentsAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LongTermInvestmentsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_LongTermInvestmentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Investments, Fair Value",
        "label": "Long Term Investments, Fair Value",
        "terseLabel": "Long-term investments, Fair Value"
       }
      }
     },
     "localname": "LongTermInvestmentsFairValue",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_NumberOfSeparateCollaborativeAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of separate collaborative agreements.",
        "label": "Number Of Separate Collaborative Agreements",
        "terseLabel": "Number of separate collaborative agreements"
       }
      }
     },
     "localname": "NumberOfSeparateCollaborativeAgreements",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_OtherProductOrServicesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to revenues from other product or services.",
        "label": "Other Product Or Services Revenue [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductOrServicesRevenueMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PaymentsOfUnchargedLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cash outflow from payments of uncharged license fees.",
        "label": "Payments of Uncharged License Fees",
        "terseLabel": "Payments made per agreement"
       }
      }
     },
     "localname": "PaymentsOfUnchargedLicenseFees",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PercentageOfNonRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of non-royalty revenue.",
        "label": "Percentage of non royalty revenue",
        "terseLabel": "Percentage of non-royalty revenue"
       }
      }
     },
     "localname": "PercentageOfNonRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PercentageOfRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of royalty revenue.",
        "label": "Percentage of Royalty Revenue",
        "terseLabel": "Percentage of royalty revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for performance-based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "PRSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ProductSupplyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Supply Revenue",
        "label": "Product Supply Revenue [Member]",
        "terseLabel": "Product supply revenue"
       }
      }
     },
     "localname": "ProductSupplyRevenueMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PutativeSecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Putative Securities Class Action Lawsuit",
        "label": "Putative Securities Class Action Lawsuit [Member]",
        "terseLabel": "Putative securities class action lawsuit"
       }
      }
     },
     "localname": "PutativeSecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "2019 KKC Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce",
        "label": "Restructuring And Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce",
        "terseLabel": "Estimated reduction in workforce as percent of total workforce"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Impacted Employees Term For Cash Payments And Benefits",
        "label": "Restructuring And Related Cost, Impacted Employees Term For Cash Payments And Benefits",
        "terseLabel": "Notice period for impacted employees cash payments and benefits"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostImpactedEmployeesTermForCashPaymentsAndBenefits",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted-Average Price Per Share",
        "label": "Sale Of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average sales price per share"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of additional details of the leases.",
        "label": "Schedule of Additional Details of Leases [Table Text Block]",
        "terseLabel": "Summary of Additional Details of Leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Shanghai Fosun Pharmaceutical Industrial Development.",
        "label": "Shanghai Fosun Pharmaceutical Industrial Development [Member]",
        "terseLabel": "Fosun Pharma"
       }
      }
     },
     "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_StockIssuanceCostCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Cost, Commission, Percent",
        "label": "Stock Issuance Cost, Commission, Percent",
        "terseLabel": "Commission on sale of stock per agreement (percent)"
       }
      }
     },
     "localname": "StockIssuanceCostCommissionPercent",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_TermOfPaymentOfLicenseFeeFirstInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of payment of first installment fee.",
        "label": "Term Of Payment Of License Fee, First Installment",
        "terseLabel": "Term of payment of license fee, first installment"
       }
      }
     },
     "localname": "TermOfPaymentOfLicenseFeeFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_ThresholdPercentageOfSalesForTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of net sales for tiered royalties.",
        "label": "Threshold Percentage of Sales For Tiered Royalties",
        "terseLabel": "Threshold percentage of net sales for tiered royalties"
       }
      }
     },
     "localname": "ThresholdPercentageOfSalesForTieredRoyalties",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_WorkforceRealignmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce Realignment",
        "label": "Workforce Realignment [Member]",
        "terseLabel": "Workforce realignment"
       }
      }
     },
     "localname": "WorkforceRealignmentMember",
     "nsuri": "http://www.ardelyx.com/20210630",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Cover"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_OtherAddressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other address for entity",
        "label": "Other Address [Member]",
        "terseLabel": "Co-Headquarter"
       }
      }
     },
     "localname": "OtherAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r85",
      "r86",
      "r207",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r206",
      "r241",
      "r278",
      "r279",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r428",
      "r462",
      "r464",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officer"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r146",
      "r266",
      "r268",
      "r430",
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r146",
      "r266",
      "r268",
      "r430",
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r206",
      "r241",
      "r269",
      "r278",
      "r279",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r428",
      "r462",
      "r464",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r206",
      "r241",
      "r269",
      "r278",
      "r279",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r428",
      "r462",
      "r464",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r33",
      "r34",
      "r85",
      "r86",
      "r207",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r149",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (discount) premium on investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r14",
      "r36",
      "r37",
      "r38",
      "r450",
      "r469",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r35",
      "r38",
      "r44",
      "r45",
      "r46",
      "r89",
      "r90",
      "r91",
      "r327",
      "r465",
      "r466",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r304",
      "r305",
      "r306",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r280",
      "r282",
      "r309",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r282",
      "r300",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r59",
      "r71",
      "r226",
      "r372"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest associated with debt discount accretion"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredCharges": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of deferred charges applied against earnings during the period.",
        "label": "Amortization of Deferred Charges",
        "terseLabel": "Amortization of deferred compensation for services"
       }
      }
     },
     "localname": "AmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r53",
      "r71",
      "r226",
      "r374"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive securities not included in computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Office space area (sq ft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r159",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r135",
      "r138",
      "r144",
      "r165",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r324",
      "r328",
      "r362",
      "r392",
      "r394",
      "r432",
      "r448"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r31",
      "r83",
      "r165",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r324",
      "r328",
      "r362",
      "r392",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Short-term investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Short-term investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r155",
      "r172"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Short-term investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r151",
      "r156",
      "r172",
      "r435"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Short-term investments, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r153",
      "r172"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r283",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r20",
      "r73"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r73",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r363"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r80",
      "r83",
      "r105",
      "r106",
      "r107",
      "r109",
      "r111",
      "r119",
      "r120",
      "r121",
      "r165",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r239",
      "r240",
      "r244",
      "r248",
      "r362",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r270",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r187",
      "r436",
      "r454"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r188",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 102,967,017 and 93,599,975 shares issued and outstanding as of June\u00a030, 2021 and December\u00a031, 2020, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r42",
      "r43",
      "r50",
      "r439",
      "r457"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r262",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r262",
      "r263",
      "r267"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r270",
      "r277",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r55",
      "r83",
      "r165",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r362"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r220",
      "r227",
      "r228",
      "r230",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowing"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Borrowing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r8",
      "r231",
      "r433",
      "r447"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Total repayment obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r203",
      "r234",
      "r235",
      "r373",
      "r375",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After second anniversary to maturity date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary through second anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r28",
      "r82",
      "r87",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r234",
      "r235",
      "r236",
      "r237",
      "r256",
      "r257",
      "r258",
      "r259",
      "r372",
      "r373",
      "r375",
      "r376",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r216",
      "r232",
      "r234",
      "r235",
      "r374"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Investment in continuous unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r71",
      "r178"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Exit Fee derivative liability",
        "verboseLabel": "Derivative liability for Exit Fee"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r34",
      "r338",
      "r339",
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r332",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Agreed amount for exit fee upon change of control or regulatory approval"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r51",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r103",
      "r105",
      "r109",
      "r110",
      "r111",
      "r115",
      "r116",
      "r349",
      "r350",
      "r440",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r51",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r105",
      "r109",
      "r110",
      "r111",
      "r115",
      "r116",
      "r349",
      "r350",
      "r440",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOnFutureEarningsAmount": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The quantified amount of the future effect on earnings.",
        "label": "Effect on Future Earnings, Amount",
        "terseLabel": "Expected effect of decrease in annual compensation costs"
       }
      }
     },
     "localname": "EffectOnFutureEarningsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of effects on future earnings and cash flows.",
        "label": "Effects on Future Earnings and Cash Flows, by Type of Effect [Domain]",
        "terseLabel": "Effects on Future Earnings and Cash Flows, by Type of Effect [Domain]"
       }
      }
     },
     "localname": "EffectsOnFutureEarningsAndCashFlowsByTypeOfEffectDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by effect on future earnings and cash flows resulting from an exit plan.",
        "label": "Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Axis]",
        "terseLabel": "Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Axis]"
       }
      }
     },
     "localname": "EffectsOnFutureEarningsAndCashFlowsResultingFromExitPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based Compensation [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average Remaining Vesting Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r44",
      "r45",
      "r46",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r118",
      "r166",
      "r255",
      "r260",
      "r304",
      "r305",
      "r306",
      "r314",
      "r315",
      "r348",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r465",
      "r466",
      "r467",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r352",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r218",
      "r234",
      "r235",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r353",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r355",
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r218",
      "r270",
      "r271",
      "r276",
      "r277",
      "r353",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r218",
      "r234",
      "r235",
      "r270",
      "r271",
      "r276",
      "r277",
      "r353",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r218",
      "r234",
      "r235",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r353",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Change in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r357",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r357",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in estimated fair value of derivative liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of Exit Fee derivative liability, ending",
        "periodStartLabel": "Fair value of Exit Fee derivative liability, beginning"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r218",
      "r234",
      "r235",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r359",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r229",
      "r253",
      "r347",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r135",
      "r137",
      "r140",
      "r143",
      "r145",
      "r431",
      "r437",
      "r442",
      "r459"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r100",
      "r101",
      "r134",
      "r313",
      "r316",
      "r317",
      "r460"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r70",
      "r383"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r47",
      "r133",
      "r371",
      "r374",
      "r441"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r65",
      "r68",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "totalLabel": "Total cash equivalents and investments, Amortized Cost"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Additional details"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest expenses"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Term of lease extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r83",
      "r139",
      "r165",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r325",
      "r328",
      "r329",
      "r362",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r83",
      "r165",
      "r362",
      "r394",
      "r434",
      "r452"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r83",
      "r165",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r325",
      "r328",
      "r329",
      "r362",
      "r392",
      "r393",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "negatedTerseLabel": "Loan payable, current portion",
        "terseLabel": "Loan payable, current portion"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r8",
      "r217",
      "r233",
      "r234",
      "r235",
      "r433",
      "r449"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Loan payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future payment obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Investments [Abstract]",
        "terseLabel": "Long-term investments:"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Loan payable, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r28",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "Loss Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r39",
      "r41",
      "r46",
      "r49",
      "r72",
      "r83",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r100",
      "r101",
      "r108",
      "r135",
      "r137",
      "r140",
      "r143",
      "r145",
      "r165",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r350",
      "r362",
      "r438",
      "r456"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r135",
      "r137",
      "r140",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r382",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "verboseLabel": "Undiscounted cash payment obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Current portion of lease liabilities",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r379",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r386",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining life (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r102",
      "r129",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r322",
      "r323",
      "r326"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Unrealized gains on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherContractMember": {
     "auth_ref": [
      "r34",
      "r270",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is classified as other.",
        "label": "Other Contract [Member]",
        "terseLabel": "Exit Fee derivative"
       }
      }
     },
     "localname": "OtherContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r283",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r10",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June\u00a030, 2021 and December\u00a031, 2020, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r19"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r64",
      "r303"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r60",
      "r61",
      "r152"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "verboseLabel": "Proceeds from maturities and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r179",
      "r394",
      "r444",
      "r453"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReducedEmployeeExpensesMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A decrease in future employee expense as a result of disposal of a business that results from an exit plan.",
        "label": "Reduced Employee Expenses [Member]",
        "terseLabel": "Workforce reduction"
       }
      }
     },
     "localname": "ReducedEmployeeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r312",
      "r429",
      "r475"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected cost remaining for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "terseLabel": "Estimated restructuring charges expected to be incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Estimated reduction in workforce"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r13",
      "r260",
      "r307",
      "r394",
      "r451",
      "r468",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r166",
      "r304",
      "r305",
      "r306",
      "r314",
      "r315",
      "r348",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r136",
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r265",
      "r266",
      "r430"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r384",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Securities Classified as Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r282",
      "r299",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r282",
      "r299",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Debt Payment Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r283",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r285",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Number of awards granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding balance, ending (shares)",
        "periodStartLabel": "Outstanding balance, beginning (shares)",
        "terseLabel": "Awards outstanding (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Value at Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r287",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding balance, ending (shares)",
        "periodStartLabel": "Outstanding balance, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r80",
      "r83",
      "r105",
      "r106",
      "r107",
      "r109",
      "r111",
      "r119",
      "r120",
      "r121",
      "r165",
      "r192",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r239",
      "r240",
      "r244",
      "r248",
      "r255",
      "r362",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r30",
      "r44",
      "r45",
      "r46",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r118",
      "r166",
      "r255",
      "r260",
      "r304",
      "r305",
      "r306",
      "r314",
      "r315",
      "r348",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r465",
      "r466",
      "r467",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r118",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (shares)",
        "verboseLabel": "Number of shares issued under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in at-the-market offering (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "verboseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r255",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in at-the-market offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r255",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r83",
      "r150",
      "r165",
      "r362",
      "r394"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r370",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r370",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r370",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r370",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r229",
      "r253",
      "r347",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r104",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted",
        "verboseLabel": "Shares used in computing net loss per share - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r103",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic",
        "verboseLabel": "Shares used in computing net loss per share - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r477": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r478": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r479": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r480": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r482": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r483": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r484": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r485": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r487": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r488": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001628280-21-016912-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-016912-xbrl.zip
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M_/EV[\8)'"HX:$DBY52#"D&[O)]BLHX (JU)]Z"%Y=):P\T!F$MOB6'6".L
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MDS8*1Z?5+0YCWG7[!;!E)8Z'OWUNA>'A"TK(_UVZ>*KM'^#9P][Q"\KPO#S
MHE2;+XY& Y2;$SQ_<&R[TPM\K]WKO_@'RAE)Z;>$KU0DVVFU3U[\SRZ2=M!H
MQL^-[5['=O_GV<!V!\4 )V%RXJ#U->(8\#'EU\^3(1+R6[O5C=,A4T;^[W@<
M(?K)GCFH97!Z\EDX'+LP8VD<]F/ZY](_?DXGM;2RF_MW_O[<5O8%&KW4R)WO
M4)(&Y7L\SXPQY;_ON?",M<15G#7,<S*]P/7Z.*["Y\V2C@?QQ?3#;Z$U.&[;
M$[1PY:N5%_TVN;WK#8>]3OF$3[$_;'G;GCRE?.#X\(3]C5G6@F<)&**H#</T
MP1/A6"Z%X_DP?'_,Z&5#KCY,ENGIL>?EO?O3$R9TX,?9ON)U^%)YUOZYQ)>^
M>>_)F]#C86/0:[="H^0+I.?D>)Y(]MW!8QNR[G]!&K1\Q-D8GI?S]&/"R(N$
M\3'O2WBUQ./S;L.D\ V3JDN8=&GE77-C=WVML;.[NKN^<Y&WS@U^44:[L_[R
MW?;&[L;Z3F.UN=98__?+?ZTV7Z\W7FYM;F[L[&QL->?X"M]JA<M?X?WJSK\V
MFJ]WMYK/&FLO&XP(,%<.^FII/GV'AQ5FQI>YH8LJS*5!G86P+@J_O]K:WOSO
M?U!)?OL=X4JWUVV..G@GWYB@FNUL1UHF425L\&@_(E!A;#0Z2:N\ .:XCI=%
M9QM=FQ%]B*T7:SU?=JC*$'!I4B?._SYQ:[U/;]CVISV^.0I'ZY_V7YNCK<Z?
MAYM'GNSM;GS=7VMV-M>VVWN[AX>;[,_.UMJ?[29;A_WW>U\WWS</W_!F>^_K
M<0O/Y2BC)YOLKZ_[1ZMD__TZ[.TV6_M'!R?[N^%PZ_7?G<VOKX[V_M9?WK#]
MD[WW7NZ__[N]?_37UZW=5;'_>N-K<VWSZ^;:QR];NW]V-O&Z+3R^B<>;:Q\_
MA==_0_C7G^U]UO[DCH[;>&T'SQ>;:^V/>T>;!*_\O+6[+C8[>R=;:QMB__V[
M$SQ.MO[6)YN[!_0#-]IY8J%05/$"-*3"YG6CGEF1!"$\6+.T0DGQ5PD:SZAP
M:HO/L\8LF.$R/+&T4FN)!=$2,]8%\EK4_R4O FYL=>.OW_'!'!"=(NHVY.7+
MBNMK4?=&3 /+1+*;,,U5'#)E G;\);/!>5%JQ_3]U/2.KV\8WN.-\\T'M_8J
MQH(Q:T-0U@ ,\>HOPQ>NUVM'VQWV1_$R"_'7"+UR=&).MN-QKS^LI+%XU7*O
MW\FM]_MH'/ZBS:-5:![]==)\_1<^Z\_VUNMUT?SZY]$FVP,T&%\V7^]-KOD;
MGR6Z^[L]L=_9;C77WK'-M0/67-L@^_F].N]PG!_Y)HZN'.O1^N?]MO[\9G=U
MN+E#ON#?'T*$D'L6%!2T*< [* PEO @^&.DED8*CO_??_S *Y&]7F9HIA]^,
M>2>^W[?\.Y;JAP?")2/_]6YU>W=]^\U>8WO][=;V;N/MN^V==ZO-W<;N5@.!
M_BZB^0;EC:WM!A6_A%\;6Z\:N_]:;YSS 4[Q_^K+W7R8&@X7)NJ"_KZCE>9W
M,]*+XG^\ZO4;P\/8^,]4EAOC@%DC=D,,ER&:V8_L\JEK/,S#+Y^6>U6K(2]O
MPCL>!GMR$FT_=B_3KN/MA];'X<Q*ZM9; _$OFU\//C@1DQ6:%$(B^@:/.%P;
M[W!.C1)1>!\<ZL<_1]W8X.19(T_U/0'R1R+J6]NS<E"N)\ U,*V!Z?T"TV3;
M@TN1Z6X?1UZ6,E4>FC;7/-U?^[/5_+J)]W_WI;GVQT<<#]O<7?V"L%0TWV_R
MK=<;L/_ZKV^A*6E^_?OC9F>#;WX]/&SNKI/-UW_QO5V$L6OK..:/=.^KA[VC
MPX_[KRY"4R(D(09(0:VC!3@M"J--+ +CSFMA/!-L DWA"4#3W>W5YLY&"4!K
M;#H';#H\E>8I.$W]7F<<"+V//X>]A9^:W(>U-<@I_$9JH4GMCG+>_46-UV<?
M#U\O:Q9>X2PWRTFNI"VY2TQ\#SXHJE#7,U?DTOL"9%2%5?B'("%)2!)_=;GN
MAQ9<@A97FH0Z5+VX":U6YZ QZ/MQ0_=32?AP0)>/C@^6&K8]O.K0Q?>0Y/C+
M;:8^7[?T?(&S;_>N8[;C0=G,I#O,ZT6>GIXY^:!X2H9I7; 8-/K\1!6.2EL8
M$ITWQ!-+T]+*ZO;:^IN]?S\;6^N-YLOE:RN<>^<E?;WLS?H7ZX>-3.9<T'-&
M^(8=-':.H\^UDJ'1ZC8VAH/&R\,R-O=]IJ=6H_/*^%4ED '7G\Y[NNWM(QEC
MWETH3_ ^@QHX)I\+78?QN-_[E&W#Q;CPV$;D#EG]XTD18=DHZV5OU!WV3U[V
M0C5-QCC,L=E9)\W7?W[<[^QW]CI_MYNO]S\VC]I'^+G3Q/MLKNU]V5_[X^/^
MT>:W88Z3O=V_R%YG&Z_<;Z%)(?N=O]C6>QSC^SV*S_W</'KU<?/U=F>37@QS
M:,-4E(P7).0,G&&VR/0K5'1 HI)*2[VTLA;;]K/MQ]G&.9X"<W_+N[OVR\9D
M(<"XKUN%':J'YMKU4ZZUDM-@="BB%:X <#[GC5EAG98D*,($YTLK3!:4$VX
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M]YCAU]J3G3TWYJV+VF\/>]VG6C5X0#YXYBP+*A6)@BF )U36)*1"!.I(H-J
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MUB_V8MW6A;3!39>JUDFN'R:Y!H>QW9ZR4.,79(PRSS1N>WZ--,[5901[<;!
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ML](:Y+:)#[;UR>+-Q5KTL6R*R>GI?)";-!%RUG\\Z*/F",5DR-['B-!T(7:
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M!2;GI55GPL)QZQ2Z'G5[+0>GW1$<ERYU#SDE[X(M+Q-7=GO/QSR90J "/G7
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M!)A:!"ZP&+@1D6:WG[<IOEZ&6V3_T<K^ J('1?8?0O:G(@E<.L>XB A+GX_
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MC/&GT7"\CJ0H^@.H>'^6MN8@?RHM!QJSEM;1(.O+?_R8FRK)9$:L7W^!E7V
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M)H7FG#Z0TOB!@WY^2CBM*=PNK^63J_G)1S8(>G;HYC2]#%_"P'6'U=7^:9;
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M48D)DL>&RA\)EXN54<O*V!E=G.%/7H5U1(1$962T-H@SK9%1D2(.7@5+0X
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M9(TN_HBY/_C:A#&<CLO23_O#JCO TT$XAE'W4WCVN>M'1^<0/_7%B53BRZ^
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M\V\@P?!BKN=ZSA0-X;+N.,ND1L2WS0Z& HP+ >.93: &8QHI WZ3HD&<4PS
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M="S-+SE9M@J\\$*2X2?KLQ$&*-.9"^;597C0'W=!-3( V!I3X):?Q[V&:=:
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M5$ I3E8 9;9JHGN17  =C^ A-&1V_9(&W+TP68/UVAG.G*VL+$='@_ZW>@7
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M<T]G ;R&IZ-IX6H%.)2!9S"OKV>"2C'"Q *$$9B"=V,WA)G/8WKU]?*RUB5
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MZ?E$^I/T7$Y(G>M15<N^^7B2JS)F0PN61S)IZ#IY\"23M=$,\FS'K>8S+C8
MCZ[\&&^0*S_[T6T)V9!,W>BV/_Y,L#+8QS58?KT!_:0=\4_/X:#DPK67](F<
M=$IKTV$I9]S$,]WQ;CLE<YT\KW.H^IW?QRQVG\<AOM\'_>&P>M\;Q%SN,1>R
M;:,TEK>B'I>0MD[#?2_Z%P\UOP?=>AS3]+OM7#Q0YZ$7\..8NB; O]R5];AF
MX'7>XO1/WN*TB!%[9.>=_>!8W=/-VG/^SK).-KN=EMW3V69ED/<\R*=T2%Q6
ML7+4VQ,Y,$DXH['0(?)@.?74\&0-\5+&Z&34YHJ->Q=ZON=%L]4+YP.=HQ>3
M3&1MK=K2#/ZFP<U),_CNY[WO;\3V[]MB[_ 5WH&Q;=-7 K[?W?N\<[#]_3^?
MM[__]F7G]VUVOAG\VP\[G[<_?SG>^]Z%\?Z%=WY__WUO]PO=^_!/!^[Q?1M&
MN/W[7WCO>T@[+R:-X-_AXT\12\>BI\@X(A%75"/+94):<&<C2S09MK:IN6C1
MJ4?EK+8G"#V3DUK*JBNKKJRZLNI6>M6UAF;E>$!-L%Z>%J(4JK48U6*G5,L2
M8S'5%FGO U MX9')352UX8&PF+#SM&U4ZRD=,+G=S_O\FRX3=0.)JT.!=+$9
MN!11'S7L,&$#2RSO=S$\VN22QH9:196E& M^->PLU):E.'Y+1:-W<XZ?(U90
M@PER0GG$/?A\1FB"F)').),<C3:CT;H4>$G'@+7HE,,5U^2;T=8BIB*F(J;'
M:1<+4[^U;9PQ=>:3T_G$8)<\12#'@ QC$H$0(V>&*I-8"VWCD\HES7H%'=FC
M.+@15;]N\.-10Y+SWCH7HB+<<!&]-E;RI'3"1G!.9:'J;82CSAQ5MY0+#"B!
MDG<8<>T],L%&Q!-UFH>0L))KFV2=WAZ-VA>Y7'%%7I4 <Q%3$=/#B^DQF,7"
MU&]M&F=,71NFF$L)148-&$0=D>/:(..<B%H&$FALGVG\"5&?[BB"P<8?ZW^Y
M\NR53Z%0=;>?>V_ZJ\I5;Y.SN+)\<<5MP0V;S!<7Z2'MP-OY,C;C):4^]V-C
MU($="!A9@REBQ%(G4Z N@HNDY;JZ?7IU(65Y1)'9E=+^6X76BVB+:(MHB\TN
M_MO=V.TY_PVL-'?<(.6(R*'-A'0T$N' B+.Y,CV)1V6WEY2#:;4'4K>80:-\
M&L=<'Y ;;9.;O/W/97*C75G7#8:5$;9QA$^I]O!GZ<Q;5U6T[HVO7[]]V2NN
M#(VA-B@F2;",$"XHS\7 @NK I)+$,+T$&K,U;0_ZNC]X!S3E972C6<^GT[8*
MN:M"?:!]83,+L)GMW:W,9)I(Q-8G%V1P##L$Q,8A3HT'/J,Q,H9Z3W3DEJBU
M34G7%3$MJAQ9DM]24*J@U ]WF?P$BKP?'X[KSJ=U1YY90Y[<U.2WNIONKOU6
M\&E1?#HYQ:<8));&>80-0!,GC",7@T"2A:@<]E(3 _A4H*E T\I#TSR!^AX'
M_6"'!\L"K-Q*J #630%K9T:HB%4VX.20L9@A;JQ"3CD)@.6\LD()S,EI2+C
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M"*/1:YNJH,"308&%JFP>& 9*K.<V,# 7ZQ&&!&.\1N#R)\2%3<@DB5%0.AJ
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M8*TCQ8!*!8S: T;?3\$HU#*C!#&B).(>>Z1!<(AB(KDW(F)."Q@5,&K#NRT
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M_&@0+2SUDZK7'\62@+\2@0)7U&K@CR$([K72.L%/B^'OQ)"$"WUH"PS-MU7
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M:X7^SQ#^^IBL[[&?WA^=YF4'/_V:0U;#/J .; P"<QWPI8IGI=\=@'LK7Q(
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M'^V.S9#O)\9W@V;(:TR] :9.!_A*;BVW'IPW8SABVBJD@HS(L"BP-EBY$%.
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MYP)LG:E?Y@?0G71*''$-UN^9=:-SRZT3$.JOW?80)*'7RKY,>G!^=W<XZ \
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MR;L2OJ<%9Y;M7_@O^^3UQ>[>#MG=@]>/_VK-Y\\T+OY*U,!G"0< $\Z:?^[
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M^M!#\+FETY(J56_P;8->,(-1X?;L4UN]7JM*![3=L] N^N<=WTOU//E5&";
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M.0/F37S**4T]:]"/'(Y:?2]U,#)U.J!LR,Y,BC]D-Q$>TSVI;\D3[<PPD5^
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M6JS68O5T&] ]JE2&V@S_\?WE?NBJ_,@&2H\A7G^3R\A(/1?:$R.<9Z$,1HA
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M'TLLREV)II4CN4*VS9HOW;R60+>=\;-;.>,^F&Y;%T>1U?V0U7,H3WC,2\X
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MG^=% Z7/N!X5G'W760J#?<5ZE^RJ?/'[9/Y[-M"GUG#1].]2-"--'VP]Q#A
MI.4%D<<K4&EX@5?!<-C:C$4[+U!._RL#:>P[S+(3.S4<S@)F1VE@<9\%/+7-
MF'WU7[RF.AK_^9UM[ 0PE_P-'D^#44GSF$.P4VPM3@3#\M(85%XS#6+'"HW(
M-FWLJ^0'GNLQEHI3#^Z!<P6!OF<P%IL&M^W0<J(XBF+/B!(W#EF4.MPW[X^$
M'[GNRS$O1R#^,!-=E(#Y"!C@B0K U/61FD'1F&A(JO;+O-HOEU]]V[0\)PST
M* H"W>%NK <Q]W0_31E+O#1-37=+:[]@2>C-K/FRB7V5C*[I^O=?-B7HAM;&
MU'CQND'@J!HO2]5XF5>P_3FMQ$R%E_^RWIA,N)2]I"J\J HO]VG-CCW',EG*
M,0[0X=P+?<N+F!\XAN.QQ#475WBY)\O,WO^-X1C>'P!T&U/ UA&<NL7I.1M(
MFTT-[[;*E/WV^\&W?ZX.=@F.P?C^<0[@VB^?_GO^91>M+Q^Q@>SWH],OWV:L
M-)_^N3K<W8?W''Z#?]\!U/TX.NWUOGR"9^Z>?S^$>P[[_[B'"/PFPA>^.U\]
MT[<-([!UV[(X>NF8'IE.K!N>!Z#/-W@<8?B"&VZ$NTX5=U%1#8]OR[Z=R+P_
M6_;R$G/*QDT 8A<TG;<L*PA6*!&ZC C].2%"(].SW=0P=,8C] ;&GAYX3JI'
M+O?\* P=-\$NVUW/V0@9NH5Y/*KRR]TZM#QVU,*- FVR;H-"@*N(KVP* 1I.
MZ)K<<?3(BPW=<7BJ!RRP], )@Y"9CA,D,2# CA&H<C J]^<^<=,=9=$C JAK
MZ\0H%'4[,32)HJP H)*5A#J+&* H.W;U*+9M/00)8R<IC^S85L5B'IZ/_TN*
M@JH4\\ @ZK$DE]A.A91N(Z*NII%2XH LPGX8@>WH3N(PG9F!J9M>S,S4< PW
M#EZ\#F;K(*OR,NO$[*J\S(:BL$E9IE#8O8BX2126QE[B,>;KMF.FNN-9E,T8
MZ(R;/#189,04V=Y=.;!=59Y1E6>> ]ZJ-TY!KEO(H\F*-"B/TLAP;</1W8BY
MNL/L2 ^Q5K'+4J")T#$#.WGQVI[5"55!&F64VG(XU*I4H[#0O<B>22QD1,SC
M0 BZ%2<^J'N>J4=.Z.J>$_C,"6W##<@B9:[8^&:-+%)K+7\^2J?U0]2FN3E[
MZ+G%?3'33!W&C-1Q4L>(DB!AAF':O@%_.#:WGS*+686$/:3<FPX)<SV7FXBT
M?!=$GF,9-NB IJG#&1AZ$=*'2PY!T[ZO\J/WP91K;B9[,+FS=F+[MF%C=UN:
M#17%BW'H[>2Q"BK;6"$\98CS+<?#/HM84D)WTM#20^:CKX$YW&!NS,T(P:>[
MHCMT+67P$EG5&YEI]HEK&;5_T%:T=_EPMN+_?<=Q_(B'00S_(CAW&0\<W[I!
M!]T_?#N!RF#X,2*S2]C$D@^>/$S+V$R!</MLR],=]^CTXX^#T\\_#W_NF8<[
M7X,T#J+(X+H!@$IW7 ,K+?N1;H=>:G#7MU(S>?%ZD,\PM_:!LA43ZB>R=#XB
MYC1><NV<7? 52=&W;2>)C=@*>.+X(6=!DCBQGP3H^4SC!74ZUH8"%RD&WC,G
MP:-_OKI8<"4Q MV+8DL'J)'H89RX.H:OQS&FA9CI=228M_*P6(F9>K.$U[U;
M4NMZI+;O]8>]_(ISF=C^85S$YPP;K/?8X [S6Y=#:G^@O>51,<:$:-RS#DH*
M.. 3C0V'1?X#6'K$>U<KR@TXM_S0"B,O,D(GL,+0B2S79+YO!2#CC$0>859U
MA%E6,&%7<%>Q*US79ZG:/;JHVCO<NO(Y"P/S:.>K97J.%5B&;G)FZ$YBASH+
M&0B F$><60;C$4!,HSN+,#4@PQ[2@-CZ*H\^SOM]_)#8A"IQT &U=_+A0U<[
MQ:-*7'[)"ZX-Y58D6G2E<;E))=KZ6/V=-L3B2_CX7VZA07$W-:,XX$[*0\>T
MG8"E<6B:CF'9/HN-4!Y=4Y0W7X.25:">+8#9OSP\^YI:G$58ZACKIH!.8C$]
MB&*N)XEM&8GI6V;J8:)+,)OHH@V!&&C[-:" <6^$IT8V@ W.0?U(2FV4:V,B
MI$FA<^V^KY_((75WH<1YQ@)GWSI$@>/'J1>Z>NR:('#\U-)9$ $ 8:#7N*&1
M^+;UXK79G4,^4N!L!9Y LJ&L=2HZ1")3( NL,'+"BPL0-5.5<ZZM*;8Y4&-^
M#:6;:R)]I+/D"(Z8G;[0<5"AP>H^5*4%0+Y>@[3=K.#Q"%:RK4IH'XK\K&#]
MCM:G(@'UD17EH$7@'XF\K=3Z#,ZC'OR!,@D^Y-D%GSKHQ D'XJN7\3%^",=<
M!N<?*\^U%$ZQKK:[DGY&D.M6E@(.G.BR.$A<FSDLC9@5A8'OFFYB!V;"PGNV
M%%P'M,3G;_.B(N%G+.Y:RM:W[P8H6Q$6OX[<5/<-TP-ERTMU.)0LW055RW!3
M.*/,8+ZR=0W$ OILD3/2VAQR!BIE<0S[22+G,AN=TY5#P1#=6=&BS<I8VKT;
MZZBYP8N;!?/C%U$AR7-X=+JGF497>^ B9'NL& !?E!4D79<"8T=O*A;8L;[T
MC[]_.>V=?_ET\//@&Y#M[C\N_.9\.?UN'/Z,S</=\W.\?YH%#G:_]+^\.^X=
M?7H+[S^X.D0;]N[WGP<_SWM'I__8AS\_ ON\A;&^;1<8<PYW/UN'EU^]*&2)
MD3IZ["387(R%>N@;J9ZD5IJ&(0 #.YDNEQ>;:0A[$<88<>^Z:>@E@.>897'#
MC<(PGBY(=KAWJKT_.CG1/NP=:R?_NW.\-UN><P& 6/[4?/V?J/C]]4QIN]F#
M[<;1WW( CWUL_\E*8)4!'VF]O"Q;4#XKX<SKQ6-1+ WT.)A.1@:A^F+X$,7-
MI?01Z4P6,1K4]9TJD2;E7,NJU#)R#NF@Z6@]#L^4EY;CZ%M]3%<J8X>@ ?\1
M]\8)JI,#'%1OC+55-9ZF<#T)2Q*@>D3Z)T-+8BELI*P@DS4<X'@3?#DQZ_90
M:?( ,>BJ,Y@WC%2\  ?$>CUMF&,]R8SUFA%,S+4#LAF'B7=.R'5$ E3.;3R$
MS[@L1%P/6\N%;5-,=5Q%R11-!<:)I^%%E4J>X=1V2F$+;B;'R[JZW>B\ !!%
M]RQI5\;:%IVI"4_N*>G["1_QH@^TE>#Z1/B.4:97*_/@@KFI#CDMHHFZ=P:)
MW/&UJ@OYZ&(;%'U *TG*@)"]6 \-;H*HCD(]")Q(!TTZ"(P@9K$53XMJWXN<
MU+$LWPT,Q_/L*#)\PW5<TXR2) K-:5&-]B!1()%X7)0OY".B1(E1!'L)@0K$
MOY@5YQ=8;.14J\;B_-.@+55O(T>MY=2?ASE[;BCY//=HNG&W-JBBI.-V@UN6
M?KRV2*/9]<R-J2BI!ON @[4>IU9GN*$5*D\),QP(K+!78P6,U[V/PIV;NBPG
M *!N7I3[*_"Z,$9G3IC.FB_=M5'>*\[XV:W<XLJGBJP46=T366U7 LK"&M2\
M8"-XUS)$LW*UOE6I:=60=#7(S1CDRJR4TO_F5Q<2/7'6@ZOFQ\(?2C5^Z0#E
M.=/=MDR(>5-<[XR&Q1G\LX$9J9VX7IA8S(L3AQN<>1ZW[8 Q)XQ,QW*D^<ZY
M)GV_A G#;RM$: "9[0_BO,_? ZVM34+8+0UZ,A?AHW&P^R7[LGMF'V$GMF__
M7'VVCL^_]/>M@V\'EY_AOH/=O\[1J#>=B_#E])_+P_Y?WX]V8^?SI_VKP]V_
MOGUY][;_^=OGJX.??^(]EP?]/?=P-VG7/;K\&GFI'? XU;F7<MWQ@U2/6&KJ
MW&*<&VGLF('_XK7C=LQ@MD3X\G6/KA%I#Y70-?7*I1.ZE#C:<''D^1Z/K#"Q
M4Y<YEIV&%O?B(&6NF3BNS84WP:C$D:'$T9.+HY^U. I,UX@=S]2# (/60YOI
MD1^;NLW@(/%9D#@V VW%Z83N;(-Q)8[6B665.+J#<U.)HR<41V:#CAPW](PP
MU:T@,74G]5P]-&*N<_@\C$,SBF) 1W[0L9W9H%8ECM:)994XDLU,+%.$C_J)
MXYBI$_DV8U$<A4&4^"E/)#HR%3I:%W%DU^+(B]S4Y$ZB,P_%46@[.L!<7W=3
MQPM-,PU3K);F^!W;6A-E[3XK:YOK9/N:;U'>Y8.\GPWNTZ8\E:F_IJ90-<K'
M'^5]VI6]KK4^O#7_D*O[9%8AIHL#2W4MHI!6#%],1-C?K6J*+0MVU@\1K)9E
M<@\&W*6AP%0U&9&W?Y2*')-6[T\*VU10806HT"KT!5#!MHTT-6W=88FG.SZ+
M]##R#4 .+/43 'MQ&FX@F<@@WAEJ481R6T))>!0$/C:%<C%SR;1<G;D._(@
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M_7CY-8HMPV&)I=LNLW4GC0,]"$R,I/*9$<=6;'CIB]>FW9TU[-7=.)%3'C<
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M/TJZVDO)HG___:;.3H(+_L(7=;03A-GG+ .97XX'@(,FE+!]8.E2<.EN"Q'
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MWU+=RPF))U &D$I419H2O[4($-.AA52;%<8]O*S6C0<8:-<3A;6TEU;7)<7
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MWWZNM&Y6VP 60_TE+25T1*,2!UI)HQK/&L(37@ZS$6_YGJ),5 JI#C=*PB0
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M@PT5FY;1B$TI-_MSY>8!L'&4][)8VXDS(/#L&L_#1@DTXK-6T$&=-U3)*\D
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MT'*G38=Y,2?0L0D^Z51&;+FF5?V)F>DSZMA>V==K&L%.7^6$HXX""C%0%R^
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MI_G'9JT;KM42='/S=)_7FMV+ -J^E?E%D=)J"_:KHB,EE9144E)IK1;LUU5
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M.>!RN9_)U/NNT$Q >L (T<T$DJ6!BRW!L'].&Q71\Y"D"J1 25$TZ]F;!??
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MOUG'9\AQG&#8L'24P99&TSF;U;A3V:EF?V6*#@2?%++'\-3J'U1D)K&?;KJ
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M)[:?^7L\[G6R.CGT[75C^![$EK#)\R;.AXY^#9?-00$'#81/?ZG:M?X[3?Y
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MZ\1A8/Y:)=N5A(\L'K/ C=%)ELC8.'&T1&?)\<'17]X=')&O*'R,<-MS5!E
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M3U #&1.4G"&,ZJ@X#4TT#T[F 2]R].W,_BH,F1WB;T;5 Q%8MAE[+#Q4L?2
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M93TFFK^-W\H&:[[&$P7&55(LX0&ZWP]9H],2C/VZE;DX<Y<Y6,R?*]+I4%@
M1J'3NLW7D;60VY$LXT6V5C!9_'<24DVWO(DK$89.@:O'KQ$_B6P#.G#E33&
MZ@R;-7BZ<3L?H>> 8SJS]$E"O01')"P,N0TL*')Q&RRS1J_!N]U3GI";SB8'
M%DDEV/6YFU%B$I-=N F3"TPKELN;:>SL3^;;G\R(OQF4*A:CHI:C;U<P$UQF
MF#'H):Y1^LG-R 0SE2(U("%E.:5$F>X28HN("S_P1E@C2%*Z3!!AZ-"C6] >
MYT9*?"XPN1D!R%5^*&A 13QI@\W6GG)BOPCOV#W<DE,+)1OJ@!"2*W OT)M7
M^N&L72\J85%%1ZIPY<5ZL9&>$)9N4CB54C.1HR4N%</10NG 8*E#E"UYN#$
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M_N$U-<SBJ>?WMK/Z>BT&MFAU;]CYN-6N!'#1"?.QS+E0JC-"U3;/6#]XNC-
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MCBAC&4'BH68,XT\=)N>TXHR'Q=T1]*0QJ"+KKDI9@'9W>[QOV.#S( RESMB
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M"C**$QX6#*?FJS+43C=E)P_)?GR7-#;J5+92,-*LEPCL9EO@FJAQ1EMI4@1
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MPL6V9K DO!(IBL+_U["BFF6*=(WX<X$E^65;"OJ43U;:(K3]%5X(+[.!"3J
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MF-FV4PZ]:)V'A*DCX@/3W2ED1KHBXO,Z=.?-Z9P2HD&&#$6?#V^SK.!LEDV
MP,<E(;H[%T9GKZ2N^G/P^NC$+"AP0HO!& >VT+R/Z= 6[ ;[ZO1UWX@Y]M3\
M%+SC&.=!!3@<#)CPNF7BJ(%+Z/.IY)('\1'<.:\APH&XI!9($ZZY1[%_?H]H
M8.R2HA6.4 _P61B&!HY:4$@>6+,T]*(H-1,0SC3(>EZ_=@6H-6"T=2*&=XH^
M)2>#X4HOW=11!/^<<,0X5Q;#1(;3?&GXA0C%C]GB9FUY)V]@4U+ITB;BL &&
MEBS"NO3?C5C"@I:3,48C=J89-32,MY9(S9BZ3K,PEK0, -F$Y;8:O^5\'7^
MKC]/F7UO,0>/6L/\8L,L9+Z7S^AF'OQZ".<$9J<N@W-K=2BU7RE M#KB8-$
MP24N*RR5;4APC,/A,!RET+W>;&I2?][[Q-G4&WO*6&E[>?==^1(>U]Z79.RZ
M)KOX"V!(9ZPY]V?X#0_.4\48(^R#5=:L \)/J*XB!M@0 9%-E-ZJ1;X">_$'
MQ+3KA!33:NX?_PL%&"AG3!!%%+%C)R5FZN4,FP3Y2)L(2VDN;,$"2#!WO9:9
MYG%@]17=1M.DI?'QX3<YD0$2ZI Z,>P26GLDHUWG'?IDFOT(BS@^\Y+T[2P
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MG)O/W/C2F:%[IJ]:S/]8XMM<[O<\@5PZ3*V_:7@[ ]\-SJA->P?S,"K',IP
M=L54D294P1/6 2%VD$<54I&1L8A6;2N-=10G,;6(6(;6,EY0]4'?(%Y6O[K9
M"!_4JBCQ&<9-+S'24 UWP,M"<RSNLG=VEWPY(X8L8._ $!,N?DA"AQ#1JC-R
M'!Y.1#<VEHTR_!<2WQB7EX!\AG8,AS_ <K['*YM%C>D?^=&$+WMNGL1D74@X
MW(8@;KSU&/WG8;?R<60P+0T,$Z4PMJT4^V"JVK&4+7!B+KC$>S%2#[=[X@;]
M$2,KR!QE9C$ID[W-)@TXY)(5)H94XC&+A^0SL>T8,!:*]N%3N*N5UDZ3FA'
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M+;!2IWF&J"TGY* +K%M.*^<3K9P$PYQPP 3&EV'!*_VL8'_5Z;RLR[Y"=]H
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M"8P/C2E+!&..<,$J9G\5B)LB_#U+D/:JO#@$Y",;PC6]" ?[SZ)^I[CAX#>
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M-6&6T&@-_;,'"A/(0C*2]9*VO&1!.6\AU3P"K?#"S)E#GXLW?@N?S'[8H4G
MA%T.)'UDC-[E'V;/>BXN_+V>HP0*?,J;I*^E31:6L*91(=@C7CJZ@M\G#^9H
M!U! !,^E+>B3<3%#NK5$"YT3EV %_<4"!W?8QE?K>JCV39+*V+!)9BVL/SQ1
MRY):.AN6E@#])Z5SWJ=0 @_"E"Z1T <T8;H3$2EY5<V>^Q,'"5K.GF0P--\
M=!=5CYX7C+YY!G7(V=_[)1%#PJ5?UBB7684/^4=[Y\<?,GY]*?(67:HS@K='
M?FID:5&%*F^94=T*-N;*143>9*:I!(J'(0@L<(FZZ/"\H7ESN$EEG/8N@8S-
M[2;(P&DB6._(/&?>K2F6PC-^$@_7-SA<W]+E<,!HG/Q%GF[A>5HU$E_Z.7U6
M- O0 NFW"-B$7\<#_#\MOO_ X,$+]Y4VK=!NF?<=OI(>)ZCA@G! AFLGL\DD
M>Y)O=J;+]S<,#!RG;_LMP"CX^GXE^^#;&ZZ>ZI05=<WB8_D?7OH53L-X"L/X
MZ!0']T<W;WI FO%OSVAPQU6ZJKH3(7(7AGX<5Z:6F>LH0/DGI'"!IB9H%\&V
M]<MF[H^&E9(7>),(DBM%:1@925V'B=71+YZM_1'6#<8#-?!@9\C'D0G2?H=\
M$+<"^0$C^FB!#1FO](Q*%IB9"HY7$3Q)-4--4BH/U0;_<,!&)9W=X&.R^$UQ
MZ6*@G90&H@H *LKRNAE\,1A[^6[0KN2MBBFS)<X@K1].JR',B@9AJ$&5D0N'
MJ3<%-68''"&+ Z0NV=C55.0K B/)'N/88O,[5W56<3O$B)L,3[G$[:=!$,+:
M(J$>98& 2^SG>\O2@GGKL(T(?)N9R J A*>[).<W+QKJVX]X,U+N"+J?GBP4
M9MEBGE9F\0WD2H,+7:"^'!*7H=H-%^\7:WP>;"_A<XV(!/FK@4*J])\C/A]T
M0_>IKOCI.CD"C^@5KKW2U/LE?@M[!!A@T8$@&$2TV>*J?UM4=L>'4$NH9L$=
M9_6[\<"&G9Z+"]#5Q%EDI6E<Y^J3*M -_*7_ !_8&[YVP>J3C -@Y"3-(-HW
M/#N04$+V!6J?>5O^^#0+D&,%AI%#T[D-B$:AK#<$J@&G\K/?*6=T0.BU] 1^
MS'_)O!DE#NF0_&6\D]\>0"F+PK[B7F;V<]I69,;!4'-&@#_1W^QV6PHR= @L
MGL<T<!2;'(-6RO0JX]H"T:JB?,1_9/:P2H-/60#*,[&:E<6FD/(T1R7B89B
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ME./KD"#,<P<$0DZ9)<9W)W9>W"1!GJ+R!,$P?EE7,+W 7A0-$CQ'+[K3AG/
ME$0IIQ6K*4)4M!756;A(H&?U@="R)'&SP:=5F\2[E450?PM]D(&H(_A,YBJM
M_TJ[VMG;V42E39U86Z/#D0G#H9SOF@8?YFXXW07#@XZHO0A ATP5/&+X$=V_
M7?!02Y:"JB3$]1OL* S5F--Q\ RJ&VM=,K$$,E'#P4:$U<CP1;6IM":%W@@A
MTJ4)AA8=-[^ +OI M$X9#5L_?=36(8!)Z]0;KC^[^?DC5401*%;<E!7"PL_T
M\M+UNT@J7)GT?^W,.3?I7L18@6\FK,"$%;C7+_ 9805N&7N\"@ICR'!#(5YB
M\>R1BGD-(N<+BO*8N@2]V[IO*>?L[3G0IB[K1<^-P?--T=+9NW)*XF@R-Y'H
MLZ'OCDYF :A=^# = U<QP,,G34TQY@I+E'/%=D:N=*9O06UKL4MR!,?\.RF5
MXHC)5(G3F RKIB?3P<EG58\\GP0I'$QSWNSV3:]AKK:MD*.]2Q"U1A#RD]G+
MNKI^I@@&J[#I?.ZO1*JXB%G/M]QRKCC89N3^DH*@HCZE2*@A@H#U@'*(JX4Q
MQ9=ZPA:OBU@#2H96U!.9Q2X).C@V\U)U2BZ);H[+O=TB[+04)8-_'8C..F7
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M$3?F&CF4,*-I-C+B8#)_.)F]98@&,ZG<Z!VR@"\:@X1#Q&LJR/!E"8*E-\J
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MHL6(79L-4KZ-B#?(^5(6[QWQLH=Z[34K^N!8O2V0%E"G9<].N=$6T">ZS18
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M"9![D^OX:G^NX^&\7N[\?];=IOS+_P502P,$%     @ 9T -4]F1$V5S#P
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M--O=YPM^:R_'[[I3\$0K].'=_P!02P,$%     @ 9T -4P#EC"S6%P  7^,
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M)0/2^-H%$#TY7\Z!R5IDAC%JW^I$P$VY@ =6H7WS8ZMI[]F:MG$/2HPN^N+
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M&'5"D,X4CD(I&1MMR?8!?TB.Q7?!V\V%?^_W/8\49EY*"& B>4RU$V8M'77
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M$SB>Y9*3X)DCT@@@/D=' H^& A@TT7>E:QRO^3LPNM=V2^H9M27;"HI^#Q/
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M468,S EG55"USK!#8#Y5+K6@E JE(SN)?Q^MT<Q*W#:)"?-;(OPJ4&M+]5.
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M9%= 2\=H%-JS3X#2@,D]R#1EQ:0&8@Q%CXWE1% J@; <J-&"![8>$VN)84>
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MB;8U?!"!&JBGPCFS%U89K.4I OIHF:-G!HI8BHLK,0K<&:UC,D^,0@]8(>?
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M#-SOCU[5E5KC@GO73KKX_JO1>-FW?M++)G.IJ2P]PB61C@MB#4@T>UV*BOF
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M6>KF?9*.9*L44U&;Y.N\UW4PU"="G[HJJI"Z_68TF3P?H=,[_ 3#^&UU(+^
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MHY$I<Z"T3K+O3EC=FVR=*/>>J=Z69@[M5[+\=ODC^ G\V[_\_U!+ P04
M" !G0 U3^#OZV"C:  "+)P$ %    &%R9'@M,C R,3 V,S!?9S$N:G!G[+P'
M6)/=UC;X("J*!4&0)D0%I DH10&!B+R B(" $'I41'I5.B0* E(C15! HB#2
MB71IB70!$:F1T F])I002)OXS3?SSS5SSLSWG?<]_[G^:\XF*SS7E<)>>ZUU
MKWNMO1\8OQA3P*G;.GHZ  L+"W"?^0,PI@%5[0#GQP!@8 !( 0!P!& U/@6P
M,*]8?C\9<P('?U\#@*R(,=?_N&;^!ABC@!9P@(7E]^,_!^LAUM_C\,&#K(?8
M#K.Q_98C1X\=/7*$_0@;&_L)=O9CQYF#[>A)CA/'3_Z^_OTEOS_^^U/,Q_$C
M;$>._[<'XRO >>3@YX.?65DN  <X65@Y61BM (@YUT,L_S& _QPL!U@/'CK,
MG!+[,>8;JDXQI\_*>H YV4,'F:JQA#)?!PYR'N(Z?T7S\&GC!VP7O+GEGR=^
M.")RLZR)QZ2/(*KPT"?L*/L97CY^ ;&+XA*24HI*5Z\IJZAJ_:&MHWM+[[;I
M/3-SB(6EE?TCA\>.3LXN3Y[Z^OD'! :%OXB(C'H9'9.4G/(Z->W-V_3LG(^Y
MG_+R"PK+*RJKJFN^U-8UM[2VM7=\Z^SJ'Q@<&L;^&L%-S^!GY^87%I>6B9M;
MVSND7?+>_F^]6 !6EO]C_$V].)EZ'6#:X"#;;[U8#OC_?@/GP4/GKQSFTC1F
M>^!]^H+\\R/<-Q,_E#4=%5$P(? \].EC/R.J."U&_*W:?VCV7U,L[!_2[/]4
M['_HA0..L[(PC<?*"8 !&C4[1@+XM_Q;_BW_EG_+?U$^8 9+MHN>* VU7OV)
M@KQNEL"K&PFQ4(N2L6 G%$!V^XPFYD6LC0=<>6=X6AP^?=S('E=;QC>F?BAH
M*R[4"OIV(*II1KK^;IYDT$4&(%*>W0"WH#7"N!8C4HWXK+]_?233F-LZ^N6'
M?%GB7OJ\+Y0LV=M,4T9>= ^B"$U]'D52UM*6[(1@\M^<&,!I?OTYY9K=B[T^
M48<7AC!1X45;+Y(H.-V?@Y!N5025)[;I"BL)?))<"$]#J)R+11J*>J@S@-MM
M#0P@[(NSQ,(JG7U0S,;KT2"7 K))< LEE1<=HF TT]8Q^Y$!2%0,Y4WGG;Y'
M]DK:^X+Z<8MR((9<ND)GWU!HHR"!#L&%HA7M=HTP%NKRNPXJ3XNYDX76U#L-
ME>L*R[)=X!/A>]BS#1;3OM7G,12?O!5N/]UFF$3P=#\#J%FB)VE,9:-Y&$!4
M%3F6'B'$RP ...30A;$S<OO<3Z'4HZEE#.!E;0MX:X\!3'$Q5\F3_"+$@ %H
M0.ALH"V-Y6RT8"53A1K76STDQ.$E'UEESHEO;ZB#0]U0LG3NC#YE@V7TVYO%
M]%HM9,$+!B#5KR'C53]Y"DNK!?=?^F''1;PY>A))PW ,WZ(\C"%/]-+9EYR6
MZ(E3UU^.JHL,M8:#3-GI9E7V#.#08T+F"UI>,_U"5")"<CHY@6;I6HZ,'KMB
M.MV&RGR,4<Y)R(M4,S*::0:GO&< D@K+R]+S- 4Z^VO",!5Q=;3MC*7H8U>)
M'^"-:.LEVXN)S&\\2=8O?&U.5$SU&#^#-ZRU&UD6D=['%FC%DV&HIKB\K71H
MAFZ:==B3?:CPR;RN$W2]K!'M0%(T!4)5(K(8>^(1)XJN?#T]D5LKGM#/LU/:
MH46$)<_XCG]:3H>]__+#O=3$ SPEBJV)_/[Y#6(WJ Q)?H2<[3U].G6&P  V
MN',YB-JH'@%N8VV_3$UM[KLL_[^2@VO\2@OP4W!7CBCX\>.Q10$5MZU?DEV#
MG4\,?MWG?GF%;25FMMV>\.M6L(W9K6;UV7YH<!DV_.M#[R<D"RN?S'KMJ_39
MMXLID$Z8!M/]R@*"#<9!D52E0I>DX\^5MHN<08.')KZK)PS82>-19$G_UMXS
M9ZR/O9-K^5P#6.#80H(KZ_=V^5"]6T9GOCQA\V5/*%H[4D-&6]!ZD.\=8%Q$
M8?D?3X?$)GST"3;]E'ZPKNVPZ./'[(7R>LH Y!A>#A<\O?&,]02D7>"XO.[N
MAX0EQ[>PLHY:9D!3&XAY;;W<5&T?WPU.5ZORA?.R*-$DI7W)ZY!%H-0/S7J%
MB,NI^_K 9"L3Q0"2VN1H$A1J_==TEUY0C&<79PW=@ E%V\G;6FT,@'#/*$KU
MZ*.!!]BJ#I#O^\I3K9.FTM(<E%GLVP 4G7TTOZ?V*?CPB#4#\--?&<X W].^
M Y_40:MEHT6$9B:Y'FJP%Z:O\:%^V/02-499IT$GIG?>B1OOIB#GA,W(PGLS
M"+*D;IO1J?4S^ZEI.=*.<^6?M9X%L\IN:M3V-@;N1H.=-UYF79(A;0@$)&F'
MK"=<7SH?QP"^GHJ@2;_(1NOSM_&W2]/P/"9VACXUX\$P-NQ],E2\F0'43SMW
M]-R\1EF#MY;ENZ19-7:\\_?V]I5<WOQFBYAQ:>2&1$A>7>_UNZ)G>8C;^-:#
MO^<CMQ/Z5,O+S$U?:38=3HH!EM6N$^O;[3C9%3$\9(21&?V($G\BF.=$^$]?
MH2(,89+*S3'3$<6.HHK.[Y]G )<V+DVG@0DRSQD <9D8(XUM(AYVC& N5:NA
M<'(2];1:G"/'W!O4;J:ZRGZSW);N4-:9WXY$KOZ:/ZQV[;W+K;QDMTU</4>!
M_'$ZSU(6$_K"4 %@DU]U'5$[-"D=91F6A&7%_<P<V&W7J2#I%2\-*6]90:/B
M)Z7]<5"\@USKWB7_B!"E:.PR%='@($:V[2" 31H$*9XA,D3T4 T1]LY1Q-?@
MAE+JP%+=W4+X =<!Q7B/WM8SKMX/ EU#/2;]K /-_P#?_!A#=2["<43[RAVS
M*QE.RX<ZUTCW6UOB>$$$L7-8G -=]2'>(:%%Q\[+ QP^3^TC!D8]#]!S?=[:
MI6%Z&QHS1WU+$=.&/0@ ,8N.O"E/&=[6_N5JXDZL:;1L#<TVZBT#0& KR&QT
M]B%5;D2;,%>DT<:8,^30E>V8.PMT.F32(>N*%_UB7^F<'@,(N@8-"423$@DJ
MR/ &S<B&?(EAZ/AKY+@LM*EBS46ZC0ZB3S* 8PTP3O#T.7K;%_B>?6&K>S7M
MT;P<%=8(UQMVVZ$<62_V*$&Y/^+7>__Z43P][F,X--MAKYT5)!S"XS0('4_R
MV]$WVP)?_RX? CM@\P8G_XD!-)Y!+4X@9BVS8Z3[U7[^RTG'7RY;GK'P*LPS
MC6-'18;5-%TO?A#6_76) ?1[5"R:!6C1]XQM E9;CH5_7'FXK,-I^Z@?&CWR
MO)MHT568P)69)]XO64,63C8>M]6U]]@R$/5JX1M;7^6Y%Y04P$/8;?,D2\V7
M%.RETD_\=-_^8GBC8="Z-S.A5>>+-MAD!NU!3B1BVB9Y/1HFN0+"388"QRZD
MVGX^OV.1=@03%D/-4R/FB#=/\!WI:JBG7J'@,.."@<BB1[!C"WQ%1B")GPC/
M&*B/'V4.+K)]?<9S;8_0.YVCST$:P<I=F!I=ND++$:?7/=)FNM@\.I#\FIEP
M;8AGBA]%-=<=1N:T9,JTK604?-MAOYJ-M/\"Z:R$S+[MB,W4C&]PZC%&.,G
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MY4Q@U"10Z$[JW9FSZ#[21+]TKE$PL1^Z=X6@TA%!57]C9]<QHK>3MTX7Z&
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M16Z"H>/)6RQC'QQV41/*3Q#E;LL_6\SF\NFMC2,A=?KT<3<JZ"693:734\U
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M^%J=,#>4"U;6O6 'IQ]B<&4^:>2'.7NUH&.QQ%'N28HLUQ4&P)V)$3N])6+
M ,*"0VP&;]90+V2/\X'2W76&O'>$'V_T5\F I]*1/!YW*Y;J;&O9!!\-VHLR
M@$D55+^J]$C>5*H6*"87P@ \=;>?X^\1:S326@R3&$"-PWX/,@,+(AB 8E[=
M_%XM<.>[Z@47R2_T %")(Q3>=%U#UC+?@?#]VEFND!)#[%P'I9]C0&G?05LU
MZ^@L%\X7\C%GORD&&?^6ZA\AOL(/2]:=,ZRB"(7<_6F6#C_HVN^^0G+2&-A@
M )>Z(9PSH$.N&IS)CTL^+@=9.PIZK-F=1I)/\5 $[V1-7,^W4K'7$_&.-+?M
M:AF#(&((TH?$Z#TQ*? V'KGN%-)E]'7[APP YU661GZ$WRL Q=V#+$\FP!^A
M(AD IUE"WA0-U .[,UP6FF02JM]Z+WGG8H/T#)3*!=<>Y-)K$)^17KOJ<:MZ
M\*[-S=#P?'/C=:UT<MQH4]S6\4Q"J5+:HSV'W=O=Z\D:DY)$I$AKU7&3U[SC
MI4XT8CUE!A'IA#(BMU"$0VZ019.,BIQ\QI;*?#Q7.7#N7W<>'IX57B^R>P!-
MPY>/F;,7?8C+D_)9$QV@!@4B\Z>>7)*]FH0*+Q!(W#B33E7=8Y90-KKW_V2#
MBN7)#>Q&B$R)U;*5^^ P9-CDZ/NL,SBB\NPIUVUQTA5:;3%=!:?%Q TN/<\'
M,XMW#_K\X>WR%<YU\D#G<CC*#'\>KEJHKU];+)N3=50T,L!&[VQBF7G\\V_G
M$C39,F/VZ1SX2YX<,XTE;#V&4&[A?NC'--W=<:>0*#XOCV,O+Z.[ZN8*0)'.
MKKS[;3M0WZR\U3F>S8U538J?>-L#SVDP[Y@V1S3WP?)&MPLNSSCJQE],&H*J
M.=B6I>@MWY3#V3+OX^._=A&#2\M"36T%J/X0 P7R%GB:^M@@+O68H*">V[[>
M4^<=(\+(2-'O"KAOYG]>:PF22>^'5V9%4:X&G*^2T8OXD>/#KTA3!W'9W0)O
M<_,+9M34GA.^XP?F"&OIYHE)BKM0.KI$>VI=DSVX\G7*FV_L#Z\O%BJ&AIVR
M&"RDW*H<LP:F&"UB*HS"3\Q-6_<\)%H^75.QYO!J(6=0RE!^U,-ZJ.^3T9.G
MJU!QP@H-V*J5]H9!.<'DO@O&N_;:=&Z[EKTD ]!IM+@KE$_-,1#EBHT/S+>[
M)I[]1\YZ>RQ5HC%J2S1]887, !#*6YRM? FW[)0#,'[J#*!1=J,<)ZT]A%D]
MR3JE!N:8WEMP?BC:N.1'7PU)@S1DH;*UN8VA2-#[/[^T9CUL-]!$PPK/O*7J
M-%XL-D$D;.+(]Z3;'9]9D\WXNDR,8^J#+SA(M,N:^.G[F:+N_>Y1VO?RPWX.
M7,*YOQG8MIG>T?]I7[/RS5!!Q'=:AV59.U22(@MO4EP-44[%+;2*Q1H/*B>I
M"UDH5=4NJ\V#5OC@3T.RZIOP*_K6%JON.9%\^$B^E L7),RTSP+ %,L2M,X+
M'OZZ3$JY8:W.>]P4>IH!G*9H('EAYC#>=N$K?2TJ#WS^*-1W-*9*4Z77@JCJ
MM8DS<%;X?3D6JN MCU*WCNBJ-X3V+>,X1:>6!J_-V-YS[[Z#&^TF"CEOYK,7
M7@;6]+7A-QT"-8[)Y*Q>5GRM3-*'0^IA[M5P]?FW[=?D2]:(0PXFMJ.C?6YI
M27J_'3AQ_F^M,@L_SS1&F '<-V*ENNB5KKFGM:CBY] C#TY9S'GN.W.P3WR,
M+S8R1_ED-XP-B#<]OF<'$M*[AWA<O67TE#IP9[N\ 2^8.FP1=P)B:#LPV5F2
MONF<LYF'WUW-FV'2!>Q=!A ]E(93K!5T$WA7^J@J39U%N>L:Y1++%%XD?<N*
M]F9H.]86?B>K:W]X8O/'TO$GFFH/;\V9#LIG'=&(1$O0BAG 5$;_8N)X0.ST
MF(*M5:G#ESX?.Z<HD_OJ-O#/,$^#,18JOAU]"ONUW>)[UHYDB<VUS%#P6_AL
M=Z\Y7-<+$CMXI3^!0[E*%:&M_D$..@??D][L X&,;R_V79>6-#<-.])T. ES
M&NSVIUL@!S>M[R3IK)U-_.S@H.P@\DISAV?7<U6:XBN7D#30A):O/U:2S^F,
MBRMYGG\R3)*#NK/MB5_:1>\V<^>OG2Z2YG%0.7CVE.L2&1)#?'ORRL//I<2@
MVW+.LKT5J[MV:4;SRD41EP-))Z:];_=;M>L'H%?JUJMAU:XD6,R>(XF;]B6'
MG.SL.#5Y9OP2[$+$07/>\AJ![.?/$HRHU:P8(C,2L<LN]*YI^KFF!65EO)=)
M@]U*,=2BJ@_5X9L#C@\(CR*^O2IO<<G-7:QB2:PO;PC<XEC(5*NQHO6?WS\J
M]9^I:5,'3?4^1X5HEHZ%9K7W!)U\]*YW/)Z-J" <OFP(B-J_;#7]<-NL2$_G
MBD'UMI[,Z-66Z65(D8#BPSE)Q22KZHE.?C"(KNZ$J>AX)JO4\]"@_VR'@U-)
MM.?C]IMR[]>MLQ,"E=FVV/#B[4*>>&3">H,FRB80"P&)>K]O-2\[X-<>7AZ'
M]-$3%TVV E=>ZZ YDF+(X1I5A5<B#WWWNWI[MLV!UT&X.*@"SKG-Q_H"-0OF
M5-XO#8TF\?GA(\-WS<=Z]W+W96-[*O:W6M LN:^F&]'G)1\^;ES 2-$MZ*BB
MS5L2V3'409K$G]]@KZ'S416'->0"<!TM^T)%MBZ\O1%"9Y3.5M32>8P[P=^G
MS"LE!DM,%)VUNTR<1:O<&Y/D47;O!'Q*S&]?B7&OR=;S&!4E0P@YMN0^O'0H
M6PO)(##4>TO8K^, 1Z-(C;9Q%GKJ>!(+3826!G\$Y:#W6)UR,E.2X[3Y--IH
M>(O0"N]5[K@N0EK^U:D.#-(RP(][.$ANA)M+=2ZQ[W1FI9<%PC^)-KR"+TK(
M^Z$\??0TXJ'#PL)D3ZV+>6<]5"0?0GNT.N'!#6A]_1HJ<H8W6FDK/:GIOG4"
M?T@F=7(W6'=^I_QW1BA"IOQ74!^D",.!/D<@VX^YHDX'F/"YA9@)O+U88R.J
M6JT>? D=WX<X09O>V\M?VA70I@[7W.UQ]W47T;XD_T$W>G"JB/7;.8(F:J1P
MKX8T1XNY3^[+M0E MI@O<<26B'S__(G']Q%TVF/"">1;CW=>A1 FN1H4$N3E
M>WS>X J'O:">]3%TCY4U>"Q\K$&)*&^AHBO5DQ=D=,N EM!EM!<,KJ +8=2<
M\L:L.YV]14W:B=V"W$]]<=]:PHZLZN;*8][Z]2$'(.C\/^L02?WKKL?R%\+T
MSF?Q<NF*NIGEW/<YP@2?A0N8FY@'T%%MC:O.WF3[UC1VM&Q%W)Y)8I7OK930
MZ=$>UHV3\AH/J#=@ 4/Q(I"ZGTKZP2N"T25R,J*6#]+%)44-\\ZG)&@>1M>'
M?\'PO+(WOX!H/.JL_#2))EJGD16?,QO0\>)R@V980-#$*KY8?%ANQZAP93D9
M_%@"Q4&+Q;C60W'7FY$/!K,$/7F=O1'5-P'M>L.P@(X\@Z^AP^K/K7;9Z=^[
M%-QD'5]$7F.3==)SGAO7Z''KHSIFS"D75_"JG9%7JXC%]E;8#HQ?_F<?G].Y
M'V/YTLPXR<@%R)TQXK(@@V\T#"GIY[M54HZD!T?/*5LDZNB!IU24]I(IMO1!
M+ .HK$F@?J.N0$\L%9L:5-B')VQ^D]=],YD4QS*6-4G:IWVVQLN]?$1 1956
M3-O*0B<-^/'WWAE-] 8,TOI^)M8CTT!7(9N3,7;GX,YF@890N3%M2D]HK1RM
M2KV^T>\6_2.AIH4!K"[K7_TN0ME#^8++>)GUD1+&X=,:,X5#8Y&5?P7-/*/8
M*(^W'BQ979U*75Y?UX[DLS?IE2YKSF<M$'T>0U.@Q3$ !U?H2/U7Z_6<!$_N
MY6^H IL#@IU"?QR!US5^H_3TWG@?,$D]#2;9GAG.F;E:ZTD9J='.UKI :YNS
MPPM3"RD>ZH/8$26:TC2(M5B&YQW>GM*)&L\C/:1CBU/'<U;RMN1B,[V(9EEZ
M86GK4PP@ (M+HF@D!N^F?<IEJED+BOSOT$*0$+Q)F\GIB 76MB%_$'I0^W](
MS[OZE2%V\E7'\ND$$%SHQOC@%3 79'6[K+BO7+5(Y$!QL?P1]7B8.WT"5-Y+
ME0"]9+W7?]^!4-HHHIYOO/FK9^B]^$"1.$7E[-I%3$:(S9195'+O9<Y=9C4;
MD*9#QVUZSFQABVJVTUZ$/"5R6@IKV&U#UD>7TW[!G%U!,JK29!FF&F'(QC]K
M*0$Z*W&X@##0-JPZ'^LKEI6;=ULL4AN<GCA^ZS>&7<#<!3LP"U(M?=I'NE!'
MH=5J]9",7UO!B&.&I?=@4,[]UQIOV5ZY;F;7&SV#GZU"C.S.R*!>*J9.SM'7
MUX?>%/M_3M[2F?PN[/55V#N&=KIE0KGHE;V*5#5A"[:_1IN;KRLM,NBO68"=
M]U*_Q #8>F]W<QH$(S"[T.3%?74_#P90D@*Y3BB:24@D)G]-%3[?)ZM&$9S]
MP;'_S<:K[\MJ5X (D?^@P&(1Y1C'RSR[3%?CI)1'R09N R,YY%W.J(*;Q?G#
ML7'9..?U]/^(=?M3_XPP1[UB,LD<<-4D5:1:@:I!&,=2[\@F"_0,NC, X3Y.
MYM,R'-V2NFW")I8P:4&K8  NTO"1END^BDB;7'25KU/E+T&D=(4AGE*0Q4:\
MRG8G<>]UP;*_P'".=Z"_8AHOQ$2Q0E_$(] VP3)Z74\%U4*UPF,*^@-E#T,;
MTW=QE"MPQV%]6-^. 6QZ6NY J$_ACS(B;1#T!<GT>>AT[&A#HX"7L38/M1UN
M^)?4D$'0522!'8X3P1]*2###WJYF /J#\W9J];XB4AR/?6XB#$863P3FPM["
MFI!,9:D2DV&I6W8W1; -.F?V*2+ST;=H@^*T(161BNL) 2@T82$"7J/@-%"(
M>6(T@4Q? E$"EY;\?Y)!G%^**!R2KV\;[0ZI_PK4*&<"E3FZVM;(<4!Q-)37
MH*:B,O)ZL/6M5+Z'FA'1W$ AVWN /2M&FG+UBIZE&YS_MD%]8W.,Q*=S_QU;
MEMKC0<WQ"GC'EG?Z+4',/YGCPCDM=BRM^I5/$HIR^Y<&-;Q)::#/8N;R=AEW
M[LW*P!S1 :/'6?&"#X@\7COV=K'>*5;.)0-6GV#JU-ODX((02>)PWO2:'4C\
M;O_\Y6]LX]Y#MD:^#N>?;U_XO+(!)4NB5A<8P%%$N AQ..VPK\PAM1+MNT_4
M/P7 GPB>90!UWXW&>0AF<"YBWO'!;Q5Z4Q.?R>\I;6M;UF"E7W3<%/IB7M:<
M5[O,Q<:1TGYK:M9*YV\4OQCZI[LO:] RZ)J9-T4E8+<3G62I)EVL^NG#D>[0
M=W7'7H FH#.L&W)G7WVA71ZH$@R%&H6M#SNMRWCD6'Y(O3J6E'.\2/+L*<V#
M E0'U.??1=9D%9)D-@;F4-/VI<=Z=5#.S)@S@'L+R1YZJV,IVRIV4QQC#6)X
M3*&9Y455:'TR;13^V&AU7V\-9U<'$YS!'@CU2/Y!N$*;A6QP48RAKL/2,.(V
M=@TGD8WYA)B_^U>'<S%'#(CK*>:%W<'!!NWBGME?SF7\@J @\\7\G'J%4^^#
MLEK2)U$_H&0)CC4]!G"LOF/REX!ZD^?Q@"#S>PY@F9UO7943RRKW2&/P6$0\
M/DLF]Y4#ZM3J<O<MW89ZC,0Z7=\/43[E<;H(.6_<LES08=E=&2RGXH;V?-0K
M3IXF(LS(&\0+#* UJ )&6JK6/**B?TOS^@7H?8X9/76]4IT8:7(-3TQ1=,DE
M[4 50X/JB;7&$5IN1'-_BW&"\(M[#[B3]!^E?F/RMP75OZ+AS_&8%J%Q&-4^
MB;@JZ<_Q-L?IG MDQ*;X^9%-O#K:L5W7EV,)FF<VA2088L(8 *%(@\7:!7)E
M=4C- F+\)G'KDG+K4080PL4 +&^MV>U"?TWP$F:ZRF\99E?=GJ#6CU"E9^N>
MNB,[-"2\!7N>U#9G-*IJS ;;AA@MR#:::&IS0Q8[%L[_ WWV@]=(EY=3%:S&
MVLZ2=CDK3=I7:A_I\$GI>FFV2V_FD3Z1A:ZMTH@9]W[Z=3V=]ZQR+L=0JZI]
M_)Z,%1PZNJ,%+7J]A:%RAT\9465 X6QVY5&PLFDAK);37FZ5\E8:_0  OQ^?
M4+47%3,F1RM*4=,6H^!XD];QI)Q=:91BFNDV V /R*%(7[,(0NV:K?&.Z*]V
M;_C!#-!1"^K,\/RFN[/X9X_OF;[/TG=.NC6>DW3U>''>\8\^1S2R,[0!6"JL
M!50E!?L)Y]!H*?B.(;QVDBB;"//R%%FL 8*WW9YZ!!S/;NS'G*>?#+$<TC@:
M\L= @]Y'O=@B?GGBE3U9>S4U(WKW2?4O(J^D=ZRG(:WC<GB.9XJ3G$Z;>ZE6
M*9K-2,RQ!(&KVP[W-?>#(#L=$6/NM(JP_2PIZ!IW:N.<4$JC>?]6Q3)<A)S3
M!/[U:[+T@3V]UVP))S_>T;<!DBZ-TF::=#EJ[N_>WO3?WT[Y3GU(+OE$Y28_
M*2 GFWMNVVK(=)]2#H[F."K )-/?;Y!FLUA^;\,&!)F@+#?;)9GUO(SU[Q)_
M1JH]@F_KMH%HZEHCE]HU.OL5BA&\N9@ IEY056_O/140<YH4%8]VE=9ZU3'R
M<4[W_?$ 951OT!CY-9'#E(S"E^BWJK9.^'THO./P"E$7GIV=T%5XX/GBH0=8
MHJZ@MYD-12%5<MS4ZJ9Z#MW3?]<MD5;2I":M?[Y;),+<5[@B=(ZN[["[_HN9
MES?9?OTE:=EOL@+5_%9#B>I$8 !1/+8E&Z5:MN69;C5&6:99'0\_"\^>W&G%
MXD $)FI%J 7$MJ=Q!CF;7]+MUWO) +YIB= ^0,V:5$ DM*_6(;& FD!XI"H&
M/;SCV$6L#J0E)F';VW!Z5N"9U-CU1MIIC9[JFH0?$\H/XNUCQ(Z\S&&/408X
M-(VR8^@SHW_ 3T[L?_Y'X3=_O<0>79W$GZ/WX.UM5>6QTH_WPZZ'2=V6"%IL
MNEJE.\L UK0('D;/08*^)8#T,>ZT-8'@T^](_2%]6V,H*:-"@:U]R@*='4&P
MIW.A(OV$+U=&^6Y$SF[*QB38#9NSBF,?97@OBCZ!LD*(<B"O#=)57\BQ0RX^
MNQ_H_$_WKG?,PMV].#CA;K.59:;^!2 _^ P"FEZ)9GHLI!WYZ,_N5/-LZU)/
MKY ^,"T@@V< 9-TJUW@T/Y&[J_C'+VO!Y,UB]'/K",_[>>3 O8F8G7*UA=.O
M[0OPA-+^<$RRK>FFJR[=,3GKT:\0+*LI2PPD;JAA8!&;'H3:!#M)H-[!I[*0
ME2/D;L(&G7/<#O^=*!Z)OW=I+:VQ>C%I/]6.$P%NUNN&])G1FA(7E)E?802*
M@*T.40>6D>E!"F2X6F<9O[GJ)U;NQL7K@4I]J(M5OP&X./ ?P=__AT#?31*,
M/7&F]#/85@19YVE]/!U$^%X<]VU29GQRW'_W:)<<]7A<),\.:&V<H@-OCB!K
MB:J&T*$O&[3J^EN<]TJPH 8D_< 15EJ>Z2_LO+.*$I4!X*_Q^F@_LK!T69-*
M76NPWR(CT^3\X#?("LUJFX'K4JK2[>\H:Y(A:)Z%GA%FB$!_.&Y;_%7GI_/C
MI0L+4Q\K \>37'?22,YD"\QA&%N ?\O< 5LK7+0L075,;ZMSI^4*ZR]VZBXM
M$LT#;QZA?7PJ&&B_=>EIE&K)Y%FW%V'O*8J12AK?77?8,3EJ)[[M.6-[/M7L
MBBP6S^VBS38=MY )E@M*M_GO"$]0&VT'87/?Z4[,U$Y_!D8V_]VD+56:5S*R
M6.;9T%!5><?Q:7^Q_=;%3R;&D.1RJ2L^?C'U,L;WMC&<SOO,LE@37=$PA1R[
M4_YT_S1$(@XO%E#_/L6!UUF:62Q)1?^]MJI"@^UT,%B0##'IJSI"'14RP>GK
M88>$;F<&3Q&"!:@Q9,24:V\D3'U8#1SRI:Y?=K;J21P;SHLO^'(+QT-ID@#Z
M% ,(*P@Y1V\BTI/QTA;5HRMEH0G$9U,V?VCHB _E?&6EOQ6@0MLSPU=4'BFH
MNDYDKS* )AGP4>N^J["^J6KXCMN/0'?=]6$(%)^ B?-<[M<P9!9W>V[TCW]%
MUU@5$0X^HR07!N52Q' YN],3\[K37I8=?<(YC?=\;(.P#Q]DIT')@?B>:S/P
M,,7>4\X*@3A8T8'>8Z"&VJFB(/G/4KH/CZ Z8O:[Z4<3*;KP9NF9MPVL148U
M1L.9/9^NUYP:P\\CELZ=A5>^MY>#E@5HM4V.D!G :L,=C*_E$DYA!#X%/;8U
MMP46(@:_@%=>!N/>.-%),=B&#_4,X*N_G<V$[OB@L3;<#-3UX<^&Y=UEJQ0!
MC7?>@;Y2UCA<^X"!=.8EI_>I#T.!@X-#FWE4[@T2D]:]T&HZ0V<;<!S-#W@>
MLG;CP]Z'2M-F8?SW!TQJE\/: HEJ?;MV%BE;],8<)ZT]870+E4%Y/:DU-MT0
M4^W]UJ1[D997M,93C.P,7>\NV(Q:,R+B\*07Y);\E8B/ME<52.Y7SS" 5/-E
MPXGK9SKMUUO]4"I,'Q?HP!?97U%HFQ%:N#H*\]P?* ?7>O$)*%]2O/S&UTE3
M-"V)7K7.C()2K>*_YOZR$J=TI=Z751GJ&C^NIF_N/ZT)4UH1J3]T5^/C<S.^
M6B6^Y1'YI!B?U&B0+[Q)BLX#OQ\B/ZQFZ7UF%''*AI8^PDRB:0$^1T$;MVQ
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MAT.VF,N)CMO[^C?WYYXQ[5H /<( IL^0*_+(Y3CY:O3%FLWU(V>/O;EA0_%
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M9L_E-Y%-/&4;,8M-TRX/75M.:-N9ND@&UCB0,\G?S=24CLZX7M<YVHD1+64
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M+4@SGOP5?^.L0JM*8^#8*'K@UZX>@N='IUV7D.>J(Y8N&W^_GCZ..DW,P@R
MTCS8<QP]DQ932S&7J,D5Z&H(/XS(%%]* ,5&-1U[<P>M'T1\C%HQ:J)>!B=&
MFN$]CX\?D>JFD+*00"@_-=J,N_+WY#1,K:STO!\=.%G;::"PX7>36 \YV+J9
MNZ3?1;]_9KN"6\Y3L^:TX33AL!SIZKC.[8HMP9--5S0_^NX[A?WL4%Z1HSNB
M5'46W,&1@O1"X*C9;J?O(;DQ4\MJ+0H8Q6;G'/S"@^T-P+?']_;+EHU+-'%,
M>U%N'BN7H8L\/LNV.H</-QYZG =424JOI0+F4*C%IVG?^:4Y-_!@+O@07;+:
M'(FR]:?]$CY_<VV\P_DJ[VA[/<$>N^$J;O]J" ,)"A70#-A6=>+"SUW&FGU^
MWP1."53$VNPR+OX0O1);KE1]8):M= @?')KWL4@:E'=RGX@97]+NJIJ+8U_3
M?A\457J;.0[NGW4<&TI9UM:#$(.1!/[\*_1/&Z)X_G?X1WG/X:/-"2+5)<?1
MR/LN/TZ\$-TU3I&;T:R16E!8N4200"M1-/""C#CCGL]W3MDXQ9T:^FV48;U?
M&=>,G"56+8KU<W2H9R+Q-P[TS] CAVI5UBY^TC N;!4NQ$^W;7!K<WF:%=/M
MTXGF@UT!.Q721:[P9HS:'4P=W.!T6EYFD3UX='ZMM@D<.@/M&_<'1_,/#742
M6G$L1P8BI !M9=:<-O>%=@?AO,&OX^$;O:<L?BX4_W9V)044DJ=&@_L<YV;]
M_%QW15^EEH0;'=]QY;?;MBM+#0#;06'9AA"!-JTGY+K-1 BU9RWB<=4$JL)T
MQVG SLL*!SC=.=T]-&DP""B]X,%&SA"S^-[/&>/N_[<C&^J'U!'735Z+O_>*
M'LI+9"BMD_I:C^<J' [IC-&[EI"QO<O0)T4];]1T1Q+=*7VJK6_UUHS897O;
M5[H^EN.838P@<#?)']S3W1>J1<<ZJ403'[TPP!3E9!+:#YSP(J8(=?3KJ2XC
M$6V#9EM,LM65AT^D+WE M[K@U)_;PF<<W-FQRF9C;_Z1>G6_YVL'(U+NW"=U
MYF:97 O(.!'ENG ZU; [(5URP& 1(8.1G86B00Q'C[8CH\23'IONYEY";(Y)
M1&3;=N@ ./?,QFR]Z[%++H1XT-\D5?SZJ+Z&CDRY)42';R3\+?S?UY&SAP<C
M(SDGA/N-+SNE+!]':^[(?A19:R?="%];?35:N*G4B/ ;8226)$0@BS#4 (K3
MZ( [)33[2Q1B?'A]/>%*O3WK:?X:1F(,Z/?FBC]&/H=KEDEGLL?ME[7W5(<M
MLU4.9ILJ=B6,83_G 4\>@+I=_/:KN[B:BC_J/O=$FO19Z9UN_5HE%.=I]S1S
MDQY"GQ/.(-$.HT()^SCG*7J>0'4O;3Q8[7HP^JL\#^:A:L) 3J$X>P4HKQCV
M;%7G+0?*K=>"-W>Z_)CY/7X9$):_(S9W>17?G D^H-5I3%9?;7RW$C(9E]6)
M.)W#E0$N,R2CEFQG)W(M&Y9T.YR5HEV4+/B9;G]XV8N_LHE^7!YL0QX#(OM;
MC"LE=2O7=C\HIK:T,M9I<A-N6PBC+\NP-EDR-I4ETK?PWR2418_L".OT]A"G
MJ1OV&@NT2#=I)^E+-VAMFF'C=ZBTS96RPF]H7'"-LHGJ\.O,9<*W4K1UN1FO
M>E-%O"O<ZGK5">5J*)45?H'DO#0C[X_\(P2LE32M=78.[G3V?7XW-;S6K"=P
MLW1[0 CG%6.2VN@: (BJ+FYOF7#I7.@[Z,CNK,3<3>+!RL2N,8BSJ6@#'FRC
M-<. ;FWU&RT_S\L@5=V,)A ^6T2Q6T VBVE%ZD!T^HS.:FGR68:23P"!6Z(@
MMZ:-'(M&W*(Z:K'2'AW?0"JQO@&$J#DOWFQJR4.[\;/Q\5R+OR-J89(Q/RQY
M,(X,_)OG"XNDAKO1_84K?9K/ -I0_ES,LC%G-\$*[."^S=]J[IIHW#OQF]:N
M#R_J0,T6)K*SA]M0<1;O^NK6#-!5B$\RPXT!VVG?16>8H#*.JQG-U!O"\.-K
M-USQ3SN1)X'\M&QN*%O%:^)!XHIO,&*1LI\'H_NLZ--<&4>-TKF);!FOK <7
M!R4LD&&KQ:$(QI0JF:8*V$53(-IRXARA^/C:60?L]]:3>82$CZ(D&<P=OK27
M KS^+FDORCE!+L'O9R0:=]ZW6W95-7@S?\MX4>.+&=<04^8E4/&=L(,C_''J
MC#175#<OHE,E;-_F]YYPMS"(6(\8,V21E3B&$49+N^B1%%M):"#QZ66F877\
MY: 1S5JI*845?4*ZYJYZ;L3Z'"?5;&03G%H'E"-1]&E.W:B']_S7E6^%6O**
M3D"(E5]'+B2P^8>K@\)5OQ;3QW+R/ULQ?'5+NI5D+%R.V_J^''L0^4'>P6X%
MEA"OIW/.X,[UVV/==B7:VZ&(E?Z/OI%HRG <V4MFR)5<@CKS4)A3:AQ8(=41
M7,^#H4'$B=ZU:AY,<I!CQ'B9[>6_Z/GVLXW>D^M)3-LW,<8?<O;Z"E7@R4;R
MK5+\1L&R=#E7:O9A G4O=J%\7T.OV>OV'R?((@!-ZPZ$S+)\3@);^]-#@/]\
MO=W6XGJL0>+TXTL7%>0K3-5W.N5=%9QUG%NDZ6%4T/NHB\$%\LE@ATZ[3:@Z
M.BK,0Z+GZYR.1PP-S]D-4 B)CA2EC8,&R[]7F7\S!9Y3SCUEP8^.<M-4Z6;
M(ZJ--S<[JKVVP/ML/XH2$<7N)Z3H4B?%[P!]YWK0N\U#8D9!,6=XD89/&O^4
M56_IE]AZ$SZO1GV'OL>0H,"%,P-+"K\K]TWF5P.::'K345.__41OG<>C7YY\
M]?(F.RO4.M6P5!W<;SV*>?@F^/:G$OWM>C[I3S GU4\;-3::O1[Q/WG^(_X.
MMU1[-P]6F<9-R7\=B% R)@K3\],$&S=\7#19>76VSC:$5@QN;_G67X0YDR-4
M4&-DI-3:!N@6+R%*OR4UQMKZIX:G4+M#HIC99>9M?#6SW/;;OTL+V)[@%LDL
MYK DK2:(PQ[LORG,$&\DL(W*J_ O""-1";@8VM::7C3PT:F])0QX?$$=4JWZ
M[#3"5XX\?OZLW0Y<WR2*J4FXA!W%BGSRU9:K1DR, 4P9X#K?%#J,6_]4MY2[
M\ZN!25PLW6Z)P8/I]V1_F(WPU^5@YOU$4(H\6(6%TAGTYG87.@_VF9@2[>'C
M4I!D)\4FZ$-OWGG,5_M K0$[W(^%2?_I!1CC@K\\ EF !^$]=3L4C:H=Z2-_
M3V[E"6J+MM0@&LE(?,]X3'P8;5$:,5@<]N85[BT8\NP-^X1+T'O3,HN.CWCY
MTU$+ ]]0WA&'2X]VQMS+Z0AQ*6]0*%B#OT-1C1 O$-0<@J.!U@4O.LKKP[4,
MO>0/TDN5VB\VT7@PZ^V^X\C.O!(_88/OW_+#;?-S7]X*5)T6/RKTS@^V_C-R
M+4(WINI$T]2(_+R1O$\Y?F(!=*1Z>"<8*S<KV,VXFAJR%$/'/I?S9RAD>O^R
M"M1& (I0<$8Z%$_7Z&[%7>1HE[4066MUS0/*-6OCKN_-?@*S[_ 8?!N<(;]8
M(SVJA-TY=;*IN*WR>]:NJU[LW]_I'8)$'SJ5?M29W]25BY\;AF<?+3%*7QB%
M2+7KFFX\"_?.RRZ*!W-ZM'%_@\U>'NP_>N-N9K4SO_/S,BKLD_^*82X2'(1#
M@D;:ZEQWS+;(Q3EMKP^D3F)S&Y;T<!^^NF:&<&W-=[Q_'6@NML$37RO$U>$&
M:RM OC7(37HBD9&ZK+K]!.+;XA:7EHD+,%/CK$MV=LESSBS!'X-+7?C7W;YL
MVJJY*><<J@'7-GQVS//%MOZ$@<&XE!+L(#.N1:J GXJ]P9GZPU1L#;29.@PH
MZ&_QK&A2VC-04[Q<N;;_S;.&[V\RU8H&#H:QUT\0$ ITM=KD/;FTR>>JAJ)7
MK>F6^9]CH]<1G3-,=0M;S\_I8"YZC5:*XH0Y]IEW/6>_+^L51W7>?W(\#"G]
M<_0@:Q>J6>K,'12RV6GB-;'DAB6$9+@P%U=J+@NHT%R;%7._DI.R]JFDCJ-,
MI,8L@C+\BG9&)/ONOYM(7"%P=G_C](,=/J\1IZRR-SVI]=I@*."X(DW#MR=P
M!B&/=1K>BNI/-PP+Y,$N?RT.LRM86'.#0@EQ6A*XX:5T+3&H"(C]&$<69>$:
MRD]?&Z=(N4ZDBS(:,,^@;9W5'?O300*H(T"%99H]XQ'YZ)ID=H9^C5O%8<4=
M6M\ =59ON2;TXT5 ?<D(P&*6\F#MMO@ FOK-TE.A&!..XUZ_R<!3$Q3TX>4X
M\A85RK&C'PBA;?-_S]"]SXB1&+@0X3MXV-E&L3!L_Q.-1X[W+O-@L<M^$U*S
M^P_R8$03E!QQ!C&G2\T"1>3FR.]NM,!C_#(NN1O\N"0<?V;_>BWS4^(X=WPW
M6KH>). NE1*+SKL1:"XBLY[-A$J,-67">_5 X/6#7-9B)!#DC3!01(+2O7<_
MA( EB,@_ M!MI/U>'X@54GNZ5Q,G^AP_]C=XGI/T.!Q[=NT'OAXAYI4V6R>E
MV*.:U3ODG67=Y'U*4JV^)D+KF_/B(D.^K4:)<:%\O>[[*MD!@HCUUL<J_B<H
MU5&[>+#U2Z_9Y_"M+/ VK42=WO?B^#=A?9,)@!+'U)$E5 -&#.DH]H'R'$?5
M[!N/\=0ZSE@_0.;GWW8B7/^E@CI6 ;@%24.Q!2GF>++$RT>N^ %N9H\>#Q87
M?/ZX(+LC5@XL$F+J%X#[O%B39-=JOSW5YB5A_5ICGAKKZA(R,7?:4A2OL\59
M4GM;DZ\E7JW+3CG2 HI^)&P"'=L>V>CGWD\K7[=XM!Q%.V''2%U"W+J;62R5
M[T+1VM=V-?>5H2.P_F;%P6F9!^]?@P<#S+/8:<JF^B8]*@Q+DT</E,WY34@?
M+OPRBX'@=WC!MP#DO0R"+274B][/^$"Z7[UC8_.AZUP5,>R,&38;\Q2)Q0P!
MT)M<P%;U[I-U$_?$CXIGIQ]8"-X] I2)O5HWHX-6"^X3I>=<M PSF]S8!K>8
M=4UZ4.XXR'## ?:.W<YZ_7O042NQ<4S]MC',+3[=M0"<_I+ ^I.75!^DO18+
MO1#.)*',[_OL2W7WSVC7J0 G%58Z"5#$O<6T5.KOJDB]\9K[P;[^[,A XV;.
M^1K,!^2JVK.E<EU+K<PFR.F?<7)'G[LDF\3YF/!@G1/\^OAFC/*?*@ :@2/2
M.R<;/Z+AE_XDBG19.*WC 8+NVEE>CP\'1G)ZP^C:ZPKK!P[$T2('8_=5 U.R
M!&V:*0\V\_T8"<*<KE>(\]0<TJS1/AZ,!/WIIBW//VYJ!YO^CKI.C<6^(+(=
MVIXQ3V[9F+)\XH'B<V+2';]DQ#"T3C-]K =<GVMKMOG]]8UF^V$>_(*]D6B2
M$/TBQ5C\INY:?>?]-ZL_!F3J:-QVP;X7?HFH7IL==X!K#=I%JHM(-(D^TXG(
M6G%<<@WSGB2J$#(JV'FB2MS2U;BILJO0;65U,(_^&HMM.0:T%D(5(JB8&*SX
MY5;'W'CQ,2/2R<RHG7#SLR8+.HZ6>?+78BPC_L$S[O6EBJMDF9[.R&HTE"DI
M^* [2>+LQ5+B.,>%^Q4G#?U=E>LJJ8K)SXRNMZQ-(*XV[X0P2YT)9CL7][2]
M5&UJN;1T477BO<9@VR'PG&3H*8Z>JCDAP&VNUSO6S@JN-:-'T.E Q\35@TOU
MCPOMB]P/;#B3OK<,A5SV!/CS%AJT_M7:3X$5-W#+5QH*W"<\M[8O6C-QL53A
MW-?[N#>5?5[&[>OK$;-O_;:@D@"JX3]2AG@>[.[9E?BQ/CO*I^VAZS$FZAPJ
M+N/0*X"HSSV G\-M76Z;/^X?IU$ZC5E T1>K>+"H_.4BC@LE4)>;B.L9,W^!
M&M8%AQF$I3N@.1^M+B(T?VD.EZ[.F#VUM_47]K$\*K#D2W_/,")MQ*A[!9RW
MZ-<X^V ;_>9#ES'F:%W.NGZ_;N(ZU .@ HG9[8?7:==T<8$O'A^<]JS>\?6[
MC:QV16G%:B0_C75H]',H6TX#_SPD3ZD%3FTR6T,CI-F^S]Q(\_>C A6-E@N.
M$VHDX22:#W\KQXQS_JT:95?Z'AXL^AO5E8N&?/7C$G'F!,8:4PDL>=A BA ?
M#ZPD6W)U\#/& L"8@1583N >%EPB1:"6U%-X,)LX,(Z_"'H [>&?1D0L8B0'
MM:3(@(/EKHB5_<YSZDPX*-0G5/ 4#9?MF%!\KQXPM<T.48\QHVK+U7).A=CP
MH8+BMQBH7+"'#$\BK+R$;^7W@MP&'/\<U)#65%'R.+X&&Z8-IXZ/$??U%I>U
M^^O9UKUYZO]8>7.;9,T3VX<]IT3(0:DTPT]X\SG"'IS(RT"I,)H(9K^<W%0,
M:>3Q:>0P9$/3A$U >P,%:!4&U70YZJX5N!5E+]QR  \63IR&TP09<:!?'0\F
M\)))X%S:(<Z#X2 Z^T,&O4O';Q)2*AOBJ:$U;-P>1L0YE9Y>4?@K$\Y, 4?]
M6A5A1<T9Q=@N\GOI(8I]/O_)LH]X,.51RMJVLAGH%L#BF'"A#I0[4)6JJ<&#
M7?3(Y\&>=D#;L>,U=9&[O9\("N@8@(?@>X"V&![L61T'6L,NMT!@$B+:/XZ
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M; $DJFTE4-S-Q$9:'2>:T<9:4ZIGY0A"EQD@R-\D9LIR("2UR%WLX%_F+I7
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MZE%#GNN3V5PB\WWTK>*]4;,5!A._VV;8A-"/8HD$V!V2FIIJ@*R+;=VM,@9
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M=O/>].973*!E"@P'=M<CMAN*[#S:N0Z!/TF!TBS9CNUA+-E<NPAH\?*GWEQ
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M;Y2K)=]WAWX@HMY<@>MP7_M@Z@YL38UF /@6%JK6#>86^'DFRQZDZD*^I$@
MV_N+H*/6 5XV+N:;V!&.[1TL:6 ;>9ST(*M'312NFP&6:LJF[^P(;1IDD2I7
M@$I&6@CQN<15):5&-7L56#?BF77,? *5V]L+8?;(]\RQBW5Y@H?YOT+] T86
M<=1#=H^8*\!GKO ?73-<9#VFO)LAY3, Q_BVGQ<7)NGOC'/'+10=Z&W0<#3L
M>3 (7DI$=^20Y>E'$X@0^@DW9.2G3M$VT!DKOB>G_S9O@K#!Z?]#<M/MF'SG
M\C(]SI[6BJU";._4,P"Q(NM/J'.-:DB*SKG<BR!XPAHWK8J(F,ZG=H.UF!A.
M;P)'_3:)&\-<SB_15#&*=LKD&N](\X;5UVZT.<?$DY:CY,,;VH@12\J%"@8
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MN=&/=1@[8V)GQY8GH\ES$#*KLU)+459:IA!=[]H> X5LU0U8.N];K^]<.\<
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M9AH&!]5&G<^D2M]*C2FGQZ4%K&C!/-(1M??R,N\H<AP8N_;]63\YJ2UVTW$
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MLM[,5K1,ZV2.12!P1F' LX]TH4LE6,(C<#LWRUS'R*(I@G"/ ?BQO2A9Z\H
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M?"9>RXE7OPR9+WLJ 7CBBU!N5A^KEMS=PQO:$D7YCXH%D]Y"(C+#CW9#^49
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M626E)L,ME:B%.4-!"+K8_2[2D[FE.D<:S/0-&# %SUZ2CX&L?E<B+< 2J1*
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MIS5=XUE:4IK-K83B\;XBF^RJ@N-C@4M[K"T\_@VW%?V-O_$W_L:_'AC)X#\
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M&5=S(WWSM.73@_J7[^KB_F&NUC^[JY0^_MAY5>T]U4I)K90HM5+^XZG!?KQ
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M?/AN:F_V>@4/ +;;>A@:OL&]2*VX;=^RM<![;OJ5T"%+'+I#%+CBH</ (Q=
M=(?BL!ZBQ[T]+>VJ%$K)^JT1_!.;*V/-_\QLT=;ETXV^_LJ*N0UI>%M6]I>?
M;,Q#8_3/.&,9TUA!P_S&$I>)ACQ-.:1YGDJ<REQ2Z7?4V%.2Z9TZKA4!]F4
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MD0Q3"D6D4X@3QB"7:6ZV-QE!/%8QB;RB&SK&FAS%&%$/3AT]0QRZH'6DES"
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MP ,SGD,^A!&[O2! 7X%>,(V6]K =>3*I#@=@^*0W'-X<JKKBB;C'6<*90IE
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M+ZO_#E)%P ^IH(:KX]"CVJE^<#PW2SWO[A\26BP;AX.U=\MFH+;?URQ/;5G
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M$Z/ZR3"U5:B1'K3B>R3S])R ;@X<"=:ACU)6"H!=:-<J@*T.8$>)/OE4/:?
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M9P>C$(&+BKNI[_3L@*S<<YO1MHH$^&,YWVZ^?ONC.<_-&,ZX%AJDG&" 2E0
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M&#)7.: 04I!S8Z0RC9F&9+94/YAYZ7M I^!P*CAQ#ZVYYT21B ?&![?@?H7
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M"+:!O$EJB9,_F__&36+NBE<<T^UJ[V]CEKF"<M'D<FY@5-^,_]O>>#;WR*5
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M7&<2Y5QHOR/ZCMZF1]B-L E?+:7W#5\7KJY'^('0BL[!.Z"J+ 8'2:/DAG+
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M\!7ES]<6OO927V^B=L+"VV<V7U@7!\-6W]BB<9&AC&59SB6 !$. J,* D+(
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M;G2Q]P^U-LD^Y=FNM$%5O'V3[%5*[/>66*6J&EE>&^\@X^G&S&.-4F1BCC]
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MFX?4"K@\#&XT$@'<R,3RJI: /4';"7VS\X0U<D>XT/'$*F*]@<M]OV']@:N
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M832$EAT3#& 9;HPP-,"$_0\,^#AL<V#RPLB:8;MPX*YBR8+'22;#A "<LQ3
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M-!#--OC:"!'\F?PH'C>/M]^_KYKKO*]2*M&N2\L53"Q"'&,<IQA(K?Y!2#C
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M\+]^^_CNEU?S='*,L]4O+Q<85IA_^7.Z^O++WS,N__%+6<R/?_G[?/&/Z;<
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MY./I;%KE4[-4%^P8%HI2I/640FT7I234L8L@)<6P3";'0ION]#\@;-R'KVV
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M\R"5BR5X6T(C)-U/S[@9@.$A-(#4.\#.!K/9+ACS)!1'1WL13M"F*!1HH,Q
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M5*'#]YFBMWT/S[[0^Q15]M(H]N3KUZ.U*,/1A2C?SLI\<7RFS NA"L]M-KQ
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M3&>_89DOZGR#";/,N5Q;NV7+2,*& QUNM2*TR,0D"TZW:0$T"/GCFN..T=U
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M!;3 M?B8_G8[-GZ(@G']PD[2-(.H9V1X?<2O)Q2-A6L&^C9+Y_44VJ'SP7%
M4?LPQ9+!>QYJSQF/2/LTL(WJ6C;"W,9DC1,U#Z/Y>6LUC'T._MOI_,_P;]/%
M=/9R_M=WJWQ1JHN1PB)2N'6&A(3!091!@5,A\%A,;8F^T<%W_^>/!XE&6IP/
M*]*Q4?'I"YGA+V'Z9KX\F7WX$A;'(2&Y?*D66>63Z@&&HVM>XL69+6PMK'+
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MG&2CPV-LW_O]2=W-!^43DM[""F\*XK*@:5*TRK8$"BF-T:#0A/I0/P&G[YK
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M/KL&UD7WZ#K?@"HZ)W)"X+D("@Q1@V,DP<P9"F^-2;E=E/ CZGKRCG9'Q),
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MAI"U)Q/4J"D4?VECZ/C7[X4[<[&X.Y->+B>M)S8G1N:(L>ZT\IA &0I,O*7
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MN\=:+8DMI#TZ@FY=;S6$.K6FFL)TN215W8Z]DY3LDN=E4!12,IQB'4JJ.,3
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MM>J\OYO='GU()1H-H60#2A0!3KL$N:"3VAMG8IM^]ET4[04T>S&K\R""[P!
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M<0O 4>-!2.)&+*(*G"D>JTRY.16>7<L2QCT ?&P#/#=$UQH73Z5/U8:*TA3
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MVU.^<.M=?88[>/^_ :[^!5!+ P04    " !G0 U3+\=]8;T'  !<(   %P
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M     &%R9'@M,C R,3 V,S N:'1M4$L! A0#%     @ 9T -4]F1$V5S#P
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M,#(Q,#8S,%]G,2YJ<&=02P$"% ,4    " !G0 U34XS/R5+0  !"I@@ %0
M            @ $4V0, 87)D>"TR,#(Q,#8S,%]L86(N>&UL4$L! A0#%
M  @ 9T -4U!HV&H6=@  ,W8% !4              ( !F:D$ &%R9'@M,C R
M,3 V,S!?<')E+GAM;%!+ 0(4 Q0    ( &= #5.X?D4GO0<  &@@   7
M          "  >(?!0!A<F1X+3(P,C$P-C,P>&5X,S$Q+FAT;5!+ 0(4 Q0
M   ( &= #5,OQWUAO0<  %P@   7              "  =0G!0!A<F1X+3(P
M,C$P-C,P>&5X,S$R+FAT;5!+ 0(4 Q0    ( &= #5,IYC,8* 4  -$5   7
M              "  <8O!0!A<F1X+3(P,C$P-C,P>&5X,S(Q+FAT;5!+!08
1    "@ * )L"   C-04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
